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Stomach cancer is an important disease for Māori in Aotearoa New Zealand.  Māori 
are more likely to be diagnosed with stomach cancer than non-Māori and have poorer 
survival.  The higher incidence in Māori can be attributed to differential distribution of 
risk factors.  Cancer survival, though, is an indicator of the access to and quality of 
cancer care with ethnic differences in survival providing a marker of the equity of 




1. Patient, disease, treatment, health care access and outcome characteristics of 
a cohort of patients with stomach cancer. 
2. Whether there were Māori/non-Māori differences in treatment timeliness, 
quality and quantity. 
3. If differences exist, how these differences contributed to Māori/non-Māori 
stomach cancer survival. 
Qualitative Phase 
4. What key informants identify as issues for stomach cancer treatment in New 
Zealand, with a focus on Māori. 
5. The interventions key informants identify that may improve access to, and 





All Māori diagnosed between January 2006 and December 2008 were identified from 
the New Zealand Cancer Registry and compared with a randomly-selected equal 
number of non-Māori.  Clinical data were obtained through a clinical notes review.  
Survival data were obtained from the national mortality database.   
Characteristics and treatment of Māori and non-Māori cohorts were compared using 
age- and sex-standardised prevalence rates.  Cancer-specific mortality hazard ratios 
were sequentially adjusted for demographic factors, disease factors, patient 
comorbidity, and health care access factors to assess their contribution to survival 
disparities. 
Fifteen key informant interviews were held to investigate those points of the 
treatment pathway that the quantitative findings suggested were inequitable for 
Māori.   
Results 
172 Māori and 163 non-Māori with stomach cancer were compared.  Stage and grade 
distributions were similar between the ethnic groups.   
Māori were more likely to live rurally and in highly deprived quintiles, and had higher 
prevalence of comorbidity than non-Māori.  Māori were more likely to be diagnosed 
with tumours located in the distal stomach (43% Māori, 26% non-Māori, p =<0.05).   
Māori and non-Māori stage I-III patients received similar rates of surgical resection.  
Māori were less likely to have surgery performed by a specialist surgeon (38% Māori, 
79% non-Māori, p<0.01), and less likely to be treated in a main centre (43% Māori, 
83% non-Māori, p<0.01).    
After adjusting for a range of factors Māori appeared to have 30% poorer survival 
(Hazard ratio 1.30, 95% CI 0.96-1.76). 
Key informants indicated that inconsistent delivery of cancer services, especially 
impacting on smaller, less well-resourced DHBs, was the primary barrier to equitable 




expected to standardise care nationally, however a range of further interventions, 
particularly focussed on better addressing regional care, communication between 
services and comorbidity, were identified.   
Conclusion 
The findings of this thesis suggest that New Zealand’s health care system delivers 
better cancer care to non-Māori in a number of respects.  Achieving equitable care for 
Māori will require a variety of interventions along the stomach cancer pathway that 
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Glossary of Māori Terms 
Aotearoa New Zealand 
Hauora Health 
Hikoi To step, stride, march, walk 
Hui Gathering, meeting, assembly, seminar, conference 
Iwi Extended kinship group, tribe, nation - often refers to a large group of people 
descended from a common ancestor and associated with a distinct territory 
Kohanga reo Māori language nest/ Māori language immersion pre-school 
Kaupapa Māori Māori approach, agenda, principles or ideology - a philosophical doctrine, 
incorporating the knowledge, skills, attitudes and values of Māori society 
Kura Kaupapa Māori language immersion school – primary or secondary 
Mainstream Providers governed by the New Zealand government and its entities 
Mana Prestige, authority, control, power, influence, status 
Māori  Indigenous person of Aotearoa New Zealand 
Marae Base or home of an iwi or hapu (family); tribal meeting place (lit. the open area 
in front of the meeting house, where formal greetings/discussions take place) 
Ora Health or wellbeing 
Pākehā New Zealander of European descent 
Tangata Whenua Local people, hosts, indigenous people - people born of the whenua, i.e of the 
land where the people's ancestors have lived and where their placenta are 
buried 
Te Puni Kōkiri Ministry of Māori Development 
Tino Rangatiratanga Self-determination, self-governance, sovereignty, rule, control, power 
Treaty of Waitangi A treaty first signed on 6 February 1840 by representatives of the British Crown 
and Māori chiefs, it is considered the founding document of New Zealand  
Waitemata  A region in the West and North of Auckland – Waitemata District Health Board, 
one of 20 District Health Boards in New Zealand 
Waikato A region of New Zealand.  The collective name of the tribes living in the Waikato 
Basin; also the name of the river from which they take their name 
Waitangi A region in Northland, New Zealand. Also a Marae where the Treaty of Waitangi 
was signed 
Wānanga  A tertiary institution that caters for Māori learning needs - established under 
the Education Act 1990 
Whānau  Family, extended family, family group 
Whānau Ora Literally meaning family health. Whānau Ora is also a contemporary cross-
government work programme jointly implemented by the Ministry of Health, Te 
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Chapter 1: Introduction 
Stomach cancer is one of the most common malignancies worldwide.   In 2008 it was 
the fourth most commonly diagnosed cancer, behind lung, breast and colorectal 
cancer.  Stomach cancer is also one of the most common causes of cancer mortality 
worldwide, with a death rate second only to lung cancer (Ferlay et al., 2010).  
Internationally there is wide geographical variation in both incidence and mortality, 
primarily due to cancers that arise in the distal (lower) region of the stomach (Kelley 
and Duggan, 2003; Crew and Neugut, 2006; Dicken et al., 2005; Forman and Burley, 
2006).  Distally located stomach cancers are strongly associated with infection by 
helicobacter pylori (H. pylori) (Crew and Neugut, 2006; Blair et al., 2012; Kato and 
Asaka, 2010; Brenner et al., 2004), and much of this variation in incidence can be 
explained by differences in infection rates of H. pylori between populations, and over 
time (Kelley and Duggan, 2003).   
Stomach cancer is an important cancer for indigenous populations.  Most indigenous 
populations are more likely to develop stomach cancer when compared to their non-
indigenous counterparts (Friborg et al., 2003; Jemal et al., 2004; Paltoo and Chu, 2004; 
Ward et al., 2004; Supramaniam et al., 2006; Vaktskjold et al., 2008; Wiggins et al., 
2008; Moore et al., 2010; Tsukanov et al., 2011; Zhang et al., 2011; Arnold et al., 
2014), in part driven by higher rates of H. pylori infection among indigenous people 
(Windsor et al., 2005; Goodman et al., 2008).  Indigenous people are also less likely to 
survive stomach cancer once diagnosed (Young et al., 1984; Gilliland et al., 1998; 
Jemal et al., 2004; Heise et al., 2009; Morrell et al., 2012). 
Stomach cancer is also an important cancer for indigenous Māori in Aotearoa New 
Zealand.  There are well documented and sustained examples of cancer related 
inequity between Māori and non-Māori (Minister of Health, 2003; Blakely et al., 2004; 
Jefferys et al., 2005; Robson et al., 2006).   New Zealand’s indigenous Māori are not 
only more likely to get cancer in the first place (Robson et al., 2006); they are less 





Robson et al., 2006; Robson et al., 2010; Jefferys et al., 2005; Haynes et al., 2008).  
Importantly to this thesis, Māori also have markedly higher incidence of stomach 
cancer (Robson et al., 2006; Blakely et al., 2010; Arnold et al., 2014; New Zealand 
Health Information Service, 2012), worse mortality (New Zealand Health Information 
Service, 2012) and poorer survival than non-Māori (Soeberg et al., 2012; Robson et al., 
2006; Jefferys et al., 2005). 
Cancer survival can be a useful indicator of the access to, quality and timeliness of a 
country’s cancer screening, diagnostic and treatment services.  Ethnic differences in 
cancer survival thus provide an indirect marker of the equity of health care delivery.  
The underlying reasons for poorer survival among Māori are likely to be a complex mix 
of factors, in part stemming from the processes of colonisation which have resulted in 
an unequal distribution of resources in current society (Orange, 2011; Durie, 1998).  
However, New Zealand has a publicly funded national health system that provides 
specialist and hospital care to all residents without charge; theoretically cancer care is 
equitably accessible to all New Zealanders.  Yet Māori are less likely than non-Māori to 
survive the majority of cancers (Alexander et al., 2010; Brewer et al., 2012b; Dachs et 
al., 2008; Gill and Martin, 2002; Haynes et al., 2008; Hill et al., 2010a; Jeffreys et al., 
2009; New Zealand Health Information Service, 2006), including stomach cancer 
(Soeberg et al., 2012; Jefferys et al., 2005; Robson et al., 2006). 
Explanations for differential cancer survival between Māori and non-Māori especially 
focus on differences in stage at diagnosis and levels of pre-existing comorbid 
conditions (Jefferys et al., 2005; Stevens et al., 2008b) as these two factors are 
important predictors of cancer treatment and subsequent survival.  However there is 
also evidence of differential receipt of treatment for Māori in New Zealand with colon 
(Hill et al., 2010a; Hill et al., 2010b; Sarfati et al., 2009), brain (Alexander et al., 2010), 
prostate (Lawrenson, 2014; Obertova et al., 2015), lung (Stevens et al., 2008b) and 
breast cancers (Seneviratne et al., 2014c; Seneviratne et al., 2014a; Seneviratne et al., 
2015b; Seneviratne et al., 2015).   Importantly, while stage and comorbidity both 
played some role in the poorer survival profile of Māori with colon (Hill et al., 2010a) 





to the poorer survival of Māori in these cancers (Hill et al., 2010a; Seneviratne et al., 
2015).   
Despite the known worse stomach cancer survival for Māori and the evidence of 
unequal treatment for a number of cancers, it is not known whether Māori/non-Māori 
differences in stomach cancer presentation, treatment and management exist.  
Neither is it known if any ethnic differences in care for stomach cancer impact on 
survival.   Thus the management of stomach cancer in New Zealand warrants further 
investigation.   
This thesis started with the hypothesis that there may be different patterns of 
stomach cancer care by ethnicity in New Zealand which may in turn affect survival.  
Thus the primary focus of this thesis is the stomach cancer treatment pathway in New 
Zealand.  It investigated whether there were differences between Māori and non-
Māori in access to and through this pathway, and how to best intervene to improve 
the quality of care.  The study was carried out in two phases.  Phase one used 
quantitative methods to examine and compare the presentation, treatment, 
management and survival of a cohort of Māori and non-Māori patients with stomach 
cancer in New Zealand.  This was carried out to determine if there were any points of 
the treatment pathway where the quality of care was inequitable, and (if present) 
whether that inequitable care contributed to ethnic survival inequities.  Patients 
residing in the North Island only were included due to logistical reasons; however the 
findings are thought to reflect the total New Zealand population.   Phase two then 
used qualitative methods to further examine the stomach cancer treatment pathway 
and to consider and recommend interventions that may improve access to, and 
quality of, stomach cancer treatment in New Zealand, with a focus on Māori.   
The specific objectives of this study were to investigate: 
Quantitative phase  
1. Patient (age, sex, comorbidity), disease (stage at diagnosis, tumour site, grade), 
treatment (receipt and timing of surgery, chemo and radiotherapy), health 
care access (deprivation, rurality) and outcome (survival) characteristics of a 





2. Whether there were Māori/non-Māori differences in treatment timeliness, 
quality and quantity. 
3. If differences exist, how these differences contribute to Māori/non-Māori 
stomach cancer survival. 
Qualitative phase 
4. What key informants identify as issues for stomach cancer treatment in New 
Zealand, with a focus on Māori. 
5. The interventions key informants identify that may improve access to, and 
quality of, stomach cancer treatment in New Zealand, with a focus on Māori. 
Stomach cancer is a complex disease with a pathway that covers a wide range of 
activities including primary prevention, screening, diagnosis and staging, treatment 
and rehabilitation, and palliative care.  This thesis primarily focuses on that part of the 
pathway encompassing the diagnosis and treatment of stomach cancer that occurs 
within secondary and tertiary health care services, from the point of referral for 
specialist assessment onwards.   
This is, however, a thesis within the discipline public health written by a former 
registered oncology nurse and health promoter.  As stomach cancer has known risk 
factors and a long latency period it is potentially amenable to both prevention, and 
early detection through screening or other measures.  So while this thesis does not 
specifically examine cancer prevention or screening, as public health research it was 
important to capture data on and, where appropriate, discuss these aspects of the 
stomach cancer pathway.  Similarly palliative care also sits outside the main focus of 
this thesis but is an important facet of the pathway for a group of people with a poor 
prognosis, as is the case for a substantial proportion of people with stomach cancer.  
Prevention, screening and palliative care are also important in terms of ethnic 
inequities in stomach cancer; so while this thesis primarily focuses on the stomach 






This thesis takes an explicit position of not blaming the victim, in this case Māori, for 
their disadvantaged health status. Within that position the thesis also rejects deficit 
framing.   Research from a deficit frame whereby Māori are seen or described as the 
‘problem’ and the research implies that the position Māori hold is their own fault or 
due to a cultural inferiority has been a persistent feature since New Zealand was first 
colonized.  This framing has been detrimental to Māori and to New Zealand society 
(Reid et al., 2000; Pōmare et al., 1995; Smith, 1999).   Instead the thesis looks to the 
structural and institutional mechanisms that drive disadvantage, especially 
highlighting the role of institutionalised racism.  In this thesis any Māori/non-Māori 
differences in the treatment or management of stomach cancer are examined in 
terms of institutionalised racism within New Zealand’s health care system.  This thesis 
assumes the position that health inequity is an outcome of deliberate policy decisions 
and therefore it must be amenable to intervention.  Thus this thesis moves beyond 
merely describing the problem of inequity into investigating how and where to 
intervene to improve access to, and the quality of, stomach cancer treatment services.  
Mandelblatt and colleagues framework regarding equitable access to cancer services 
(Mandelblatt et al., 1999), the details of which are described in a later chapter, is used 
as the overarching theoretical approach within this thesis.  Using Mandelblatt’s 
framework enables the thesis and its recommendations to remain focussed on system 
and provider change rather than on interventions which expect people’s behaviour to 
change in order to obtain better quality of care.    
The Treaty of Waitangi is key in the New Zealand context and to a thesis examining 
Māori/non-Māori health disparity.  The Treaty is New Zealand's founding document 
(Boulton et al., 2004; Orange) and remains highly relevant in today's society.  The 
Treaty Is incorporated within New Zealand legislation (New Zealand Parliament, 2000; 
New Zealand Government, 1988; New Zealand Government, 1987) and health policy 
(King, 2000; King, 2001; Ministry of Health, 2002b).  It has particular relevance to the 
role and accessibility of health services and to health equity between Māori and non-
Māori.  The Treaty of Waitangi provides further impetus to ensure health services, 





As previously stated, stomach cancer is an important cancer for indigenous Māori in 
New Zealand, yet no previous research has investigated whether unequal treatment 
for stomach cancer exists in Aotearoa New Zealand.  Thus this thesis examines in 
depth the presentation, management and survival of stomach cancer in a cohort of 
newly diagnosed Māori and non-Māori New Zealanders.  It also explores how the 
health care system may improve access to, and quality of, stomach cancer services for 
all New Zealanders, with a focus on Māori. 
Study Chapters 
The specific chapters and their main purpose within this thesis are as follows: 
Chapter 1 – Introduction: introduces the topic, and describes the main research 
questions and objectives of this thesis. It provides some clarity about the focus of the 
thesis, what is covered and what is not, and gives a brief outline of the structure and 
content of each chapter. 
Chapter 2 – Background: provides important background and context for this thesis. It 
sets out in four sections topics of relevance to Māori/non-Māori inequities in stomach 
cancer treatment and survival.  
i. What is stomach cancer - describes stomach cancer, gives a synopsis of the 
stomach cancer treatment pathway, highlights controversies in its treatment 
and management and outlines international guidelines for the management of 
stomach cancer. 
ii. The structural and institutional mechanisms of inequity - briefly describes the 
joint history of Māori and non-Māori in New Zealand.  
iii. The position of Māori and non-Māori in current society - describes 
contemporary Māori/non-Māori access to the determinants of health, 





iv. The New Zealand health care system - provides an overview of the health care 
system along with current cancer policy and interventions. 
Chapter 3 – Literature Review: Indigenous Cancer Inequities: outlines the evidence 
regarding inequity in cancer, and stomach cancer, for indigenous people both 
internationally and in New Zealand.    The chapter discusses incidence and mortality 
inequities first followed by a section on survival inequities.  
Chapter 4 – Understanding Inequity and Interventions: explores why survival 
inequities exist and how, and where, it may be possible to intervene to minimise 
them.   
Chapter 5 – Methods: describes the methods used in in this thesis in two sections. 
i. Quantitative Methods outlines the practical details of the quantitative phase of 
this study including identifying the target population, selecting the study 
cohort, collecting the data, preparing the data, and data analysis.  
ii. Qualitative Methods outlines the practical details of the qualitative phase of 
this study including participant sampling and recruitment, development of the 
interview schedule, interviewing and transcription, data management and data 
analysis. 
Chapter 6 – Quantitative Results: starts with an overview of the study cohort 
selection, then following the three research questions pertinent to this phase it 
provides: a comparison of the Māori and non-Māori study cohorts, a comparison of 
Māori/non-Māori treatment and management and finally, a comparison of patient 
survival. 
Chapter 7 – Qualitative Results: presents the issues identified by key informants along 





interventions suggested by key informants and summarises these according to 
Mandelblatt’s levels of barriers to access to cancer services (Mandelblatt et al., 1999).   
Chapter 8 – Discussion: provides a brief summary of the key findings then discusses 
the strengths and limitations of this study.  Next it considers the implications of key 
findings in light of national and international research, discusses why Māori may 
receive differential access to cancer care compared to non-Māori and highlights 
possible solutions.  To conclude, key messages in regard to action to improve stomach 





Research with Māori 
While this study is primarily interested in stomach cancer equity for Māori, it has been 
carried out by a non-Māori researcher.    
The Health Research Council of New Zealand has guidelines for researchers 
undertaking research involving Māori participants or research on issues relevant to 
Māori health (Health Research Council of New Zealand, 2010).  These guidelines 
identify a range of approaches to Māori health research ranging from kaupapa Māori 
research (Māori controlled) to research where Māori are involved as participants but 
control remains with mainstream or non-Māori.   
This thesis is not kaupapa Māori research; rather it seeks to uphold key principles of 
Māori centred research, with the overarching objective of facilitating positive 
outcomes for Māori.   The study and its analysis employed the following principles 
consistent with a Māori-centred research approach:  
1. Ensuring Māori are placed at the centre of the research: in Māori-centred 
research the needs of Māori are given priority and ultimately the research is 
beneficial to Māori (Cram et al., 2003) 
2. Setting out to make a positive difference for Māori  (Barnes, 2000; Smith, 
1999) 
3. Challenging inequity and power relationships: based on the assumption that 
health inequities are unjust, avoidable, detrimental to the whole of society and 
that interventions to avoid or address inequity are cost-effective (Woodward 
and Kawachi, 2000)  
4. Avoiding victim-blaming and cultural deficit explanations: using a systems 
approach where solutions to the problem are focussed on changing systems, 
rather than changing individuals or those who participate in the systems 






There is debate in the literature regarding who can carry out appropriate research 
with Māori (Cram, 1997; Jahnke and Taiapa, 2003; Smith, 1999).  However, Māori-
centred research does not preclude those who are non-Māori from participating in 
that research (Smith, 1999; Barnes, 2000), rather it is important to get the approach 
right, employ appropriate research methods and utilise appropriate people (Smith, 
1999; Pipi et al., 2004; Barnes, 2000).   
The work described in this thesis has been carried out with the points above in mind.  I 
was privileged to have been supervised by two Māori researchers, one with a clinical 
focus and one with a research focus.  This work also had the oversight of a Māori 
advisory group which was formed to ensure the overall C3 research was relevant, that 
the interpretations of results were both appropriate and reasonable, and to ensure 
the proposed interventions were compatible with community and clinical expectations 
and priorities.  In addition, I have endeavored to ensure my research practice is 
culturally safe by reflecting on my own cultural values and world-view as a non-Māori 
New Zealander.  
Finally this thesis sets out to make a positive difference for Māori.  Stomach cancer is 
an important cancer for Māori.  This thesis seeks to understand the underlying causes 
of unequal stomach cancer outcomes in New Zealand, particularly focussed on the 
role that structural and health system factors play in creating, maintaining and 
potentially reducing these inequities.   Inequity is an issue that should concern society 
as a whole.  Certainly inequity is damaging to all New Zealanders not just those who 
are disadvantaged (Woodward and Kawachi, 2000: 734).  If as put forward, inequity 
arises and is perpetuated from institutionalised racism within ‘mainstream’ 
organisations, addressing inequity then requires involvement from both Māori and 





Chapter 2: Background  
This chapter provides context to this thesis in four distinct sections: 
1/ Section one gives a background of stomach cancer; it presents an overview of 
stomach cancer and describes the major features of its epidemiology and risk factors.  
It highlights important clinical and prognostic factors of stomach cancer along with 
components of its treatment and management.  Finally, this section provides an 
outline of international stomach cancer guidelines that have been developed to guide 
clinical practice. 
2/ Section two outlines two topics of relevance to the current Māori/non-Māori 
inequities in stomach cancer.  These topics are colonisation and neo-liberalism.  This 
thesis in part looks to how and where we can intervene to minimise inequities 
between Māori and non-Māori but in order to minimise inequities we must first have 
insight into the mechanisms by which they arise and are perpetuated.  Much of the 
stomach cancer inequity seen in in New Zealand today can be attributed to the social 
and economic position of Māori in current New Zealand society.  This position has 
been constructed by the shared histories of a predominantly British immigrant 
population and the indigenous Māori.  As with other indigenous people throughout 
the world, Māori have been negatively impacted by colonisation.  Māori have also 
been negatively impacted by the neo-liberal economic reforms that New Zealand 
experienced starting in the 1980s.   
3/ Section three provides an overview of the position of Māori in contemporary New 
Zealand.  The impacts of the processes of colonisation and neo-liberalism are clearly 
seen in the disparity between Māori and non-Māori in New Zealand’s current 
economic, health and social statistics, including that Māori have differential exposure 
to the risk factors for stomach cancer.  This differential exposure leads to a vastly 
greater incidence rate for Māori which is then potentially exacerbated by differential 




within the system – which is discussed in a later chapter.   
4/ Section four provides an overview of the health care system in New Zealand, 
reviewing the funding and delivery of care including that of cancer treatment services.  
The chapter closes by summarising recent Government policy on both health inequity 





What is Stomach Cancer? 
Stomach cancer, also called gastric cancer, is a cancer that usually arises in the cells 
that form the innermost lining of the stomach (American Cancer Society, 2013).   The 
majority of stomach cancers, around 90%, are adenocarcinomas (Kelley and Duggan, 
2003; Mercer and Robinson, 2008).  The remaining 10% of stomach cancers are 
composed primarily of non-Hodgkin’s lymphomas, gastrointestinal stromal tumours 
(GIST) and leiomyosarcomas (Kelley and Duggan, 2003). 
The development of stomach cancer in an individual is thought to be slow, potentially 
taking several decades and following a number of intermediate or pre-cancerous 
stages: chronic gastritis, gastric atrophy, intestinal metaplasia and dysplasia (Ferlay et 
al., 2010).  If investigated, these precursor states are able to be detected and treated, 
preventing progression into cancer (Abrams and Wang, 2010).  Once stomach cancer 
has developed there is often a significant time period where it remains localised to the 
stomach and is potentially curable (Mann and Thomas, 2001).   This is true for both 
adenocarcinoma and GIST (Zhao and Yue, 2012). 
Anatomy of the Stomach 
The stomach is divided into four regions (Figure 1):  the cardia sits next to the junction 
of the oesophagus and stomach (the oesophagogastric (OG) junction), the fundus 
projects upward above the cardia and OG junction, the body is the largest portion of 
the stomach and located immediately below the fundus, the antrum extends from the 
body of the stomach to its junction with the duodenum (Mercer and Robinson, 2008; 
Semrin and Russo, 2010). Proximal to the stomach, the mucosal cells lining the OG 
junction change from the stratified squamous epithelium of the oesophagus to the 
simple columnar epithelium of the stomach (Maish, 2008).  Collectively tumours 




tumours while those arising in the antrum or pyloric region can be referred to as distal 
tumours (American Cancer Society, 2013). This is the distinction made in this study. 
Figure 1: Divisions of the stomach  
 
Source: Mercer and Robinson, Sabiston Textbook of Surgery (Mercer and Robinson, 2008) 
The stomach wall is made up of four layers: the mucosa, submucosa, muscularis 
propria, and serosa and has an extensive lymphatic system that drains to four main 
groups of lymph nodes surrounding the stomach (Semrin and Russo, 2010; Mercer and 
Robinson, 2008).   
Risk Factors 
Stomach cancer (adenocarcinoma) has a number of risk factors.  However infection 
with helicobacter pylori (H. pylori) is the single most important modifiable risk factor; 
H. pylori and its related risk factors are discussed first below.   The remaining risk 
factors for stomach cancer are then discussed, grouped into unmodifiable and 




Helicobacter Pylori Infection and Related Risk Factors 
In 1994, the World Health Organisation declared H. pylori to be a human carcinogen 
(International Agency for Research on Cancer, 1994).  Infection with H. pylori has a 
known strong association with the development of stomach cancer (Crew and Neugut, 
2006; Blair et al., 2012; Kato and Asaka, 2010).  It is proposed to be an almost 
necessary causal factor for stomach cancer which arises distally (Brenner et al., 2004; 
Kato and Asaka, 2010; Talley et al., 2008).  The World Health Organisation estimates 
that at least 63% of all cases of non-cardia stomach cancer are due to infection with 
the bacterium (World Health Organisation, 2008).  However, systematic reviews of 
case–control studies report a much higher percentage, with up to 80% of non-cardia 
stomach cancer reported as attributable to H. pylori infection (Talley et al., 2008).   
Additionally much of the variation of stomach cancer incidence observed worldwide 
can be explained by differences in infection rates of H. pylori between populations, 
and over time (Kelley and Duggan, 2003).    
Helicobacter pylori is a Gram-negative, microaerophilic bacterium found in the 
stomach (Herrera and Parsonnet, 2009) which passes from person to person via the 
gastro/faecal oral route (McLoughlin, 2004; Talley, 1996).  Infection with H. pylori is in 
turn associated with poverty, overcrowding and poor sanitary conditions, particularly 
those experienced in childhood (Crew and Neugut, 2006; Blair et al., 2012; Talley, 
1996; Herrera and Parsonnet, 2009).  It is thought that infection in childhood, unless 
treated, sets up a lifelong infection with H. pylori (McLoughlin, 2004; Crew and 
Neugut, 2006). 
Infection with H. pylori causes gastritis, a precursor to adenocarcinoma, and accounts 
for nearly all cases of chronic gastritis (Kelley and Duggan, 2003).  Chronic gastritis in 
turn increases the risk of developing stomach cancer and is present in many patients 
diagnosed with the disease (Kelley and Duggan, 2003; Herrera and Parsonnet, 2009).    
Differing strains of H. pylori are shown to be more likely to be associated with 




atrophic gastritis and ensuing cancer development (Mercer and Robinson, 2008; Kelley 
and Duggan, 2003; Herrera and Parsonnet, 2009; World Health Organisation, 2008).   
In New Zealand the likelihood of being infected with H. pylori varies by ethnicity, with 
prevalence rates being consistently higher for Māori (and Pacific peoples) than New 
Zealand Europeans (Fraser et al., 1996; Fraser et al., 2010; McDonald et al., 2015).  
Increased rates of H. pylori are linked to household crowding with those living in 
conditions with the greatest household crowding having 1.82 (95% CI, 1.55-2.14) times 
increased risk of infection with H. pylori, compared to those experiencing the least 
crowding, independent of age and socioeconomic status (Baker et al., 2013).  H. pylori 
is also shown to be the major contributor to the excess stomach cancer incidence 
among Māori in New Zealand (MacDonald, 2013).  
It is debated whether H. pylori infection alone can be responsible for the development 
of stomach cancer (World Health Organisation, 2008; Forman and Burley, 2006) or 
whether other cofactors need also be present (Brenner et al., 2004; Crew and Neugut, 
2006).   However, it is true that the vast majority of people infected with H. pylori do 
not go on to develop stomach cancer (Crew and Neugut, 2006).  It is also thought that 
infection with the bacterium creates an internal environment that when combined 
with one or more other risk factors creates a much higher risk of stomach cancer than 
that seen by any one risk factor alone; H. pylori is thus considered an effect modifier 
of the other risk factors (Blair et al., 2012; World Health Organisation, 2008; Crew and 
Neugut, 2006; Gonzalez and Lopez-Carrillo, 2010; Brenner et al., 2002).  
There is evidence of a strong deprivation gradient, in both incidence and mortality, for 
stomach cancer overall (Soeberg et al., 2012; Blakely et al., 2010) with consistent 
evidence of increased risk within lower socio-economic groups within any given 
population (Kelley and Duggan, 2003; Forman and Burley, 2006); this excess incidence 
mirrors a similar excess of infection with H. pylori in these populations (Kelley and 
Duggan, 2003; MacDonald, 2013).  In New Zealand the higher proportion of Māori 
living in more deprived regions accounts for up to 14% of the differences in both 
incidence of, and mortality from, stomach cancer seen between Māori and non-Māori 




An association between previous stomach surgery and subsequent development of 
stomach cancer was first reported in 1922 (Kelley and Duggan, 2003).  Infection with 
H. pylori is now hypothesised as the underlying cause as H. pylori causes gastritis, 
which in turn leads to stomach ulcers necessitating surgery (Abrams and Wang, 2010).  
Likewise, the 20% excess risk of stomach cancer in people with Type A blood group, in 
comparison to other blood groups (World Health Organisation, 2008) is now thought 
to be linked to infection with H. pylori.  The bacterium adheres to a surface antigen of 
the blood cell, facilitating chronic infection with H. pylori (Dicken et al., 2005).   
Non-Helicobacter Pylori Unmodifiable Risk Factors 
Ethnicity 
Ethnicity is important to stomach cancer: differential rates by ethnicity within 
countries are common (Dicken et al., 2005; Crew and Neugut, 2006).   Indigenous 
people in the United States of America (USA) (Dicken et al., 2005), Australia (Zhang et 
al., 2011) and New Zealand (New Zealand Health Information Service, 2012; Arnold et 
al., 2014) all have higher incidence rates than do their non-indigenous counterparts.  
These differing rates by ethnicity are largely due to different patterns and prevalence 
of risk factors among ethnic groups, especially H. pylori (MacDonald, 2013).  Of 
importance, ethnicity matters to cancer sub-site.  Incidence of non-cardia stomach 
cancer is high among African-Americans (Crew and Neugut, 2006; Forman and Burley, 
2006) and American Indians and Alaskan Natives (Arnold et al., 2014).  Whereas white 
Americans are twice as likely as African-Americans (Crew and Neugut, 2006; Forman 
and Burley, 2006) or American Indians and Alaskan Natives (Arnold et al., 2014) to 
present with tumours located in the cardia region of the stomach.  In New Zealand 
Māori have higher proportions of distally located tumours in comparison to New 
Zealand Europeans who have higher proportions of proximal or cardia tumours 





While incidence of stomach adenocarcinoma has been declining in both sexes for 
several decades, worldwide it has a higher incidence in males than females 
(McLoughlin, 2004; World Health Organisation, 2008).  The magnitude of this 
difference overall is in the ratio of 1.5–2.5 for males to 1 for females (Crew and 
Neugut, 2006; Ferlay et al., 2010).  However, this ratio varies depending on tumour 
sub-site.  Non-cardia stomach cancer has a male-to-female ratio of approximately 2:1 
whereas cancer located in the cardia of the stomach has a much higher male to female 
ratio (Crew and Neugut, 2006; Kelley and Duggan, 2003).    
Age 
Stomach cancer is rare in people under 30 years of age, thereafter its incidence rises 
progressively to reach its highest rates in older populations (Kelley and Duggan, 2003; 
McLoughlin, 2004; Mercer and Robinson, 2008) with the majority of patients between 
60 and 80 years of age at diagnosis (Forman and Burley, 2006).    
Potentially Modifiable Risk Factors 
Tobacco 
The use of tobacco is shown to be linked to stomach cancer (Kelley and Duggan, 2003; 
Forman and Burley, 2006).  While there has been some international disagreement, 
studies have shown an important relationship between smoking and stomach cancer 
(Chao et al., 2002; Tredaniel et al., 1997; Nomura et al., 2012).  Notably, the 
International Agency on Research in Cancer concluded in 2004 that tobacco plays a 
causal role in stomach cancer, attributing between 11% and 18% of cases of stomach 
cancer worldwide to smoking (Forman and Burley, 2006). This relationship has been 
shown to be stronger for tumours located distally (Crew and Neugut, 2006; Brenner et 




relationship with a higher risk shown the more cigarettes smoked per day and the 
longer duration (years) of smoking (Nomura et al., 2012).    
Additionally there appears to be a positive interaction between infection with H. pylori 
and tobacco smoking on the subsequent development of stomach cancer (Gonzalez 
and Lopez-Carrillo, 2010), especially those located distally (Gonzalez and Lopez-
Carrillo, 2010; Brenner et al., 2002).  This effect is reported to be 17-fold in smokers 
also infected with CagA-positive H. pylori compared with uninfected nonsmokers 
(Brenner et al., 2002).  Thus, smoking is considered to be an effect modifier in the 
relationship between H. pylori infection and the development of stomach cancer.  
Alcohol 
The association between the use of alcohol and stomach cancer has been extensively 
studied with a meta-analysis reporting a pooled relative risk of 1.3 for a high alcohol 
intake (100 g/day) compared to a non-drinker (Forman and Burley, 2006).  Despite 
this, the causal link between alcohol and stomach cancer has not been conclusively 
established (Forman and Burley, 2006; Kelley and Duggan, 2003).   
Obesity 
In comparison to alcohol use, the evidence linking obesity and adenocarcinoma of the 
cardia and proximal stomach is stronger (Forman and Burley, 2006).  Obesity can 
cause gastro-oesophageal reflux that in turn can cause Barrett’s oesophagus, a cellular 
change and precursor for adenocarcinoma of the distal oesophagus or OG junction 
(Crew and Neugut, 2006; Koppert et al., 2004).   
Dietary Factors 
A number of dietary factors are thought to increase stomach adenocarcinoma risk, 
particularly of cancers located in the distal stomach. These factors primarily include 
diets high in nitrates, found in dried, smoked and salted or pickled foods, and low in 




Robinson, 2008).   Conversely, diets high in fruit and vegetables have been shown to 
have a protective effect for stomach cancer perhaps due to the micronutrients and 
antioxidants contained within them (Mercer and Robinson, 2008; Kelley and Duggan, 
2003).    
Pernicious Anemia 
Pernicious anemia, an autoimmune disease, results in a chronic gastritis in those with 
it and increases their risk of developing stomach cancer (Mercer and Robinson, 2008) 
by up to three times in comparison to patients without pernicious anemia (Kelley and 
Duggan, 2003).  
Genetics 
Familial Clustering 
Stomach cancer shows familial clustering in around 5-10% of cases (Abrams and 
Wang, 2010; McLoughlin, 2004; Lynch et al., 2005; Hu et al., 2012; Vogelaar et al., 
2012).   While familial clustering might well be due to non-hereditary factors, such as 
exposure to H. pylori, higher prevalence of smoking within a family or a common diet, 
having a first-degree relative with stomach cancer is shown to be a consistent risk 
factor for stomach cancer (Yaghoobi et al., 2009).    
Familial Stomach Cancer 
Only 1-3% of confirmed stomach cancers arise from known inherited cancer 
predisposition disorders (Lynch et al., 2005; Hu et al., 2012), including syndromes such 
as Lynch syndrome, Peutz-Jeghers syndrome (PJS), Cowden syndrome, Li-Fraumeni 
syndrome, familial adenomatous polyposis (FAP), and hereditary diffuse gastric cancer 
(HDGC) (Lynch et al., 2005).  The latter of these, HDGC, is the best described form of 
hereditary stomach cancer and is well known in New Zealand (Abrams and Wang, 




researchers, published seminal work describing a molecular basis for familial stomach 
cancer (Guilford et al., 1998).   
In the 30 years prior to Guilford et al’s study being published, 25 members of the 
family had died of stomach cancer, with an average age of 33 years (Guilford et al., 
1998; Blair et al., 2012).  It was the family’s search to uncover the reasons behind this 
high incidence of early-onset stomach cancer that led to the discovery of a mutation in 
the CDH1 gene, which carries a code for E-cadherin molecule (Blair et al., 2012). A 
person in a HDGC family who carries the gene mutation has an estimated 70% lifetime 
risk of developing stomach cancer; however since gene testing began only two 
members of the original family discussed above have died (Abrams and Wang, 2010; 
Blair et al., 2012; Framp, 2006).  Subsequent to this research CDH1 mutations have 
been identified in two other unrelated Māori families and in a number of families with 
a high incidence of diffuse stomach cancer worldwide (Blair et al., 2012; Yu and Li, 
2011). 
However studies show that at a population level, hereditary risk is much less 
important to stomach cancer; the environmental risk factors already discussed play a 
more important role (Blair et al., 2012).  Certainly the development of stomach cancer 
in 25 members of one Māori family over a 30 year time period, while important, is not 
enough to create the three to five-fold increased incidence seen within the New 
Zealand Māori population, nor would this impact noticeably on age at diagnosis at a 
population level. 
Risk Factors for Gastrointestinal Stromal Tumors 
Currently, there are very few known risk factors for gastrointestinal stromal tumors 
(GIST) with age, being older than 50, the primary known risk factor.  In rare cases GIST 
can be due to inherited familial gastrointestinal stromal tumor syndrome (Zhao and 





Stomach cancer is one of the most common malignancies worldwide.  In 2008 it was 
the fourth most commonly diagnosed cancer, behind lung, breast and colorectal 
cancer and represented 7.8% of the total new incident cases worldwide.  It is also one 
of the most common causes of cancer mortality worldwide (9.7% of the total number 
of deaths), with a death rate second only to that attributable to lung cancer (Ferlay et 
al., 2010).   
There is wide geographical variation in both incidence and mortality worldwide (Crew 
and Neugut, 2006; Dicken et al., 2005; Forman and Burley, 2006).  Nearly three-
quarters of all cases of stomach cancer (70%) occur in developing countries with half 
of all cases in Eastern Asia (Ferlay et al., 2010; Crew and Neugut, 2006).  It is thought 
that most of the geographic variation worldwide is due to cancers that arise in the 
distal region of the stomach (Kelley and Duggan, 2003). 
There has been a steady decrease globally in overall stomach cancer incidence during 
the last 50 years (McLoughlin, 2004).  There has also been a notable change in the site 
of stomach cancer - a ‘proximal migration’ - over the last few decades (World Health 
Organisation, 2008; McLoughlin, 2004; Forman and Burley, 2006).   In comparison to 
the steady global decrease overall, cancer of the cardia region of the stomach has 
shown a rapid increase in incidence, especially in the developed countries of the West 
(Kelley and Duggan, 2003; McLoughlin, 2004; World Health Organisation, 2008; Crew 
and Neugut, 2006).  The rate at which the incidence of proximally located stomach 
cancers has risen is said to exceed the rate of increase of any other cancer (Alberts et 
al., 2003).  This rise is thought to be primarily due to an increased prevalence of 
obesity and its associated gastro-oesophageal reflux (Forman and Burley, 2006; Crew 
and Neugut, 2006; McLoughlin, 2004).  Many studies over the last 20 years have 
identified similar epidemiological patterns for proximal stomach cancer and distal 
oesophageal cancer suggesting these cancers share the same risk factors of obesity 
and gastric reflux disease (Forman and Burley, 2006; McLoughlin, 2004; Crew and 




males of more affluent societies (Kelley and Duggan, 2003).   In comparison, as 
previously discussed tumours of the distal stomach are shown to have a strong 
negative socioeconomic gradient and are linked to infection with H. pylori (Kelley and 
Duggan, 2003; Kamangar et al., 2006; World Health Organisation, 2008; Crew and 
Neugut, 2006; Huang et al., 1998). 
The decline in stomach cancer incidence over the last 50 years is primarily due to 
decreased rates of distally located tumours and has corresponded with increasing 
global affluence and better living conditions (McLoughlin, 2004).  Two factors are 
thought to be important.   The widespread introduction of refrigeration has led to a 
decrease in the intake of preserved or salted foods and a higher intake of fresh fruits 
and vegetables (Crew and Neugut, 2006; Abrams and Wang, 2010), while 
improvements in sanitation and less household overcrowding have led to an overall 
decline in the prevalence of H. pylori infection (Crew and Neugut, 2006).     
Additionally, efforts of tobacco control leading to reduced smoking, especially among 
males, may have contributed to declining stomach cancer incidence over the last 50 
years in some countries (Crew and Neugut, 2006).  The prevalence of, or decline in, 
these risk factors is not however equally distributed between, or within countries, 
thus differing epidemiological patterns remain evident (World Health Organisation, 
2008).   
Characteristics and Classification  
 Stomach cancer can be classified in a number of ways: 1/ histologically depending on 
major morphological features, 2/ by grade according to how aggressive the cells look 
under a microscope, 3/ according to the site, or region, within the stomach from 
which the tumour arises and 4/ by stage at diagnosis.  These four characteristics play 






The histologic classification of stomach cancer has historically been based on Lauren’s 
criteria, developed in 1965, in which adenocarcinomas are subdivided into two major 
subtypes: intestinal type and diffuse type adenocarcinoma (McLoughlin, 2004; Kelley 
and Duggan, 2003; Hu et al., 2012).  These two subtypes have differing risk factors and 
thus differing epidemiological profiles, often requiring different clinical decision 
making and have differing prognostic outlooks (Lynch et al., 2005; Hu et al., 2012; 
Mercer and Robinson, 2008).  Generally the prognosis for the intestinal subtype is 
better than that of the diffuse subtype (Mercer and Robinson, 2008).   
Grade 
Tumour grading aims to predict how a cancer will behave depending on the degree of 
cellular differentiation. Those that look the most like the normal tissue from which 
they originated are classified as well differentiated while those that look least like the 
original tissue are classified as poorly differentiated (National Cancer Institute, 2013a).  
Well differentiated tumour cells tend to grow more slowly and in a more orderly 
pattern and thus these cancers have a better prognosis compared with moderately or 
poorly differentiated tumour cells which tend to indicate a faster growing and more 
aggressive cancer (Burton, 2001; National Cancer Institute, 2013a). 
Anatomic Site 
Adenocarcinoma can occur anywhere within the stomach.  The anatomic sub-site, or 
region, of the stomach that a tumour develops in impacts both treatment options and 
prognosis (Mann and Thomas, 2001; Abrams and Wang, 2010).  Proximally located 
tumours are often larger in size and more advanced in stage at diagnosis than distal 
tumours (Dicken et al., 2005).  Consequently proximal tumours tend to have higher 




and a poorer prognosis than more distally located tumours (Mercer and Robinson, 
2008; McLoughlin, 2004; Dicken et al., 2005).   
Stage 
Cancer stage describes how much cancer there is in the body and where it is located.  
It is important in determining treatment options and patient prognosis (Abrams and 
Wang, 2010; Mercer and Robinson, 2008).  A number of systems have been used to 
classify stomach stage however the most commonly used system is the TNM (tumour, 
node, metastasis) system (Edge et al., 2010; Sobin et al., 1997).  In the TNM system, 
cancer stage can be based on the results of physical examination, clinical or imaging 
results as well as histo-pathological findings (Abrams and Wang, 2010).  The TNM 
system for staging contains 3 key pieces of information: T (tumour) indicates the 
depth of penetration into the stomach, N (nodes) indicates the amount of lymph node 
invasion, and M (metastasis) indicates the presence, or not, of distant metastases 
(American Joint Committee on Cancer (AJCC), 2012; Abrams and Wang, 2010).   After 
the TNM categories have been determined they are combined and grouped to assign a 
stage denoted by a roman numeral I – IV, with Stage I having the best prognosis and 
Stage IV the worst (American Joint Committee on Cancer (AJCC), 2012).  
Prognosis 
Stomach cancer has a poor prognosis, with many patients diagnosed at an advanced 
stage (Abrams and Wang, 2010; Dicken et al., 2005; Allum et al., 2011).  Data from the 
USA show that 65% of patients are diagnosed with locally invasive tumours (T3 or 4, as 
explained above) and 85% of patients are diagnosed with accompanying lymph node 
metastases (N as explained above) (Dicken et al., 2005).   In the United Kingdom 
around 50% of patients are diagnosed with distant metastases (Allum et al., 2011).  
Most countries report overall five-year survival rates between 10% and 30% (Mercer 
and Robinson, 2008; Crew and Neugut, 2006; Dicken et al., 2005; Forman and Burley, 




Prognosis differs when statified for stage at diagnosis.  Early stomach cancers, those 
confined to the mucosa or submocosa, have a five-year survival rate of 90% or greater 
(McLoughlin, 2004; Crew and Neugut, 2006; Yada et al., 2013).  Whereas patients 
diagnosed with Stage IV metastatic disease have a five-year survival between 5% and 
16% (Abrams and Wang, 2010).  These stage-stratified prognosis rates emphasise how 
important it is to detect stomach cancer at the earliest possible stage.   
The Stomach Cancer Pathway 
The stomach cancer pathway extends from interventions that aim to prevent the 
disease, to those aimed at early detection, staging, treatment and ultimately, 
palliative care.  Given that stomach cancer has known risk factors and a long latency 
period it is potentially amenable to both prevention and early detection through 
screening.   It is also treatable, and potentially curable if diagnosed at an early stage, 
with the mainstay of curative treatment being surgical intervention.  Stomach cancer 
though has a poor prognosis with many patients diagnosed at an advanced stage of 
disease.  Palliative care consequently plays an important role in the treatment 
pathway for those diagnosed with stomach cancer. 
Primary Prevention  
At a population level, preventing new H. pylori infections is likely to be the most 
effective long-term primary prevention strategy for reducing stomach cancer.  As 
infection with H. pylori is primarily associated with household crowding (Baker et al., 
2013) addressing household overcrowding is fundamental (Baker et al., 2013; 
McDonald et al., 2015) and could also have the advantage of reducing other infections 
associated with poverty (McDonald et al., 2015). 
Reducing the prevalence of H. pylori infection through measures to detect, and 
eradicate, H. pylori could also contribute to reducing incidence of stomach cancer in 




showed that H. pylori eradication resulted in much lower rates of stomach cancer (OR: 
0.56; 95%CI 0.4–0.8) (Fock and Ang, 2010).   In another meta-analysis a relative risk of 
0.66 (95%CI 0.46 to 0.95) was reported (Ford et al., 2014).  The Asia-Pacific Gastric 
Cancer Consensus meeting has recommended such a strategy in high-risk populations, 
those with high prevalence of both H. pylori infection and stomach cancer, since 2008 
(Fock et al., 2008; Talley et al., 2008).  
Other primary prevention measures of particular import to stomach cancer consist of 
dietary measures, such as reducing salt or nitrite intake, reducing levels of obesity and 
tobacco control (Talley et al., 2008; Pasechnikov et al., 2014; Allum et al., 2011).  All of 
these measures would have broad population health benefit, although evidence is 
limited regarding their impact on future rates of stomach cancer (Talley et al., 2008; 
Pasechnikov et al., 2014). 
Screening  
Population-based screening is not cost-effective in countries where incidence is not 
high (Mann and Thomas, 2001; Pasechnikov et al., 2014) and so screening to detect 
stomach cancer early has not been routinely implemented in most countries except 
for people at high-risk (Pasechnikov et al., 2014).    In contrast, because of its high 
incidence of stomach cancer, Japan has been carrying out population based screening 
since 1983, using double-contrast barium swallow (photofluography) followed by 
endoscopy in patients with abnormal results (Guillou, 2005; Hamashima et al., 2008).  
As a consequence Japan has shifted its stage at diagnosis profile with 50% of cancers 
diagnosed at a localised stage (Mann and Thomas, 2001; Inoue and Tsugane, 2005; 
Layke and Lopez, 2004), a high percentage compared to countries without population 
screening programmes.    Japan and other countries with population-based screening 
programmes also have better five-year survival rates than counties without 
(Maduekwe and Yoon, 2011; Forman and Burley, 2006).  These improved survival 
rates may reflect a true improved survival rate through more cancers being diagnosed 
at an early, and thus curable, stage.  They may also be in part due to artefacts such as 




the outcome.   There is however evidence that the Japanese screening programme is 
effective in reducing mortality, with case control studies showing a 40 – 60% reduction 
in mortality (Hamashima et al., 2008; Tsubono and Hisamichi, 2000), suggesting a real 
improvement in survival. 
Screening for stomach cancer in New Zealand is limited to high risk populations with 
known heredity disease (New Zealand Familial Gastrointestinal Cancer Service, 2009).  
The Stomach Cancer Treatment Pathway  
Adenocarcinoma of the stomach is a treatable disease; especially if it is diagnosed at 
an early stage (Crew and Neugut, 2006; McLoughlin, 2004).  However, as the 
epidemiology of stomach cancer has been changing over the last decades so too has 
its management and treatment (Palser et al., 2009; Martin, 2002; Okines et al., 2010; 
Nakajima, 2002; Allum et al., 2002; Allum et al., 2011; NHS Executive, 2001).    
A similar diagnostic and treatment pathway is recommended for gastrointestinal 
stromal tumors (GIST) (Tarn and Godwin, 2012; Zhao and Yue, 2012; Casali and Blay, 
2010; Zalcberg et al., 2008), although lymph node resection is not recommended as 
GIST does not commonly metastasise via the lymphatic system (Casali and Blay, 2010).  
Targeted adjuvant chemotherapy has survival benefit in both first-line (initial 
treatment) and relapse GIST settings (Zalcberg et al., 2008). 
Detection of Signs and Symptoms 
In the absence of screening most stomach cancers are diagnosed after investigation 
for suspicious signs and symptoms.  As both the stomach and the abdominal cavity in 
which it resides are large, and able to distend, early signs and symptoms are often 
absent, or non-specific and vague (Mercer and Robinson, 2008; Abrams and Wang, 
2010; Dicken et al., 2005).  The most common symptoms of stomach cancer are 
epigastric discomfort or abdominal pain and weight loss (Abrams and Wang, 2010; 




cancer.  Dysphagia (difficulty swallowing) occurs more commonly in patients with 
proximal cancers; in contrast, symptoms of gastric outlet obstruction such as nausea, 
vomiting, and early satiety occur more often among patients with distal cancers 
(Abrams and Wang, 2010; Mann and Thomas, 2001).  Physical findings, if present, tend 
to indicate locally advanced or metastatic disease (Guillou, 2005; Mercer and 
Robinson, 2008; McLoughlin, 2004; Dicken et al., 2005). 
Investigations: Diagnosis and Staging 
Flexible endoscopy is the diagnostic tool of choice for stomach cancer, with definitive 
diagnosis confirmed via endoscopic biopsy in the majority of cases (Dicken et al., 2005; 
Mercer and Robinson, 2008; Allum et al., 2011).  As with all tests, endoscopy can fail 
to diagnose with a failure rate of approximately 10%, primarily due to too few biopsy 
samples being taken (Allum et al., 2011).   The upper gastrointestinal barium study 
while still sometimes ordered in the primary care setting as part of the diagnostic 
workup has been superseded by endoscopy. 
Computed topography (CT) of the abdomen and chest is useful to determine if 
regional lymph node or distant metastases are present (Abrams and Wang, 2010).  It 
can also identify malignant ascites, an accumulation of fluid in the peritoneal cavity 
which indicates metastatic disease (Mercer and Robinson, 2008).  Computed 
topography is unable to accurately evaluate early stomach cancer, nor can CT 
accurately detect lymph node metastases less than 5mm in size or peritoneal or 
hepatic carcinomatosis (seeding) (Mercer and Robinson, 2008; Abrams and Wang, 
2010).   Endoscopic ultrasound (EUS) on the other hand is considered to be one of the 
most valuable tools for preoperative staging of stomach cancer (Dicken et al., 2005).   
It is particularly useful in providing accurate assessment of the depth of tumour 
invasion through the stomach wall (T stage) and thus tumour resectability and in local 
(perigastric) lymph node involvement (Dicken et al., 2005; Abrams and Wang, 2010).  
The use of EUS, in combination with endoscopy and CT, greatly increases the 
information gained in the staging of stomach cancer (Abrams and Wang, 2010; Allum 




Staging laparoscopy is often the final staging procedure performed.  Laparoscopic, or 
keyhole, surgery is minimally invasive surgery where an operation is performed 
through small incisions using a laparoscope (Sotiropoulos et al., 2005).  It is employed 
for patients with cancers shown to be surgically resectable (those with Stage II and III 
disease) by the previous clinical staging examinations, providing additional treatment 
(Allum et al., 2011; Abrams and Wang, 2010).  Importantly, with this additional 
information patients can avoid non-therapeutic (‘open and close’) surgery if their 
cancer is presumed to be localised but is in fact inoperable (Sotiropoulos et al., 2005). 
Pathology 
Pathological examination of any initial biopsy and subsequent surgical specimen is an 
important part of the stomach cancer staging process (Allum et al., 2011; Mercer and 
Robinson, 2008; Dicken et al., 2005).  A pathologist can determine the tumour type, 
grade and thus the aggressiveness of the tumour cells and often the level of invasion 
into the stomach wall from initial biopsy.  These factors and others such as site and 
size of the tumour, lympho-vascular spread, whether surgical margins are disease-free 
and whether tumour cells are present in local or regional lymph nodes can be 
determined from a surgical resection specimen (Allum et al., 2011).  
Surgical Treatment 
Surgery is the mainstay of treatment for stomach cancer (Maduekwe and Yoon, 2011) 
and is the only therapy that is potentially curative (Okines et al., 2010; Allum et al., 
2011).  However there are a number of controversies in surgical management of 
adenocarcinoma of the stomach.  A particular controversy is the optimal extent of 
both resection of the stomach and regional lymph node dissection.  
The type of surgery performed is tailored to the extent and location of the tumour and 
dictated by the need to obtain resection margins free of disease (Mercer and 
Robinson, 2008; Allum et al., 2011; Dicken et al., 2005).  Very early stomach cancer, 




(removal of the stomach) is recommended for tumours of stage IB - III (Okines et al., 
2010).  For tumours located distally or in the mid-stomach a partial, or sub-total, 
gastrectomy is recommended (Maduekwe and Yoon, 2011; Mercer and Robinson, 
2008; Palser et al., 2009) as long as a margin of at least 5cm is obtainable between the 
tumour and remaining stomach.   
There has been significant debate regarding the extent of resection for proximally 
located tumours with both total gastrectomy and proximal gastrectomy advocated 
(Palser et al., 2009; Mercer and Robinson, 2008).  While there appears to be little 
difference in tumour resectability between the two surgical options there is evidence 
of greater post-operative complication, morbidity and mortality when proximal 
gastrectomy is performed (Mercer and Robinson, 2008; Maduekwe and Yoon, 2011).  
Thus for tumours located proximally, in the cardia and proximal stomach, total 
gastrectomy may be the operation of choice (Mercer and Robinson, 2008).  Total 
gastrectomy is often also employed for tumours of the diffuse morphology subtype, 
irrespective of original tumour location due to their pattern of diffuse intramucosal 
spread (Dicken et al., 2005).   If the tumour is also extending into the lower third of the 
oesophagus an oesophagogastrectomy or removal of a portion of the lower 
esophagus and proximal stomach is indicated.  These latter two operations necessitate 
using both thoracic (via the chest wall) and abdominal surgical approaches greatly 
complicating the surgery and post-operative recovery (Mann and Thomas, 2001; 
Mercer and Robinson, 2008; Abrams and Wang, 2010).    
The extent of lymphadenectomy during surgical resection has been the most notable 
topic of ongoing debate in the treatment of adenocarcinoma of the stomach 
(Maduekwe and Yoon, 2011; Dicken et al., 2005).   The extent of lymphadenectomy 
can impact on local recurrence and survival and improves staging accuracy due to 
more lymph nodes being pathologically examined (Maduekwe and Yoon, 2011).  There 
is however common agreement in the West that at least 15 lymph nodes should be 
resected and pathologically examined in order to gain adequate staging information 
(Allum et al., 2011; Dicken et al., 2005; Mercer and Robinson, 2008; Mann, 2004). 




least in North American and European surgical centres; with a facility based study in 
the USA showed around 27% of its patients had 15 or more lymph nodes resected 
while a national study in the USA showed as few as 18% of patients nationwide had 
this recommended number resected (Dicken et al., 2005). It is important to stress that 
the total lymph node harvest identified following surgery is a function of both the 
extent of the surgical resection and the thoroughness with which the histological 
specimen is examined by the pathologist (Allum et al., 2011). This supports the 
importance of treating stomach cancer patients in a facility with a commitment to, 
and expertise in, their management and a multidisciplinary team approach (Allum et 
al., 2011; National Health Service Scotland, 2006; Cancer Services Coordinating Group, 
2005; Department of Health, 2009; Okines et al., 2010). 
Adjuvant Treatment 
Stomach cancer has a high incidence of recurrence even after ‘curative’ surgery 
(Dicken et al., 2005; Mercer and Robinson, 2008; Maduekwe and Yoon, 2011) hence 
there has been increasing interest in adjuvant therapies over the last decades to 
improve patient outcomes (Dicken et al., 2005; Allum et al., 2002; Allum et al., 2011).  
Current practice in the West supports the use of neo-adjuvant (pre-surgery) 
chemotherapy followed by surgical resection and adjuvant (post-surgery) 
chemotherapy with evidence of significant survival benefit using this treatment 
approach (Okines et al., 2010; Allum et al., 2011; Abrams and Wang, 2010; Dicken et 
al., 2005).  Adjuvant chemotherapy or adjuvant chemo-radiation is recommended for 
patients at high risk of recurrence and who did not receive chemotherapy prior to 
surgery (Allum et al., 2011).  Adjuvant chemo-radiation appears to have better 
acceptance within the treatment pathway in the USA (Allum et al., 2011; Layke and 
Lopez, 2004).  
Preoperative chemotherapy has also been shown to be useful in down-staging 
patients with locally advanced cancer, thus offering the possibility of a curative 
resection if the tumour responds well to chemotherapy (Okines et al., 2010).  Intra-




treatment or prevention of peritoneal metastases remains experimental (Allum et al., 
2011). 
Palliative Care 
With large numbers of patients diagnosed with unresectable or metastatic disease, 
and a high chance of recurrence after curative treatment, symptom palliation is an 
important aspect of the overall management of adenocarcinoma of the stomach 
(Dicken et al., 2005; Mercer and Robinson, 2008).  Surgical resection or bypass and 
external beam radiation can control bleeding, obstruction or pain while radiation can 
also be used to relieve dysphagia of oesophageal involvement.  Endoscopic 
procedures, such as dilation or stent placement can palliate symptoms of either 
oesophageal or gastric outlet obstruction (Mercer and Robinson, 2008; Allum et al., 
2011; Okines et al., 2010).  There is also a role for systemic chemotherapy in the 
palliation of stomach cancer, with studies showing improved patient quality of life and 
median survival benefits of up to 10 months over supportive care alone (Dicken et al., 
2005; Allum et al., 2011; Okines et al., 2010).  There is however no international 
consensus on which chemotherapy protocol to use as first-line palliation (Allum et al., 
2011). 
Comorbidity 
In part due to the combination of risk factors for stomach cancer, such as tobacco use 
and obesity, along with stomach cancer being a disease predominantly of an older age 
group, many patients have high levels of comorbid conditions (other conditions as well 
as the disease of interest) when diagnosed (Koppert et al., 2004; Palser et al., 2009; 
Sarfati et al., 2014b).  Comorbidity is known to impact on the quality of care received 
by patients and on the likelihood of survival from cancer (Hill et al., 2010a; Lemmens 
et al., 2005; Sarfati et al., 2009; Sarfati et al., 2014a; Sogaard et al., 2013).  As Māori 
are more likely to have comorbid conditions alongside their cancer than non-Māori 




Zealand comorbidity impacts on Māori/non-Māori cancer survival equity (Brewer et 
al., 2011; Hill et al., 2010a).   
Patient comorbidity can either affect cancer survival directly, whereby certain 
conditions directly impact on prognosis through sheer physiological burden of disease, 
or indirectly through limiting treatment options or decisions (Brewer et al., 2011; 
Sarfati et al., 2009; Sogaard et al., 2013).  The use of different treatment options due 
to comorbidity can be clinically indicated; in particular comorbidity limits the ability of 
many patients with stomach cancer to be treated aggressively with surgery or 
chemotherapy.  Age greater than 75 years and the presence of obesity or heart 
disease have been significantly associated with post-operative complications after 
surgery for stomach cancer (Kim et al., 2012; Park et al.; Kubota et al.). Comorbidity 
and advanced age are also associated with early postoperative mortality after surgical 
resection of stomach cancer, with some association found up to 90 days post-
operatively (van Gestel et al., 2012). 
However while a less aggressive treatment approach is often considered in the elderly 
or comorbid with stomach cancer, a less aggressive approach is not always indicated 
and may represent under-treatment (Saif et al., 2010). Chemotherapy, for example, is 
shown to be reasonably well tolerated and effective in controlling disease in the 
elderly (Kim et al., 2012).  A study of 1135 patients, of whom 5% were older than 70 
years of age, receiving chemotherapy at one Korean hospital aimed to investigate 
outcomes associated with receipt of chemotherapy. The study found that, neither age 
nor level of comorbidity (defined by the Charlson index - mild comorbidity vs. 
moderate/severe comorbidity) was a significant independent prognostic factor for 
survival.  Rather receipt of surgery, tumour grade and response to first-line 
chemotherapy were associated with survival (Kim et al., 2012).  Thus while each 
patient should be individually assessed, and treatment decisions and possible 
complications adequately discussed, neither chronological age alone, nor the presence 
of comorbidity, is necessarily sufficient reason to withhold treatment (Saif et al., 2010; 




Management and Treatment Guidelines  
Up until December 2013 New Zealand did not have guidelines to inform clinical 
practice or the level of service provided to patients with cancer.  However recognising 
the need for nationally coordinated and consistent care for cancer, the Ministry of 
Health (through working groups and expert advisors) developed national service 
provision standards for a number of key cancers, including for upper GI and 
hepatobiliary cancers (National HBP/Upper GI Tumour Standards Working Group, 
2013).  These are however management, rather than clinical, guidelines (National 
HBP/Upper GI Tumour Standards Working Group, 2013). 
A number of countries do have clinical guidelines, principally countries of the West 
and those Asian countries with particularly high incidence of the disease.  The key 
guidelines are listed in the table below (Table 1).   As discussed earlier there are 
controversies in the treatment and management of stomach cancer which tend to 
differ primarily between Asian and Western countries.  For example there are 
significant differences in the management and treatment of stomach cancer in Japan, 
the country with the highest incidence rates worldwide, over that of Western 
countries.  Controversy surrounds indications for treatment of early stomach cancer, 
the surgical approach taken and the extent of lymph node dissection.   Also, until 
recently the Japanese Gastric Cancer Association had its own staging system for 
stomach cancer preventing accurate comparison between studies carried out in Japan 
to those carried out in the West (Dicken et al., 2005).   
Table 1: International stomach cancer treatment or management guidelines 
Country Year  Guideline name Guideline focus 
Australia 2009 South Australia Upper Gastrointestinal Cancer 
Care Pathway (Department of Health, 2009) 




includes  consideration 









Guidelines for the management of 
oesophageal and gastric cancer (Allum et al., 
2002; Allum et al., 2011) 
Clinical Guidelines for 
oesophageal and 
stomach cancer 
Scotland 2006 Scottish Intercollegiate Guidelines Network 
(SIGN) 87.  Management of oesophageal and 
gastric cancer: A national clinical guideline 




includes a significant 
section on risk factors 
Wales 2005 
National Standards for Upper Gastro-intestinal 
Cancer Services (Cancer Services Coordinating 
Group, 2005) 




Europe 2010 Gastric cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Okines et al., 2010) 
A shorter clinical 
guideline on stomach 





Gastric Cancer Clinical Practice Guidelines in 
Oncology (TM) (Ajani et al., 2010) 
Clinical Guidelines for 
stomach cancer only 
Japan 2001, 
2010  
Japan Gastric Cancer Association: Gastric 
cancer treatment guidelines (Japanese Gastric 
Cancer Association, 2011) 
Clinical Guidelines for 
stomach cancer, not 
originally published in 
English 
Japan 2008 The Japanese guidelines for gastric cancer 
screening (Hamashima et al., 2008) 
Screening guidelines for 
stomach cancer  
Commonalities seen in Guidelines 
As already mentioned there are significant differences in the management and 
treatment of stomach cancer in Japan when compared to Western countries.  The 
following section highlights the commonalities regarding the management of stomach 




Diagnosis, Staging and Treatment  
In all Western guidelines, upper GI endoscopy is the procedure of choice to diagnose 
cancer of the stomach, while CT, endoscopic ultrasound and laparoscopy, used in 
combination, are recommended to provide the most accurate pre-operative staging 
information (Allum et al., 2011; National Health Service Scotland, 2006). 
Surgical resection is regarded as the mainstay of treatment in all countries.  All 
resections are recommended to be carried out in high volume specialized units by 
experienced Upper GI surgeons (Allum et al., 2011; National Health Service Scotland, 
2006; Cancer Services Coordinating Group, 2005; Department of Health, 2009).  The 
UK also recommends that surgeons and surgical units should be audited against 
national standards (Allum et al., 2011). 
The use of Upper GI Cancer Nurse Specialists is commonplace within the management 
of patients with stomach cancer in some countries (Allum et al., 2011; Department of 
Health, 2009) 
Multidisciplinary Teams 
The guidelines of the West have advised that treatment decisions for patients with 
stomach cancer should be carried out in the context of multi-disciplinary team 
meetings (MDM) since at least 2002 (Allum et al., 2002).  It is proposed that MDM 
comprise endoscopists, surgeons, medical and radiation oncologists, 
gastroenterologists, radiologists, pathologists and upper GI nurse specialists and that 
the team takes note of all available clinical information, the patients co-morbid 
conditions and general nutritional status, along with patient preference in their 
decision making.  The MDM should also have access to supporting services such as the 
primary health care team, psycho-oncology, social work and allied health professionals 
(Allum et al., 2011; National Health Service Scotland, 2006; Cancer Services 




Timeliness of Treatment 
Timeliness of treatment, where discussed, focuses more strongly on the initial phase 
of the patient journey. Both the UK and Australia recommend that patients at high risk 
of upper GI malignancy should have fast-tracked access to endoscopy investigation; 
this should be carried out within two weeks from initial presentation (Department of 
Health, 2009; Allum et al., 2011).  Once diagnosed, Australian guidelines recommend 
that staging investigations be completed within two weeks and initial consultation 
with a cancer specialist should also occur within two weeks (Department of Health, 
2009). Following the initial consultation discussion regarding the patient at MDM 
should take place no later than 42 days after initial presentation (Department of 
Health, 2009).  Wales recommends that definitive treatment should start within two 
months from receipt of referral at the hospital (Cancer Services Coordinating Group, 
2005).  
Summary of Stomach Cancer 
Stomach cancer, is a cancer that arises in the cells that form the innermost lining of 
the stomach.  It is the fourth most commonly diagnosed cancer worldwide and one of 
the most common causes of cancer mortality.   There is wide geographical variation in 
both incidence and mortality rates, with ten-fold difference between high-risk and 
low-risk populations noted, primarily due to different prevalence rates of infection 
with H. pylori and associated incidence of distally located tumours.  Stomach cancer 
rates worldwide have declined over the last 50 years but there has been a notable 
change in tumour site (a ‘proximal migration’) over recent decades, due to different 
risk factors for tumours located within different sub-sites of the stomach. 
Adenocarcinoma of the stomach is curable, if it is diagnosed at an early stage.  
However, many patients are diagnosed at an advanced stage and most countries 
report overall five-year survival rates between 10% and 30%.  Surgery is the mainstay 
of curative treatment but there remains ongoing debate regarding overall surgical 




dissection to be carried out, with general consensus in the West being that at least 15 
nodes should be resected.  There has been a growing role for chemotherapy with 
curative intent, with and without radiotherapy, over the last few decades.  Palliative 
care is an important part of overall patient management for stomach cancer.    
At the time that patients involved in this study were diagnosed and treated, New 
Zealand had no guidelines to inform clinical practice.  Service delivery standards 
intended to enable nationally coordinated, and consistent care, have been developed 
during the time of writing (National HBP/Upper GI Tumour Standards Working Group, 





The Structural and Institutional Mechanisms 
of Inequity 
In order to minimise inequities we must first have insight into the mechanisms by 
which they arise and are perpetuated.  Rather than blame Māori for their 
disadvantaged health status this thesis focuses attention on the structural and 
institutional mechanisms that drive the disadvantage.  Much of the stomach cancer 
inequity seen in in New Zealand today can be attributed to the social and economic 
position of Māori in current New Zealand society.  This position has been constructed 
by the shared histories of a predominantly British immigrant population and the 
indigenous Māori.  As with other indigenous people throughout the world, Māori have 
borne the brunt of colonisation.   
In essence, colonisation permits the (mis)appropriation and transfer of 
power and resources from indigenous peoples to the newcomers.   This 
process of transfer is enabled by layer upon layer of new systems 
established to determine how resources will be obtained and how they 
will be redistributed and to whom.  These systems, therefore, construct 
who will benefit and be privileged (Robson and Harris, 2007a).  
The Treaty of Waitangi 
The Treaty of Waitangi is recognised as New Zealand's founding document (Boulton et 
al., 2004; Orange, 2011).  The Treaty was an agreement between the Crown and 
Māori, offering peaceful settlement rights to the British in return for the Crown's 
protection.  When the Treaty was signed in 1840 Māori had a strong tribal identity and 
communal economy, reliant on the land on which they lived with sophisticated public 
health and law and order systems (Durie, 1998; Orange, 2011).  Life expectancy for 
Māori was estimated to be about the same as that of their European equivalents, 




For the British, the Treaty was to serve three primary needs: legal (to prove New 
Zealand's changed status to that of a British colony), diplomatic (to give British 
subjects entitlement to settle peacefully in New Zealand), and humanitarian 
(appeasing groups in Britain who were becoming increasingly concerned about the 
treatment of indigenous people worldwide) (Orange, 2011).   
The motivation for Māori to sign the Treaty is less clear. What is clear is that the Māori 
response was not universal, with some Chiefs refusing to sign the Treaty at all.   It 
appears though that Māori hoped to gain British protection of their country against 
claims by other nations.  Māori were especially distrustful of the French due to a 
previous massacre in 1772 (Orange, 2011).  They also wanted some control of British 
settler’s land purchases and Pākehā lawlessness; now British law would govern the 
British people.  Māori expected an increase in trade, Māori were already proficient 
traders and though collective efforts dominated key sectors of New Zealand economy 
for some time after signing the Treaty.  They wanted protection of, but control over, 
their lands, mana and customs. They saw shared authority, a partnership and 
participation by Māori and the British.  They did not intend to hand over all rights of 
sovereignty to the British people or British Crown (Orange, 2011).    
The Treaty was written by a Crown representative with no formal legal training and 
translated into Māori by missionaries.  Unfortunately there were substantial 
differences between the English and Māori texts (Orange, 2011).  These differences 
remain the focus of much debate today (Boulton et al., 2004).  The Treaty allowed for 
British governance, provided guarantees to Māori relating to property rights, 
conferred citizenship rights on individual Māori people and, in the Māori version at 
least, allowed for continued tribal authority (Durie, 2005).   Central to the Treaty was 
the establishment of government, a government that looked after and protected all of 
its citizens (Reid, 1999a).  Initially the aims of the Treaty were heeded by the Crown.   
Yet the Treaty was increasingly marginalised as the years went on and in 1877 the 
Treaty was declared ‘a simple nullity’ in a court of law and abandoned by the Crown 




Treaty would be written into New Zealand legislation and again formally considered by 
the Crown (Orange, 2011). 
Colonisation 
The signing of the Treaty of Waitangi marked the beginning of a formal relationship 
between Māori and their British colonisers.  In reality, it was through a combination of 
this Treaty along with processes of colonisation that the sovereignty of New Zealand 
moved from the hands of Māori into the British Empire (later Commonwealth) 
(Orange, 2011; Durie, 1998).  These processes of colonisation included: settler 
occupation, depopulation of Māori via the introduction of firearms and diseases, 
policies of assimilation, land acquisition, the use (or misuse) of parliamentary 
representation to ensure Māori had no voice in the making or administration of law 
and organised military suppression of Māori resistance (Orange, 2011; Durie, 1998; 
Koea, 2008).  Throughout this time new systems and institutions were established, 
based on British models, which determined how the resources of Aotearoa New 
Zealand were obtained and distributed and in which Māori interests were often 
excluded or marginalised  (Sinclair, 2000; Orange, 2011; Ministry for Culture and 
Heritage, 2014; Pihama et al., 2004).   
The consequences of the processes of colonisation left Māori as the minority 
population, displaced from their land, their culture and their language and with little 
sway over how colonial New Zealand was administered (Orange, 2011; Durie, 1998).  
Unsurprisingly inequities existed between Māori and non-Māori and Māori health 
suffered (Durie, 1998).   
The Modern Welfare State 
New Zealand's welfare state was introduced in the 1930s, partly in response to the 
‘great depression’ of previous years (Belich, 2001).  It provided tax funded income 




and free education and health systems, although secondary not primary care (O'Brien, 
2008).  Modern New Zealand society, at least Pākehā society, was built on values of 
democracy, equality, full employment and an interventionist state with universal state 
assistance for those in need.  In fact, until the neoliberal reforms of the 1980s and 90s 
markedly changed New Zealand society, the government intervened in nearly all 
aspects of New Zealanders’ lives: housing, health, education, finance, transport, 
telecommunications, forestry, farming and more (Bassett, 1998; Boston, 1999; 
O'Brien, 2008).    
While not targeted toward Māori this state intervention was generally good for all 
New Zealanders, including Māori.  Mortality trends, including infant mortality and life 
expectancy are useful ways of measuring the health status of a population overall and 
in determining equity between groups within that population.  Between the 1940s and 
60s the life expectancy of the New Zealand population overall rose steadily and a 
sharp reduction in the difference between Māori and non-Māori mortality occurred 
(Woodward and Kawachi, 2000).  Life expectancy for Māori increased so rapidly over 
this time that up until the early 1980s the gap between Māori/non-Māori life 
expectancy was closing (Ajwani et al., 2003).  Infant mortality rates dropped markedly 
for Māori from 94 per 1000 live births in 1929 (Durie, 2001) to 18.4 per 1000 in the 
early 1980s (Pōmare et al., 1995).  Despite this dramatic reduction, Māori infant 
mortality remained high compared to the non-Māori rate of 11.4 per 1000 in the early 
1980s (Pōmare et al., 1995). 
Urbanisation 
Urbanisation, following the World Wars, created immense social dislocation among 
Māori.  Whānau ties were broken and many Māori became further alienated from 
their land and culture (Durie, 1998).  Before World War II, over 80% of Māori were 
living in rural areas, primarily within their own tribal districts; however following 
World War II Māori migrated to the cities in large numbers.  With little Māori-owned 




time employment opportunities were becoming centralised in major cities (Te Ahu 
Poata-Smith, 2013).  This relocation was though also due to explicit government 
policy; after the 1961 Hunn Report made recommendations on social reforms for 
Māori the relocation of Māori in cities became official policy (Durie, 1998; Orange, 
2011).  However, employment opportunities for Māori were often limited to low-
paying blue-collar jobs and they lived in poor quality overcrowded houses in 
communities often separate from those in which Pākehā lived.  Although the 
prevailing view by Pākehā was one of a class-less New Zealand, compared to non-
Māori Māori occupied a relatively impoverished and peripheral place in New Zealand 
society (Te Ahu Poata-Smith, 2013).  
Māori Resurgence 
During the 1970s and 80s Māori development was gaining momentum and the Treaty 
of Waitangi was elevated in New Zealanders thinking (Reid, 1999b).  Māori women 
and health workers were becoming better organised.  Holistic Māori models of health 
were being developed by Māori, moreover they were acknowledged in mainstream 
services (Durie, 1998).  Māori language nests or Kohanga Reo were established helping 
to not only improve participation rates of Māori in early childhood education but also 
to revive the Māori language (Durie, 2001).  Although initially established with ‘limited 
power’ the Waitangi Tribunal was set up in response to Māori demands for reparation 
for land-loss and began to restore resource to Māori communities (Orange, 2011).  
Māori protests were heard throughout the country; most notably the 1975 Hikoi or 
Land-March and the 1977 occupation of Bastion Point.  Gone were the ‘Pākehā’ 
perceptions of harmonious race relations and an absence of class based inequity.  
Mainstream New Zealand was at last beginning to hear Māori dissent about the Treaty 




Neo-Liberalism and Market-based Reforms  
It is said that "the fourth Labour Government came into office in 1984 with a greater 
commitment to the Treaty of Waitangi than any Government previously" (Durie, 1998: 
88).  The Waitangi Tribunal was given the power to consider historical claims, those 
going back until 1840, not only contemporary claims as originally directed to do 
(Orange, 2011).  State departments were required to consult with Māori and consider 
applications for the Treaty in all legislation (Durie, 1998). The Department of Health 
was one of the first to respond by establishing Māori health as a priority, including 
Māori viewpoints in its policy and by forming Māori specific teams and committees.  
The 1988 Treaty principles recommended by the Royal Commission on Social Policy, 
those of partnership, participation and protection, better enabled the application of 
the Treaty in practice. Still, a gap persisted between recognition of the Treaty and its 
translation into performance indicators, outputs and Māori health gain (Durie, 1998).   
Structural Readjustment 
The fourth Labour Government also inherited a country that had long been living 
beyond its means (Kelsey, 1995).  So in 1984 an exercise began to change the 
involvement of the state in most aspects of New Zealand life, "one hundred and forty-
four years of interventionism had run its course"(Bassett, 1998: 14).  
Informed by the Washington consensus for structural adjustment and driven by 
neoliberal ideology, New Zealand went from being one of the most regulated and 
interventionist countries within the 34 Organisation for Economic Cooperation and 
Development countries (OECD) to one of the most deregulated and privatised, all 
within a timeframe of less than two decades (Kelsey, 1995).   Control of inflation was 
given priority over all policy decisions; the finance sector was deregulated, the New 
Zealand dollar floated, tariffs on imports reduced and subsidies to domestic industries 
removed.  State owned enterprises were downsized or turned into commercial 




enterprises and existing companies bought by international enterprises.  The labour 
market was restricted.  The vision of creating economic growth and employment in 
fact brought restructuring, loss of jobs and services and profits leaving the country.  
Compounding this, the income tax system was flattened, a regressive consumption tax 
(GST) introduced, user charges introduced for health and education, government 
benefits cut and more strictly targeted and market rentals introduced for state 
housing (Kelsey, 1995; Belich, 2001).   
The impacts of these free-market policies were not however evenly distributed 
throughout New Zealand society.  In response to the changes so rapidly imposed upon 
New Zealand, Māori leaders at Hui Taumata (Māori Economic Summit) in 1984 
predicted that “Māori will be the shock absorbers of the economy” (Blakely et al., 
2004).  These fears were borne out.   
Māori Inequity 
In conjunction with these economic and social reforms throughout the 1980s and 90s, 
New Zealand also experienced the fastest increase in income inequity of any OECD 
country (Woodward and Kawachi, 2000).  While income inequities were seen, up until 
1984 the divide between rich and poor was not conspicuous.  That situation changed 
markedly under neoliberal ideology though, impacting most heavily on Māori.  Māori 
were overrepresented in the job sectors where most job losses occurred (Kelsey, 
1995).  Between 1986 and 1990 the unemployment rate for Māori increased from 
8.5% to 20.6%.   The corresponding rate from non-Māori rose from 3 to 6.5% (Reid, 
1999a).   
Employment did not necessarily provide a buffer though with the spending power for 
the wealthiest 20% of New Zealand’s employed rising by 7% between 1987 and 1992.  
At the same time it fell by 2.9% for the poorest 20%, the section of society where 
Māori were more highly concentrated (Kelsey, 1995).    By 1996 Māori were much 
more likely to be economically deprived with an average income less than 80% of the 




be living in a household whose income was within the lowest 20% (28% Māori versus 
17% European) and less likely to be living in households in the top 20% (9% Māori 
versus 21% European) (Howden-Chapman and Tobias, 2000).  Moreover, during this 
time inequity between Māori and non-Māori widened in all areas that are considered 
to be key underlying determinants of health; not only employment and income but 
also indicators of educational attainment and healthy housing (Howden-Chapman and 
Tobias, 2000). 
Māori Health Inequity 
Not surprisingly Māori health was also affected over this time.   Māori life expectancy, 
which had been rising rapidly and converging with the non-Māori rate up until the 
1980s, began to plateau while non-Māori continued to experience increases in life 
expectancy (Ajwani et al., 2003).  From the 1980s the gap between Māori and non-
Māori for this important population health indicator began to widen as did inequities 
in mortality from ischaemic heart disease, diabetes, chronic lung diseases and a 
number of cancers (Ajwani et al., 2003).  In a telling indicator of increasing ‘social dis-
ease’, suicide rates rose markedly over the 1980s and 90s, especially among young 
Māori men.  Where previously 25 – 44 year old Māori men were 22% less likely than 
non-Māori to commit suicide, by 1996 – 99 they were 70% more likely to (Ajwani et 
al., 2003).  In fact suicide rates rose so much that by the 1990s New Zealand was 
experiencing some of the highest rates in the OECD (Kelsey, 1995).  As summed up by 
Reid (Reid, 1999a: 93) “Premature death is the ultimate cost for being on the losing 
side of social change”. 
Restructuring the Health System 
The health system was also significantly restructured during this period of economic 
and social reform.  It underwent four major changes within 20 years.  The health 




the most radical health sector restructurings witnessed anywhere in the world” 
(Gauld, 2001: 79).  The system from 1993 until 1996 was characterised by a purchaser 
and provider split.  There were expectations on the health system to run as a business 
and return profits to the Government.  Government appointed boards replaced 
formerly elected ones.  Board members and Chief Executive positions were populated 
by businessmen, often with little health sector experience (Gauld, 2001; Cumming and 
Mays, 2002).  The education and social housing systems underwent similar 
commercialisation reforms (Te Ahu Poata-Smith, 2013).   
While the focus of the health reforms was on fiscal restraint rather than improved 
health outcomes, one arena where Māori were able to gain traction over the time of 
the purchaser/provider split and contestable contracts was that of primary health care 
delivery (Reid, 1999b; Cunningham and Durie, 1999).  The number of Māori providers 
increased quickly from just 30 in 1993 to over 200 in 1997 (Cunningham and Durie, 
1999).  Although limited by issues such as instability of contracts, lack of consistent 
policy, changing personnel in government agencies, varying approaches to Māori 
health around the country and still receiving a very small amount of the health 
budget, the growth of ‘by Māori for Māori’ providers offered a real opportunity to 
address Māori health issues in ways likely to be acceptable to many Māori 
(Cunningham and Durie, 1999). 
Personal Responsibility 
Another feature of this era of neo-liberalism was the moving of political attention 
from population health to individual health, from public health to private medicine.   
Health in effect became an individual responsibility where people were blamed for 
their ill-health.  Differences in health were attributed to ‘self-inflicted lifestyle choices’ 
(Durie, 1998).  Mainstream media supported the view “… with an editorial that 
described the first cause of poverty as ‘a culture of personal irresponsibility’’’ (Kelsey, 
1995: 380).  The 2003 report Decades of Disparity (Ajwani et al., 2003) clearly outlined 




expectancy over the time of significant social and economic reform in New Zealand.  
Media coverage however framed the reasons as poor choices and behaviours by 
Māori, portraying Māori as responsible for their own ill-health (Hodgetts et al., 2004).  
Public discourse largely concurred, and continues to concur with this view, ignoring 
the histories of Māori and non-Māori in New Zealand and the influence of these 
histories on Māori and their access to the underlying determinants of health (Nairn, 
2011; Nairn et al., 2014; Rankine et al., 2014).  And despite stark evidence of 
Māori/non-Māori inequity public discourse also often expounded the view that Māori 
are ‘privileged’ and that they ‘benefit’ from Treaty settlements and targeted initiatives 
intended to close gaps between Māori and non-Māori  (Te Ahu Poata-Smith, 2013). 
Summary of the Mechanisms of Inequity 
Māori have suffered greatly through the impacts of colonisation.  Deliberate policy 
decisions leading to loss of Māori control and authority, loss of language, loss of 
identity as Māori and cultural breakdown, social dislocation from loss of land and 
urbanisation, alienation from physical resources, limited access to society’s wealth and 
organised oppression all combined to make Māori vulnerable (Orange, 2011; Durie, 
1998).  The position of Māori was then compounded through neoliberal policies 
applied by successive governments from 1984 through the 1990s (Te Ahu Poata-
Smith, 2013; Kelsey, 1995).  Widening inequities between Māori and non-Māori were 
a predictable outcome of the neoliberal reforms initiated in New Zealand from 1984.  
Inequity between Māori and non-Māori widened in all areas considered to be 
underlying determinants of health as a consequence of the reforms of the 1980s and 
1990s (Kelsey, 1995; Reid, 1999a).  Not surprisingly Māori health also suffered (Blakely 




The Position of Māori and non-Māori in 
Current Society 
According to the 2013 census (Statistics New Zealand, 2014) the total population of 
New Zealand has surpassed 4.5 million, with Māori comprising 598,602 or 
14.9 percent.  New Zealand Europeans remain the majority population at 68 percent 
although there are sizeable Asian (12%) and Pacific Island (7%) populations.   Māori 
are a youthful population; their median age at 23.9 is significantly lower than that of 
New Zealand Europeans at 41 years, or the total non-Māori population at 38 years.    
Most New Zealanders live in urban centres with over 65 percent of both Māori and 
non-Māori living in urban areas (Statistics New Zealand, 2014).  Māori are more likely 
to live in minor urban or rural areas (Robson and Harris, 2007a), especially in 
Northland or the east coast of the North Island.   English is the most commonly spoken 
language but over 20 percent of Māori also speak Te Reo (the Māori language) 
(Statistics New Zealand, 2014).    
However Māori today continue to be significantly disadvantaged in New Zealand 
society – a pattern which holds true in educational attainment, employment, income 
and housing, all of which are considered underlying determinants of health (Craig et 
al., 2014; Commission on Social Determinants of Health, 2008; National Health 
Committee, 1998).  In turn, Māori are ultimately disadvantaged in most indicators of 
health (Robson and Harris, 2007a; Durie, 2001).    
Educational Attainment 
Māori are now more likely to participate in education at all levels (Robson and Harris, 
2007a).  Through the development of Kohanga Reo, Kura Kaupapa and Wānanga a 
Māori-focussed total immersion education is possible, from early childhood through to 
tertiary level.  Despite the achievements of Māori-based education the majority of 




achieve equitable results for Māori (Robson and Harris, 2007a).  The 2013 census 
showed that 66.7% of Māori (aged 15 years and over) had some sort of a formal 
qualification.  While this was an increase from previous years it remains lower than 
the 78.7% of New Zealand Europeans who had a formal qualification.  At a higher 
level, 10% of Māori had a Bachelor’s degree or higher compared to 20% of the total 
population (Statistics New Zealand, 2014).  In other indicators such as school retention 
rates, unjustified absences, and numbers of suspensions or expulsions Māori do poorly 
compared to non-Māori.  Clearly the education system does not meet the needs of 
Māori (Craig et al., 2014).  Level of educational attainment is an important 
determinant of health as it is a critical precursor to future employment and 
occupational status and thus to level of income.  Evidence suggests that people with 
university qualifications earn 62% more over their lifetime than those who don’t have 
university qualifications (Robson and Harris, 2007a). 
Employment and Income 
Māori are much more likely to be unemployed with an unemployment rate of 15.6% 
compared to 5.4% of New Zealand Europeans.  Māori youth are particularly burdened 
with less than half of 15 – 29 year old Māori employed (Statistics New Zealand, 2014).  
Uptakes of the domestic purposes, sickness and invalids benefits are all higher for 
young Māori relative to non-Māori (Craig et al., 2014).  When employed Māori remain 
more likely to be in low-paid occupations and experience discrimination in the labour 
market in a number of ways: getting a job, the type of job gained and in wages paid 
(Robson and Harris, 2007a).    
Correspondingly the income gap between Māori and non-Māori remains sizable.   The 
median income for Māori adults (15 years and older) in 2013 was $22,500 compared 
to $30,600 for New Zealand Europeans (Statistics New Zealand, 2014).  Māori are 
much more likely to live in a household in the lowest income quintile (25% compared 
to 12% of non-Māori).  Children are particularly affected.  In 2004, 27% of Māori 




median, after housing costs) compared to 16% of European children (Robson and 
Harris, 2007a).   Child poverty appears to be worsening, especially for Māori.  By 2010 
– 2012 (using the same measure as above) 34% of Māori and 17% of European 
children were living in poverty (Craig et al., 2014). 
Although income inequity between Māori and non-Māori in New Zealand fell between 
2004 – 2007, in part due to the ‘Working for Families’ tax credits, it has begun to 
increase again since (Craig et al., 2014).  The Working for Families package has 
however been criticised for disadvantaging Māori children.  Working for Families is a 
‘Welfare to Work’ policy which excludes beneficiary families, yet in today’s unstable 
job market Māori are more likely to be beneficiaries (Robson and Harris, 2007a).   In 
another area of disparity, as Māori have lower levels of asset wealth than non-Māori 
they are more reliant on wage income for financial security and thus are doubly 
disadvantaged by differential employment and income (Robson, 2008).   
Māori figure highly in criminal justice statistics. There is however also evidence of 
discrimination in the justice system.  For example more Māori are referred to the 
youth court rather than for family intervention for minor offences and have higher 
rates of conviction than non-Māori despite similar offending records and 
socioeconomic backgrounds (Robson and Harris, 2007a).   
Housing 
Housing is also an important determinant of health with household crowding, poor 
housing conditions and insecure tenure all shown to impact on one’s level of 
wellbeing (Robson and Harris, 2007a).  In 2013 only 28.2% of Māori stated that they 
owned or partly owned the home that they lived in.  Fifty-three percent of Māori lived 
in rental accommodation with a significant proportion of them (20%) having the 
government as their landlord through Housing New Zealand (a Crown agency that 
provides housing for New Zealanders in need).  In comparison 57.4% of New Zealand 
Europeans owned their own home and of those that rented only 7.5% had Housing 




discrimination in the housing market, both when renting and when buying houses 
(Harris et al., 2006a). 
Household crowding is also unevenly distributed in New Zealand with children and 
Māori much more likely to live in crowded housing than adults or non-Māori (Baker et 
al., 2012).  2006 Census data shows that 22.8% of Māori lived in crowded conditions 
compared to just 4.7% of European/Other.  Māori children are further exposed, with 
10.1% Māori children younger than five years living in extremely crowded conditions 
versus only 1.9% of European/Other.  In other words Māori children are five times 
more likely to be living in conditions that contribute to poor health, not only in 
childhood but throughout their lifetime (Baker et al., 2012).   Māori children are 
doubly impacted by socioeconomic status as the proportion of children living in 
crowded households increases as each level of deprivation increases, with the highest 
rates in the most deprived households (Craig et al., 2014). Additionally, the relative 
differences in household crowding between Māori and European New Zealanders 
have increased over time (Baker et al., 2012).  
Health  
As shown above the social and economic position of Māori in today’s society is 
different to that of non-Māori.  Māori are predominantly disadvantaged, non-Māori 
are advantaged.  Given the unequal exposure between Māori and non-Māori to the 
upstream determinants of health the most pronounced inequities in health and health 
outcomes seen in New Zealand today are those between Māori and non-Māori.  
According to Durie (Durie, 2005) there is considerable evidence that structural causes 
account for health inequities.  Furthermore much of the burden of ill health 
experienced by Māori is not only preventable; it breaches the human right to good 
health.  It is also costly; not only to the health system, but to society as a whole (Craig 
et al., 2014). 
Māori are more likely to be obese than their non-Māori counterparts.  In 2011 – 2013 




non-Māori despite similar levels of physical activity (Ministry of Health, 2013c).  Food 
security (having enough nutritionally adequate food for a healthy life at all times) is 
much poorer for Māori with only 34.8% of Māori identified as being of fully or almost 
fully food secure compared with 64.2% of New Zealand Europeans (Stevenson, 2012).  
In keeping with the finding that Māori have poorer food security they are less likely 
than non-Māori to eat the Ministry of Health recommended three serves of vegetable 
or two serves of fruit a day (Ministry of Health, 2013c). 
Māori adults are twice as likely to smoke relative to non-Māori (Ministry of Health, 
2013c).   Findings of the 2013 census showed 32.7% of Māori 15 years and over were 
regular smokers versus 14.1% of New Zealand Europeans.   Māori women continue to 
have the highest rates of smoking at 34.7% (Statistics New Zealand, 2014).  
Unsurprisingly second-hand smoke and maternal exposure is also higher for Māori 
children (Craig et al., 2014).  
Immunisation coverage rates for Māori children are lower than those of non-Māori.  
Well child visits (Government funded home visits by registered nurses for babies in the 
early weeks, and then clinic or further home visits for children up to 5 years old) for 
Māori babies are less than those of non-Māori (Craig et al., 2014).     Admissions for 
injuries arising from assault in Māori infants 0 – 4 years old and Māori young people 
are significantly higher when compared to non-Māori.  Alcohol related hospital 
admissions are significantly higher for young Māori than young non-Māori.  Both self-
harm and suicide mortality rates are also significantly higher in Māori youth compared 
to non-Māori (Craig et al., 2014). 
Currently Māori have an 8–9 year lower life expectancy than non-Māori and 
experience differential incidence and outcomes across most major chronic diseases, 
cancers, infectious diseases, and injuries (Harris et al., 2006b; Robson and Harris, 
2007a).  Many of these gaps exist even after controlling for factors such as level of 
deprivation and health care access, so no matter their occupation, level of income or 
education Māori have poorer health status than non-Māori.  What is more, not only is 




between Māori and non-Māori increase as level of deprivation increases (Ajwani et al., 
2003; Jansen et al., 2008).  
One consequence of the unequal distribution of the determinants of health is that 
Māori today have much higher exposure to the risk factors for developing stomach 
cancer, key of which are poverty and subsequent household crowding leading to an 
increased prevalence of H. pylori infection, tobacco smoking and poor diet.  It follows 
then that Māori also have a much higher incidence of stomach cancer than their non-
Māori counterparts.  Māori are also less likely to survive their stomach cancer once 
diagnosed (Soeberg et al., 2012) with evidence of poorer access to and through health 
and cancer services (Cormack et al., 2005).  Cancer survival and health care access are 
discussed in the following chapters. 
The Role and Significance of the Treaty of Waitangi for 
Current Māori Health  
Although it was written and signed in 1840 the Treaty of Waitangi has considerable 
relevance in today's society.  While it is a product of British ideology regarding 
‘aboriginals’ of its time (Reid, 1999a), it is also referred to as an agreement written for 
the future (Durie, 1998).  The Treaty speaks to the rights and responsibilities of the 
New Zealand government (as the successor to the Crown).  It has implications for 
health and health policy today, especially policies regarding access to the underlying 
determinants of health, the role and accessibility of health services and health equity 
between Māori and non-Māori. 
In 1998 a key government report identified social, cultural and economic factors as the 
main underlying determinants of health for New Zealanders (National Health 
Committee, 1998).  These factors, most important of which are income and poverty, 
also include employment, education, housing, access to culture and social cohesion.  
These social, cultural and economic factors have a causal relationship to health by 
influencing exposure and vulnerability to health risks (Commission on Social 




behaviours such as tobacco smoking are more common among low socioeconomic 
groups as is a higher likelihood of working within unsafe working conditions or living 
within unhealthy housing (National Health Committee, 1998).    As previously outlined, 
through breaches of the Treaty and the process of colonisation Māori were left with 
uneven access to the resources and opportunities of New Zealand society.  This 
differential access was then compounded by the market-based reforms of the 1980s 
and 90s which disproportionately affected Māori communities in further breach of the 
Treaty’s promises.   
Just as the determinants of health can be negatively impacted on by policy decisions 
they can also be positively impacted on by government policy.  The New Zealand 
government has an obligation to address historical Treaty breaches and to ensure 
current policy enables Māori to participate equally in the benefits of New Zealand 
society and so reduce health inequity (Baragwanath, 2006).  Today the Treaty is 
recognised within New Zealand legislation (New Zealand Parliament, 2000; New 
Zealand Government, 1988; New Zealand Government, 1987).  The Waitangi Tribunal 
(a permanent commission of inquiry) is helping to redress current and historic Treaty 
breaches (Stokes, 1992; Shoebridge and Tribunal, 2012) and the Treaty been 
interpreted and applied within key government policy (King, 2000; King, 2001; 
Ministry of Health, 2002b), in particular social and health policy (Barrett and Connolly-
Stone, 1998; Pōmare et al., 1995; Oda and Rameka, 2012).  
The Treaty also has relevance for the accessibility of health services and their role in 
addressing the health needs of Māori (Pōmare et al., 1995).  In keeping with the 
principle of tino rangatiratanga (or self-governance) Māori governed health services 
have improved access to services for many Māori, particularly in the primary health 
setting (Cunningham and Durie, 1999).  Still the majority of Māori access their health 
services through mainstream providers (governed by New Zealand government and its 
entities) (French et al., 2001), this is especially so for cancer treatment services which 
are primarily delivered through mainstream hospitals and clinics.  In order to address 
the health needs of Māori these services need to ensure they are accessible and 




Despite a higher awareness of the Treaty in contemporary New Zealand its place in 
society has remained contentious since its signing, at times many Pākehā (including 
judicial courts and the New Zealand Government) have ignored the Treaty or 
breached its guarantees (Orange, 2011).   Māori however see the Treaty of Waitangi 
as the basis of their partnership with the State; a binding agreement between tangata 
whenua and the Crown (Reid, 1999b; Durie, 1998; Orange, 2011).  Article Three of the 
Treaty guarantees Māori equity with British subjects.   That equity has been 
interpreted as equity of resource control, equity of representation and participation in 
society and equity of health outcomes (Reid, 1999b; Pōmare et al., 1995; Barrett and 
Connolly-Stone, 1998).   Quite clearly Māori have not shared equitably in New Zealand 
society over the years since signing the Treaty.  Nor do they now.  
Summary the Position of Māori in Current Society 
Māori today comprise nearly 15% of New Zealand’s population with Europeans the 
majority ethnic group.  Māori are on average younger (Statistics New Zealand, 2014) 
and are more likely to live in minor urban or rural areas (Robson and Harris, 2007a) 
than New Zealand Europeans.   The Treaty of Waitangi remains the founding 
document of New Zealand and while article three guarantees that Māori will share 
equally in society quite clearly Māori do not share equally, or equitably, in current 
New Zealand society.  Māori today live in social disadvantage with differential access 
to the underlying determinants of health.  Māori are more likely to face discrimination 
in the labour (Robson and Harris, 2007a) and housing markets (Harris et al., 2006a).  
They experience differential outcomes in education (Statistics New Zealand, 2014; 
Craig et al., 2014), employment (Statistics New Zealand, 2014; Craig et al., 2014), 
justice (Robson and Harris, 2007a) and housing (Statistics New Zealand, 2014; Baker et 
al., 2012).  Māori also have poor health relative to non-Māori New Zealanders (Robson 
and Harris, 2007a; Ministry of Health, 2013c; Harris et al., 2006b).  They are 
disproportionately impacted on by a large number of diseases, including stomach 




The New Zealand Health Care System  
New Zealand’s political, economic and social systems, including its health care system, 
were built on a British model (French et al., 2001) that mainstreams Pākehā and 
requires non-Pākehā to adapt to its language, culture and protocols.  New Zealand’s 
health care system is primarily one of universal access.  However it is characterised by 
a publicly funded hospital sector with a government subsidised but private fee-for-
service primary health care sector (French et al., 2001).  This structure can lead to low 
use of primary health services and a correspondingly high use of secondary services, 
especially for Māori (Durie, 1998).  Additionally there is much evidence outlining 
differential access to, and quality of care for, Māori across all parts of the health 
system, including cancer care - which will be discussed in a later chapter.  The section 
below provides a brief overview of the current structure of the health care system in 
New Zealand and outlines the key strategies relevant to Māori health and cancer 
control.   
The Funding and Delivery of Care 
Health care in New Zealand is funded and organised by an interrelated network of 
organisations.  Nationally the Ministry of Health provides advice to the Minister of 
Health on health issues, develops policy and works with other government agencies to 
implement those policies (Ministry of Health, 2013d).   Recently a National Health 
Board has been established as an independent body, although sited within the 
Ministry of Health, to monitor, fund and organise New Zealand’s 20 district health 
boards (DHB) and to service a National Health IT Board and Health Workforce New 
Zealand (Gauld, 2012; Ministry of Health, 2013d).   Other national organisations 
include PHARMAC, a national drug purchasing agency, a Health Quality and Safety 
Commission and an independent National Health Committee that carries out 




Health care delivery in New Zealand is primarily a mix of publicly and privately funded 
mainstream providers, along with non-government organisations (NGOs).  Around 
81% of health services are publicly funded with general taxes contributing around 88% 
of this cost with New Zealand’s accident compensation scheme (ACC) and local 
government comprising the remainder.  Private co-payments are required for primary 
care services and pharmaceuticals while patients bear the full-cost of privately 
provided dentistry, elective surgical and allied services.  Private health insurance tends 
to provide supplementary rather than comprehensive cover and is held by 35% of the 
population (Gauld, 2012).  The proportion of New Zealanders holding private health 
insurance differs by ethnicity with coverage in Māori about half of that of non-Māori 
(Ministry of Health, 2008).   Medical insurance cover also decreases with increasing 
deprivation (Ministry of Health, 2008).  New Zealand spends (USD) $2983.00 per 
capita per annum on health well below the OECD average of (USD) $3233 (Gauld, 
2012). 
The 20 regional DHBs plan, manage, purchase and provide health services for their 
populations.  They are responsible for primary care, hospital services, public health 
services, aged care services, and services delivered by non-governmental health 
providers, including Māori and Pacific providers within their geographical boundaries 
(Ministry of Health, 2013d; Cumming et al., 2014).  Despite this publicly funded health 
system, not all hospitals can offer the same level of services as each DHB manages its 
own budget and has differing financial thresholds for services (McLeod et al., 2004). 
Performance indicators are used to assess the performance of each DHB against set 
targets with significant differences in performance between DHBs evident (Cumming 
et al., 2014).   
Māori representation in health governance is increasing with DHB boards now 
comprised of a mix of elected members and members appointed by the Minister of 
Health and a requirement to have at least two Māori representatives.  DHBs are also 
required to involve Māori in service delivery, and to build Māori capacity in the health 




Primary Health Care 
Thirty six primary health care organisations (PHOs) and a number of newly developed 
Integrated Family Care Centres provide the bulk of primary care services with General 
Practitioners (GPs) acting as a first point of contact with the health system and as 
gatekeepers to secondary and tertiary services.   The move to organise primary care 
providers into PHOs in the early 2000’s was intended to make primary care more 
accessible and less costly (King, 2001; Cumming et al., 2014).  Capitated funding of 
PHOs based on an enrolled population replaced the former fee-for-service 
government subsidy.  As with DHBs, PHOs are required to include Māori 
representation on their boards of governance.  They must also develop services that 
reflect the priorities and needs of their enrolled population and pay particular 
attention to health outcomes for Māori within the populations they serve (Ashton, 
2005; King, 2001; Cumming et al., 2014). 
Māori Health Providers 
Most health care in New Zealand is delivered through mainstream or Pākehā-centred 
services (French et al., 2001).    Until recent decades there has been almost no Māori 
involvement in decision making within the health sector.  Māori input within 
mainstream has improved recently though with changes such as the requirements for 
Māori representation on DHB boards.   In conjunction with these changes in 
mainstream the development of Māori health providers since the 1980s has enabled 
many iwi (tribe or tribal organisation) to attend to their own health needs and 
participate in the planning of future development of Māori health (Durie, 2001).   
There are now a large number of Māori health providers contracted to DHBs 
throughout New Zealand.  These organisations are unique in that they are Māori-led 
and operate from a kaupapa Māori framework; their services are integrated with 
Māori culture and are based on Māori aspirations and thus are more likely to be 




deliver primary health care services only with secondary and tertiary care remaining 
the domain of mainstream organisations.  Māori providers also tend to deliver health 
and disability services to a largely Māori client base, although access is not limited 
solely to Māori clients.   There is evidence that Māori health providers have increased 
access to care for many Māori however the majority of Māori continue to access 
health care through mainstream organisations (Robson and Harris, 2007a).   Thus it is 
imperative that mainstream providers ensure their services are accessible and 
acceptable to all New Zealanders.  
Māori Health Workforce 
Even with advances in bringing health into a Māori context, which has included an 
emphasis on Māori health workforce development, Māori remain significantly 
underrepresented in all parts of the health workforce (Durie, 1998). Despite a 
population comprising nearly 15% of the total New Zealand population, Māori make 
up 5% of the national health workforce overall (Durie, 2005).  Within the regulated 
health professions, Māori comprise only 7% of all active registered nurses, 3.1% of 
dieticians, 2.9% of medical radiation technologists, 2.6% of medical practitioners and 
2.1% of dentists (Ministry of Health, 2007).  The more a health worker is able to 
appreciate the cultural needs of clients the greater the opportunity is for effective 
health care (Boulton et al., 2004; Durie, 1998), thus having proportionately too few 
Māori in the health workforce can exacerbate health inequity (Boulton et al., 2004).    
Cancer Treatment Services 
Detection of cancer is often initiated within the primary health care sector in New 
Zealand.  Some cancer support and navigation services are provided by Māori health 
providers but cancer treatment is provided solely through mainstream secondary or 
tertiary health services.  District Health Boards are the major funder of cancer 




cancer related activity within their District Annual Plans (Cancer Control Taskforce, 
2005).  Diagnostic and surgical treatment services are provided by DHBs throughout 
the country. Medical and radiation oncology are provided through six regional cancer 
treatment services sited in Auckland, Hamilton, Palmerton North, Wellington, 
Christchurch and Dunedin.  These six regional cancer treatment services also offer 
specialist appointments and medical oncology services through peripheral clinics in a 
number of smaller centres.  
Private health services in New Zealand deliver specialist secondary health care, 
concentrating mainly on elective surgical services (French et al., 2001; Cumming et al., 
2014).  Many surgeons and specialists in New Zealand practice in both the public and 
private health systems (Cumming et al., 2014).  The delivery of cancer treatment 
within the private sector has increased over the last decade.  It is now possible to 
receive not only cancer related surgery but also medical and radiation oncology 
treatment privately, although the latter is limited to a small number of providers.  Of 
note the majority of treatment for stomach cancer is provided by publicly funded 
health services rather than within the private sector. 
Recent Government Policy on Health Inequity and 
Cancer Control  
Health Inequity 
Although New Zealand health legislation began to recognise the Treaty of Waitangi 
and the need to reduce inequities within policy in the 1990s, the New Zealand Public 
Health and Disability Act of 2000 (New Zealand Parliament, 2000) is particularly 
significant.  The passing of the Act saw the Treaty of Waitangi incorporated within 
national legislation for the first time.  The Public Health and Disability Act provided 
mechanisms for Māori participation in decision making around resource allocation and 




responsibility for improving Māori health and reducing inequities (Boulton et al., 2004; 
New Zealand Parliament, 2000).   
A number of key strategies followed the New Zealand Public Health and Disability Act.  
All to some degree outline a commitment to ensuring equitable access to health 
services, to reducing inequities in the health of different population groups, and 
specifically to improving the health of Māori.  The partnership relationship between 
Māori and the Crown established under the Treaty of Waitangi is also recognised in 
these strategies. 
The New Zealand Health Strategy (King, 2000) and Primary Health Care Strategy (King, 
2001) both outline actions and priorities to improve the health of all New Zealanders 
including that of Māori.  The key strategy document for Māori health He Korowai 
Oranga (Ministry of Health, 2002b) built on these previous two strategies.  For the 
first time the health system was required to consider individual patients as part of a 
whānau (extended family, recognised as a foundation of Māori society), to attend to 
whānau ora (families supported to achieve health and wellbeing) and to take a 
multidisciplinary and wider social approach in their care (Boulton et al., 2004; Ministry 
of Health, 2002b).  
Whānau Ora has since been developed as a key government initiative, launched in 
2010 (Office of the Auditor-General, 2015).  Whānau Ora is not only a health initiative, 
rather it is a key cross-government work programme involving the Ministry of Health, 
Te Puni Kōkiri (Ministry of Māori Development) the Ministry of Social Development 
and other agencies.  The programme has defined whānau ora in a number of ways, as 
a philosophy, a model of practice, an outcome goal and a mechanism for funders 
(Taskforce on whānau-centred initiatives, 2010).  Essentially it is an approach that 
places families or whānau at the centre of service delivery requiring the integration of 
health, education and social services to improve outcomes for whānau (Office of the 
Auditor-General, 2015).   DHBs have been required to report on Whānau Ora activities 





The New Zealand Cancer Control Strategy (Minister of Health, 2003) and its 
accompanying Cancer Control Action Plan (Cancer Control Taskforce, 2005) were the 
first comprehensive Government policy documents on cancer control in New Zealand.   
These documents outline the dual purposes of reducing the incidence and impact of 
cancer and reducing inequities with respect to cancer.  They include specific reference 
to the Treaty of Waitangi and offer a framework to address New Zealand cancer 
statistics and inequities, especially those between Māori and non-Māori.   
One objective of the Action Plan (Cancer Control Taskforce, 2005) is to ensure 
appropriate programmes and services are accessible to Māori across the cancer 
control continuum, from prevention through to palliative care.  This accessibility is 
stated to also include policy, planning and funding, research and monitoring.   Outside 
of health, the Action Plan discusses addressing the underlying economic and social 
inequalities between Māori and non-Māori in New Zealanders. 
The Action Plan (Cancer Control Taskforce, 2005) also identifies the need to develop 
formal structures to enhance cooperation and collaboration for cancer control.  From 
this, four Regional Cancer Networks were developed in 2008 to work with the Ministry 
of Health and DHBs to facilitate and coordinate cancer services at all levels.   All 
Regional Cancer Networks have a stated and explicit commitment to improving Māori 
cancer outcomes and improving equity. 
The Ministry of Health leads the work within cancer control through a national work 
programme, which is guided by the New Zealand Cancer Plan: Better, faster cancer 
care 2015-2018 (Ministry of Health, 2014b).   The programme aims to reduce waiting 
times for cancer related appointments, investigations and treatment, to improve 
support for patients and their families and to standardise care pathways for cancer 
patients.   This work programme has an explicit focus on equity, stating that it aims to: 
improve cancer outcomes for all New Zealanders. This means that 
people, irrespective of their ethnicity, gender, locality or socio-




services that will reduce their risk of developing cancer, enable their 
cancer to be detected earlier as well as getting high-quality cancer 
treatment quickly (Ministry of Health, 2014b: 2).   
The work programme involves DHBs and the regional cancer networks and includes a 
number of key initiatives: 
 The ongoing development of, and service review against, national tumour 
standards for ten tumour types describing the level of service that a person 
with cancer should have access to, promoting nationally coordinated and 
consistent levels of service provision across the country. 
 A service improvement fund, with funding of $11.2 million over four years 
made available to support DHBs to deliver faster cancer treatment.  
 Improving the coverage and functionality of multidisciplinary meetings so that 
more patients benefit from a range of expert opinion and there is better 
continuity of care with less duplication of services. 
 Implementing the Cancer Nurse Coordinator Initiative so that patients who 
need more personalised support have access to a specialist nurse (Ministry of 
Health, 2014b: 6). 
Stomach Cancer Control 
New Zealand has two guidelines related to stomach cancer, one focuses on the 
primary care sector and the other on secondary and tertiary services.  In addition, 
surgeons performing surgery for stomach cancer in New Zealand have the option of 
joining the Australian and New Zealand Gastric and Oesophageal Surgical Association. 
Suspected Cancer in Primary Care 
Suspected Cancer in Primary Care released in 2009, advise primary care practitioners 
about the detection, investigation and referral pathways for a number of important 
cancers, including stomach cancer (New Zealand Guidelines Group, 2009).  In keeping 




guideline specifically advises the consideration of stomach cancer at a younger age 
(suggesting ten years earlier) when treating Māori patients compared to the general 
population. 
Service Provision Standards 
The Standards of Service Provision for Upper Gastrointestinal Cancer Patients in New 
Zealand – Provisional (National HBP/Upper GI Tumour Standards Working Group, 
2013) was released in 2013 as part of the better, faster cancer care 2015-2018 work 
programme.  The Standards provide advice to DHBs about the expected level of 
service delivery to patients with upper GI cancers (including stomach cancer) aiming to  
promote nationally coordinated and consistent standards of service provision across 
New Zealand, with a focus on equity.  The standards are outlined in ten separate 
areas: 
 Prevention and early identification. 
 Timely access to services. 
 Referral and communication. 
 Investigation, diagnosis and staging. 
 Multidisciplinary care. 
 Supportive care. 
 Care coordination. 
 Treatment. 
 Follow-up and surveillance. 
 Clinical performance monitoring and research. 
They are currently deemed to be provisional standards only and not mandatory for 
DHBs.  The expectation is that all DHBs will work with their respective Regional Cancer 
Network to review the delivery of services and outcomes against the level expected 




Australian and New Zealand Gastric and Oesophageal Surgery Association 
In 2006 the Australian and New Zealand Gastric and Oesophageal Surgical Association 
(ANZGOSA) was formed as a mechanism for improving the surgical management of 
diseases of the upper GI tract through: peer networking and support, fellowships and 
training opportunities, coordination of clinical research/audit and the development of 
clinical guidelines (Australian and New Zealand Gastric and Oesophageal Surgical 
Association, 2006).  
The ANZGOSA manages a clinical audit database which aims to evaluate, improve and 
maintain the quality of care provided by upper GI surgeons.  Participating surgeons are 
able to enter pathological, clinical and surgical outcome data of patients undergoing 
resection for upper gastrointestinal cancer and gastrointestinal stromal tumour (GIST).  
Surgeons can then self-assess their performance and compare their performance 
against that of peers.   New Zealand surgeons began contributing data to the audit in 
2010.  As of 31 July, 2014 the database contained a total of 1469 cases of which 69 
were from surgeries performed in New Zealand (Royal Australasian College of 
Surgeons, 2014). 
Guidelines were published in 2013 for hospitals and health services to assist in the 
assessment of surgeons performing stomach cancer surgery (Australian and New 
Zealand Gastric and Oesophageal Surgery Association (ANZGOSA), 2013). The 
guidelines include direction on credentialing of, and expected training for, surgeons.  
Direction is also given on the levels of services, including MDT requirements, required 
by hospitals along with surgical audit outcomes. Of note, membership and 
participation in any ANZGOSA activity is voluntary.  
Summary of the New Zealand Health Care Sector  
Health care in New Zealand is characterised by publicly funded and delivered care, 
with free, albeit secondary and tertiary only, services.   Primary health care is provided 
on a fee for service basis with GPs acting as gatekeepers to the rest of the health 




population within their geographical boundary.  However DHBs provide different 
levels of service to their respective population with differences also evident in 
performance indicators by DHB. 
Most health care in New Zealand is delivered through public (or mainstream) 
organisations.  The development of Māori health providers since the 1980s has 
increasingly enabled Māori to attend to their own health care needs, although Māori 
providers predominantly deliver primary care-based health care services only.   The 
majority of cancer services are delivered through the public system, with cancer 
treatment services delivered solely by mainstream organisations.   Six regional cancer 
treatment services spread across New Zealand provide the bulk of medical and 
radiation oncology services.  Diagnostic and surgical oncology services are provided by 
DHBs throughout the country although private facilities provide some specialist 
outpatient and surgical care to patients (French et al., 2001).  The majority of 
treatment services for stomach cancer are provided by publicly funded services rather 
than the private sector. 
A number of recent government policies include a stated commitment to reducing 
health inequities and the burden of cancer.  As well guidelines, albeit non-mandatory, 
specifically address the diagnosis and treatment of stomach cancer for the primary, 
secondary and surgical sectors. 




Chapter 3: Indigenous Cancer Inequities  
This chapter outlines the evidence regarding inequities in stomach cancer for indigenous 
people both in New Zealand and internationally.    While there are well documented 
inequities in stomach cancer incidence, mortality and survival among ethnic minority 
groups, especially African Americans in America, this study is primarily interested in 
whether there are disparities between indigenous Māori of New Zealand and their 
majority non-Māori counterparts.  Thus indigenous inequity forms the main focus of this 
chapter. 
This chapter opens with a brief overview of cancer in New Zealand, it then focuses on the 
most obvious and sustained example of cancer related inequity in New Zealand, that seen 
between Māori and non-Māori.  The chapter highlights the evidence of differential cancer 
and stomach cancer incidence and mortality seen within Māori.   Incidence and mortality 
inequities, those of both cancer and stomach cancer, are then examined for other 
indigenous peoples.    
Finally the focus of this chapter is turned to survival from cancer once diagnosed.  Cancer 
survival is determined by a number of factors.  However survival is a useful way to gauge 
the overall effectiveness of a country’s cancer screening, diagnostic, treatment and 
management services, and so differences in cancer survival between ethnic groups within 
a country provides important background to this thesis.  Thus cancer and stomach cancer 
survival inequities evidenced in indigenous people internationally and for New Zealand 
Māori are discussed. 
 
  









Cancer in New Zealand 
Cancer is a significant public health issue in New Zealand (Minister of Health, 2003; 
Ministry of Health, 2002a; Blakely et al., 2010).  Currently cancer is the leading cause of 
death in New Zealand, accounting for nearly a third (28.9%) of all deaths in 2009 (New 
Zealand Health Information Service, 2012).  Incidence and mortality rates are projected to 
stop increasing over the coming decades, although it is predicted that the overall burden 
of cancer will still increase due to the increasing size and aging of New Zealand’s 
population (Ministry of Health, 2010a). 
Compared with other countries New Zealand has high incidence and mortality from a 
number of cancers (Jemal et al., 2011; Minister of Health, 2003).  New Zealand also has 
well documented inequities in both cancer incidence and mortality (Blakely et al., 2010; 
Robson et al., 2006; Soeberg et al., 2012). 
Cancer incidence and mortality inequities in New Zealand exist along a number of axes: 
socio-economic, gender, geographic and ethnic (Minister of Health, 2003; Blakely et al., 
2010; Robson et al., 2010).  These inequities do not happen by chance but rather are due 
to a complex mix of factors, including differential access to the underlying determinants 
of health and differential access to, and through, health services including cancer services 
(Robson and Harris, 2007a).   
Socioeconomic position plays a large role in a person’s risk of developing and dying of 
cancer (Blakely et al., 2011; Blakely et al., 2005).  Inequities in cancer mortality by 
socioeconomic position are widening in New Zealand (Blakely et al., 2005; Soeberg et al., 
2012) with increases seen in both relative and absolute socioeconomic cancer mortality in 
New Zealand between 1981 and 1999 (Blakely et al., 2005).  Ethnicity also plays a large 
role in a person’s risk of developing and dying of cancer.  Pacific Island New Zealanders 
are differentially impacted by number of key, and often preventable, cancers (Tukuitonga 
et al., 1992; Foliaki et al., 2004; Blakely et al., 2004; Meredith et al., 2012); however, one 




of the most stark and sustained examples of cancer related inequity in New Zealand is 
that seen between the indigenous Māori population and non-Māori.   
Māori/non-Māori Cancer Incidence and 
Mortality  
It is well documented that the burden of cancer disproportionately impacts Māori in New 
Zealand (Minister of Health, 2003; Blakely et al., 2004; Jefferys et al., 2005; Robson et al., 
2006; Blakely et al., 2010).  Overall between 1996 and 2001 Māori were 18% more likely 
to be diagnosed with cancer but 93% more likely to die from it compared with non-Māori 
(Robson et al., 2006).  Not only do Māori and non-Māori rates differ for all cancers 
combined, Māori have been shown to have significantly higher incidence of a number of 
specific cancer sites; namely the preventable and poorly prognostic cancers of the lung, 
cervix, liver and stomach along with breast cancer (Robson et al., 2006; Moore et al., 
2015).   Māori also have somewhat higher rates of cancers of the oesophagus, pancreas, 
uterus, testis and thyroid than non-Māori (Robson et al., 2006).  Māori are also more 
likely than non-Māori to die from the majority of cancers, even many cancer sites where 
their incidence rate is similar or lower than that of non-Māori (Robson et al., 2006).   
Furthermore, for many cancers inequities between Māori and non-Māori are widening 
(Blakely et al., 2004; Ajwani et al., 2003; Blakely et al., 2007; Blakely et al., 2010).  During 
the period from 1981 to 2004 wide and increasing Māori/non-Māori inequities in 
tobacco-related cancer incidence were reported; inequities in non-tobacco-related cancer 
incidence were smaller though, and trends varied (Blakely et al., 2010).    
In addition, while it is true that increasing deprivation is associated with increased cancer 
incidence and mortality for both Māori and non-Māori the association is stronger for 
Māori (Robson and Harris, 2007a; Robson et al., 2010).  These disparities also hold true 




for stomach cancer (Blakely et al., 2011; Dockerty et al., 1991; Thompson, 2002; New 
Zealand Health Information Service, 2012). 
Māori/non-Māori Stomach Cancer Incidence and Mortality  
New Zealand does not have a high incidence of stomach cancer on an international scale; 
the combined world age-standardised rate for cancer incidence is 14.1 per 100,000 
(Ferlay et al., 2010) while the overall rate for New Zealand males is 8.2 per 100,000 and 
females is 3.8 per 100,000 (New Zealand Health Information Service, 2012).   However in 
2009 the age-standardised rate of stomach cancer for Māori males was two and a half 
times that of non-Māori males (19.3 vs 7.3 per 100,000 respectively); the rate for Māori 
females five times that of non-Māori females (15.2 vs 2.8 per 100,000 respectively) (New 
Zealand Health Information Service, 2012).  These findings are consistent with a number 
of individual studies which all find at least a two-fold increase in stomach cancer 
incidence for Māori when compared to non-Māori (Blakely et al., 2011; Dockerty et al., 
1991; Thompson, 2002). Mortality rates mirror this pattern of inequity (New Zealand 
Health Information Service, 2012). 
Incidence trends show decreasing rates of stomach cancer in New Zealand over the time 
period from 1981 to 2004 (Blakely et al., 2010). This is true at least for non-Māori/non-
Pacific New Zealanders, whose rates fell by 33% for men and 42% for women.  With a 
smaller number of incident cases over this time the rates for Māori were not stable but 
appeared to decrease, albeit to a lesser degree.  What is clear is that the disparity 
between Māori and non-Māori remains, with Māori having two to three times the 
incidence of non-Māori over this time period (Figure 2 and Figure 3).  Furthermore a 
widening relative incidence between Māori and non-Māori women was observed (Blakely 
et al., 2010). 




 Figure 2: Male stomach cancer registration rate, by ethnicity, 1999–2009  
 
 Age-standardised rate per 100,000 population; standardised to the WHO world standard population. 
Source: New Zealand Cancer Registry, Cancer: New Registrations and Deaths 2009 (New Zealand Health Information 
Service, 2012). 
Figure 3: Female stomach cancer registration rate, by ethnicity, 1999–2009 
 
Age-standardised rate per 100,000 population; standardised to the WHO world standard population. 






























Differences in Stage at Diagnosis 
There are high numbers of stomach cancer registrations on the New Zealand Cancer 
Registry that do not have extent of disease at diagnosis recorded, with ‘unknown’ 
recorded for a third of all registrations (Robson et al., 2006).  In a population-based study 
using Cancer Registry data, linked to mortality data, that accounted for all registrations 
between 1996 and 2001, Māori were less likely than non-Māori to have extent of disease 
at diagnosis recorded (Robson et al., 2006).  Of those people for whom extent at diagnosis 
was recorded, Māori were more likely to be diagnosed with localised disease however 
Māori were 50% more likely than non-Māori to die of their disease no matter their extent 
at diagnosis (Robson et al., 2006).  In contrast another smaller institution-based study 
that was able to ascertain stage at diagnosis for its total cohort (n=133) through clinical 
notes review found no significant difference in stage at diagnosis between Māori and 
non-Māori (Biggar et al., 2011).   Importantly to this thesis, no previous New Zealand 
study has investigated stomach cancer at a population level based on complete data on 
staging. 
Differences in Tumour Site 
Two New Zealand studies point to differential distribution of tumour site between Māori 
and non-Māori (Biggar et al., 2011; Armstrong and Borman, 1996).  Notably, it appears 
that the tumour sub-site in Māori with stomach cancer defies international trends of 
increasing proportions of tumours located in the proximal stomach, and corresponding 
lower proportions of tumours located distally (McLoughlin, 2004; Forman and Burley, 
2006; World Health Organisation, 2008).   
An older study (1978 – 1992) using New Zealand Cancer Registry data reported an 
average annual incidence of adenocarcinoma of the cardia among non-Māori men over 
twice the rate in Māori men (0.9 per 100,000 in Māori men vs 2.2 per 100,000 in non-
Māori men), while the converse was shown for adenocarcinoma elsewhere in the 




stomach (9.7 per 100,000 in Māori men vs 3.7 per 100,000 in non-Māori men) (Armstrong 
and Borman, 1996).  Among Māori women the average annual incidence of non-cardia 
(distal stomach) adenocarcinoma was over four times that of non-Māori women (7.9 vs 
1.9 per 100,000 respectively).  There was however also a high percentage of stomach 
cancers overall (41%) with unspecified sub-site (Armstrong and Borman, 1996).   The 
more recent single institution-based study of Biggar et al (Biggar et al., 2011)  which was 
able to ascertain tumour sub-site for all 3% of patients supported the findings of 
Armstrong and Borman.  Biggar et al reported that New Zealand European patients were 
more likely to be diagnosed with proximal (47%) than distal tumours (16%).  Again the 
converse was true for Māori patients (proximal 12% vs distal 44%).    
It has been suggested that the higher prevalence of distally located tumours for Māori is 
linked to their much higher rates of infection H. pylori compared to non-Māori New 
Zealanders (Fraser et al., 1996; McDonald et al., 2015).   Importantly, except for the one 
institution-based study above there has been little recent work investigating stomach 
cancer tumour sub-site in New Zealand. 
Gender 
Stomach cancer incidence rates in men are around double those of women in most 
population groups worldwide (Ferlay et al., 2010), including most indigenous groups 
(Arnold et al., 2014).  In Māori however, women appear nearly as likely to develop 
stomach cancer as men.  In 1996-1997 Māori men had an incidence of 26.5 per 100,000 
while the corresponding rate for Māori women was 24.0 per 100,000 (Skegg and 
McCredie, 2002).  The data of the New Zealand Health Information Service supports this 
finding; in 2009 the age-standardised rate of stomach cancer for Māori women at 15.2 
per 100,000 was 80% of that of Māori men at 19.3 per 100,000 (New Zealand Health 
Information Service, 2012).  In addition, proportionately more Māori women were 
diagnosed than non-Māori women when compared to their male groups (New Zealand 
Health Information Service, 2012). 




Stomach Cancer and Socioeconomic Status 
As with cancer overall, stomach cancer incidence and mortality are linked to 
socioeconomic status.  While this is true for both Māori and non-Māori, the association is 
stronger for Māori. The higher proportion of Māori living in more deprived regions 
accounted for up to 14% of the differences in both incidence and mortality seen between 
Māori and non-Māori.   Socioeconomic status did not however explain the differential 
extent of disease at diagnosis for stomach cancer (Robson et al., 2010).  
Indigenous/non-Indigenous Cancer Incidence 
and Mortality  
There is a large international body of work supporting the existence of cancer disparities 
due to socioeconomic inequity.  Literature on cancer disparity by indigeneity is more 
limited.  In part this is due to ethnicity not being systematically and accurately recorded 
by cancer registries worldwide (Gordon-Dseagu, 2007; Zhang et al., 2011; Foote et al., 
2007; Sarfati and Robson, 2015). There is however enough evidence to show a scenario 
similar to that seen in New Zealand, one of differential cancer incidence and mortality for 
indigenous people within a country when compared to the non-indigenous population.   
Often it is the preventable and poorly prognostic cancers, including stomach cancers, 
which are disproportionately borne by indigenous people (Roder, 2005; Moore et al., 
2010; Condon et al., 2005; Zhang et al., 2011; Ward et al., 2004; Paltoo and Chu, 2004; 
Jemal et al., 2004; Friborg et al., 2003; Arnold et al., 2014; Moore et al., 2015). 




Indigenous Cancer Incidence and Mortality in Australia 
Significant differences have been found between Indigenous Australians and other 
Australians especially in potentially preventable and poorly prognostic cancers of the 
liver, head and neck, lung, oesophagus and cervix (Roder, 2005; Moore et al., 2010; 
Condon et al., 2005; Zhang et al., 2011; Moore et al., 2015).  Additionally markedly higher 
incidence rates for Indigenous Australians have been shown for colorectal, breast, 
pancreatic and oropharynx cancers (Zhang et al., 2011; Condon et al., 2005).   
Cancer mortality is also differential for Indigenous Australians compared to other 
Australians.  Indigenous Queenslanders are 21% less likely to be diagnosed with cancer 
than the total Queensland population but 36% more likely to die from it (Moore et al., 
2010) while Indigenous Australians in the Northern Territory and South Australia are 40% 
more likely to die from their cancer than their non-Indigenous counterparts (Roder, 2005; 
Condon et al., 2004).    
Stomach Cancer 
Stomach cancer appears to follow a similar pattern, that of higher incidence and mortality 
for Indigenous Australians when compared to non-Indigenous Australians.  The numbers 
of Indigenous Australians diagnosed with stomach cancer is however low, thus firm 
conclusions cannot be reached and study results are varied.     
One study showed an apparent lesser risk of developing and dying from stomach cancer 
for  Indigenous Australians of the Northern Territory compared to non-Indigenous 
(Condon et al., 2005).  However this finding was based on only 13 Indigenous cases.    
In contrast, Indigenous Australian men in a Queensland study had an 80% higher risk of 
developing stomach cancer than non-Indigenous men (Moore et al., 2010), while in New 
South Wales Indigenous men had an 85% higher risk (Morrell et al., 2012).  Reported 




incidence in Indigenous Australian women varies from an apparent lower incidence 
(standardised incidence ratio 0.68; 95% CI, 0.32–1.24) (Moore et al., 2010) to a probable 
higher incidence (standardised incidence ratio 1.35; 95% CI, 0.73-1.98) (Morrell et al., 
2012).  Nationally, a larger cohort study (using data which covers 84% of the Indigenous 
Australian population) found a 30% higher risk of stomach cancer for Indigenous 
Australian compared with non-Indigenous men (incidence rate ratio 1.3; 95% CI, 1.0-1.7).   
Again the rate for Indigenous Australian women appears lower than non-Indigenous, 
although it was based on only 29 cases (Zhang et al., 2011).   
Mortality for Indigenous Australian men has been shown to be greater than two-fold 
increased than that of the total New South Wales population (Supramaniam et al., 2006; 
Morrell et al., 2012).  Despite their apparent lower incidence, mortality for Indigenous 
Australian women was higher when compared to non-Indigenous women (Moore et al., 
2010), in one study reaching statistical significance (1.98; 95% CI, 1.15-3.16) (Morrell et 
al., 2012). 
Despite the lack of power within most of these studies due to low numbers of Indigenous 
Australian cases,  the magnitude and direction of these findings are consistent with higher 
stomach cancer incidence and worse mortality for the Indigenous Australian population .  
However the magnitude of difference may be greater than presented here as 
underestimation of Indigenous Australian cancer incidence is likely in these studies.  None 
of these studies report stomach cancer by tumour sub-site, although there is documented 
evidence of a high prevalence of H. pylori in Indigenous Australians (Nogrady, 2005) with 
rates two to three times higher than that of the non-Indigenous Australian population 
(Windsor et al., 2005). 
Indigenous Cancer Incidence and Mortality in America 
Historically studies have shown lower cancer incidence rates overall among the American 
Indian and Alaskan Native (AI/AN) population when compared to the majority white 




population of North America (Paltoo and Chu, 2004).  This lower incidence rate was 
thought to be due to lower rates than white Americans of the major cancers such as 
breast, prostate and colorectal.  However there is mounting State-based evidence of 
significant undercounting of AI/AN ethnicity in cancer registries and thus in national SEER 
datasets from which many studies have drawn data (Partin et al., 1999; Foote et al., 2007; 
Wiggins et al., 2008).   
In order to improve classification of American Indian cancer cases some States in America 
have linked State-based data to data of their Indian Health Service, which has more 
accurate ethnicity classification.   After data linkage,  American Indians were shown to 
have similar cancer incidence when compared to the total population, over twice that 
reported by SEER (Foote et al., 2007) while the risk of developing breast cancer was twice 
as high as previously estimated (Partin et al., 1999).   Incidence rates of a number of other 
specific cancers were also higher in AI/AN groups compared to the total population; 
cancer of the gallbladder was up to 4 times higher, liver up to 2.3 times higher and kidney 
twice as high (Paltoo and Chu, 2004).  A more recent study by Moore et al (Moore et al., 
2015) which derived its data from population-based cancer registries, reported an overall 
standardised rate ratio between indigenous Alaskan Native women and white American 
women of 1.30 (95% CI, 1.21- 1.40) along with higher rates of breast, head and neck, 
colorectal, lung and liver cancers among Alaskan Natives.  
Cancer mortality overall appears to be lower for AI/AN people but higher for certain 
cancer sites.  Specifically cancer mortality was higher for AI/AN compared to white 
Americans for preventable cancers of the cervix, liver and stomach, although the study 
used SEER data so undercount is likely (Ward et al., 2004).  Additionally, over the last 
decade cancer mortality remained stable for AI/AN while at the same time falling by more 
than 1% annually for every other racial/ethnic group in America (Siegel et al., 2012). 





Even in studies likely to have underestimated rates, AI/AN men have been up to 20% 
more likely to be diagnosed with stomach cancer than white American men.  For women 
this differential was up to 50% (Ward et al., 2004; Paltoo and Chu, 2004; Jemal et al., 
2004).   
One study, which linked SEER data to Indian Health Service records, confirmed a 
substantially differential burden of stomach cancer in AI/AN’s populations across America 
for the period 1999 to 2004 (Wiggins et al., 2008).  A stomach cancer rate of 14.7 was 
reported for AI/AN males compared to 8.5 for white males, a 30% greater risk; while for 
AI/AN females a rate of 7.9 was reported compared to 3.6 for white females, a risk 
greater than 50% (Wiggins et al., 2008).  Wiggins et al also found that in many regions 
AI/ANs were diagnosed with higher proportions of tumours located in the central or distal 
stomach indicating a differential burden of H.pylori infection within the AI/AN population 
(Wiggins et al., 2008).   
Two papers discuss stomach cancer trends over time for AI/ANs however they present 
contradictory results.  Paltoo and Chu (Paltoo and Chu, 2004) reported increasing trends 
in AI/AN people between 1992 and 1999, significantly so for women.  They also reported 
concurrent decreasing trends in white Americans.   In comparison cancer of the 
oesophagus was reported to be increasing in white males while decreasing in AI/AN males 
(Paltoo and Chu, 2004).  However a large study, using SEER data linked to Indian Health 
Records (Espey et al., 2005) reported declining incidence rates of stomach cancer for 
AN/AIs, men and women, from 1975 to 2004.   However despite the contradictory results, 
both of these studies present consistently higher incidence rates of stomach cancer 
among AI/AN persons than in the non-indigenous comparison groups.  
All of the above studies have aggregated data for AI/AN populations.  American Indians 
and Alaskan Natives include many different tribal groups, who each have unique cultural 
and lifestyle practices and who live in diverse geographical regions.  Cancer risk and 




mortality in AI/ANs have been shown to be different dependent on geographical or tribal 
region (Espey et al., 2005).  Kelly and colleagues (Kelly et al., 2006) aimed to address the 
limitation of aggregated data.  They compared cancer incidence rates for the period 1993 
to 2002 among Indians in Alaska and New Mexico –the most complete indigenous 
datasets– and white Americans.  Overall stomach cancer was one and a half times higher 
in Alaska Indians than New Mexico Indians.  It was twice as high in Alaska Indian men as in 
whites (Alaskan/White rate ratio 2.3; 95% CI, 1.5-3.6), while it was three times higher in 
Alaska Indian women than in whites (Alaskan/White rate ratio 3.0; 95% CI, 1.8-5.1).  
Differing prevalence of risk factors undoubtedly plays a role with Alaska Native people 
previously reported to have a high prevalence of H. pylori infection (Kelly et al., 2006).  
This finding of a threefold increase of stomach cancer risk among Alaskan Natives 
compared to American whites is supported by 1994 – 2008 data from the Alaska Native 
Tumor Registry (Kelly et al., 2012).    In addition, the recent study by Moore et al (Moore 
et al., 2015) also supports this finding of threefold stomach cancer risk with an Alaskan 
Native/white American standardised rate ratio of 3.19 (95% CI, 1.95−5.20) reported for 
men.   The corresponding ratio for women was 3.75 (95% CI, 1.92−7.36).  However 
stomach cancer rate ratios between American Indians and white Americans were 
consistently lower in the indigenous people across all States of America. 
While stomach cancer mortality rates overall are falling, mortality is up to four times 
worse for AI/ANs compared to white Americans (Kelly et al., 2012; Jemal et al., 2004).  
Additionally, stomach cancer mortality is decreasing at a much faster rate for white 
Americans (annual percentage change for white men -3.6 versus AI/AN  men -1.2; white 
women -2.8 versus AI/AN women -1.4) (Jemal et al., 2004).  These findings are likely to be 
more pronounced due to the aforementioned issues with misclassification of AI/AN 
leading to undercounting within SEER databases.  Still the findings indicate not only a 
higher likelihood of dying of stomach cancer for AI/AN peoples but an increasing mortality 
gap between AI/ANs and white Americans.   




Other Indigenous Groups  
Stomach Cancer 
Other than the indigenous peoples already discussed, elevated stomach cancer incidence 
and mortality rates are found in most other indigenous peoples globally.  The highest 
rates are seen in indigenous Siberians (Tsukanov et al., 2011), the Mapuche people of 
Chile (Heise et al., 2009) and Inuit (Friborg et al., 2003; Arnold et al., 2014). Additionally 
there an increased risk of developing stomach cancer among the Sami of Sweden and 
Sami women of Norway and Finland (Hassler et al., 2008), while the Skolt Sami of Finland 
have particularly high stomach cancer mortality, which is reported to be four fold that of 
their non-indigenous countrymen (Soininen and Pukkola, 2008).  
It is likely that infection with H. pylori drives these high rates for indigenous peoples.  A 
higher proportion of distally located tumours was found among the total cohort in the 
Chilean study (1.0 distal tumour for each 0.7 proximal tumour) when compared to 
proportions seen in developed countries suggestive of H. pylori driven disease (Heise et 
al., 2009).  Inuit in Nunangat Canada are more likely to live in crowded housing and have a 
lower median income than their non-indigenous countrymen both in Nunangat and the 
rest of Canada (Carriere et al., 2012).   The combination of a high rate of H. Pylori 
infection along with the tobacco and dietary practices among indigenous Siberians are 
put forward by the authors as contributing factors to their extremely high rates of 
stomach cancer (Tsukanov et al., 2011).  Furthermore the high risk of stomach cancer 
within the Inuit population of Greenland remains once they migrate to the lower risk 
Denmark region (Boysen et al., 2008) indicating that long term or early risk factors, most 
probably infection with H. pylori, play a role in the high observed incidence.    




Summary of Indigenous Stomach Cancer Incidence and 
Mortality  
Differential incidence and mortality rates have been noted in most indigenous peoples for 
a number of cancers, including stomach cancer (Blakely et al., 2010; Condon et al., 2004; 
Moore et al., 2015; Condon et al., 2005; Zhang et al., 2011; Paltoo and Chu, 2004; Ward et 
al., 2004; Wiggins et al., 2008; Heise et al., 2009; Friborg et al., 2003). 
The differential stomach cancer rates most probably point to a disproportionate burden 
of H. pylori-associated disease for indigenous peoples (Paltoo and Chu, 2004; Ward et al., 
2004; Wiggins et al., 2008; Arnold et al., 2014).   One study reported on increased 
household crowding for the indigenous people of investigation (Carriere et al., 2012) and 
while most of the studies do not investigate tumour site, those that do, reported higher 
proportions of distally located tumours (Biggar et al., 2011; Armstrong and Borman, 1996; 
Heise et al., 2009) – adding weight to the H. pylori hypothesis of disease.   
  




Cancer Survival Inequities 
Cancer survival is a useful indicator of the overall effectiveness of a country’s cancer 
screening, diagnostic and treatment services.  Survival is positively associated with a 
country’s gross domestic product and level of spending on health (Coleman et al., 2008).  
The five-year relative survival ratio for all cancers combined in New Zealand over the ten 
years from 1994 to 2003 was 0.605; thus around 60% of New Zealanders diagnosed with 
cancer lived at least five years after diagnosis (New Zealand Health Information Service, 
2006).  This combined survival ratio and the survival ratio of individual cancers in New 
Zealand was similar to those seen in other developed countries (Coleman et al., 2008; 
Soeberg et al., 2012).  Poorer survival overall from cancer is usually seen in less developed 
countries, in part due to a higher prevalence of cancers with worse prognosis such as 
stomach and liver cancers but also due to issues of health system access and quality 
(Ferlay et al., 2010; Coleman et al., 2008).   
The existence of cancer survival inequities by ethnicity is well evidenced in a number of 
countries and across a number of cancer sites (Soeberg et al., 2012; Ferlay et al., 2010; 
Coleman et al., 2008; Walters et al., 2011).  Survival once diagnosed is determined by 
patient, tumour and treatment related factors and survival inequities are thought to be 
due to a combination of these factors rather than one factor alone.  More specifically 
survival inequities are potentially explained by differences in: cancer incidence rates of 
rapidly fatal or poorly prognostic cancers (for all cancers combined), tumour morphology, 
access to cancer screening or primary health care, stage at diagnosis and level of 
comorbidity as well as access to cancer treatment and the quality and timeliness of that 
treatment (Coleman et al., 2008; Ferlay et al., 2010; Soeberg et al., 2012; Jemal et al., 
2004).  Ethnic differences in cancer survival within a country can then provide an indirect 
marker of the equity of health care delivery.   




In New Zealand a 2012 population-based study highlighted significant and sustained 
ethnic survival disparities across a number of cancers (Soeberg et al., 2012).  This study’s 
findings are supported by a large body of work evidencing ethnic survival disparities for a 
variety of cancers in New Zealand (Alexander et al., 2010; Brewer et al., 2012b; Dachs et 
al., 2008; Gill and Martin, 2002; Haynes et al., 2008; Hill et al., 2010a; Jeffreys et al., 2009; 
New Zealand Health Information Service, 2006).   There are also gaps in cancer survival by 
socioeconomic position both internationally (Baastrup et al., 2008; Kuwahara et al., 2010; 
Woods et al., 2006; Yu et al., 2008) and in New Zealand (Soeberg et al., 2012; Robson et 
al., 2010; Jefferys et al., 2005).   
However in keeping with cancer incidence and mortality the most stark and sustained 
survival inequities in New Zealand are those seen between Māori and non-Māori.   This 
survival inequity for New Zealand Māori is outlined below, but firstly it is placed in 
relation to survival inequity seen within the indigenous people of Australia and North 
America. 
Indigenous/non-Indigenous Cancer Survival  
There is much evidence showing worse survival from cancer for indigenous people 
internationally.  However few international studies include, or individually report on, data 
regarding stomach cancer survival disparities. 
Survival Inequities in Australia 
Overall cancer survival is worse in Indigenous Australians compared with other 
Australians.  In part this poorer survival is due to Indigenous Australians being more likely 
to be diagnosed with rapidly fatal and poorly prognostic cancers, such as oropharynx, lung 
and liver cancers (Morrell et al., 2012; Moore et al., 2010; Chong and Roder, 2010; 




Condon et al., 2005; Moore et al., 2015).  At the same time they are less likely to be 
diagnosed with cancers that have better survival, such as melanoma or breast cancer 
(Chong and Roder, 2010; Moore et al., 2010).  One national multi-cancer study and a 
number of state-based multi-cancer studies provide comprehensive evidence of 
Indigenous/non-Indigenous survival disparity across Australia.  These studies are 
reviewed below. 
The national study reported an overall (all cancers combined) poorer survival for 
Indigenous than non-Indigenous Australians (age adjusted one year survival 63.8% 
Indigenous vs 83.4% non-Indigenous) and poorer survival for most individual cancer sites 
(Condon et al., 2014).  This study used national cancer registration data between 1991 
and 2005 to calculate relative survival for Indigenous Australians compared with non-
Indigenous Australians.  It was unable to account for stage at diagnosis as this information 
was not available, nor does the study attempt to investigate clinical explanations for 
differential survival, it does however report on geographical remoteness as a possible 
explanatory factor.    At five year post-diagnosis age adjusted likelihood of survival for 
Indigenous Australians was 46.7% and 70% for non-Indigenous, thus the majority of the 
disparity arose within the first year post-diagnosis.  Survival was also lower for rural and 
remote residents than those residing in urban areas; this disparity was much greater for 
Indigenous Australians (Condon et al., 2014).  These results, the first at a national level, 
are supported by those of a number of individual states. 
Marked survival disparities were found between Indigenous and non-Indigenous 
Queenslanders in the first year after cancer diagnosis (HR 1.50; 95% CI, 1.38 – 1.63) 
(McCramb et al., 2012).   However these disparities nearly disappeared after two years 
(HR 1.03; 95% CI, 0.78 – 1.35), so that Indigenous Australians who survived the first two 
years after diagnosis experienced similar on-going survival as their non-Indigenous 
counterparts (McCramb et al., 2012).   This study linked data of the Queensland cancer 
registry for all Queenslanders diagnosed with cancer from 1997 to 2006 (of which 1.2% 
were Indigenous) to a national death index register and investigated possible 




explanations for differential survival.  One limitation of the study is the inability to 
account for stage at diagnosis as stage data were not collected by the registry during the 
study period.  The fact that Indigenous Australians have a much higher risk of developing 
cancers of poorer prognosis is accounted for through adjusting for broad prognostic stage 
groupings; however Indigenous survival remains worse than that of non-Indigenous up to 
two year post diagnosis even after adjustment for this factor.  The study is limited by the 
comparatively small Indigenous Australian cohort, meaning analyses for individual 
cancers could not be investigated with precision.   Only 50% of the differential survival 
between the Indigenous and non-Indigenous Australian study cohorts in the first year 
post diagnosis was accounted for by geographical remoteness, socioeconomic factors, 
age, sex or cancer grouping by survival.  The authors propose that comorbidity and 
differential access to, and through treatment, play a role in the remaining disparity 
(McCramb et al., 2012). 
Two studies by Moore and colleagues both find poorer survival overall for Indigenous 
Australians in Queensland compared to that of non-Indigenous Queenslanders (Moore et 
al., 2010; Moore et al., 2014a).  The first study reports a standardised Indigenous/non- 
Indigenous mortality ratio of 1.36 (95% CI 1.28 – 1.45) (Moore et al., 2010).  This study, 
reporting on the years 1997–2006, was the first to report on cancer incidence and survival 
state-wide in Queensland.  However as the study used both data from the Queensland 
Cancer Registry along with estimates of the Indigenous Australian and total populations 
of Queensland obtained from the census, a numerator-denominator bias was likely.  This 
would have resulted in undercounting of the Indigenous Australian cohort within this 
study and an underestimation of the survival disparity (Moore et al., 2010).    Work 
undertaken in New Zealand to link census data to that of the New Zealand Cancer 
Registry showed an underestimation of indigenous cancer incidence of up to 30% within 
the Cancer Registry (Shaw et al., 2009). 
The second study by Moore and colleagues (Moore et al., 2014a) was a frequency-
matched cohort study that investigated cancer survival and reasons for poorer survival of 




Indigenous Australians from 1998 to 2004.  The study found that Indigenous Australians 
were more likely to live remotely (27% vs 20%, p <0.001) and in the most deprived 
quintile (37% vs 25%, p <0.001) than non-Indigenous. Indigenous Australians also had 
more advanced cancer stage (p = 0.03), more comorbidities (p < 0.001) received less 
cancer treatment (77% vs 86%, p = 0.001) and were less likely to survive their cancer 
(cancer specific unadjusted HR 1.30; 95% CI, 1.15-1.48).  This study has a number of 
strengths.  It is fairly large and utilises a number of data sources, including individual 
patient records, in order to ascertain more accurate ethnicity, stage and treatment data 
than would have been gained through the use of administrative level data alone.  With 
the known misclassification of Indigenous Australian ethnicity in state-based cancer 
registries there is the possibility that some Indigenous Australian patients with cancer 
were not included in the study.  However this is unlikely to be a major source of bias as, 
unlike the previous study, the numerator and denominator are obtained from the same 
data source.  The reported 30% poorer survival of Indigenous Australians was largely 
explained by demographic and clinical factors (age, sex, stage, remoteness, deprivation 
and any treatment) with an adjusted hazard ratio of 1.10 (95% CI 0.96-1.27).  Although 
with only the unadjusted and fully adjusted HRs reported the individual effect of these 
factors is unable to be assessed. 
Valery and colleagues (Valery et al., 2006) also compared a matched sample of all 
Indigenous Australian Queenslanders diagnosed with cancer between 1997 and 2002 with 
an equal number of non-Indigenous cancer patients and also reported a 30% higher 
likelihood of dying from cancer for Indigenous Queenslanders (HR 1.3, 95% CI, 1.1 – 1.5).  
This hazard ratio was adjusted to account for differential stage, treatment and level of 
comorbidity between the Indigenous Australian and non-Indigenous cohorts.    Like the 
study above, this study used cancer registry data and clinical data obtained from medical 
note review and so has similar strengths (Valery et al., 2006).   Also like the study above, 
Indigenous Australian people were more likely to live remotely (20% vs 11%) and in the 
most deprived quintile (39% vs 28%), had less localized cancer stage (p = 0.007), more 




comorbidity or multi-morbidity and were less likely to undergo cancer treatment.   
Stomach cancer was included in the study but hazard ratios were not reported for 
individual cancers.  To reiterate, after accounting for differential stage, treatment and 
level of comorbidity, overall survival was 30% poorer for Indigenous Australian 
Queenslanders (Valery et al., 2006).   
After adjusting for socioeconomic factors and time-period of diagnosis a relative risk of 
2.0 for death from all cancers combined was reported for Indigenous Australians , when 
compared to non-Indigenous in a large South Australian study (Chong and Roder, 2010).  
The authors attribute much of the lower survival seen in the Indigenous South Australians 
to the fact that the cancers of poorer prognosis are more prevalent among them and 
thus, when all cancers are combined, Indigenous Australians are more likely to die.  The 
study did though find poorer survival for Indigenous than non-Indigenous Australians for 
a number of specific cancers, namely breast, colorectal, cervical and unknown primary 
cancers.   This study included all 671 Indigenous Australian people diagnosed with cancer 
in South Australia during the study period along with a random sample of non-Indigenous, 
matched only for year of diagnosis (n=15,799).  Data were gained from the South 
Australian Cancer Registry and linked to the register of deaths.  While this study does rely 
upon cancer registry data with a known Indigenous Australian ethnicity undercount it 
shows differential survival for Indigenous South Australian people (Chong and Roder, 
2010).    
An Indigenous Australian/total population hazard ratio of 1.9 (95% CI, 1.7 – 2.1) is 
reported in a Northern Territory study for thirteen major cancer sites combined (Condon 
et al., 2005).  The study identified all new incident cases of cancer in the Northern 
Territory from 1991 to 2001 from the state cancer register and used Cox proportional 
hazard modelling to compare survival of Indigenous Australians of the Northern Territory 
to that of the Western Australia and Tasmania population diagnosed with cancer over the 
same time period.  Eight of the individual cancer sites (oropharyngeal, pancreas, breast, 
uterus, cervix, vulva, lymphoma and leukaemia) had a statistically significant hazard ratio 




of 3.0 or greater, adjusted for age at diagnosis and (where applicable) for sex.  This 
represents an over three times greater relative risk of dying of primarily preventable or 
treatable cancers than the non-Indigenous population.   The study was not however able 
to take account of stage at diagnosis so it is possible that differential stage plays some 
role in this survival disparity (Condon et al., 2005).  
Another Northern Territory study that was able to take account of stage, investigated 
1197 people (of whom 242 were Indigenous Australians) diagnosed between 1991 and 
2000 with colorectal, lung, breast and cervical cancers and non-Hodgkin lymphoma 
(Condon et al., 2006).  The study found a higher risk of cancer death (adjusted for cancer 
type, age and stage) in Indigenous than in non-Indigenous Australians (relative risk 1.7; 
95% CI, 1.4–2.1). This difference was greater still in Indigenous Australians with an 
Indigenous first language (relative risk 2.9; 95% CI, 2.2–3.8).  For the Indigenous 
Australian cohort, being diagnosed with more advanced stage disease was more likely for 
four of the five cancers investigated.  Lung cancer was the exception.  Patients were 
identified from the Northern Territory Cancer Registry and stage and clinical data 
gathered through medical note review which was then linked to state and national death 
databases.   Ethnicity was also confirmed by medical note review thus it is likely the study 
relied on accurate data for ethnicity and other key variables.  Stage (and cancer type) 
accounted for over half of the differential survival noted in the study.  The 
aforementioned 1.7 relative higher risk of cancer death for Indigenous Australians was 2.5 
when adjusted for age only (95% CI 2.1–3.0) (Condon et al., 2006). 
Likewise a New South Wales (NSW) multi-site study that was also able to account for 
stage reported significantly poorer survival for Indigenous Australians than that of their 
non-Indigenous counterparts (Morrell et al., 2012).  In Indigenous Australian people 51% 
of men and 43% of women had died of their cancer by five years following diagnosis.  This 
compared to 36% and 33% of non-Indigenous Australians men and women respectively.  
This study aimed to account for known undercounting of Indigenous Australians in the 
NSW cancer registry by using multiple imputation to assign ethnicity status where those 




data were missing, reported at 12-18% over the time period of the study (1999 – 2007).  
Five year survival was reported and cox proportional hazard modelling used to produce 
cancer specific hazard ratios for 18 key cancer sites (including stomach cancer).    
However while hazard ratios were adjusted for age, year of diagnosis and stage at 
diagnosis only the final hazard ratio is reported thus it is impossible to assess the impact 
of these factors on survival based on their manuscript.  Overall, for all cancer sites, 
Indigenous Australians were less likely to be diagnosed with localised disease and 
correspondingly more likely to be diagnosed with regional or distant disease than their 
non-Indigenous counterparts.  However, they were significantly and substantially more 
likely to die at each stage grouping (including unknown stage) than non-Indigenous 
people, even when diagnosed at the potentially curable localised stage.  Significantly 
poorer survival was also reported for a number of individual cancer sites; these were 
often preventable cancers, head and neck, lung, cervix, or amenable to early detection, 
bowel and breast, and include stomach cancer (Morrell et al., 2012).     
Those studies above that investigated reasons for the differential survival observed 
provided evidence that Indigenous Australians were more likely to live in areas remote 
from cancer treatment facilities, came from more deprived quintiles in society, were 
more likely to have more advanced disease when diagnosed, were more likely to have 
comorbid conditions and were less likely to receive curative treatment for their cancer 
than non-Indigenous Australians (Condon et al., 2014; McCramb et al., 2012; Moore et al., 
2014a; Moore et al., 2011; Condon et al., 2006; Valery et al., 2006; Chong and Roder, 
2010).    Furthermore higher levels of comorbidity, less favourable stage at diagnosis and 
differential receipt of treatment all played a role in the poorer survival outcomes seen 
within the Indigenous Australian peoples (Moore et al., 2014a; Condon et al., 2006; Valery 
et al., 2006; Chong and Roder, 2010).  In addition, much of the survival disparity occurs in 
the first years after diagnosis when access to treatment is most likely to play a key role in 
subsequent survival (Condon et al., 2014; McCramb et al., 2012). 




A number of individual cancer site studies add to the literature.  Similar survival between 
Indigenous and non-Indigenous Australians was reported for colorectal (Moore et al., 
2014b) and oral cancers (Frydrych et al., 2014).  Poorer survival was reported for 
Indigenous Australian women with cervical (unadjusted HR 2.46; 95% CI, 1.03–5.90) (Diaz 
et al., 2015a) and breast cancers (age adjusted HR 1.88; 95% CI, 1.36–2.51) (Supramaniam 
et al., 2014), when compared to non-Indigenous women.  As well poorer survival was 
reported for Indigenous Australians with lung (unadjusted HR 1.48; 95% CI 1.14–1.92) 
(Coory et al., 2008) and head and neck cancers (unadjusted HR 2.19; 95% CI, 1.36–3.53)  
(Moore et al., 2011), when compared to non-Indigenous Australians.  Differences in stage, 
receipt of treatment and level of comorbidity accounted for some of the survival 
disparities between the ethnic groups for breast (Supramaniam et al., 2014) and head and 
neck cancers (Moore et al., 2011).   Ethnic differences in treatment and level of 
comorbidity accounted for most of the lung cancer survival disparities (Coory et al., 2008) 
while stage and treatment differences accounted for all the survival disparity in cervical 
cancer (Diaz et al., 2015a). 
Stomach Cancer Survival - Australia 
Only three Australian studies report on stomach cancer individually.  These studies show 
that non-Indigenous Australians are twice as likely as Indigenous Australians to survive for 
five years once diagnosed with stomach cancer.    Indigenous Australian women are 
particularly adversely affected.  All three studies have been described in the section 
above. 
Poorer stomach cancer survival for Indigenous Australians living in NSW compared to 
non-Indigenous was reported by Morrell and colleagues (HR 1.36, 95% CI 1.01–1.82, 
adjusted for age and stage at diagnosis) (Morrell et al., 2012).  Stage at diagnosis (extent 
of disease) was only reported on cumulatively for all cancer sites and only the adjusted 
hazard ratios were reported so it is impossible to determine the effect of stage specifically 




on stomach cancer from their manuscript.  The study found that for Indigenous men the 
likelihood of surviving five years was 19.9% compared to 29.6% for non-Indigenous.  
While in women these likelihoods were 11.4% compared with 29.5%.  The female 
Indigenous Australian/non-Indigenous hazard ratio was 1.98 meaning that non-
Indigenous women were nearly twice as likely to survive than Indigenous Australian 
women (Morrell et al., 2012).   
The Queensland study by Moore and colleagues (Moore et al., 2010) reported Indigenous 
Australian/non-Indigenous mortality ratios of 1.57 (0.98–2.37) for men and 1.11 (0.53–
2.04) for women.  So despite the finding of a lesser incidence rate among Indigenous 
Australian women within this study (as previously outlined) it appears that Indigenous 
Australian women remained more likely to die from their stomach cancer than their non-
Indigenous counterparts.   
The national survival study (Condon et al., 2014) reported one year stomach cancer 
survival of 39.8% for Indigenous Australian people and 56.1% for non-Indigenous people.  
The corresponding five year survivals were 16.9% and 30.7%.  These are age-adjusted to 
the age distribution of Indigenous Australians with stomach cancer, but stage was unable 
to be included.   
Taken together, these studies point to much poorer survival from stomach cancer for 
Indigenous Australians compared to their non-Indigenous countrymen and women.   
Survival Inequities in North America 
A number of American studies have investigated indigenous inequities in cancer survival.   
They show a higher risk of dying from cancer, and poorer survival once diagnosed, for 
most indigenous peoples, relative to the majority white American population.  Of all 
population groups in America, American Indian/Alaskan Natives (AI/AN) (and although 
not indigenous also African Americans) consistently fare worst in terms of survival.   




American Indians and Alaskan Natives 
Indigenous Americans have persistently poorer cancer survival relative to the non-
indigenous American population with AI/AN men showing the poorest survival of any 
ethnic group in America (Gilliland et al., 1998).  One State based study (Gilliland et al., 
1998) and two large studies using Surveillance and End Results (SEER) population data 
(Clegg et al., 2002; Jemal et al., 2004) provide the most evidence of these survival 
disparities.  As detailed below, all three studies report markedly poorer cancer survival for 
the AI/AN population compared with white Americans.   
A large study looking at trends in cancer survival across 27 cancer sites in residents of 
New Mexico and Arizona not only found consistently poorer cancer survival among AI/AN 
peoples compared with non-Hispanic whites but also evidence of widening survival 
disparities (Gilliland et al., 1998).   The study used data from the New Mexico Tumour 
Registry which has worked to ensure accurate ethnicity data for the indigenous 
populations it serves.  Relative five year survival rates and death rates were calculated.   
In the first time period investigated 1969 – 1982 non-Hispanic whites had better survival 
than American Indians for all cancer sites combined and for the majority of individual 
sites.  For all sites combined five year cancer survival probabilities were 53% for whites 
compared to 48% for American Indians.    In the second time period 1983 – 1994, and 
again for all sites combined, five year cancer survival probabilities were 64% for whites 
compared to 53% for American Indians. Therefore while cancer survival improved for 
both ethnic groups over time, the survival improvement was greater for whites than for 
American Indians leading to widening survival disparities (Gilliland et al., 1998).   
The first of the SEER studies by Clegg and colleagues (Clegg et al., 2002) focussed on 
ethnic disparity in cancer survival in four major cancers, breast, colorectal, lung and 
prostate. The study utilised data from nine of the SEER cancer registries, covering 9% of 
the total American population and 14% of AI/ANs for the years 1975 to 1997.  While stage 
distributions were reported and stage was adjusted for in survival analyses, hazard ratios 




adjusted for age only were not reported.  Thus the effect of stage at diagnosis is unable to 
be assessed in the data presented within this manuscript.  The study did however find 
that AI/ANs were more likely than non-Hispanic whites to be diagnosed with advanced 
stage at diagnosis for each of the four cancers.  American Indians and Alaskan Natives also 
had the poorest survival overall of any ethnic group in the study compared with non-
Hispanic whites. The male AI/AN to white hazard ratio for all four cancers combined was 
1.7 (95% CI, 1.5 – 1.8) and female 1.8 (95% CI, 1.7 – 2.0).  That AI/AN had the poorest 
survival of any ethnic group was also true for each of the individual cancers, except 
colorectal cancer in men where African American men presented with the highest relative 
risk of death.   While the risk of dying decreased over time for all ethnic groups this 
improvement differed by ethnicity and cancer site and survival disparities persisted 
throughout the study period (Clegg et al., 2002). 
The second of the SEER studies by Jemal and colleagues (Jemal et al., 2004) utilised data 
from 12 SEER cancer registries covering 14% of the US population and 21% of AI/ANs.   
While it was not solely focussed on survival it does include a comprehensive analysis of 
survival across five ethnic groups for 15 cancer sites, using Cox proportional hazard 
modelling.  After adjusting for age and stage at diagnosis the AI/AN to white hazard ratio 
for all cancers combined was 1.69 (95% CI, 1.59 – 1.79) in men and 1.54 (95% CI, 1.45 – 
1.64) in women.   These represent the poorest relative risk of any of the ethnic groups 
included in the study.    
Stomach Cancer Survival  
A number of studies that specifically investigate or include stomach cancer with their 
analyses found both that indigenous people were more likely to be diagnosed with 
advanced stomach cancer and more likely to die of their stomach cancer, even when 
stage was taken into account (Young et al., 1984; Gilliland et al., 1998; Samet et al., 1987; 
Jemal et al., 2004).  




In the same SEER based study by Jemal and colleagues as above (Jemal et al., 2004) five-
year stomach cancer survival probabilities were 19% in AI/AN men and 35% in white men.  
For women these probabilities were 22% and 31% respectively.  After adjustment for age 
and stage the AI/AN to white hazard ratio was 1.87 (95% CI, 1.52 – 2.30) for men and 1.53 
(95% CI, 1.19 – 1.97) for women. While these confidence intervals are wide they remain 
statistically significant, suggesting substantially poorer survival among AI/ANs (Jemal et 
al., 2004).   
Two studies investigated stomach cancer as an individual cancer.  The studies by Samet 
and colleagues (Samet et al., 1987) and Gilliland and colleagues (Gilliland et al., 1998) in 
New Mexico and Arizona are also described above.  The studies both found that the five 
year survival from stomach cancer was poor for both white Americans and American 
Indians (and Hispanics).  However the survival probability for whites at 17% was better 
than that of American Indians at 14%.  American Indians were reported to be less likely to 
be diagnosed with localised disease and less likely to receive treatment appropriate to 
their stage of disease compared to white Americans.  These factors made some difference 
to their likelihood of survival but did not explain all of the disparity.  The American Indian 
to white hazard ratio for 1969 – 1982 was 1.11 (95% CI, 0.95–1.29).  This ratio decreased 
to 1.07 (95% CI, 0.92–1.25) once adjusted for stage and treatment receipt (Samet et al., 
1987; Gilliland et al., 1998).  In the time period 1983 – 1994 the same hazard ratio 
decreased from 1.21 (95% CI, 1.01–1.45) to 1.08 (95% CI, 0.91–1.30).  These results 
suggest that most of the survival disparity between American Indian and white Americans  
with stomach cancer was due to a greater likelihood of being diagnosed with more 
advanced disease and a lesser quality of treatment received by indigenous Americans 
(Gilliland et al., 1998).  
One further study investigated stomach cancer survival for eight ethnic groups in 
America, including whites and American Indians (Young et al., 1984).  This study used 
SEER data from patients diagnosed 1973-79 who were then followed up until December 
31, 1981 in order to assess their survival.   American Indians had the poorest one, three 




and five year survival of any of the ethnic groups looked at.  With a relative five year 
survival of 7% for men and women combined the American Indians in the study were only 
half as likely to survive their disease as white Americans.  The study merely investigated 
and compared cancer survival for the different population groups, it did not attempt to 
explain or account for these disparities. 
Other Indigenous Groups 
Stomach Cancer Survival 
One final paper reported stomach cancer survival in an indigenous population.  Along 
with their high incidence and mortality the indigenous Mapuche people of Chile also have 
poorer survival than their non-indigenous counterparts once diagnosed with the disease.  
This in a region where the probability of surviving stomach cancer is poor overall 
compared to international survival probabilities (Heise et al., 2009).  In this study 79 
Mapuche and 369 Hispanic/white people were eligible for survival analysis.  Of these 392 
people died of stomach cancer, 11 from other causes and only 42 people overall 
remained alive five years after diagnosis.  This represents a 10.6% survival rate when 
survival rates in other countries are often around 20%.  When compared to the majority 
Hispanic/white population of the region the indigenous Mapuche had even poorer 
survival still.  Looking at three year survival 7.3% of the Mapuche cohort remained alive 
compared with 16.9% of the non-indigenous population, while only 4.4% of the Mapuche 
cohort were alive at five years compared to 11.9% of the non-Mapuche cohort (Heise et 
al., 2009). 
Summary of Indigenous Stomach Cancer Survival  
In each country reviewed above indigenous people are less likely than the non-indigenous 
population to survive their cancer once diagnosed.  Where investigated, indigenous 




people were more likely to live in geographically (in terms of cancer treatment) and 
socioeconomically disadvantaged areas, were more likely to be diagnosed with advanced 
disease and/or comorbidities and were less likely to receive curative treatment for their 
cancer than non-Indigenous.    Furthermore these factors played a role in the poorer 
survival outcomes observed. 
Poorer survival for indigenous people is especially true of stomach cancer.    In Chile over 
twice as many non-indigenous people diagnosed with stomach cancer are alive five years 
after diagnosis than the indigenous Mapuche people.  A similar pattern is seen in 
Indigenous Australians with stomach cancer whom were reported as half as likely to 
survive for five years after diagnosis than non-Indigenous Australians.  Indigenous 
Australian women were particularly adversely affected.  Likewise American Indians were 
only half as likely to survive their stomach cancer as white Americans.  American Indians 
were also less likely to be diagnosed with localised disease and less likely to receive 
treatment appropriate to their stage of disease compared to white Americans and these 
factors appeared to account for most of the survival disparity observed. 
Māori/non-Māori Cancer Survival  
There is a growing body of work that describes differential cancer survival between Māori 
and non-Māori New Zealanders.  Three large and two smaller studies that investigate 
survival across a number of key cancers all find significant survival disparities, with poorer 
survival for Māori when compared to non-Māori (Soeberg et al., 2012; Robson et al., 
2006; Robson et al., 2010; Jefferys et al., 2005; Haynes et al., 2008).   A number of  
cancer-site specific studies add to the literature (McLeod et al., 2010; Hill et al., 2010a; 
Brewer et al., 2012b; Alexander et al., 2010; Stevens et al., 2008b; McKenzie et al., 2011; 
Obertova et al., 2014b; Chamberlain et al., 2013; Swart et al., 2013; Campbell et al., 
2015). 




The first of the multi-cancer site studies by Jefferys et al (Jefferys et al., 2005) found 
significantly poorer survival across a number of cancer sites for Māori when compared to 
non-Māori.   The authors linked cancer registrations over an eight year period across 20 
key cancer sites (n=124,599) to mortality data and compared survival for Māori, Pacific 
and non-Māori non-Pacific New Zealanders, using a prioritised ethnicity classification.  
They report a poorer five year survival  for Māori than that of non-Māori non-Pacific New 
Zealanders for the majority of cancer sites, including breast (relative survival rate; Māori 
0.74 vs non-Māori non-Pacific 0.81), cervix (RSR 0.63 vs 0.75), colorectal (RSR; 0.41 vs 
0.60), lung (RSR; 0.06 vs 0.10), prostate (RSR; 0.69 vs 0.83) and uterus (RSR; 0.62 vs 0.75).  
Once age and stage were accounted for, five year survival continued to be poorer for 
Māori across the majority of the 20 cancers investigated.  Additionally while stage at 
diagnosis explained much of the survival disparity for breast, ovarian and prostate 
cancers, very little of this differential survival was explained by stage for cancers of the 
bladder, cervix, colon/rectum, head/neck/larynx, lung or uterus.  The authors point to 
differential socioeconomic position and differential health care access as possible 
contributors to this remaining disparity (Jefferys et al., 2005) 
Likewise the reports Unequal Impact and its sequel Unequal Impact II both find 
significantly poorer cancer survival across most cancer sites for Māori when compared to 
non-Māori (Robson et al., 2006; Robson et al., 2010).  Both of these reports are based on 
cancer registry data linked to mortality and census databases.  In contrast to the previous 
study these reports use an ever-Māori method of ethnicity classification to minimize a 
known under-count of Māori in these databases, whereby if a person has ever been 
identified as Māori in any of the data sources they are assigned Māori ethnicity in the 
study.  The reports also age-standardise to the average Māori population, to better reflect 
the relatively young Māori age structure.   The first study Unequal Impact reports that 
Māori have a greater than two-fold increase in dying for cancers of the testis, cervix, 
prostate, bladder, rectum and mouth compared to non-Māori.  The authors adjusted for 
stage (extent of disease) at diagnosis and found that for most cancers some of the 




survival disparity could be explained by stage, however for other cancers Māori remained 
more likely to die from their cancer despite being diagnosed at the same stage as non-
Māori (Robson et al., 2006).  In the second report Unequal Impact II the authors attempt 
to explain this remaining disparity by looking at cancer survival between Māori and non-
Māori accounting not only for stage at diagnosis but also socioeconomic position and 
rural-urban status; the latter as a proxy for health care access (Robson et al., 2010).  They 
found that after adjusting for stage at diagnosis the risk of dying for Māori remained 
significantly higher for all the investigated cancers when compared to non-Māori (Figure 
4).  They also report that Māori living rurally have significantly lower survival from 
cervical, prostate and uterine cancer than those living in urban areas and Māori have a 
non-significant but steeper deprivation gradient than non-Māori for most cancers.   They 
conclude that while stage at diagnosis, socioeconomic status and place of residence do 
play a role in differential survival between Māori and non-Māori New Zealanders, the 
gaps in survival from cancer remain even after accounting for these factors (Robson et al., 
2010).  




Figure 4: Māori/non-Māori cancer-specific mortality hazard ratios 1996–2006  
 
Adjusted for age and sex, rurality, deprivation and stage; the difference in the height of the bars indicates how much of 
the survival disparities between Māori and non-Māori can be accounted for by differences in each additional factor.  
Source: Robson et al, Unequal Impact II (Robson et al., 2010). 
A further multi-cancer site survival study undertaken on New Zealand’s five most 
common cancers diagnosed between 1994 and 2004 (n=99,062) also found consistent 
gaps in survival between Māori and non-Māori non-Pacific New Zealanders (Haynes et al., 
2008).   This study utilised cancer registry and mortality data and then matched these 
data to New Zealand census data in order to determine if not only stage but also 
socioeconomic position and travel time to primary care or a cancer treatment centre 
impacted on survival.  Gaps in survival were however still found between Māori and non-
Māori non-Pacific New Zealanders across all five cancers.   Prostate cancer showed the 
widest gap with Māori having nearly twice (93.5% higher) the likelihood of dying from 
their cancer once diagnosed compared to non-Māori non-Pacific New Zealanders.  Once 
the authors controlled for extent of disease at diagnosis these ethnic inequities remained, 
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study by Jefferys et al, it appears that extent of disease at diagnosis explained all of the 
ethnic survival disparity.   The authors also found that survival was negatively associated 
with increasing deprivation for colorectal, lung, and breast cancers along with melanoma 
but not for prostate cancer.  Travel time was important to survival from colorectal and 
prostate cancers.  The authors conclude that while extent of disease at diagnosis is the 
most important predictor of survival age, sex, socioeconomic position and especially 
ethnicity all play roles in the likelihood of survival from these five cancers.  However, with 
the exception of breast cancer, the factors investigated did not explain all of the observed 
ethnic survival disparities; again these authors point to differential access to health care 
services as playing a role in the remaining disparity for Māori (Haynes et al., 2008).  
The most recent multi-site study Cancer Trends: trends in cancer survival by ethnic and 
socioeconomic group report presented not only information on disparities in cancer 
survival for 21 cancers over a 13 year period - 1991 to 2004 - but also reported on trends 
over this time period in disparities for these cancers (Soeberg et al., 2012).  Cancer Trends 
linked Cancer Registry registrations, mortality data and New Zealand Census records for 
around 145,000 patients; ethnicity was classified according to self-identification in the 
census dataset and assigned to either Māori or non-Māori.    Excess mortality findings are 
reported for each cancer site, ethnic group and income group; these are adjusted for age, 
sex, ethnicity (for income analyses), time since cancer diagnosis, and calendar period of 
diagnosis.  However, these findings were unable to be adjusted for stage due to poor data 
quality.  Māori were shown to experience excess mortality, of 10% or more, in 17 of the 
21 sites of cancer investigated.  Averaged across the 21 cancer sites, Māori with cancer 
experienced excess mortality 29% higher than non-Māori with cancer (Soeberg et al., 
2012).  And while survival improved over this time period for all 21 cancer sites, this 
improvement was differential by ethnicity and by cancer site.  Overall there was no 
increase in the survival gap between Māori and non-Māori but for some cancers a large 
survival gap remains.  Cancers that already had a higher likelihood of cure, such as breast 
cancer, prostate and thyroid gland cancers show greater improvements in survival than 




those with a poor prognosis, with the latter including stomach cancer (Soeberg et al., 
2012). 
A number of cancer specific studies all report poorer survival among Māori compared to 
non-Māori New Zealanders for cancers of the brain (Alexander et al., 2010), colon (Hill et 
al., 2010a), cervix (Brewer et al., 2012b; McLeod et al., 2010), breast (McKenzie et al., 
2011; Campbell et al., 2015; Seneviratne et al., 2014a; Seneviratne et al., 2015), rectum 
(Swart et al., 2013), liver (Chamberlain et al., 2013), testis (Gurney et al., 2015) and 
prostate (Obertova et al., 2014b).    
The studies above highlight sustained and, at times, unexplained disparities in cancer 
survival between Māori and non-Māori.   Factors such as stage (or extent of disease) at 
diagnosis, age, sex, socioeconomic status and place of residence all appear to play a role 
in the differential survival seen between Māori and non-Māori New Zealanders.  However 
these factors do not fully explain the disparity (with the exception of breast cancer).   The 
authors of these studies point to the fact that differential health care access may be a 
contributor to the remaining disparity.    
Summary of Māori/non-Māori Cancer Survival  
The studies above highlight sustained and, at times, unexplained disparities in cancer 
survival between Māori and non-Māori.   The five multi-cancer site studies all find 
significant survival disparities, with poorer survival for Māori when compared to non-
Māori (Soeberg et al., 2012; Robson et al., 2006; Robson et al., 2010; Jefferys et al., 2005; 
Haynes et al., 2008).  While survival improved over time for all cancer sites in the large 
study on survival trends, this improvement differed by ethnicity and cancer site.  
Furthermore a large survival gap, with poorer survival for Māori than that of non-Māori, 
remained for many cancers.   Factors such as stage (or extent of disease0 at diagnosis, 
age, sex, socioeconomic status and place of residence all appear to play a role in the 
differing survival seen between Māori and non-Māori New Zealanders.  However these 




factors do not fully explain the disparity (with the exception of breast cancer).   The 
authors all point to the role that differences in health care access may play as a 
contributor to the remaining disparity.    
Māori/non-Māori Stomach Cancer Survival  
The prognosis for people diagnosed with stomach cancer in New Zealand is poor, with a 
five year survival rate for patients with stomach cancer of 20%, compared to a five year 
relative survival rate of 60% for all cancer sites combined (New Zealand Health 
Information Service, 2006).   This poor prognosis is experienced by both Māori and non-
Māori.  Nevertheless results from the Cancer Trends study showed that from 1991 to 
2004 Māori diagnosed with stomach cancer experienced poorer survival, with 25% 
greater excess mortality than that of non-Māori aggregated over these years (Soeberg et 
al., 2012).  Additionally while overall survival for patients with stomach cancer in New 
Zealand improved over the time of the Cancer Trends study with a 14% decrease in excess 
mortality evident for each 10 year period of the study, there was no evidence of changes 
in the excess mortality experienced by Māori with stomach cancer when compared to 
non-Māori over this time (EMRR 0.84; 95% CI, 0.60 – 1.17) (Soeberg et al., 2012).   
Jefferys et al (Jefferys et al., 2005) reported worse stomach cancer survival for Māori 
relative to non-Māori/non-Pacific people in their large multi-cancer site study.  This study 
investigated stomach cancer survival in 259 Māori and 1543 non-Māori/non-Pacific 
people diagnosed between 1994 and 2002.  The probability of being alive five years after 
diagnosis was similar for the two groups when the data were only age standardised with a 
relative survival rate of 0.20 for Māori versus 0.22 for non-Māori/non-Pacific.  However, 
when stage was also accounted for, the likelihood of being alive at five years among 
Māori deceased to 0.15, whereas the non-Māori/non-Pacific likelihood remained the 
same at 0.22.  This represents a rate ratio of 0.68 or, in other words, Māori in the study 




were nearly a third less likely to survive their stomach cancer once diagnosed than the 
non-Māori/non-Pacific people in the study (Jefferys et al., 2005). 
The Unequal Impact report found very poor prognosis overall from stomach cancer with 
around 20% survival at five years (Robson et al., 2006).   However the study relied upon 
Cancer Registry data which has poor staging data for stomach cancer with over 33% of 
people recorded with unknown stage.   While some caution should be taken when 
interpreting findings based on inadequate stage data, the report found poorer survival for 
Māori when compared to non-Māori, unexplained by stage.  The Māori/non-Māori hazard 
ratio adjusted for age and sex was 1.57 (95% CI, 1.35 – 1.83), when further adjusted for 
stage (extent of disease at diagnosis) the hazard ratio rose to 1.73 (95% CI, 1.49 – 2.01).  
Stomach cancer was one of the few cancers in Unequal Impact where Māori were more 
likely than non-Māori to be diagnosed at a localised stage yet Māori remain more likely to 
die from their disease.  As shown in the table below, when stratified by stage groups the 
Māori/non-Māori hazard ratio was significantly higher for Māori within each stage group, 
including unknown stage (Table 2).  In other words, Māori survival from stomach cancer 
remains poorer than non-Māori even when diagnosed at the same stage as non-Māori.  
However to reiterate, as this study was based on inadequate stage data caution should be 
taken when interpreting the findings. 
Table 2: Māori/non-Māori hazard ratios for stomach cancer survival, by stage, 1996–2001  
 Localised Regional Distant Unknown 
 HR   (95% CI)      p value HR   (95% CI)        p value HR   (95% CI)          p value HR   (95% CI)         p value 
Total 
(a
  1.98 (1.14–3.43)   0.015 1.70 (1.28–2.25)   0.0002 1.77 (1.37–2.29)  < 0.0001 1.68 (1.32–2.15)  < 0.0001 
Female
(b 
2.17 (0.96–4.94)   0.064 1.54 (1.00–2.38)   0.052 2.07 (1.38–3.10)     0.0004 1.45 (1.00–2.10)      0.049 
Male
b)
 1.86 (0.89–3.90)   0.10 1.78 (1.24–2.57)   0.002 1.62 (1.17–2.25)     0.004 1.97 (1.43–2.71)  < 0.0001 
a) Age- and sex-standardised 
b)    Age standardised 
Source: Robson et al, Unequal Impact (Robson et al., 2006) 




Unequal Impact II demonstrated a 24% higher risk of dying from stomach cancer for 
Māori compared to non-Māori over the period 1996–2006 (Māori/non-Māori HR 1.24; 
95% CI, 1.10 – 1.38, adjusted for age and sex) (Robson et al., 2010).  As in the previous 
report, stage does not appear to play a role in this differential survival with the hazard 
ratio increasing once additionally adjusted for stage (extent of disease) at diagnosis 
(Māori/non-Māori HR 1.34; 95% CI, 1.20 – 1.49).  This trend remained when the unstaged 
cancers were removed from analyses.  However it appears that level of deprivation plays 
some role in the disparity seen in stomach cancer survival with the previously mentioned 
Māori/non-Māori hazard ratio decreasing from 1.24 to 1.20 (95% CI, 1.07–1.34) when 
adjusted for deprivation (Robson et al., 2010).   
One further study adds to the pattern of stomach cancer survival disparity experienced by 
New Zealand Māori.  This study found differential survival by ethnicity across all upper 
gastrointestinal (GI) cancers, including stomach (Gill and Martin, 2002).  It used Cancer 
Registry data - assigning each of its key variables according to the Registry’s classification - 
to evaluate the effects of socioeconomic status, ethnicity, age, gender and distance from 
a cancer treatment centre on survival.   It did not adjust for stage at diagnosis.  The study 
found that across all upper GI cancers Māori have poorer survival than non-Māori (HR 
1.28; 95% CI, 1.13 – 1.46).  However for stomach cancer, age is the only independent 
predictor of survival.   Younger Māori patients (< 50 years) with stomach cancer are 
shown to have significantly poorer survival when compared to non-Māori (p = <0.05) 
while there is no survival disparity in older patients.   The study also found poorer survival 
for all patients with stomach cancer, regardless of ethnicity, living 51 – 100km from a 
cancer treatment centre, while those living closest and furthest distances fared better, 
although the study did not assess distance to specialized surgical treatment services.  
Given that surgery is the mainstay of curative treatment for stomach cancer this would 
have been a more interesting variable to assess.  In this study level of deprivation did not 
impact on survival (Gill and Martin, 2002).  




Summary of Māori/non-Māori Stomach Cancer Survival  
While the studies discussed above may not be directly comparable to each other due to 
different methodologies (years of analysis, ethnicity classification, comparison groups and 
standardisation methods) they do provide evidence of survival disparities between Māori 
and non-Māori diagnosed with stomach cancer in New Zealand.  However the studies 
above all share similar limitations in that they are all based on routine level Cancer 
Registry data, which has poor staging data for stomach cancer, linked to the national 
mortality database.  Thus they are unable to provide this evidence based on accurate data 
on the most important prognostic factor, stage at diagnosis.  Nor do the studies move 
beyond describing the ‘problem’ into assessing the impact of patient and treatment 
factors on subsequent survival.  As summarised by Robson and colleagues ‘Stomach 
cancer is a high priority for Māori cancer control. Efforts to improve outcomes for Māori 
should be strengthened throughout the cancer continuum’ (Robson et al., 2006: 192).  This 
includes investigating disparity and why it exists (and thus what can be done about it) 
based on good quality data, including accurate stage and clinical data.  
Summary of Indigenous Cancer and Stomach Cancer 
Inequities 
Cancer inequities exist internationally and in New Zealand across a number of axes.  
These inequities do not happen by chance but rather are due to a complex mix of factors, 
including differential access to the underlying determinants of health and differential 
access to, and through, health services including cancer services.  The inequity observed 
between Māori and non-Māori is the most evident cancer-related inequity in New 
Zealand.  Overall between 1996 and 2001 Māori were 18% more likely to be diagnosed 




with cancer but 93% more likely to die from it compared with non-Māori (Robson et al., 
2006).   
Differences in stomach cancer incidence and mortality between non-indigenous and 
indigenous people are evidenced in New Zealand (Blakely et al., 2011; Dockerty et al., 
1991; Thompson, 2002; New Zealand Health Information Service, 2012), Australia 
(Condon et al., 2005; Moore et al., 2010; Zhang et al., 2011; Supramaniam et al., 2006; 
Morrell et al., 2012), America (Ward et al., 2004; Paltoo and Chu, 2004; Jemal et al., 2004; 
Wiggins et al., 2008; Espey et al., 2005), Siberia (Tsukanov et al., 2011), Chile (Heise et al., 
2009), Canada and Greenland (Arnold et al., 2014; Friborg et al., 2003). 
Ethnic differences in cancer survival within a country provide an indirect marker of the 
equity of that country’s health care delivery.  Poorer survival from stomach and other 
cancers is observed among indigenous people in a number of countries (Soeberg et al., 
2012; Ferlay et al., 2010; Coleman et al., 2008; Walters et al., 2011).  At times this poorer 
survival is explained by differential stage at diagnosis, higher levels of comorbidity and 
differential receipt of treatment (Moore et al., 2014a; Moore et al., 2011; Condon et al., 
2006; Valery et al., 2006; Samet et al., 1987; Gilliland et al., 1998).  The evidence of 
differential cancer treatment for New Zealand Māori is discussed in the following chapter.   
However while a number of studies provide evidence of significant survival disparities 
between Māori and non-Māori diagnosed with stomach cancer in New Zealand (Jefferys 
et al., 2005: , Soeberg, 2012 #66; Robson et al., 2006; Robson et al., 2010; Gill and Martin, 
2002), the studies attempt to assess the impact of patient or treatment factors on 
subsequent survival.  In addition, and importantly to this thesis, these studies all share a 
common limitation.  These studies are all based on Cancer Registry data, and thus on poor 
stomach cancer staging data.  Therefore, they are unable to provide the evidence of 
stomach cancer survival disparity based on accurate data on the most important 
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Chapter 4: Understanding Inequity and 
Interventions 
This chapter provides further background and context to this thesis.  There are a 
number of possible explanations for ethnic differences in cancer survival, many of 
these at an individual or patient level.  Explanations such as patients’ socioeconomic 
status, level of comorbidity or stage at diagnosis while valid are, with a public health 
lens on, actually a reflection of differential access to the underlying determinants of 
health.  As this thesis is positioned in the historical and contemporary contexts of 
Māori and non-Māori New Zealanders, it acknowledges the importance of processes 
such as colonisation and neoliberalism in shaping and perpetuating differential access 
to those determinants of health and so impacting on health equity.   
As stated in the previous chapter cancer survival is a useful indicator of the overall 
effectiveness of a country’s cancer screening, diagnostic and treatment services;  
inequitable survival between population groups (as is seen for stomach cancer in New 
Zealand) then provides an indirect marker of the equity of access to, and quality of, 
those services.  Thus the main focus of this thesis is on whether different ethnic 
groups in New Zealand (Māori and non-Māori) receive differential access to, and 
quality of care for stomach cancer, and if so, whether that contributes to differential 
survival.  Māori with stomach cancer deserve excellence in cancer care, including 
equitable and timely access to high quality cancer services, thus the thesis also turns 
its focus to where we can intervene to minimise any disparities.  If health disparities 
are said to arise from deliberate policy options then it follows that any disparities 
should be amenable to intervention, although the nature of institutionalised racism 
means that unequal treatment is entrenched in organisations, often not visible and 
difficult to change. 
This chapter firstly outlines a theoretical model that helps to explain health disparity 
or inequity between ethnic groups.   Secondly it focuses on whether Māori and non-
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Māori in New Zealand are likely to receive differential cancer care once diagnosed 
with stomach cancer.  It does this by examining the literature on whether Māori and 
non-Māori receive differential health care more generally, and cancer care (for 
cancers other than stomach cancer) more specifically.  Finally the chapter outlines a 
framework for examining ethnic inequities in cancer care and looks to the literature to 
explore potential interventions to improve access to, and quality of, cancer services 
for Māori in New Zealand. 
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A Model to Understand Differential Access to, 
and Quality of, Health Care 
Camara Jones, an American researcher, argues for three pathways through which 
health inequities occur (Jones et al., 2009).  These are: differential access to the 
underlying determinants of health (discussed in relation to Māori and non-Māori in a 
previous chapter), differential access to health care and differential quality of health 
care received.   
Jones also developed a theoretical model that helps to explain why differential access 
to, and quality of, health care may occur between ethnic groups (Jones, 2000; Jones, 
2002; Jones et al., 2009).   Jones’ model outlines three levels at which racism exists in 
society: that is, internalised, personally-mediated and institutionalised racism (Jones, 
2000).  With this model Jones describes the mechanisms by which racism produces 
and maintains ethnic health disparities within a population.  In particular the model 
highlights the roles that historical injustices play in shaping patterns of disadvantage 
or privilege in current society.  This disadvantage (or privilege) is then, according to 
Jones, perpetuated through contemporary structural factors (Jones, 2000).   
Jones describes internalised racism as “acceptance by members of the stigmatized 
races of negative messages about their own abilities and intrinsic worth” (Jones, 2000: 
1213). This acceptance is said by Jones to reflect the values within a society including 
those that privilege certain groups within that society.   
Personally-mediated racism is the most explicit of the three levels of racism, whereby 
people behave in discriminatory ways toward members of different ethnic groups 
based on assumptions about their abilities or motives.  Personally-mediated racism 
can be intentional or non-intentional and includes acts of commission and omission 
(Jones, 2000).   
Institutionalised racism on the other hand is expressed as “differential access to the 
goods, services, and opportunities of society by race” (Jones, 2000: 1212).  By this 
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definition institutionalised racism can mean differential access to physical conditions 
(or the underlying determinants of health) that impact on health as well as access to 
power and control.  Institutionalised racism can also manifest as inaction in the face of 
need.  While institutionalised racism can describe any system of inequity based on 
ethnicity, it occurs in the institutions of society such as media organisations and 
universities along with government and its entities, including health care 
organisations. 
While all three levels play a part in creating health disparities between different ethnic 
groups, Jones places most emphasis on addressing institutionalised racism in 
interventions to address health disparities (Jones, 2000; Jones, 2002; Jones et al., 
2009).  That is, addressing the structural causes of inequity.  This includes addressing 
the underlying determinants of health which cause certain groups to be sicker than 
others, as well as addressing access to, and quality of, care within the health system 
itself.   
Other international researchers also examine and acknowledge the impact of racism 
on ethnic health inequities with increasing recognition internationally of the need to 
consider racism as an underlying determinant of health and a driver of health inequity 
(Feagin and Bennefield, 2014; Williams and Mohammed, 2009; Krieger, 2003).   
However Jones’ model has been described as it provides a useful framework for 
thinking about racism in the New Zealand context.  Jones’ model resonates with the 
history of Māori and non-Māori which has been highlighted in an earlier chapter.  
Jones’ model has also been utilised to examine the relationship between ethnicity and 
cancer care, as well as to recommend interventions to address disparities, in New 
Zealand (Walker et al., 2008).  
The nature of institutionalised racism means that it is a longstanding issue, deeply 
embedded in organisations, often not visible and difficult to change (Williams and 
Mohammed, 2009; Krieger, 2003; Feagin and Bennefield, 2014).  It can exist, or 
persist, even when individuals within organisations are not prejudiced and do not 
behave in discriminatory ways (Williams and Mohammed, 2009; Krieger, 2003).  
Institutionalised racism within society can however be changed (Feagin and 
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Bennefield, 2014) and as argued by Jones ‘inaction in the face of need’ is a form of 
institutionalised racism (Jones, 2002). 
There is a growing body of work in New Zealand explicitly recognising the impact of 
racism on health.  This work provides evidence that Māori experience higher levels of 
racial discrimination and subsequently have poorer health outcomes.  Two studies 
based on consecutive New Zealand Health Survey data (Harris et al., 2006a; Harris et 
al., 2012) found that of all the ethnic groups surveyed Māori reported experiencing 
the highest levels of discrimination and were ten times more likely to report multiple 
types of discrimination than non-Māori.  These higher levels of reported 
discrimination were associated with poorer self-rated health for Māori compared to 
non-Māori.  Further, although the Ministry of Health has recognised institutional 
racism as a determinant of health in policy documents since the 1990s, recent 
research indicates that institutional racism is common within health policy in New 
Zealand (Came, 2014).  According to Came (2014), institutional racism is seen within 
decision-making practices with policy decisions primarily made by the dominant ethnic 
group, the use of evidence to favour the dominant ethnic group viewpoint, 
deficiencies in cultural competencies such as low levels of cultural competency 
training among senior management, flawed consultation processes, and ‘Crown filters’ 
that dilute Māori content in policy (Came, 2014).   
There is also much evidence of inequitable access to, and quality of, health care and 
cancer care for Māori in New Zealand.  In this thesis Māori/non-Māori differences in 
the treatment or management of stomach cancer are interpreted as reflecting 
institutionalised racism within New Zealand’s health care system. 
Māori/non-Māori Access to Health Services 
A body of health services research in New Zealand shows how racism might affect 
Māori health; how that Māori, who need healthcare the most, receive it the least or in 
lesser quality. 
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Racism manifests within the primary health care sector in Māori/non-Māori disparities 
in primary health care utilisation, poorer quality services and inferior patient-provider 
relationships (Crengle et al., 2005; Jansen et al., 2008; Ministry of Health, 2014a).  This 
is important as the majority of cancer in New Zealand, including stomach cancer, is 
detected within the primary care setting.  Māori (and low-income groups, in which 
Māori predominate) are more likely than non-Māori to report unmet primary health 
care need and are less likely to access general practitioner services than other groups, 
despite subsidies intended to raise Māori levels of engagement with primary health 
care (Scott et al., 2003; Crengle et al., 2005; Ministry of Health, 2014a). Cost, distance, 
transport and cultural differences between providers and patients are cited as barriers 
to utilisation of primary care services by Māori (Jansen et al., 2008).    
Once Māori do access primary care services they can receive a differential quality of 
care.  A nationally representative survey of primary medical care services, entailing 
data collected from 244 general practitioners (GPs) across New Zealand, found that 
when Māori did see a primary care provider their consultation was of shorter time 
than that of a non-Māori patient (mean length 13.7 minutes for Māori patients vs. 
15.1 minutes for non-Māori patients) (Crengle et al., 2005).  In the same study Māori 
were also less likely to be referred on for tests (Māori referred in 21.0% of visits 
compared to non-Māori in 25.4% of visits) or to a specialist service (Māori referred in 
14.7% of visits compared to non-Māori in 16.2% of visits) (Crengle et al., 2005).  Māori 
have also been shown to be less likely than non-Māori to collect a prescription due to 
cost, with Māori reported in the 2006/2007 New Zealand Health Survey as being 2.3 
times less likely to have collected a prescription due to cost than non-Māori/non-
Pacific people (Ministry of Health, 2008); using this same measure Māori were 2.4 
times less likely in the 2013/2014 Health Survey (Ministry of Health, 2014a). 
Furthermore the patient–provider relationship has been reported to be of lesser 
quality for Māori (Jansen et al., 2008; McCreanor and Naim, 2002; Crengle et al., 
2005).  Patient–provider communication is cited as a major barrier to Māori receiving 
quality healthcare (Jansen et al., 2008; McCreanor and Naim, 2002).  Doctors in the 
nationally representative survey of primary medical care services described in the 
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paragraph above reported lower levels of rapport with Māori patients (Crengle et al., 
2005).   Furthermore discourse analysis has been used to analyse the way 25 non-
Māori GPs talk about Māori health.  The analysis showed that GPs largely spoke in a 
way that blamed Māori for their poor health status and supported the view of 
individual responsibility for health, while ignoring the advances made by Māori which 
described health in holistic ways (McCreanor and Naim, 2002).  Moreover Māori 
patients have reported that they have been treated with disrespect by non-Māori 
health providers merely because they were Māori, based on the findings of ten focus 
groups across New Zealand (Jansen et al., 2008). 
Likewise, specialist and hospital services show differential accessibility and quality of 
care for Māori and non-Māori.  The 2006/07 New Zealand Health Survey (Ministry of 
Health, 2008) indicates that, despite high need for health care, Māori are less likely to 
see a specialist in an outpatient setting yet more likely than European/Other to access 
emergency department care or to be hospitalised.  Māori also have substantially 
higher rates of amenable or avoidable mortality and avoidable hospitalisation than 
non-Māori.  This suggests lesser access and uptake of primary prevention, primary 
health care and ambulatory treatment (Ministry of Health, 2010b).   
A number of studies show a lesser quality of secondary or tertiary health care received 
by Māori (Davis et al., 2006; Wilson and Barton, 2012; Westbrooke et al., 2001; 
Tukuitonga and Bindman, 2002; Harris et al., 2007). One of the most extensively 
researched examples is from cardiac care. 
Māori experience higher rates of, and mortality from, cardiovascular disease than do 
non-Māori (Curtis et al., 2007; Ministry of Health, 2013c) and so might also be 
expected to have higher rates of intervention cardiology (treatment to restore the 
heart’s blood supply that has been shown to reduce morbidity and mortality from 
cardiovascular disease).  Yet two studies that analysed intervention rates for 
cardiovascular disease through the 1990’s (Westbrooke et al., 2001; Tukuitonga and 
Bindman, 2002) found that Māori, while more likely to be hospitalised for heart failure 
(Westbrooke et al., 2001), were less likely to undergo intervention cardiology for that 
heart failure (Westbrooke et al., 2001; Tukuitonga and Bindman, 2002).  This disparity 
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remained after controlling for age, sex and deprivation level (Westbrooke et al., 2001), 
although the authors do not report adjusting for comorbidity which could have 
impacted results.  The differences by ethnicity are described as “disturbing” 
(Westbrooke et al., 2001) and as a failure of the health system as a whole to provide 
quality care (Tukuitonga and Bindman, 2002).   
Cardiac intervention rates have increased since the 1990’s, for both Māori and non-
Māori.  Yet, at least up until 2005, they remained lower for Māori despite much higher 
mortality (Curtis et al., 2007).   In more recent research on cardiac care within one 
large New Zealand hospital, Māori who received a coronary bypass (CABG) were more 
likely to have died at both 30-days and 1-year after surgery than non-Māori (Wang et 
al., 2013).  These differences remained after the authors adjusted for cardiac mortality 
risk factors such as smoking status, comorbidity and level of deprivation.  A national 
level study supports these mortality findings with Māori having substantially higher 
risk of mortality at 28-days and one-year than Europeans/Others after hospitalisation 
for acute coronary syndrome (unstable angina and any myocardial infarction or heart 
attack) (Grey et al., 2014).  Again the ethnic mortality disparity persisted after 
adjustment for socioeconomic status however treatment differences were not 
investigated.   So despite higher levels of cardiovascular disease in Māori (Ministry of 
Health, 2013c; Chan et al., 2008) and it being over a decade since the work of 
Westbrooke et al. clearly identified differential treatment by ethnicity, it appears that 
Māori continue to receive suboptimal cardiac care; certainly Māori have worse 
outcomes after a cardiac event than their non-Māori counterparts providing indirect 
evidence of Māori/non-Māori treatment disparity. 
Treatment disparity within cardiac care is likely in part to be related to access to and 
type of treatment facility.  A series of national audits undertaken through the last 
decade looking at the management of patients with acute coronary syndrome found 
considerable differences according to treatment facility type (Ellis et al., 2013; Ellis et 
al., 2010; Ellis et al., 2004).  In New Zealand a number of large tertiary public hospitals 
and three private hospitals, all sited in main centres, provide intervention cardiology 
services.  Patients admitted to these intervention hospitals waited less time and were 
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more likely to receive comprehensive cardiac investigations than patients admitted to 
non-intervention hospitals.  Intervention hospital patients were also more likely to 
receive state-of-the-art treatment than those admitted to non-intervention hospitals 
(Ellis et al., 2004; Ellis et al., 2010; Ellis et al., 2013).  Māori were significantly more 
likely to be admitted to a non-intervention hospital (Ellis et al., 2004; Ellis et al., 2010) 
meaning they were less likely to receive timely and quality care.  This provides an 
example of how structural issues, in this case the funding and location of health 
services, can in turn affect the accessibility of those services resulting in poorer care 
and poorer outcomes for certain groups in society.  
One further study that highlights differential receipt of quality care between Māori 
and non-Māori used adverse events while hospitalised as an overall indicator of 
treatment quality (Davis et al., 2006).  Adverse events can be a useful measure of 
quality as they reveal systematic failures to provide adequate staffing, training or 
policies and protocols resulting in undesirable health outcomes.  In this study Māori 
were more likely than non-Māori to experience any adverse event while hospitalised.   
Moreover after controlling for age, other demographic factors, and reason for 
hospitalisation Māori were 47% more likely to experience a ‘preventable’ adverse 
event defined as an error in health-care management due to failure to follow accepted 
practice at an individual or system level. Furthermore the study showed that despite a 
higher likelihood of harm when hospitalised Māori had shorter hospital stays than 
non-Māori (Davis et al., 2006).   
Summary: Māori/non-Māori Access to Health Services 
The findings above indicate that New Zealand health services are more accessible for 
non-Māori compared with Māori.  Māori are more likely to report unmet primary 
health care need; accordingly Māori are less likely to see a GP than non-Māori.  When 
they do see a primary care provider Māori are less likely to be referred on, less likely 
to fill a prescription, their consultation time is shorter than that of non-Māori patients 
and the provider-patient relationship is reported to be of lesser quality.    
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Likewise specialist and hospital services show differential accessibility for Māori and 
non-Māori patients.   Using cardiac care services as an example, while Māori have 
higher rates of, and mortality from, cardiovascular disease they also receive lesser 
rates of cardiac care, at lesser quality than non-Māori.  Māori are less likely to undergo 
intervention cardiology and when they do, they are more likely to die post-surgery 
than non-Māori.  These disparities are in part likely to be due to differences in access 
to intervention cardiology hospitals, with Māori significantly more likely to be 
admitted to a non-intervention hospital.  Furthermore, when hospitalised, Māori are 
more likely to experience an adverse event than non-Māori.  
These observations raise questions about why health services in New Zealand perform 
less well for Māori compared with non-Māori patients.  They point to institutional 
factors that privilege non-Māori and discriminate against Māori within New Zealand’s 
health care system.   
Māori/non-Māori Access to Cancer Services 
The inequity in observed between Māori and non-Māori in the provision of health care 
extends to the cancer context.  This section reviews recent studies, covering a number 
of cancers, which together provide compelling evidence of differential accessibility 
and quality of cancer care for Māori in New Zealand (Hill et al., 2010a; Hill et al., 
2010b; Sarfati et al., 2009; Alexander et al., 2010; Lawrenson, 2014; Obertova et al., 
2015; Stevens et al., 2008b; Seneviratne et al., 2014c; Seneviratne et al., 2014a; 
McLeod et al., 2010; Swart et al., 2013; Chamberlain et al., 2013; Seneviratne et al., 
2015).   None of these studies specifically examined Māori/non-Māori differences in 
treatment of stomach cancer. 
Colon Cancer 
Differences between Māori and non-Māori New Zealanders have been noted in the 
presentation and management of colon cancer.  These differences impact on survival.   
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Māori within the study by Hill et al (Hill et al., 2010a) outlined in the previous chapter, 
had poorer survival with unadjusted hazard ratios showing that Māori were 33% more 
likely than non-Māori to die from their colon cancer (HR 1.33; 95% CI, 1.03 -1.71).  
Adjusting for demographic, disease and patient factors (particularly comorbidity) 
accounted for one-third of the disparity (HR 1.20; 95% CI, 0.89 – 1.63).  While further 
adjusting for health care process and access factors (i.e. type of treatment received, 
timeliness to treatment, facility and surgeon type, deprivation and rurality) brought 
the hazard ratio close to null (HR 1.07; 95% CI, 0.77 – 1.47).  Māori in this study were 
more likely to present acutely in a hospital emergency room rather than through a 
primary care referral, more likely to live in highly deprived and/or rural areas, and 
more likely to be treated within a smaller non-cancer centre public hospital than 
either a tertiary or private facility.  These latter three factors were considered as 
markers of health service access.  In the case of deprivation the authors argued that 
while a patient’s level of deprivation may impact on survival through later stage at 
diagnosis and differential treatment, both of these factors were adjusted for prior to 
adjusting for deprivation in multivariable modelling.  This means that the remaining 
effect of deprivation was likely to have occurred primarily through its influence on 
access through health and cancer care services.  The results suggest that the majority 
of the colorectal cancer survival disparity evident between Māori and non-Māori is 
explained by these latter factors, with factors associated with access to health care 
services, accounting for around one-third of the differential survival outcomes (Hill et 
al., 2010a).    
In this study, Māori and non-Māori had similar rates of surgical resection however 
Māori patients were less likely to undergo extensive lymph node clearance and were 
more likely to die during the postoperative period, indicating receipt of a lesser quality 
surgical care than that received by non-Māori patients (Hill et al., 2010a).  
Furthermore most Māori patients who died post-operatively underwent their surgery 
in a smaller non-cancer centre public hospital (Hill et al., 2010b).  In addition Māori 
with stage III disease were 20% less likely than non-Māori to be offered chemotherapy 
and 30% less likely to receive chemotherapy within 8 weeks of surgery, even after 
clinical factors were adjusted for (i.e. age, sex, year of diagnosis, tumour site, tumour 
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grade and comorbidity).  Māori were also substantively more likely to experience a 
delay of at least 8 weeks before starting chemotherapy (RR, 1.98; 95%CI, 1.23-3.16). 
This is despite adjuvant chemotherapy within 8 weeks of surgery being the 
recommended treatment for stage III colon cancer patients at the time (Hill et al., 
2010b).   
Comorbidity was common among patients in this study overall but Māori patients 
were more likely than non-Māori to have each of the comorbidities that were 
recorded within the study, except neurological disorders (Hill et al., 2010b; Hill et al., 
2010a).  Further analysis from this study provided evidence of a pathway through 
which disparities in cancer care and outcomes could occur; the analysis suggested that 
comorbidity played a role in the differential receipt of chemotherapy and 
subsequently on survival (Sarfati et al., 2009).  Both presence of comorbidity, and 
increasing age, were significantly associated with a lesser likelihood of being offered 
chemotherapy (16% of patients with a Charlson score of 3 or more were offered 
chemotherapy compared with 81% of patients with a score of 0).  Not being offered 
chemotherapy was in turn associated with poorer survival (HR 2.32; 95% CI, 1.34 – 
4.00, colon cancer specific survival, adjusted for age, sex and comorbidity).  Those with 
higher levels of comorbidity had substantially poorer survival than those without, but 
those with comorbidity who were offered chemotherapy had 60% better survival than 
those with comorbidity who were not offered chemotherapy (Sarfati et al., 2009).    
Overall this study showed that Māori with colon cancer are less likely to get high 
quality, and timely, cancer care and that this differential care impacts negatively on 
subsequent survival for Māori.   In part, this poorer survival is due to higher levels of 
comorbidity among Māori.  Further analyses by Sarfati et al (Sarfati et al., 2009) clearly 
shows that were those with comorbidity were substantially less likely to receive 
chemotherapy despite the fact that chemotherapy was found to reduce the mortality 
risk in patients with stage III disease, even in those with the highest levels of 
comorbidity.  In other words this paper suggested that patients with comorbidity, of 
whom Māori comprise a higher proportion, might be undertreated with adjuvant 
therapy – and that if they were treated, their survival would likely improve.  These 
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observations raise questions.  Why are Māori with colon cancer less likely to receive 
chemotherapy than non-Māori, and when they do receive it why is its receipt more 
likely to be delayed?  Why do Māori patients receive lesser quality surgical care than 
non-Māori?  Is this a deficit on the part of Māori with colon cancer or could it be that 
the health system performs better for non-Māori New Zealanders and thus privileges 
them with better survival outcomes? 
Breast Cancer 
New Zealand has a publicly funded breast cancer screening programme (BreastScreen 
Aotearoa) which is open to all women aged 45 to 69 years.  However, participation is 
known to differ by ethnic group with substantially lower participation for Māori 
women than non-Māori women (Page and Taylor, 2008; Sarfati et al., 2010b).  In turn, 
Māori women with breast cancer have been shown to be more likely to be diagnosed 
with advanced cancer than non-Māori women, in part explained by their lower rate of 
screen detected cancer (Seneviratne et al., 2015a).    Māori women also had higher 
rates of mastectomy for cancers potentially amenable to breast conserving surgery 
(Seneviratne et al., 2015b) and longer waiting times for both surgical care (Seneviratne 
et al., 2014c) and adjuvant therapy (Seneviratne et al., 2014a) when compared with 
non-Māori women.  The waiting times experienced by Māori fall outside of current 
recommendations and in the case of adjuvant therapy impact negatively on survival 
(Seneviratne et al., 2015a).  Survival was also significantly lower for Māori women, 
compared to NZ European women who were diagnosed symptomatically rather than 
through BreastScreen Aotearoa (Seneviratne et al., 2015a).    Furthermore the age-
adjusted risk of death from breast cancer for Māori women, which was more than 
twice that for NZ European women, was largely explained by differences in stage at 
diagnosis, screening, treatment and patient factors (comorbidity, obesity and 
smoking) (Seneviratne et al., 2015).  The study on which these papers were based 
used Waikato (a region of New Zealand) breast cancer register data (WBCR) which is a 
comprehensive database of breast cancers diagnosed since 1999 within the Waikato 
region.  The data held by WBCR has been shown to be more accurate than that of the 
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NZCR (Seneviratne et al., 2014b), including not only accurate staging data but also 
detailed presenting, diagnostic and treatment information from both public and 
private treatment facilities.  
Several papers by Seneviratne and colleagues reported the analysis of the WBCR data.   
The first paper on 1846 women of screening age diagnosed with breast cancer 
between 1999 and 2012 (Seneviratne et al., 2015a) reported that Māori women were 
significantly more likely to be diagnosed with more advanced cancer compared with 
NZ European women (OR = 1.49, p =<0.05, adjusted for age).   Half of this stage 
difference was explained by lower rate of screen detected cancer for Māori women 
(OR = 1.25, p =0.101, adjusted for age, year of diagnosis and screening status).    For 
those cancers detected symptomatically, Māori had significantly lower 5-year (64.2% 
vs. 83.2%, p< 0.001) and 10-year breast cancer survival compared with NZ European 
(46.5% vs. 73.2%, p< 0.001).  No significant survival differences were observed for 
screen detected cancer by ethnicity or socioeconomic deprivation (Seneviratne et al., 
2015a) which highlights the potential for organised screening to improve survival and 
reduce disparities in breast cancer outcomes in New Zealand.  
Another paper by Seneviratne and colleagues investigated ethnic differences in the 
surgical management of breast cancer for 2848 women newly diagnosed between 
1999 – 2012 (Seneviratne et al., 2015b).  Māori were significantly more likely to 
undergo mastectomy for cancers, which were potentially amenable for breast 
conserving surgery (42% vs. 34%, P = <0.05), but were significantly less likely to 
undergo post-mastectomy breast reconstruction (12% vs. 35%, P < 0.001), than NZ 
Europeans.  While women treated within a public sector hospital also appeared more 
likely to undergo mastectomy (36% vs. 33%, p = <0.05) and less likely to undergo post-
mastectomy breast reconstruction (23% vs. 42%, p= 0,002) than women treated 
within the private sector.  No differences were observed in rates of sentinel node 
biopsy or local therapy for stage I – II cancers (Seneviratne et al., 2015b). 
Of the 1264 women undergoing primary surgery for their breast cancer between 2005 
and 2010 (Seneviratne et al., 2014c) Māori women were on average younger at 
diagnosis than NZ European women.  As well a significantly higher proportion of Māori 
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lived in areas of higher deprivation and at a distance greater than 100kms from a 
treatment facility.   Compared to NZ Europeans, Māori were also more likely to be 
diagnosed with later stage disease.  In regards to treatment Māori women were less 
likely to receive surgery at a private facility than were NZ European women (8.1% vs. 
32.5%, p= 0.001) and waited significantly longer for surgery than did NZ European 
women (mean = 37.1 days vs. mean 30.4 days, p = 0.005).  In multivariable modelling a 
number of factors were associated with these longer wait times to receipt of surgical 
care.  These factors included treatment within the public sector, stage at diagnosis, 
higher co-morbidity scores, having a mastectomy rather than breast conserving 
surgery and earlier year of diagnosis (after adjusting for age, socioeconomic status, 
mode of diagnosis and distance from hospital).  Of note, nearly two-thirds of NZ 
European women (within the screening age) were diagnosed through Breast Screen 
Aotearoa (BSA), while less than half of the Māori women in the study were (63.7% vs. 
49.7%, p = < <0.05).  This is important as a much higher proportion of non-BSA 
diagnosed women compared to BSA diagnosed women - who were subsequently 
treated within the public sector s- had a delay in treatment longer than 31 days (55.7% 
vs. 47.3%, p = <0.05).  This difference was even greater for Māori women; 59.6% of 
Māori women who were diagnosed symptomatically and treated publicly had a delay 
in treatment longer than 31 days compared with 37.3% of Māori women who were 
diagnosed through BSA (p = <0.05).  Thus the ethnic difference in BSA participation 
rates in effect meant that fewer Māori received the advantage that the quality 
standards and auditing of the programme confer on those diagnosed in this way 
(Seneviratne et al., 2014c).   Thirty one days is the threshold for the longest acceptable 
delay in access to surgical treatment as set by the Ministry of Health in their Faster 
Cancer Treatment Indicators (Ministry of Health, 2014b). 
Further analysis on the Waikato data by Seneviratne and colleagues (Seneviratne et 
al., 2014a) focussed on chemotherapy use in 1918 women with non-metastatic breast 
cancer.   Factors associated with delay in adjuvant chemotherapy (using a 60-day 
threshold) and radiotherapy (using a 90-day threshold) for breast cancer were 
investigated and compared between Māori and NZ European women.  As with surgical 
care, higher proportions of Māori women compared with NZ European women 
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experienced delays longer than thresholds for adjuvant chemotherapy (37.3% vs. 
30.5%, p= 0.103) and radiation therapy (39.8% vs. 30.6%, p = <0.05), although in the 
former case p values do not denote statistical significance.  In multivariate modelling 
being Māori, living rurally rather than in an urban area, requiring a surgical re-excision 
and receipt of surgical treatment in public compared with private hospitals were all 
associated with longer delays for first adjuvant therapy (p = < 0.05), although being of 
Māori ethnicity was only statistically significant for delay to radiation therapy.   Delay 
in receiving first adjuvant therapy also appeared to impact on mortality with a hazard 
ratio of 1.45 (95% CI, 1.05-2.01) and non-significant hazard ratios for delay in 
chemotherapy and radiotherapy, 1.34 and 1.28 respectively (adjusted for a large 
number of patient and tumour factors) (Seneviratne et al., 2014a). 
A final paper by Seneviratne and colleagues (Seneviratne et al., 2015), which included 
2,679 women, attempted to explain the survival disparity between observed Māori 
and non-Māori women.  It reports significantly lower 5 year (86.8 vs. 76.1 %, p < 
0.001) and 10 year (79.9 vs. 66.9 %, p < 0.001) crude cancer-specific survivals for 
Māori compared with NZ European women.   Māori women also had significantly 
higher age-adjusted cancer-specific mortality (HR 2.02; 95 % CI, 1.59-2.58).  When this 
was incrementally adjusted for various explanatory factors, stage at diagnosis 
explained 25-40 % of the survival disparity, while screening, treatment and patient 
factors (comorbidity, obesity and smoking) contributed approximately 15% each 
toward the observed survival disparity with almost all of the cancer survival disparity 
accounted for within the final model (HR 1.07; 95 % CI, 0.80-1.44) (Seneviratne et al., 
2015). 
Taken as a whole these papers by Seneviratne and colleagues are consistent with non-
Māori women receiving care that could be conducive with a survival advantage over 
their Māori peers through a number of mechanisms; they were less likely to live 
rurally further from a cancer treatment centre, less likely to live in a socioeconomically 
deprived area, less likely to have comorbidity, more likely to be diagnosed early, more 
likely to be diagnosed through the national screening programme BSA and thus 
privileged by the programmes quality standards, more likely to be treated privately 
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with less lengthy waiting times and when treated within the public system waited less 
time for surgical and adjuvant care than did Māori women.  Furthermore non-Māori 
women were more likely to undergo breast conserving surgery and when they did 
have a total mastectomy were more likely to undergo breast reconstruction post-
mastectomy.  These differences appear to impact on survival.   Women whose first 
adjuvant therapy was delayed, of which a higher proportion were Māori, had a 45% 
higher likelihood of dying than women whose therapy was not delayed (95% CI, 1.05-
2.01).  Additionally in women whose breast cancer was diagnosed symptomatically 
both 5-year and 10-year survival was poorer for Māori women compared with NZ 
European women, while no significant ethnic difference in survival was observed for 
women whose breast cancer was screen-detected.   This latter finding highlights the 
potential for organised screening, with agreed and monitored pathways of care, to not 
only improve survival overall but to also reduce survival disparities between Māori and 
non-Māori women. 
Prostate Cancer 
Despite having lower incidence rates Māori men are nearly twice as likely to die of 
prostate cancer as non-Māori men (Obertova et al., 2014b).  In part this differential 
survival is shown to be due to higher rates of prostate specific androgen (PSA) 
screening in non-Māori men which results in over-diagnosis of cancers with 
questionable clinical significance and thus very high survival rates (Obertova et al., 
2014a).  In addition, Māori had higher Gleason scores (extent of disease) at diagnosis 
and greater likelihood of being diagnosed with stage IV metastatic disease (Obertova 
et al., 2015).  However two studies suggest that differential treatment contributes to 
the poorer prostate cancer survival profile seen in Māori men. 
The first of the two studies that investigated prostate cancer treatment patterns 
examined the use of surgery (orchidectomy), androgen deprivation therapy (ADT) and 
chemotherapeutic agents in 15,947 New Zealand men diagnosed between 2006 and 
2011 (Lawrenson, 2014).  The study identified men from the NZCR and linked data 
with the Pharmaceutical Collection and the National Minimum Dataset to identify 
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receipt of treatment in the first year post-diagnosis.  Māori, Pacific and non-
Māori/non-Pacific men were compared.  Chemotherapy and ADT was received by few 
patients overall (0.2% and 31.2% respectively).  Māori men were more likely to receive 
ADT and be treated with orchidectomy than non-Māori/non-Pacific men.   In 
regression modelling Māori men with advanced disease (regional or metastatic) were 
twice as likely to receive ADT as non-Māori/non-Pacific men with advanced disease, 
adjusted for age and combinations of age, year of diagnosis and orchidectomy.    One 
limitation of the study is that it relied on NZCR staging data, which has largely missing 
stage data for prostate cancer, thus 71.7% of patients in the study were recorded as 
having ‘unknown’ extent of disease and treatment by stage was unable to be 
accurately assessed.   Despite this limitation it appears there is some treatment 
differential between Māori/non-Māori in this study, however the authors do not 
comment on this ethnic difference specifically, rather they conclude that overall ADT 
and chemotherapy are under-utilised in New Zealand patients with prostate cancer 
(Lawrenson, 2014). 
The second study looking at prostate cancer treatment patterns investigated the 
disease in 136 Māori and 400 NZ European men (Obertova et al., 2015).  The study 
identified patients through the NZCR but used data gathered through clinical note 
review to circumvent the largely missing stage data held by the NZCR.  The authors 
reported stage and demographic data for the total cohort and went on to investigate 
treatment disparities for the 406 (76.1%) men with localised prostate disease only.  
Overall, Māori men in this study were more likely to have metastatic disease, more 
likely to live in the most deprived areas and more likely to have multiple comorbidities 
than non-Māori men.  For those men that were diagnosed with localised prostate 
cancer, which is potentially highly curable with a fifteen-year survival rate of around 
80%, Māori men were 34% less likely to be treated with surgery (radical 
prostatectomy) and 73% less likely to be treated with low-dose brachytherapy.  Māori 
men were substantially more likely (more than twice) to be treated with either high-
dose brachytherapy or external beam radiation, both of which carry the risk of more 
severe side-effects than does low-dose brachytherapy.  Māori men were also more 
likely to be treated conservatively with either active surveillance or watchful waiting, 
UNDERSTANDING INEQUITY AND INTERVENTIONS  
129 
 
than were non-Māori men in the study.  Multivariate analysis showed that even once 
adjusted for comorbidity, age, socioeconomic status and extent of disease factors 
Māori men were in fact 74% more likely to be managed conservatively than non-Māori 
men (Obertova et al., 2015).   
While neither study investigated survival they show markedly differential treatment 
for Māori and non-Māori males.  In the case of localised prostate cancer these 
treatment differentials are not explained by patient characteristics, such as 
comorbidities or extent of disease factors at diagnosis. So while poorer survival 
outcomes for Māori men may be related to later stage at diagnosis, which most 
probably reflects differential access within the primary care setting, differences in 
treatment once diagnosed with prostate cancer may also be a factor. 
Brain Cancer 
A study on high grade glioma, also reviewed in the previous chapter, investigated both 
receipt of treatment and survival by ethnicity.  It reported differential treatment 
between Māori and non-Māori (Alexander et al., 2010).   Although with only 19 Māori 
(6.3%) within the study the findings must be interpreted with caution.  In this case, 
Māori were more likely than non-Māori to have their tumour completely resected (OR 
3.59, 95% CI 1.01-12.76).  However Māori were also more likely to not have extent of 
surgery recorded (16% Māori vs. 5% non-Māori, p= 0.048).    Waiting times for 
radiotherapy are an important predictor of survival for patients with high grade glioma 
and this study provided some evidence that Māori patients waited longer than non-
Māori for radiotherapy (median 47 days vs. 34 days, p = 0.065).  Hazard ratios failed to 
reach statistical significance, however they did suggest survival disparity for Māori (HR 
adjusted for age, grade, performance status at presentation and extent of surgery 
1.55; 95% CI, 0.95 – 2.55, p = 0.082) (Alexander et al., 2010).  




In a study that investigated the management of lung cancer comparing (n=565) Māori, 
Pacific peoples and New Zealand (NZ) Europeans, Stevens et al highlight lower rates of 
curative treatment for Māori (Stevens et al., 2008b).  As the study was based on data 
from a clinical note review it utilised detailed information on patient, tumour and 
clinical management factors.   Māori within the study were on average 10 years 
younger at diagnosis than NZ Europeans; they were also more likely to be a current or 
past smoker, to live in the most deprived communities and more likely to have COPD 
or diabetes.  As with prostate cancer Māori were diagnosed with poorer stage disease.  
Māori were half as likely to be diagnosed with localised disease (Māori/NZ European 
Odds Ratio 0.5, 95% CI, 0.3 – 1.00) and 2.5 times more likely to be diagnosed with 
locally advanced disease than NZ Europeans (Māori/NZ European Odds Ratio 2.6, 95% 
CI, 1.3 – 5.3, p < 0.01).  Both of these odds ratios were adjusted for age, gender, level 
of deprivation and comorbidity.  In terms of receipt of treatment once diagnosed with 
lung cancer, treatment with curative intent was given to only 12% of Māori compared 
with 22% of NZ European patients; this difference was not accounted for by 
differences in either patient or disease factors (age, gender, level of deprivation, 
comorbidity, tumour type, stage, and the patient declining treatment). Māori also 
waited on average 44 more days from diagnosis until start of treatment than did NZ 
Europeans (Māori 43 days (25–62) vs. NZ European 29 days (12–52)).  This delay until 
treatment remained statistically significant (p =<0.05) even after adjusting for 
documented patient-related delays such as deferring or missing appointments 
(Stevens et al., 2008b).  This study identified substantial differences in management 
between Māori and non-Māori for lung cancer; including less curative treatment and 
longer waiting times for that treatment in the Māori patients. The authors concluded 
that, while later stage disease played a role, these treatment differences would likely 
impact on subsequent survival. 




Three further separate studies investigating cervical (McLeod et al., 2010), rectal 
(Swart et al., 2013) and hepatocellular (Chamberlain et al., 2013) cancers all found 
that Māori and non-Māori patients received similar levels of treatment for these 
cancers, although there were delays in referral for adjuvant treatments for Māori with 
rectal cancer (Swart et al., 2013).  In each study however survival appeared to be 
poorer for Māori compared to non-Māori.  With small numbers, the rectal and 
hepatocellular studies were underpowered to determine this definitively, however in 
the larger cervical cancer study the association was statistically significant (Māori/non-
Māori HR 2.07; 95% CI, 1.63-2.62) (McLeod et al., 2010).  Māori had higher prevalence 
of comorbidity in both the rectal and hepatocellular cancer studies which is likely to 
have impacted on their survival.  Within the cervical cancer study Māori women were 
likely to be diagnosed with more advanced stage disease which is likely to be in part 
attributable to their documented lower enrolment and participation in New Zealand’s 
National Cervical Screening Programme than that of non-Māori women (Sadler et al., 
2004; Independent Monitoring Group, 2008).  Stage at diagnosis accounted for some 
but not all of the difference in cervical cancer specific survival between Māori and 
non-Māori in the study.  Although this finding must be interpreted with some caution 
as the study used national level data in which 36.9% of Māori and 33.2% of non-Māori 
women were recorded as stage unknown (McLeod et al., 2010).  
Summary: Māori/non-Māori Access to Cancer Services 
As with the health system in general the findings above suggest that Māori and non-
Māori New Zealanders diagnosed with cancer experience differential access to, and 
quality of, health care with Māori less likely to receive quality, and timely, care.  
Furthermore this differential care impacts negatively on subsequent survival for 
Māori.   
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In a number of cancers Māori were more likely than non-Māori to be diagnosed with 
later stage disease (Hill et al., 2010a; Obertova et al., 2015; Stevens et al., 2008b; 
McLeod et al., 2010).  For women with breast cancer, this later stage was in part 
explained by a lower rate of screen detected cancer (Seneviratne et al., 2015a).   
Māori were also more likely than non-Māori to present acutely rather than through 
the primary care pathway (Hill et al., 2010a), to have comorbidity (Swart et al., 2013; 
Chamberlain et al., 2013; Hill et al., 2010a; Obertova et al., 2015; Stevens et al., 
2008b) and to live in highly deprived (Hill et al., 2010a; Stevens et al., 2008b; 
Seneviratne et al., 2014c; Obertova et al., 2015), and/or rural areas (Hill et al., 2010a; 
Seneviratne et al., 2014c) further from cancer treatment centres.    
In terms of treatment and management, Māori were more likely than non-Māori to be 
treated within a smaller non-cancer centre public hospital than either a tertiary or 
private facility (Hill et al., 2010a; Seneviratne et al., 2014c), were less likely to receive 
curative treatment for their cancer (Hill et al., 2010a; Stevens et al., 2008b; Obertova 
et al., 2015), were more likely to die post-operatively (Hill et al., 2010a) and were 
more likely to experience longer times through the treatment pathway (Swart et al., 
2013; Hill et al., 2010b; Stevens et al., 2008b; Alexander et al., 2010; Obertova et al., 
2015; Seneviratne et al., 2014a).  In the case of breast cancer these waiting times were 
partly explained by lesser access to organised cancer screening and the benefits 
imparted through being involved in its standardised, and monitored, pathways of care 
(Seneviratne et al., 2015a), and partly explained by differences in the type of facility 
patients were treated in (Seneviratne et al., 2014a).   
Delays in receiving adjuvant therapy impacted negatively on breast cancer survival 
(Seneviratne et al., 2014a).  One third of the differential colon cancer survival 
outcomes observed between Māori and non-Māori were due to factors associated 
with access to health care services (Hill et al., 2010a).   One third was also due to 
comorbidity (Hill et al., 2010a).  Furthermore, when patients with the highest levels of 
comorbidity in this study did receive chemotherapy their mortality risk was 
substantially reduced.  This suggests under-treatment of patients with comorbidity, of 
whom Māori comprised a higher proportion (Sarfati et al., 2009).   
UNDERSTANDING INEQUITY AND INTERVENTIONS  
133 
 
While survival differences are in part due to the lesser access to screening and later 
stage at diagnosis along with the higher levels of comorbidity observed in Māori 
compared with non-Māori, the poorer cancer survival seen within New Zealand’s 
indigenous Māori is also in part due to differential access to, and quality of, cancer 
treatment services (Hill et al., 2010a; Seneviratne et al., 2015).  These differences 
reflect evidence of health system factors that privilege non-Māori and disadvantage 
Māori.   
Taken together these studies raise the questions: why do Māori receive differential 
cancer care compared to the majority non-Māori population, especially in the New 
Zealand context of a publicly funded (and theoretically accessible) secondary and 
tertiary health care system? Does this reflect institutionalised racism within health 
care?  Finally, what can be done to mitigate this? 
How and Where to Intervene 
With the known stomach cancer survival disparity between Māori and non-Māori in 
New Zealand, this thesis started with the premise that the different ethnic groups 
(Māori and non-Māori) may receive differential access to, and quality of, care for their 
stomach cancer.  As a thesis in the discipline of Public Health it was also important to 
also explore how to intervene to better enable equitable access to, and through, 
treatment services.  This approach is supported by leading researchers on racism in 
health care (Jones, 2002; Feagin and Bennefield, 2014; Krieger, 2003).  Indeed 
Woodward and Kawachi (Woodward and Kawachi, 2000) argue that as health 
disparities arise from deliberate policy options of successive governments (such as the 
finance, health and welfare policies through eras of colonisation and neoliberalism 
outlined in Chapter 2) they should be amenable to intervention.   
The following section firstly outlines a framework for thinking about strategies and 
actions to address cancer care disparities for Māori.   The framework, by Mandelblatt 
and colleagues (Mandelblatt et al., 1999), has been used previously in New Zealand to 
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investigate Māori/non-Māori cancer care disparity and recommend interventions to 
improve access to care (Hill et al., 2013; Cormack et al., 2005; Walker et al., 2008).   
Importantly, the framework is also used to consider the qualitative results of this 
study in a following chapter and to organise this study’s discussion.  
Secondly the following section goes on to review interventions that have the potential 
to improve access to, and through, cancer services for Māori in New Zealand.  A search 
for literature on interventions specific to stomach cancer was undertaken however no 
previous studies were found that described interventions to improve minority group, 
indigenous or Māori access to stomach cancer services.  Instead the section below 
draws on related literature which provides context to improving Māori access to, and 
through, cancer services more generally.  The framework of Mandelblatt et al 
(Mandelblatt et al., 1999) is also used to consider this literature. 
Mandelblatt: A Framework to Guide Intervention 
Thinking  
According to Mandelblatt et al (Mandelblatt et al., 1999), inequities in accessing 
cancer care may arise at a number of levels.  Inequities can stem from structural 
barriers, factors that influence physician recommendations and factors that affect 
patient choice.  These levels have since been grouped into a three-tiered conceptual 
framework which considers barriers at: a) the level of the health system as a whole, b) 
the health care processes within that system or c) at the level of the individual or 
patient (Shavers and Brown, 2002; Cormack et al., 2005).   Importantly while the 
framework does include a patient level, a key feature of the framework is that it looks 
beyond the individual (both the individual patient and the health care worker) to 
consider the role the health system as a whole plays, in access to cancer services (Hill 
et al., 2013). 
The health system level includes factors related to the context of the health system 
and the environment in which it operates.  Factors such as the funding, location and 
resourcing of cancer services each contribute to issues around accessing those 
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services (Mandelblatt et al., 1999).  In the New Zealand context the universal (or 
monocultural) focus of the system and the cultural responsiveness of services have 
also been recognised as factors to do with the health system which impact on access 
to cancer services for Māori (Cormack et al., 2005; Hill et al., 2013).  
In contrast the health care process level includes factors to do with the way in which 
services and providers of care work and communicate, both with each other and with 
patients and/or whānau, and how these impact on pathways through care.  This level 
includes the predominantly non-Māori composition of the health workforce along 
with other characteristics of the workforce such as age, gender, cultural competence, 
bias and communication skills and the impact these characteristics have on the 
patient-provider relationship (Mandelblatt et al., 1999; Cormack et al., 2005; Hill et al., 
2013).   
Finally individual or patient level factors that have been shown to impact on access to, 
and through, cancer services include patient demographics such as age, ethnicity, sex, 
socio-economic position, level of education and/or income along with personal 
decision making or patient choice.   Stage at diagnosis and level of comorbidity are 
also said to be patient level factors although both reflect in part access to and the 
distribution of underlying determinants of health and resultant disadvantage or 
privilege (Cormack et al., 2005; Mandelblatt et al., 1999; Hill et al., 2013).   
Conventionally, when discussing access to cancer services, the focus has been on 
factors at an individual level such as patient socio-economic status although in reality 
access is likely to be multidimensional and multilevel with some factors fitting under 
more than one level (Cormack et al., 2005).  For example one’s socio-economic status 
and concomitant level of ability to pay for costs associated with cancer care (i.e. travel 
to a regional cancer centre or time away from work) could be viewed either as an 
individual level factor or in another way as a health system factor where the focus is 
on the location and resourcing of cancer services (Hill et al., 2013).  
Hill and colleagues (Hill et al., 2013) urge that focus is placed beyond the individual in 
order to improve the quality and equity of cancer services and impact on cancer 
survival in indigenous people.  Indeed placing focus on the individual or patient plays 
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into the individual responsibility espoused within the era of neo-liberalism where in 
effect people are blamed for their ill-health.  With this focus, interventions then target 
individual people or population groups to change their behaviour in order to receive 
‘better’ health care.  In comparison placing focus on the health care system and 
processes levels corresponds with Jones’ model of racism and health and places focus 
on institutional racism as a key driver of unequal treatment.  In other words, if the way 
in which health services are organised and delivered means some ethnic groups 
receive better care than others, including both access to and quality of cancer care, 
this then reflects institutional racism within the health system.  Thus under this lens, 
interventions become focussed on the health care system and processes within it and 
how these can better meet the needs of all people.    
Improving Access to, and through, Cancer Services in New 
Zealand 
As identified by Cormack (Cormack et al., 2005) the pathway for someone diagnosed 
with cancer is likely to be complex, often involving multiple health professionals within 
multiple providers, and so the interventions to improve access to services also need to 
be complex.  Certainly, patients diagnosed with stomach cancer have diverse and 
complex needs (NHS Executive, 2001) which necessitate care from many different 
professional groups (Palser et al., 2009; NHS Executive, 2001).  In addition the causes 
of ethnic disparities in cancer are multi-level, and therefore according to Cormack et al 
(Cormack et al., 2005) approaches to addressing disparities in cancer care should also 
be multi-level and comprehensive.   Others support addressing multiple issues or 
implementing multi-factor interventions in order to optimise cancer services 
responsiveness to priority groups and effectively address equity (Porter, 2008; New 
Zealand Guidelines Group, 2009; Power et al., 2009).  In line with this call for a multi-
factorial approach this section looks at possible interventions within the different 
levels of the Mandelblatt et al framework introduced above.   
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Three key reports, and three qualitative studies, summarise how and where to 
intervene to improve access to cancer services, generally rather than specifically for 
stomach cancer, for Māori in New Zealand.    The interventions suggested below are 
primarily based on key informant views highlighting the general lack of evidence on 
the effectiveness of interventions to improve equity in health care, although the work 
of Cram (Cram, 2014a; Cram, 2014b) does include a review of available equity-related 
intervention literature.   
The first of the key reports, that of Cormack et al identified above (Cormack et al., 
2005), outlined barriers to access for Māori at each of the three levels of the 
Mandelblatt framework.  However while Cormack et al undertook a stock take of 
interventions to improve access they conclude that there was a “lack of 
comprehensive interventions, current or planned, to specifically address Māori access 
to cancer services” and that “those interventions that were identified were limited 
and isolated” (Cormack et al., 2005: 48).   The report did though identify a range of 
high level interventions that the authors considered would contribute to improved 
access.  While supported through review of relevant literature the interventions 
recommended within the report appear to be based primarily on the findings of key 
informant interviews, albeit (as health professionals working within the health care 
system) informants well informed about the provision of cancer services to Māori in 
New Zealand.   Some of these interventions have been wholly or in part addressed in 
the time since this report was released in 2005.  For example, initiatives such as the 
nationally funded 57 Cancer Nurse Coordinators have begun to address the call for 
patient navigation or case coordination to enable patients to better navigate the 
complex cancer care system. Although these positions are based in DHBs and the 
report also calls for additional resource for Māori Health Providers to better enable 
Māori to attend to the needs of people with cancer.   Other interventions are likely to 
be on-going, including interventions such as strengthening the inequalities focus of 
cancer control policies, providing community-based or outreach cancer services, 
comprehensive training of the cancer control workforce to provide culturally safe and 
responsive services for Māori, involving Māori expertise in multidisciplinary teams and 
improved service coordination and discharge planning.  Table 3 below summarises the 
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interventions put forward by Cormack et al according to the framework of 
Mandelblatt et al. 
The second and third more recent reports both by Cram are results of a literature 
review (Cram, 2014a) and health professional key informant interviews (Cram, 2014b).  
Although this key informant work focussed not only on access to cancer care but also 
to care for diabetes and cardiovascular disease for Māori, the findings are relevant.  In 
the literature review Cram reviewed 42 individual and seven review papers on 
interventions to improve access to cancer care for indigenous people and minority 
groups.  Importantly Cram also did not find papers specific to stomach cancer (Cram, 
2014a).  Following the review of literature Cram then utilised 41 New Zealand health 
professional key informant interviews to identify further interventions (Cram, 2014b).  
The key findings from the two reports by Cram are outlined below within the 
framework popularised by Mandelblatt.  Again, see Table 3 below for a summary of 
interventions. 
Health systems factors identified by Cram included the health system having the 
commitment to, as well as leadership in, improving equity, the use of local and/or 
relevant data to plan and monitor services along with the establishment of universal 
health targets, rather than different targets for different ethnic groups.   
Health care process factors identified by Cram centred around developing health 
practitioners cultural competency and skill in communicating with Māori patients as 
well as utilising brokers (such as community health workers or patient navigators) to 
help bridge any cultural gap between Māori and the predominately mainstream (non-
Māori) cancer services.  Both of these approaches improved both knowledge and self-
reported efficacy of health professionals in dealing with indigenous patients with 
cancer.  Patient navigation was shown in the literature reviewed by Cram to improve 
access, adherence and timeliness through the cancer pathway over that of non-
navigated control groups.  Importantly though Cram highlighted the need for health 
care organisations to also make services easier to navigate alongside the use of 
patient navigators or nursing care coordinators.  Key informants also advocated for 
changes in health workforce roles and funding formulas especially those that support 
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an increased nursing workforce.  Specific interventions suggested by key informants to 
improve cultural competency included educating health practitioners, taking time to 
develop a personal connection with Māori patients and partnering to include 
culturally competent practitioners within teams.  As well, the development of 
decision-making tools and guidelines were shown to support equitable decision 
making by practitioners.  
Patient factors identified by Cram’s key informants included the need to mitigate 
barriers such as cost of, and transport to, services and to support whānau-based and 
holistic self-management.  While the need for improved health literacy was seen as 
important, it was framed as the responsibility of health care system and the services 
within it to provide culturally tailored and responsive information and services thus 
making them more likely to be acceptable to Māori. 
Three further qualitative studies made similar recommendations to those above 
(Walker et al., 2008; Slater et al., 2013; Dew et al., 2015).   Each of these three studies 
examined Māori experiences of cancer and cancer care, based on focus groups and 
interviews.  Together these studies represent the views of 75 Māori patients, survivors 
and whānau.  Walker and colleagues (Walker et al., 2008) explicitly used the 
framework of Mandelblatt to organise the findings while the remaining two studies 
can be considered in this way.   Their findings are summarised here and in Table 3.  
Participants’ suggestions at the health systems level included providing more frequent 
specialist clinics in rural areas, better coordination of service delivery and better 
resourcing of Māori health providers to deal with cancer.  At the health care process 
level participants suggested recruiting more Māori health care staff, increasing cultural 
competence of all staff, allowing longer consultation times and the use of cancer 
navigators.  Patient level suggestions focussed on finding ways to better include 
whānau and to integrate Māori medicines or approaches to health in cancer care and 
taking a more active approach to informing Māori of the support available to them. 
Importantly the findings and recommendations of each of the reports and studies 
above are similar.  To rephrase, key informants, both health care professionals 
working within the cancer sector and Māori themselves who have experienced cancer 
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care, have for the preceding decade concurred on how to improve cancer services for 
Māori.  Interventions highlighted as being effective in improving equity within these 
reports and studies are summarised below in Table 3.  The interventions are 
considered again within the discussion of this thesis also using the framework of 
Mandelblatt et al.  Importantly though, while relevant, none of these studies are 






Table 3: Interventions identified within the literature according to the framework of barriers to access; Mandelblatt et al 
Framework Level Issue identified Interventions suggested  
Health system-
level 
Total population or 
mono-cultural focus 
Develop cancer control policy for Māori and strengthen equity focus in existing policy 
Have commitment to, and leadership in, improving equity 
Use local and/or relevant data to plan and monitor services by equity 
Establish universal health targets 
Engage with Māori leaders,  communities and organisations 
Involve Māori expertise in multi-disciplinary teams 
Incorporate Māori healing interventions and a whānau-based approach to care 
Funding, resourcing and 
location of cancer 
services 
Address differential access to services and to entitlements by region 
Provide community based or outreach cancer services  
Ensure any guidelines are implemented and monitored for equity 
Better resource Māori Providers and locate services in Māori settings where appropriate 
Strengthen networks with other health organisations, that have commitment to improving access to health 






Patient navigation or care coordination 
Change health workforce roles and funding formulas to support an increased nursing workforce 
Engage community health workers to provide a bridge between community and cancer services  
Make services easier to navigate alongside the use of patient navigators or nursing care coordinators 




Patient – provider 
communication 
Build a culturally competent workforce i.e. through training of health practitioners  
Provide health literacy communication education for health practitioners 
Partner to include culturally competent practitioners within teams 
Provider bias Debunk health practitioner stereotypes of Māori 
Develop clear decision-making tools and guidelines 
Cancer workforce Employ more Māori within cancer care including in governance roles 
Improved cultural safety and responsiveness of ‘mainstream’ 
Patient-level Socio-economic status Address financial barriers of cancer care and proactively inform of available support 
Travel Address transport barriers to cancer care 
Patient preference/ 
choice 
Support whānau-based and holistic self-management 
Health literacy Provide culturally tailored and responsive information and services 
UNDERSTANDING INEQUITY AND INTERVENTIONS 
143 
 
Intervening at Key Points of the Stomach Cancer Pathway 
In addition to the suggestions above that are targeted towards improving cancer 
services overall for Māori, there are likely to be specific issues relating to improving 
particular points of the stomach cancer pathway for all.  While not focussed 
specifically on providing more equitable outcomes for Māori, improving the pathway 
overall has the potential to impact on those groups currently disadvantaged through 
it.   Monitoring and evaluation for equity of access, and outcomes, for different groups 
would need to be paramount throughout the pathway. 
The interventions points outlined above may all be important and it is likely that a 
combination of interventions is needed to in order to improve the responsiveness of 
stomach cancer services to Māori.  It must be noted though, that even a well-
designed, fully functioning and equitable health system is only intervening at the level 
of health services.  The broader underlying determinants of health, or issues related to 
the “differential access to the goods, services, and opportunities of society by race” 
(Jones, 2000: 1212), are not being fully addressed by this approach.   In the case of 
stomach cancer, the determinants of health impact greatly on the risk of developing 
the disease in the first instance.  The determinants are also highly likely to influence 
access to, and through, stomach cancer services irrespective of how well designed and 
implemented those services are.  Still institutionalised racism can also manifest as 
inaction in the face of need, and with such disparate stomach cancer incidence, 
mortality and survival seen within New Zealand (as outlined in Chapter 3) there is 
clearly need to investigate stomach cancer services in New Zealand. 
Summary of Inequity and Interventions 
This chapter has noted three pathways through which health inequities occur: 
differential access to the underlying determinants of health, differential access to 
health care and differential quality of health care received (Jones et al., 2009).  This 
chapter has been concerned with the latter two pathways or Māori/non-Māori 
disparities in access to, and quality of, cancer care. 
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There is much evidence of inequitable access to, and quality of, health care between 
Māori and non-Māori in New Zealand, at primary, secondary and tertiary levels (Scott 
et al., 2003; Crengle et al., 2005; Ministry of Health, 2014a; Ministry of Health, 2008; 
Jansen et al., 2008; McCreanor and Naim, 2002).   As with the health system in 
general, findings from a number of studies suggest that Māori and non-Māori New 
Zealanders diagnosed with cancer experience differential access to, and quality of, 
health care with Māori less likely to receive quality (Seneviratne et al., 2014c; Hill et 
al., 2010a; Stevens et al., 2008b; Obertova et al., 2015), and timely care (Hill et al., 
2010b; Stevens et al., 2008b; Alexander et al., 2010; Obertova et al., 2015; Seneviratne 
et al., 2014a).  Furthermore this differential care impacts negatively on subsequent 
survival for Māori (Hill et al., 2010a; Seneviratne et al., 2015).    
As a thesis within Public Health it was considered important to not only investigate 
whether Māori/non-Māori disparities exist but to also consider how, and where, to 
intervene to minimise any inequities.  No previous studies were found that described 
interventions to improve indigenous peoples or Māori access to stomach cancer 
services, instead this chapter draws on related literature that investigates how to 
improve cancer services more generally for Māori.   A number of studies, published 
over the preceding decade (Cormack et al., 2005; Cram, 2014a; Cram, 2014b; Walker 
et al., 2008; Slater et al., 2013; Dew et al., 2015) all argue for similar interventions to 
improve cancer services for Māori, thus for the preceding decade key informants have 
concurred on how to improve the responsiveness of cancer services to Māori.    The 
framework, of Mandelblatt and colleagues (Mandelblatt et al., 1999), is used to 
consider possible interventions and to remain focussed on structural responses 
however it is likely that a multilevel and comprehensive approach encompassing both 
Māori-centred interventions and improvements to the treatment pathway overall are 
needed.   
While the broader underlying determinants of health are not being addressed by 
intervening in differential access to, and quality of, health care, the Māori/non-Māori 
inequities in stomach cancer (documented in Chapter 3) and in access to health and 
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cancer services (documented in this chapter) provide clear need for action to improve 








Chapter 5: Methods  
This study uses a mixed method approach, with both quantitative and qualitative phases.  
To begin, this chapter briefly discusses the mixed methods approach used in this study. 
This chapter next outlines the quantitative methods used to create an historical cohort of 
people diagnosed with stomach cancer and to explore their presentation, subsequent 
treatment and survival.   
It does this in three separate sections: 
 The first section outlines the creation of an historical cohort through clinical note 
review including identifying and selecting the study population, data sources and 
data collection and extraction. 
 The second section describes the preparation and analysis of the quantitative data 
including data preparation, how missing data were managed and the variables 
used in analyses. 
 The third section describes data analyses including how and why age and sex 
standardisation was used, how the Māori and non-Māori cohorts were compared 
in their patient, disease treatment and health care access factors, and survival.   
Finally, this chapter outlines the methods used in the qualitative phase of the study, 
including key informant sampling, recruitment, data collection, and analysis.  The 
objectives of this phase were to qualitatively investigate key informant views of those 
points of the stomach cancer treatment pathway that the quantitative findings suggested 
were inequitable (if present), along with how and where to intervene to improve the 











This study uses a mixed method approach, with both quantitative and qualitative phases.  
When using mixed methods it needs to be clear why mixed methods are appropriate and 
justification provided for the sequence of the methods, along with how and where the 
methods will be synthesised (Padgett, 2011; Lingard et al., 2008). 
Sequential methods have been used in this study: a quantitative phase followed by a 
qualitative phase.  Sequential methods are useful when the results from one method help 
to inform the other method (Creswell, 2003).   This was the intention of this study.   In this 
study quantitative methods were used to investigate the stomach cancer treatment 
pathway and whether there were points on the pathways that were inequitable for 
Māori, and if present whether that inequitable care contributed to ethnic survival 
inequities.  Then qualitative methods were used to explore possible interventions or 
solutions to improve the stomach cancer treatment pathway.  These interventions were 
focussed on those points of the treatment pathway that the quantitative data suggested 
were inequitable for Māori.   The study research questions 1 – 3 (below) are answered 
using quantitative methods and 4 – 5 using qualitative methods. 
The specific objectives of this study were to investigate: 
1. What are patient (age, sex, comorbidity), disease (stage at diagnosis, tumour site, 
grade), treatment (receipt and timing of surgery, chemo and radiotherapy), health 
care access (deprivation, rurality) and outcome (survival) characteristics of a 
cohort of patients with stomach cancer in New Zealand? 
2. Are there any Māori/non-Māori differences in treatment timeliness, quality and 
quantity? 
3. If differences exist, how do these differences contribute to Māori/non-Māori 




4. What do key informants identify as issues for stomach cancer treatment in New 
Zealand, with a focus on Māori? 
5. Which interventions do key informants identify that may improve access to, and 
quality of, stomach cancer treatment in New Zealand, with a focus on Māori? 
The two methods were integrated during interpretation (Lingard et al., 2008).  As the two 
methods answer distinct but related research questions, they each have a separate 
results section.  Synthesis of these results occurs within the discussion chapter only.  
Analytic Framework 
As discussed previously this study uses Mandelblatt et al’s conceptual framework of 
barriers to accessing cancer services (Mandelblatt et al., 1999) as the overall theoretical 
approach.  Using this framework informed how the variables used in quantitative data 
analyses were organised.  It also informed the research design of the qualitative phase of 
this study impacting on participant sampling, the development of the interview schedule 
through guiding the types of questions to ask participants and qualitative data analysis.  In 
addition, this framework guided the organisation of quantitative/qualitative results 






Background to the Quantitative Phase  
The purpose of the quantitative phase of this study was determine the presenting 
characteristics, treatment and survival of Māori and non-Māori patients with stomach 
cancer in New Zealand, to compare the results between Māori and non-Māori and to 
examine the contribution of any observed differences to survival disparities. 
Quantitative Phase Research Questions 
As mentioned in the introduction to this chapter, three research questions guided the 
quantitative phase of this study, they were: 
1. What are the patient (age, sex and comorbidity), disease (stage at diagnosis, 
tumour site and grade), treatment (receipt and timing of surgery, chemo and 
radiotherapy), health care access (deprivation and rurality) and outcome (survival) 
characteristics of a cohort of patients with stomach cancer in NZ? 
2. Are there differences in stomach cancer treatment timeliness, quality and quantity 
between Māori and non-Māori?  
3. If differences exist, how do these differences contribute to differences in 




Creating a Historical Cohort through a Clinical Note Review 
Study Population 
The target population of this study was all patients diagnosed with stomach cancer 
between 2006 and 2008 in Aotearoa/New Zealand (Table 4).  This target population was 
then restricted to those 25 years or over with a histological diagnosis of stomach 
adenocarcinoma or gastrointestinal stromal tumour (GIST).  Adenocarcinoma and GIST 
are distinct neoplasms originating from different cell layers but as they both have a 
similar well-defined treatment pathway it was decided to include GIST within this study.  
For practical reasons, only cancers registered to patients who resided in the North Island 
at time of diagnosis were included.  The reasons were 1) the majority (around 90%) of 
Māori reside in the North Island (Statistics New Zealand, 2007) and thus substantial 
resources would have been needed to obtain data on the remaining 10% of Māori and 2) 
the two major Christchurch earthquakes, September 2010 and February 2011, impacted 
on the resources available to Canterbury DHB, limiting their ability to provide data and 
participate in the study.  Cancer treatment and survival were key outcomes of interest so 
the target population was also restricted to those with a cancer diagnosis confirmed prior 





Table 4: Study eligibility criteria 
Eligibility criteria 
Newly diagnosed stomach cancer (ICD code C16.0-16.6, 16.7, 16.8).  
Cancers registered between 1 January 2006 and 31 December 2008. 
No previous diagnosis of stomach cancer. 
Aged 25 years or over at diagnosis. 
Normally resident in the North Island of New Zealand. 
Diagnosis made prior to death or post-mortem.  
Morphology consistent with adenocarcinoma or gastrointestinal stromal tumour. 
The target population was identified from all cases of primary stomach cancer notified to 
the New Zealand Cancer Registry with a registration date between 1 January 2006 and 31 
December 2008 (Table 5: Step 1).  The target population was grouped into Māori and 
non-Māori groups, based on the ethnicity data from the Cancer Registry.  The study 
eligibility criteria were then applied using the information available from the Cancer 
Registry records (Step 2).  
Table 5: Steps in the study selection process 
  Māori non-Māori 
1 Cancer Registrants 2006 – 2008 with primary stomach 
cancer 
all all 
2 Target populations meeting study eligibility criteria 
based on Cancer Registry records 
all all 
3 Sampled study cohorts all Māori and random sample of 
non-Māori 
all random sample 
4 Eligible study cohorts meeting study criteria after 
medical notes review 
all eligible all eligible from 
random sample 
The sampled study cohort included all Māori cases and an equal number of non-Māori 




random six-digit number to all non-Māori cases, placing these in numerical order and 
selecting the first 181 cases (i.e. the size of the Māori cohort).  The sampled cohort was 
then comprised of the Māori cases combined with the randomly-sampled non-Māori 
cases (Step 3). 
Following a full clinical note review (see ‘Data Sources’ below) it was found that a number 
of cases included in the sampled study cohort did not actually meet the criteria of the 
study and were thus excluded.  In these cases information was incomplete or miscoded in 
the Cancer Registry records.  Even though these patients had appeared to meet the study 
eligibility criteria at Step 3, if they failed to meet the study eligibility criteria based on 
clinical records they were considered ineligible and excluded from the final study cohort 
(Step 4).   
Despite a detailed review of all available clinical records complete data could not be 
obtained for some patients.  However for each relevant variable only a small fraction of 
patients had missing data and no patients were excluded from the study due to missing 
data.  Proportions of missing data are identified within appropriate places in the 
descriptive analyses of the Quantitative Results chapter.  The method for how missing 
data for key variables within survival analyses was managed is detailed later in this 
chapter.  
Data Sources  
This study used a combination of national routinely-collected data and data derived from 
a full review of clinical records within patient medical notes.  Data on incident stomach 
cancer cases, ethnicity (the exposure of interest), demographic details, health care access 
measures and mortality were gained from the national-level databases.  Data on patient 
and clinical factors such as stage, comorbidity at time of diagnosis, disease characteristics 
and receipt of treatment were gained from a manual review of clinical records in patient 




Figure 5: Data sources used in this study 
 
National Level Data Sources 
New Zealand Cancer Registry 
Incident cases of stomach cancer were identified from the New Zealand Cancer Registry 
(NZCR).  The NZCR is a population-based register of all primary cancers diagnosed in New 
Zealand, with the exception of non-melanoma skin cancers.   While the  prime function of 
the NZCR is to collect and store cancer incidence data it is also used to assess and 
compare cancer rates and trends and acts as a resource for cancer screening programmes 
and research (Cancer Control New Zealand, 2010; Stevens et al., 2008a). 
The NZCR has been operating since 1948 however in 1993 the Registry Act was passed.  
The Act made pathological reporting of cancer diagnoses by laboratories mandatory, 
binding the Crown and its entities to report cancer within 21 days after the end of the 
calendar month in which the cancer test was carried out. A small proportion of data (< 
10%) is also gained from discharge summaries from public and private hospitals, death 
certificates, and autopsy reports when needed (New Zealand Cancer Registry (NZCR), 
2008). 
The information captured in the NZCR system is outlined below (Table 6). The NZCR 
collects demographic information (to ensure that each new cancer is recorded only once 
Cancer Registry Data
Patient Medical Notes
Demographic & Health Care Access factors
Study Cohort
Ethnicity (Exposure)
National Health Service Data
Mortality Data





in incidence statistics) and detailed pathological information about each tumour where 
this information is available (New Zealand Cancer Registry (NZCR), 2008).   
Table 6: Information held by the New Zealand Cancer Registry  
In relation to the person: 
name  




In relation to the tumour: 
date of diagnosis  
site of primary cancer (or secondary site if primary unknown)  
type of diagnostic test  
morphology 
grade  
tumour site-specific information (eg, Breslow's thickness for melanoma, ER/PR status for breast 
cancer)  
extent of disease at diagnosis 
Source: NZCR, Data Dictionary (New Zealand Cancer Registry (NZCR), 2008) 
The clinical coding of tumour site and histology on the NZCR is applied according to the 
International Classification of Disease, an international standard in clinical coding 
(Steindel, 2010).  During the timeframes of this study the NZCR used the Tenth Revision of 
the International Classification of Diseases, Australian Modification, second edition (ICD-
10-AM 2nd ed.) to record tumour site and histology (New Zealand Cancer Registry (NZCR), 
2008).  Stage (or, more accurately, extent of disease) is assigned on the NZCR according to 
the National Cancer Institute’s Surveillance, Epidemiology, and End Results Programme 
(SEER) summary staging system (National Cancer Institute, 2013b; Stevens et al., 2008a), 
based on information obtained up to four months following the date of diagnosis (New 




into five main categories (Table 7).  In addition, the regional stage can be subcategorised 
by the method of spread. 
Table 7: SEER Summary Staging 
Code Definition Description 
A In situ Abnormal cells are present only in the layer of cells in which they 
developed 
B Localised Cancer is limited to the organ in which it began, without evidence of 
spread 
C Regional Cancer has spread beyond the primary site to nearby lymph nodes or 
tissues and organs 
D Regional Cancer has spread to regional lymph nodes 
E Distant Cancer has spread from the primary site to distant tissues or organs or to 
distant lymph nodes 
F Unknown There is not enough information to determine the stage 
Source: National Cancer Institute, SEER Summary Staging Manual (National Cancer Institute, 2000). 
National Health Service Data 
National level health service data were used primarily to identify hospital admissions and 
generate a list of hospitals for the medical note review that provided care to patients 
within the study cohort.  National data were obtained from two national datasets, the 
National Minimum Data Set (NMDS) and National Non-Admitted Patient Collection 
(NNPAC) databases.   
The NMDS is a database containing public and private hospital inpatient discharge 
information.  It also includes some day patient information.  Data has been submitted by 
public hospitals since 1993 and by private hospitals, for publicly funded events only, since 
1997.   Clinical information including data on the date and type of diagnostic or treatment 
procedure, length of stay, any surgery, chemotherapy or radiotherapy received as part of 
an inpatient stay, patient comorbidities and (sometimes) complications of treatment are 




The NNPAC is a database containing non-admitted patient, outpatient and emergency 
department, information.  It provides procedure or diagnosis information including date, 
facility and type of service or treatment.  It holds information on chemotherapy or 
radiotherapy received as an outpatient and first specialist appointments (FSA) when these 
are held as an outpatient (Ministry of Health, 2013b). 
For a research capacity these national datasets have limitations.  These datasets have the 
primary purpose of assisting the Ministry of Health and DHBs in the determination of 
funding for provision of services (Ministry of Health, 2011) and there is known 
underreporting of cancer treatment, both medical and surgical oncology.   Additionally 
private providers are not mandated to report data on services which are privately funded 
and these data are largely missing within these datasets (Gurney et al., 2013a).  For these 
reasons the clinical treatment data held within national datasets can be either missing or 
limited in detail.  For example little information was available within the national datasets 
regarding the purpose of an oncology visit and whether treatment was actually received.   
Clinical data from medical note review has been shown to be more accurate than that 
within national datasets (Stevens et al., 2008a).  For this reason, study data on treatment 
were obtained directly from patient medical notes for the current study.   
Mortality Records 
Mortality data were obtained from the national Mortality Collection.  The Mortality 
Collection holds information on all deaths in Aotearoa/New Zealand.  The Mortality 
Collection provides data for policy, monitoring, cancer survival studies and research, 
including international comparisons of mortality statistics by the World Health 
Organisation (WHO).  The underlying cause of death for all deaths registered in New 
Zealand is classified using the ICD-10-AM 6th Edition and the WHO Rules and Guidelines 




Collection of Clinical Data from Patient Medical Notes 
A manual review of clinical records within patient medical notes provided the core of 
clinical data for the study.  In New Zealand patient medical notes are held at each 
individual hospital, including private hospitals, which the patient has attended.  The data 
gathered provided detailed clinical information on the presentation (including stage at 
diagnosis and comorbid conditions) and management of all eligible patients; much of 
these data were not available from the administrative databases nationally.   
Patients’ medical notes included letters pertaining to clinic appointments, outcomes of 
diagnostic tests, pathology reports and notes of both inpatient and outpatient events.  
These detailed note review data thus allowed a comprehensive comparison of patient 
factors, tumour or disease characteristics and health care received by Māori and non-
Māori patients diagnosed with stomach cancer, and to then assess the impact of these 
factors on survival outcomes.   
The order of determining the study data is shown below in Table 8. 
Table 8: Order of determining study data 
 Order of Determining Study Data  Data Source 
1 Total cohort/target population identified by date of 
diagnosis, ethnicity (the exposure), age and sex 
 New Zealand Cancer Registry 
2 Sampled study cohort determined by randomisation of non-Māori cohort 
3 Treatment hospitals for sampled study cohort identified by receipt 
of treatment events around diagnosis 
 National Health System Data 
(NMDS & NNPAC) 
4 Collection of patient (comorbidity), disease (stage, site, grade), and 
treatment factors (receipt and timing), including definitive date of 
diagnosis 
 Review of clinical data in individual 
patient medical notes 
5 Eligible study cohort determined by meeting study criteria after medical notes review 
6 Collection of health care access factors (deprivation and rurality)  New Zealand Cancer Registry 
7 Collection of mortality data including date of and underlying cause 
of death up to 31 Dec 2010 




Ethics Approval  
The quantitative phase of this study was given ethical approval by the Multi-Regional 
Ethics Committee in 2010 (ref. # MEC 10/042/EXP).   All aspects of this phase of the study 
were carried out in accordance with the approved study protocol.  
Once ethics approval was gained, study data were obtained from national and cancer 
treatment centre databases and clinical data were obtained from a manual review of 
individual patient notes held in hospitals throughout the North Island of New Zealand. 
Identification of Providers and Inpatient Episodes 
For each patient within the cohort, public and private hospital admissions were identified 
from NMDS data and outpatient events from NNPAC data.  The receipt of treatment 
events that occurred around the time of each patient’s cancer diagnosis were then 
identified and used to generate a list of hospitals providing care to patients within the 
study cohort.  For each hospital, a list of patients was generated.   Patients were often 
cared for at more than one facility during their cancer journey, necessitating review of 
medical notes at multiple hospitals for many patients.   
Approval to Review Patient Medical Notes at Individual Hospitals  
For each public and private hospital the Chief Medical Adviser (or equivalent) was 
contacted to seek permission to review notes from that facility.  In most cases permission 
was fairly quickly granted.  However some hospitals had specific protocol pertaining to 
approval of medical note review; this often involved protracted consultation that delayed 
the collection of data, in some cases by more than a year.  Once permission was obtained 
the list of patients treated at each individual institution was sent to the Medical Records 





A standardised proforma was developed for the extraction of clinical data (See Appendix 
1).  The proforma was developed in consultation with the clinical advisory team set up to 
support the C3 group of studies (as outlined in the Statement of Participation), including 
specialist surgeons (Upper GI and rectal), medical oncologists and public health 
researchers with expertise in Māori health, survey design, epidemiology and biostatistics.  
The questionnaire contained 70 variables covering the treatment pathway from date of 
first presentation and initial signs and symptoms to referral and receipt of palliative care.  
It was piloted using clinical records, in both electronic and paper form, of 50 patients 
cared for at one major cancer centre public hospital. 
Review of Patient Medical Notes in Public and Private Health Facilities 
All clinical data were obtained through a manual review of individual patient’s medical 
notes.  These data were primarily obtained from public hospitals as in New Zealand 
stomach cancer is more likely to be treated in a public hospital due to clinical complexity 
(National HBP/Upper GI Tumour Standards Working Group, 2013).  A number of the 
larger public hospitals operated either fully or partially computerised clinical records 
systems i.e. Auckland, Hamilton and Wellington hospitals; however the majority of 
medical note review was completed through manual review of paper-based patient files. 
Data gathered included details of patients’ presentation, investigation and diagnosis, 
comorbid conditions present at the time of diagnosis, tumour characteristics (including 
stage, tumour site and grade), surgical treatment, medical and radiation oncology 
treatment and referral to palliative care services.    
In total 362 patient’s medical notes were reviewed in 13 public and one private hospital.  
This process is further discussed in the selection of study cohort in Chapter 6: 




remote computer access or through the physical transport of the paper-based medical 
notes to a larger facility within the jurisdiction of the relevant DHB/hospital.  
Three study participants’ data were substantially incomplete after the review of public 
hospital medical notes.  These were augmented with data obtained through review of 
specific medical notes requested from a private hospital and a private specialist physician. 
Pathology Reports 
Pathology reports were viewed within the medical notes for all study patients.  They were 
reviewed to confirm histological diagnosis (often by biopsy report), for information on 
tumour site, grade, size (where reported) and for operative details such as cancer margins 
and extent of lymph node resection.  The pathology reports also contributed to 
determining the stage at diagnosis for many patients in the study.  
Data Extraction, Entry and Checking 
All data were extracted and entered onto the standardised proforma, including the data 
obtained through private physicians.  Where there were queries regarding key pieces of 
clinical data, such as exact diagnosis, date of diagnosis or stage, photocopies were made 
of the relevant patient note (often a histology report, operation report or specialist clinic 
letter) and these were reviewed by this study’s primary supervisor (Diana Sarfati) and/or 
the Upper GI cancer surgeon supervising this study (Jonathan Koea). 
Data from all study proforma were entered into an electronic database.  Validation of 
data extraction and entry was carried out in two ways.  Firstly validation of the extraction 
of data was carried out on a randomly selected subset of patients treated at one major 
cancer centre facility.  In this case data extraction was completed for all data points on 
the standardised proforma and double checked to the data already extracted.  Secondly 
validation of data entry was carried out by double entry of specific key data points.  This 




were date of diagnosis, date of surgery, TNM stage at diagnosis, date of first appointment 
with medical oncology and/or radiation oncology and finally date of receipt of 
chemotherapy and/or radiotherapy.  Validation checks were undertaken and any 
discrepancies in data extraction, or recording, were resolved by referencing back to the 
paper-based proforma and any clinical information on the patient held with the 
proforma. 
Challenges and Benefits of Data Collection and use of a Reflective 
Diary 
Manual review of individual patient medical notes was the most time intensive and costly 
part of this study; however it also added immense value.  The data gathered provided 
more detailed information than that routinely available from administrative databases, 
especially with respect to staging and detailed treatment data.  The review of patient 
medical notes also had a number of other benefits.  In depth review of medical notes in a 
variety of hospitals in the North Island of New Zealand provided a good understanding of 
the strengths and limitations of the data gathered, allowed the visualization of the patient 
journey as a whole and created opportunity for discussion with clinical staff.  It also 
provided insight into the context of the delivery of cancer care in the many different 
facilities of Aotearoa New Zealand.   
A reflective diary was kept during the data collection process, a summary of which is 
included as an appendix to this thesis (see Appendix 2).   Use of reflexivity is common 
within qualitative research, while less common within quantitative research it is a useful 
tool in the collection and analysis of quantitative data (Hesse-Biber and Johnson, 2015) 
and has been used previously in the clinical note review process (Walker et al., 2013).  
Use of reflexivity during the process of note review was said to add value to the data 
collected, helped assess data quality and provided transparency of the impact of the 




Data Preparation and Variables 
Data Preparation 
Results of the clinical note review were entered and managed in a Microsoft Access 
(2010) dataset.  Data from the NZCR and mortality records were linked together with the 
results of the medical notes review using individual patient identifiers.  This created one 
integrated dataset with a single line of data for each patient within the study cohort.  The 
dataset was then imported into SAS (version 9.3, SAS Institute Inc., Cary, NC) and the data 
cleaned. 
Variables used in Study Analyses 
All variables used in study analyses are outlined in Table 14 (pg 174).  Explanation for 
selected key variables (marked in Table 14 with an asterisk) is provided below.   
Exposure: Māori or non-Māori 
As this study is primarily interested in comparing stomach cancer treatment and survival 
between Māori and non-Māori, accurate ethnicity data was essential.   Ethnicity for 
patients in this study was assigned on the basis of NZCR ethnicity data, up to the point of 
cancer registration.   The NZCR uses an ‘ever-Māori’ approach where patients are 
classified as being Māori if they have identified as Māori on any previous health record 
(including all in- and out-patient events).  This ethnicity classification method is used to 
minimise a known historical under-count of Māori in health service databases (Robson et 
al., 2006; Robson et al., 2010).   There is some evidence that under-count of Māori in 
hospitalisation databases and the NZCR continues (Robson and Purdie, 2007b; Swan et 
al., 2006) although a 2008 – 2009 study shows this to be of smaller magnitude than once 




cancer registration to reduce the chance of follow-up bias, where those who have had 
more contact with health services subsequent to their cancer diagnosis are more likely to 
be identified as Māori.  Additionally, patient ethnicity was checked during the manual 
review of patient medical notes with no misclassifications noted. 
In this study patients were classified as Māori if their ethnicity was recorded as Māori by 
the NZCR.  All other patients were classified as non-Māori.   
Date of Diagnosis 
An indicative date of diagnosis was identified from the national level databases (largely 
the NZCR).  This was used to generate the list of hospitals providing care to these patients 
around time of diagnosis and to determine which hospitals to visit during the clinical note 
review.    
Definitive patient date of diagnosis was determined through the medical note review.  It 
was determined through supporting evidence within patient notes such as histology 
report, gastroscopy findings, radiological report or specialist letter.  Date of diagnosis was 
most commonly based on the date of histology that included a diagnosis of stomach 
cancer, or if this was absent it was based on information within the remaining supporting 
evidence. 
Date of diagnosis was used to determine time until key points in the treatment pathway 
and in survival analyses. 
Comorbidity 
Comorbidity is the presence of health conditions other than the disease of interest, in this 
case stomach cancer.  During the clinical note review information was collected on a list 
of comorbidities.  These comorbidities were identified as being important from review of 
literature and with reference to the C3 clinical advisory group which helped to identify 




comorbid conditions documented by clinicians in the patients’ medical notes were 
assumed to be important.  All comorbid conditions present at the time of diagnosis were 
recorded, with the exception of previous malignancies and past conditions that had 
completely resolved at time of diagnosis (e.g. appendicitis or cholecystitis resolved with 
surgery).   Gastrointestinal (GI) ulcers, GI bleeding and blood loss anaemia were collected 
but not included in any analyses as these conditions may reflect symptoms relating to 
undiagnosed stomach cancer.  
The 12 most common comorbid conditions in this study were included in the analysis.  
These conditions were: angina, hypertension, myocardial infarction, arrhythmia, mild 
chronic pulmonary disease, moderate/severe chronic pulmonary disease, congestive 
heart failure, cerebrovascular accident, obesity, diabetes, other malignancy and renal 
disease. Comorbidities were analysed both as individual conditions and as a categorised 
‘count’ to assess the overall burden of comorbidity at diagnosis. The comorbidity count 
was categorised into 1, 2, 3 and 4+ comorbidities for the purposes of descriptive analysis, 
and kept as a continuous variable (0-12) for the purposes of survival analyses.  
Small Area Deprivation  
Level of deprivation was conceptualised as a marker of access to cancer services in this 
study.  Patient domicile at time of diagnosis from the NZCR was used to assign each 
patient to the New Zealand Index of Deprivation 2006 (NZDep) (Salmond and Crampton, 
2012).  The NZDep is a measure developed from nine variables collected within the 
Statistics NZ 2006 Census of Population and Dwellings: income, benefit receipt, single 
parent family, home ownership, employment, qualifications, living space, access to 
communication and access to transport. The NZDep uses these variables to provide a 
summary deprivation score (1 – 10, with 1 being the least deprived and 10 the most 
deprived) for small geographical areas.  For this study the deciles were collapsed into 





Place of domicile was also conceptualised as a marker of access to cancer services in this 
study and the patients rural/urban profile was also based on the patient’s domicile from 
the NZCR at time of diagnosis.  Statistics New Zealand assigns a seven level urban/rural 
classification code to each census unit in New Zealand (Statistics New Zealand, 2004). For 
this study these seven levels were aggregated into three categories: urban (including 
main urban and satellite urban areas), independent urban (independent urban areas) and 
rural (including rural areas with high or moderate urban influence, rural areas with low 
urban influence and highly rural areas).  
Surgical Facility Type 
For the purposes of describing the place where definitive surgery was performed health 
care facilities were classified into one of three categories: main centres, smaller centres 
and private centres.  Main centres were public cancer hospitals and included the 
following hospitals: North Shore, Auckland, Middlemore, Manukau Super Clinic, Waikato, 
Palmerston North, and Wellington.  Smaller centres were public non-cancer center 
hospitals and included: Whangarei, Tauranga, Thames, Rotorua, Whakatane, Gisborne, 
Hawkes Bay, New Plymouth, Taranaki, Whanganui, Masterton and Hutt.  Private centres 
were any privately funded hospital including: Wakefield, Gilgit Road Specialist Centre, 
MercyAscot, Braemar, and Southern Cross.  The name of the primary surgical facility was 
obtained from manual review of surgical records and clinical letters.  
Tumour Stage 
The TNM staging classification system was used to analyse variables in this study. TNM 
stage was determined during the clinical note review using all available information:  




letters.  In keeping with the approach used by the NZCR, data up to four months post-
diagnosis were included.  
In the TNM system, cancer stage can be based on the results of physical examination, 
clinical or imaging results as well as histo-pathological findings (Abrams and Wang, 2010).  
This study used a combination of clinical and pathological staging.  If pathological stage 
information was available within four months of patient diagnosis it was used as the basis 
for determining stage, otherwise all available clinical information was used.  The TNM 
system for staging contains 3 key pieces of information: T (tumour) indicates the depth of 
penetration into the stomach, N (nodes) indicates the amount of lymph node invasion, 
and M (metastasis) indicates the presence, or not, of distant metastases (American Joint 
Committee on Cancer (AJCC), 2012; Abrams and Wang, 2010).  The TNM staging system is 





Table 9: AJCC TNM staging definition for stomach cancer  
T category definitions 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria 
T1  Tumour invades lamina propria, muscularis mucosae, or submucosa 
T1a  Tumour invades lamina propria or muscularis mucosae 
T1b  Tumour invades submucosa 
T2  Tumour invades muscularis propria 
T3  Tumour penetrates subserosal connective tissue without invasion of visceral peritoneum or 
adjacent structures and those extending into the gastrocolic or gastrohepatic ligaments, or into the 
greater or lesser omentum, without perforation of the visceral peritoneum covering these 
structures 
T4  Tumour invades serosa (visceral peritoneum) or adjacent structures 
T4a  Tumour invades serosa (visceral peritoneum) 
T4b  Tumour invades adjacent structures such as spleen, transverse colon, liver, diaphragm, pancreas, 
abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum 
N category definitions 
NX Regional lymph node(s) cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 2 regional lymph nodes 
N2 Metastasis in 3 to 6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes 
M category definitions 
M0 No metastases  
M1 Distant metastases present 
Source: Washington, AJCC cancer staging manual: stomach (7th Ed.) (Washington, 2010) 
In the TNM system, after the TNM categories have been determined they are combined 
and grouped to assign a stage denoted by a roman numeral I – IV, with stage I having the 
best prognosis and stage IV the worst (Table 10) (American Joint Committee on Cancer 
(AJCC), 2012).  In this study the stage groupings below were then grouped into broader 
categories: stage I, stage II, stage III, and stage IV rather than using the subcategories (IIA, 




Table 10: TNM stage grouping for adenocarcinoma of the stomach  
Stage Grouping Tumour Nodes Metastasis 
Stage 0 Tis (carcinoma in situ)  N0 M0 
Stage IA T1 N0 M0 
Stage IB T2 N0 M0 
T1 N1 M0 
Stage IIA T3  N0 M0 
T2 N1 M0 
T1 N2 M0 
Stage IIB T4a N0 M0 
T3 N1 M0 
T2 N2 M0 
T1 N3 M0 
Stage IIIA T4a N1 M0 
T3 N2 M0 
T2 N3 MO 
Stage IIIB T4b N0 or N1 M0 
T4a N2 M0 
T3 N3 M0 
Stage IIIC T4b N2 or N3 M0 
T4a N3 M0 
Stage IV Any T Any N M1 
Source: Washington, AJCC cancer staging manual: stomach (7th Ed.) (Washington, 2010) 
Tumour Grade 
Tumour grade was classified according to the WHO International Classification of 
Tumours (Hamilton and Aaltonen, 2000) see Table 11 below.  Histological grade was 
obtained from the patients’ pathology report, either biopsy or subsequent resection 
report.  Generally these pathology reports used the terminology as defined by the WHO 
below (Table 11).  However in some cases the terms low grade or high grade were used 




high grade to mean poorly-differentiated (National Cancer Institute, 2013a).  Tumour 
grade was unable to be obtained for 40% of the final cohort overall, 49% of the Māori 
cohort and 37% of the non-Māori cohort.  As this variable was only used in descriptive 
statistics no attempt was made to impute missing data. 
Table 11: Tumour grade according to WHO International Classification of Tumours  
Histological Grade Description 




An adenocarcinoma intermediate between well differentiated and poorly 
differentiated. 
Poorly differentiated An adenocarcinoma composed of highly irregular glands that are recognized with 
difficulty, or single cells that remain isolated or are arranged in small or large 
clusters with mucin secretions or acinar structures. 
Source: Hamilton and Aaltonen, World Health Organization Classification of Tumours (Hamilton and 
Aaltonen, 2000) 
Tumour Site 
Tumour site, or where in the stomach the tumour has originated, was obtained from a 
number of sources within the patients’ medical notes.   If the patient had undergone 
surgical resection the pathology report of the resection was the primary source of tumour 
site data.  In some cases the information gained from pathology report was augmented 
with the written operative report.  If surgical resection did not occur, or this information 
was not available from this source, the biopsy report was reviewed for site data.  If the 
site data were not obtained from either of these pathological sources the remainder of 
the patients’ clinical record was reviewed for this information.   Tumour site was recorded 
as one of four categories (Table 12).  These categories were determined after 





Table 12: Tumour site categories used in this study 
Tumour site Description Corresponding ICD Codes 
Proximal Includes the cardia, fundus and body of the 
stomach,  along with tumours originating in the 
cardia that cross the OG junction 
C160, C161, C162   
Distal Includes the antrum and pylorus of the stomach C163  
Proximal and Distal Overlapping lesion of the stomach including both 
distal and proximal sites 
C168 
C164  
Other Description Lesser curvature or greater curvature of the 
stomach without specifying further 
C165, C166   
Post-operative Complications 
Post-operative complications were defined as complications which occurred in the 30 
days following surgical resection of the primary tumour.  The presence of any of a list of 
specific conditions in this time-period was categorized as a post-operative complication 
(Table 13).    
Table 13: Post-operative complications as defined in this study 
Complication Description 
Reoperation  Reoperation related to the surgical resection of the primary tumour.   Reasons 
for reoperation included anastomotic leakage, bleeding, infarcted bowel, 
adhesions requiring division and intra-abdominal abcess 
Sepsis Generalised sepsis or localised sepsis with systematic symptoms 
Pneumonia Documented diagnosis of pneumonia 
Heart failure Documented heart failure requiring organ support (intravenous medication) 
Respiratory failure Documented respiratory failure requiring organ support (artificial ventilation) 
Renal failure Documented renal failure requiring organ support (renal dialysis) 





Time, until the study participant dies, is the outcome of interest in survival analyses 
(Kleinbaum and Klein, 2012).  In order to calculate survival, mortality data from 2006 to 
2010 were obtained from the Ministry of Health’s National Collections and linked to 
individual study members using their national health system identifier (NHI number).   
The mortality data were then merged with study data.  Each death was classified as either 
attributable to stomach cancer, or due to other causes, based on the NZHIS information.  
Three non-Māori in the cohort whose death was classified as malignant neoplasm of 
lower third of oesophagus (C155) were assumed to have died of stomach cancer and their 
death attributed to stomach cancer.  In all three cases the patient was originally 




Table 14: Variables used in study analyses 
Variable set Variables Values Comments/Definitions 
Ethnicity Ethnicity* Māori or non-Māori Prioritised ethnicity, as determined from the NZCR.  Options include 
Māori and non-Māori.  A patient was considered non-Māori if they 
belonged to a non-Māori ethnic group (or had ‘missing’ residency 






1 January 2006 – 31 
December 2008 
 
Date on which a diagnosis of stomach cancer was made, based on 
supporting evidence: histology report, gastroscopy findings, 
radiological report or specialist letter 
Demographics Gender Male or female Gender as recorded on index hospital admission sheet 
Age at 
diagnosis 
25 - 99 Age at cancer diagnosis, based on date of birth and the diagnosis date 
from notes review 
Age at 
diagnosis  - 
categories 
25 – 49 
50 – 64 
65 – 74 
75+ 
Age at cancer diagnosis, grouped into categories 
Patient characteristics Comorbidity* Yes or no for each 
condition 
The presence or absence of comorbid conditions: angina, 
hypertension, myocardial infarction, arrhythmia, mild CPD, 
mod/severe CPD, CHF, CVA, obesity, diabetes, other primary cancer, 
renal disease.  NB: Blood loss anaemia, GI ulcer disease and GI 
bleeding were excluded as these were likely to be present in the 
buildup to diagnosis 
Comorbidity  - 
count 
0, 1, 2, 3,  4+ The number of comorbid conditions present at diagnosis, from the 12 
most common in this study 
 
Comorbidity  - 0 – 12 The number of comorbid conditions present at diagnosis, from the 12 




count continuous  
 Smoking status Current, ex-smoker, unknown Patient smoking status at diagnosis according to clinical records 
Health care access Small area  
deprivation* 
1 - 5 Measured at New Zealand Deprivation Index 2006 (NZ Dep). Values 
aggregated into quintiles (1 – 5) for descriptive and survival analyses  
 Rurality* Urban, Independent  
urban, Rural 
Calculated through patient domicile code at time of diagnosis.  Values 
aggregated into three categories for descriptive and survival analyses 
    
Disease characteristics Stage* TNM, stages I – IV and 
unstaged 
Tumour stage as determined, based on supporting evidence histology 
report, gastroscopy findings, surgical report, radiological report or 
specialist letter 
Tumour site* Proximal, distal, both 
proximal and distal, other 
description 
Tumour site as recorded in histology report, gastroscopy findings, 
radiological report or specialist letter 
Tumour grade* Well- , moderately- or  
poorly differentiated 
Tumour grade as recorded in histology report or specialist letter 
Investigations 
 
Gastroscopy Yes or no Gastroscopy/endoscopy of stomach, performed as part of diagnostic 
work-up for stomach cancer 
CT Scan Yes or no Computerised topography performed as part of the diagnostic work-
up or staging for stomach cancer 
MRI Scan Yes or no  Magnetic resonance imaging scan performed as part of the diagnostic 
work-up or staging for stomach cancer 
Endo Ultrasound Yes or no  Endoscopic ultrasound of the stomach performed as part of the 
diagnostic work-up or staging for stomach cancer 
Laparoscopy Yes or no  Surgical laparoscopy performed as part of the staging for stomach 
cancer 
Surgical treatment Removal of  
primary tumour 
Yes or no Surgical removal of primary tumour either during gastroscopy or 




Type of surgery  Type of surgery as documented in operative report. Local 
excision/EMR = local excision during gastroscopy, Ivor-Lewis 
oesophagogastrectomy = resection of distal oesophagus and proximal 
stomach, Gastrojejunostomy = resection of distal stomach with 
anastomosis between the stomach and the proximal loop of the 
jejunum, Partial Gastrectomy = resection of the distal stomach, Total 
Gastrectomy = resection of the whole stomach, Laparotomy without 
resection = open and close procedure 
Surgical facility type* Main centre, smaller 
centre or private 
Main centre = North Shore, Auckland, Middlemore, Manukau Super 
Clinic, Waikato, Palmerston North, and Wellington.  Smaller centre = 
Whangarei, Tauranga, Thames, Rotorua, Whakatane, Gisborne, 
Hawkes Bay, New Plymouth, Taranaki, Whanganui, Masterton and 
Hutt.  Private hospitals = Wakefield, Gilgit Road Specialist Centre, 
MercyAscot, Braemar, and Southern Cross 
Surgeon type Specialist or generalist The most senior surgeon involved in the operation, as self-identified 
in clinic letters, on operative report or (if not clear) confirmed with 
DHB records 
Nodes resected 0-14 
15+ 
The number of lymph nodes resected during surgery, as recorded on 
pathology report or in specialist letter 
Postoperative 
complications* 
Yes or no for each 
condition 
Presence or absence of specific conditions in the 30 days following 
surgical removal of primary tumour: Reoperation, sepsis, pneumonia, 
heart failure, respiratory failure, renal failure, death 
Oncology treatment Referred to  
oncologist 
Yes or no Documented referral to medical or radiation oncologist 
Date referred Date Documented  date referred to medical or radiation oncologist 
Reviewed by 
oncologist 
Yes or no Documented review by medical or radiation oncologist 
Date reviewed Date Documented  date reviewed by medical or radiation oncologist 
Offered chemo/radiation Yes or no Documented discussion of chemotherapy or radiation therapy with 




Received chemo/radiation Yes or no Documented receipt of chemotherapy or radiotherapy 
Date received 
chemo/radiation 






0 – 308 (highest recorded) Time, in days, from date of diagnosis until first intervention, one of: 
chemotherapy, radiotherapy, definitive surgery or other intervention 
(i.e. stent, paracentesis,  jejeunostomy feeding tube) 
Diagnosis – 
Definitive surgery 
0 – 483 (highest recorded) Time, in days, from date of diagnosis until surgical removal of primary 
tumour 
Diagnosis – 
Referred to Med 
Onc             
0 – 330 (highest recorded) Time, in days, from date of diagnosis until referred to medical 
oncology 
Referred Med 
Onc – Review by 
Med Onc 
0 – 48 (highest recorded) Time, in days, from referred to medical oncology until reviewed by 
medical oncology 
Review Med Onc – 
Received 
chemo         
0 – 238 (highest recorded) Time, in days, from reviewed by medical oncology until documented 
receipt of chemotherapy 
Diagnosis – 
Received chemo                   
0 – 442 (highest recorded) Time, in days, from date of diagnosis until documented receipt of 
chemotherapy 
Palliative care Referred to  
Palliative care 
Yes or no Documented referral for palliative care; any of palliative chemo, 
palliative radiotherapy or palliative care services 
Date referred Date Documented  date referred to palliative care 





Missing Data for Key Variables 
Many patients within the study had missing data for some variables, proportions of 
which are identified within appropriate places in the descriptive analyses (Chapter 6).   
Data were also missing for some of the key ‘covariates’ determined during the course 
of this study: namely tumour stage, tumour site, deprivation and rurality.   These 
variables were used within survival analyses and the management of missing data for 
these variables is further discussed below.  No patients were excluded from the study 
due to missing data. 
Date of diagnosis was determined for all patients within this study.  This variable is 
important as it is the beginning point for all survival analyses and thus essential to 
these analyses.   
Unstaged Cancer 
Tumour stage was determined for all but five (2%) non-Māori patients after reviewing 
all relevant supporting evidence (histology report, gastroscopy findings, surgical 
report, radiological report or specialist letter), and discussing with study supervisors 
when tumour stage was unclear.  These five patients therefore represented an 
important category whereby a decision had been made not to proceed with 
investigations rather than just having the absence of information.  On this basis it was 
decided to include an ‘unstaged’ group as a category for both the descriptive and 
survival analyses. 
Deprivation and Rurality 
Deprivation and rurality variables were missing data for 4% (n=12) of patients. As 
these variables were considered as indicators of level of access to cancer services it 
was decided to impute the missing data.  Additionally as level of deprivation is closely 
linked to tumour site, through the H. pylori causal pathway, the imputed deprivation 





Tumour site was ascribed based on data from the notes review, or if that was missing, 
from the NZCR. The NZCR usually receives its first notification of a stomach cancer 
diagnosis from a biopsy report.  If there is no indication of where in the stomach the 
biopsy was taken the initial ICD-10-AM code is assigned as C169 - Malignant neoplasm 
of stomach, unspecified.  If there is information in the report of where in the stomach 
the biopsy was taken from a more specific site code is entered.  When and if the NZCR 
receives subsequent information, generally an operative histology report, the site 
code will be reviewed and updated to the more specific sub-site as indicated. The site 
code can be updated at any time subsequent information is received, not just within 
four months from date of diagnosis as for the extent of disease field (personal 
communication, Shirley Miles, Team Leader, NZ Cancer Registry, Classification and 
Terminology).  
Even using all available data sources, tumour site was missing from 22% of cases (15% 
Māori, 24% non-Māori, age- and sex-standardised). Given the importance that tumour 
site plays in patient prognosis (McLoughlin, 2004; Abrams and Wang, 2010), it was 
decided to impute the missing data. 
Imputation of Missing Data for Tumour Site, Deprivation and Rurality 
Multiple imputation for missing tumour site, deprivation and rurality was carried out 
using Stata (Version 12) before analysis was continued in SAS. 
Before tumour site imputation was carried out the four level tumour site variable was 
collapsed into two levels.  Tumours that were categorised as both proximal and distal 
(n= 5) were combined with proximal, as these two categories would both be surgically 
treated with a total gastrectomy; other description (n= 11) was combined with distal. 
A binary logistic regression model was then used to impute the missing tumour site 
data.  The predictive model included variables for ethnicity, age at diagnosis, gender, 




The imputed model was imported back into SAS and run 35 times using the SAS Phreg 
procedure.  This produced 35 cohort datasets with imputed estimates of tumour site, 
deprivation and rurality for patients with missing data.  The logistic regression 
analyses were re-run using the imputed tumour site, deprivation and rurality 
variables.  Models produced 35 estimates (based on the 35 cohorts generated by 
multiple imputations); coefficients and variance estimates from these 35 cohorts were 
then pooled to give a single result for each variable using the SAS Mianalyze 
procedure. 
Data Analyses 
Data analyses were carried out in three parts (Table 15).  Firstly, the presentation of 
the Māori and non-Māori cohorts was compared descriptively.  This step involved 
comparing patient factors, tumour or disease factors and markers of health care 
access.  Secondly, the management of the Māori and non-Māori cohorts including the 
receipt and timing of treatment were compared descriptively.  In these two steps the 
variables were adjusted for age and sex only, since these were considered pure 
confounders.  Thirdly, survival analyses were carried out.  Kaplan-Meier cancer 
survival curves were compared for Māori and non-Māori cohorts and Cox proportional 
hazards models were fitted to produce cancer specific hazard ratios.  These were 
adjusted in a sequential fashion for age and sex, stage and tumour site, patient 
comorbidity and deprivation and rurality.  All analyses were carried out using SAS 
(Version 9.3). More detail about these methods is provided in the following section.  
While significance of differences was assumed at P values of less than 0.05, a 
considered decision was made when presenting the results to not focus and report 
solely on the basis of whether results were statistically significant (or not).    This 
approach is in line with concerns by leading practitioners that labelling results as 
“statistically significant” or “statistically non-significant” dependent on a calculated p-
value being below/above 0.05 is too reductionist and simplistic to provide useful 




(Kyriacou, 2016; Nuzzo, 2014; Sterne and Davey Smith, 2001; Wasserstein and Lazar, 
2016).  
Table 15: Cohort analysis and statistical methods 
Analysis Statistical Methods 
1. Comparison of cohorts  Crude and standardised prevalence rates 
2. Comparison of treatment and 
management 
 Crude and standardised prevalence rates 
 Crude median waiting times for cancer treatment 
 Surgeon and surgical facility type by stratification and 
logistic regression 
3. Comparison of survival  Kaplan-Meier survival curves 
 Cancer-specific hazard ratios (Cox proportional models) 
sequentially adjusted for: 
I. Demographics 
II. Disease factors 
III. Patient comorbidity 
IV. Health care access factors 
Linking Data Analyses to the Mandelblatt Framework 
The variables used in these data analyses were organised according to the 
Mandelblatt et al framework (Mandelblatt et al., 1999) pertaining to Māori/non-Māori 
treatment disparities as discussed in Chapter 4 (see Table 16).  Comparing the 
treatment and management received by Māori and non-Māori and adjusting for 
variables in survival analyses in a sequential manner allowed this thesis to remain 
focussed on health system-level factors (small area deprivation and rurality) and 
health care process-level factors (surgical and medical oncology intervention rates and 
waiting times, and surgical facility type and surgeon type) while also acknowledging 
the importance of patient-level factors (patient characteristics – age, sex and 




Table 16: Framework and variables used in data analysis 
Framework Level Variables 
Patient-level  Patient factors 
- Age 
- Sex 
- Comorbidity  
 Disease factors 
- Stage 
- Grade 
- Tumour site  
Health care process-level  Intervention rates 
 Timeliness to treatment  
 Surgical facility type 
 Surgeon type  
Health system-level  Deprivation  
 Rurality 
Patient-level factors lie outside of the dominion of the secondary and tertiary cancer 
care system.   While patient (comorbidity) and disease factors (grade and tumour site) 
existing at presentation to secondary services are important influencers of cancer 
treatment and subsequent survival, they reflect differences in the underlying 
determinants of health and institutionalised racism in society as a whole.   In this study 
they have been conceptualised as patient-level factors, as have age and sex. 
Stage at diagnosis could be thought of as a process-level factor, with differences by 
ethnicity reflecting differential access to primary health care, prompt referral and 
timely diagnostic investigation; however in this study stage has been conceptualised 
as a patient-level factor as it also represents a crucial individual patient measure 
influencing patient survival.  
Health care process-level factors include communication between services and 
patients and their whānau which in turn may impact on the pathways of care 
experienced by patients.  Thus surgical and medical oncology intervention rates and 
waiting times are conceptualised as process-level factors, with any differences by 




and surgeon type are presented as health care process level factors within the 
descriptive results, however they could also be conceptualised as health system-level 
factors. 
Health system-level factors include the focus, funding and location of cancer services 
which in turn affect the accessibility of services according to socioeconomic status and 
geographical location.  Thus small area deprivation and rurality, while broad 
measures, are conceptualised as markers of health care access reflecting 
institutionalised racism that may privilege or discriminate according to ethnicity.    
Age (and Sex) Standardisation 
Standardising for age (and sex) is important when two groups being compared have 
different underlying age (and/or sex) distributions and these variables are related to 
the outcome of interest, as in the case of this study.  Māori have a younger age 
structure as well as differential sex distribution compared to non-Māori (Statistics 
New Zealand, 2007).  All age- and sex-standardised rates were calculated by direct 
standardisation, using the total New Zealand cancer population (2006-2008) as 
standard (Table 17).   The use of a New Zealand cancer population standard creates 
rates that are a closer approximation of the crude overall cancer rates than would 
rates standardised to other standard populations such as Segi’s world population or 
the World Health Organization (WHO) population.  Standardising to these populations 
would result in rates that are generally higher (because these standard populations 
are younger than cancer populations).   Thus the use of a New Zealand cancer 
population standard better reflects the age structure and experience of cancer 





Table 17: New Zealand cancer population (all new cancer registrations diagnosed 2006-2008), used as 
the standard population for age standardisation 
Age Category Women (n) Men (n) Total (n) 
25-49 9936 3236 13172 
50-64 10255 9810 20065 
65-74 6955 10373 17328 
>75   9189 10916 20105 
Total 36335 34335 70670 
Comparison of Māori and Non-Māori Cohorts and Treatment 
Prevalence rates (proportions) were calculated for key patient characteristics, tumour 
or disease factors, markers of health care access, receipt of diagnostic 
investigations/treatment and timing of treatment (Table 14: Variables used in study 
analyses).  The crude prevalence rates were adjusted for the pure confounders, age 
and sex only.  To do this, study participants were stratified by age and sex, then overall 
Māori and non-Māori standardised prevalence rates were calculated by summing the 
strata-specific prevalence rates weighted by the proportion of the New Zealand cancer 
population in each strata (defined above).   
Survey methods were used to calculate population estimates for the total New 
Zealand stomach cancer cohort over the time frame of the study. Because all Māori 
patients were included and a sample of non-Māori the final Māori and non-Māori 
samples were weighted to the total eligible Māori and non-Māori stomach cancer 
populations (Table 18).   
To test the significance of any Māori/non-Māori differences P values were calculated 
on crude data.  They were calculated from Cochrane-Mantel-Haenszel chi-squared 
tests stratified by age or age-sex group, or by t-test in the case of mean age at 
diagnosis. Crude, age- and sex-standardised and total weighted prevalence rates along 





Table 18: Population estimate calculations for weight 
Calculations Māori Non-Māori 
Study sample after exclusions applied 181 584 
Total sample 181 181 
Final cohort (after excluding patients found 
ineligible during medical note review) 
172 163 
Actual eligible population   (172/181) x 181 = 172    (163/181) x 584 = 526 
Weight (actual eligible pop/final cohort)  172/172 = 1.00 526/164 = 3.2 
Access to Specialist Surgical Care: Further Assessment of Surgeon Type 
and Facility Type 
Initial analysis suggested that stage I – III Māori patients were less likely to receive 
specialist surgical care and care within main centres.  To ascertain whether these were 
related to the differences in surgery type (due to the different tumour site distribution 
between Māori and non-Māori), stratified analyses were done by surgery type.  For 
these analyses main centres and private centres were collapsed together.   
A logistic regression model was also fitted for receipt of specialist surgeon within a 
main centre as the outcome, ethnicity as the primary exposure of interest and age 
(continuous), tumour site (proximal and distal) and stage (collapsed to a binary 
variable stages I/II and III) (Table 19).  Age was fitted to the model first as a pure 
confounder.  Then, in order to ascertain if the different tumour site distribution 
between Māori and non-Māori explained the type of surgeon performing surgery, 
tumour site was fitted next to the model.  Site impacts on the extent of surgery 
needed and thus on the level of specialised skill needed by the surgeon.  Finally stage 
was adjusted for as stage also influences the complexity of the surgery performed and 





Table 19: Variables used to calculate receipt of specialist surgical care in Māori and non-Māori 
cohorts (n= 81) diagnosed at stage I – III and who had surgery in a main centre 
Variable Values Reference group 
Ethnicity Māori, non-Māori non-Māori 
Age Continuous  
Tumour site Proximal, distal Proximal 
Stage Stages I/II, III Stage I/II 
Adjusted for   
Ethnicity and Age   
Ethnicity, Age and Tumour site   
Ethnicity, Age, Tumour site and Stage    
Access to Multidisciplinary Meetings  
Data on access to multidisciplinary meetings (MDM) were gathered but this 
information was often missing within patient notes and thus there was a substantial 
amount of missing data.  These data were not analysed further.  
Comparison of Timeliness to Cancer Treatment 
Median times between key steps in the treatment pathway were calculated for the 
stage I - III study population.  In cases where the date (day) of a key treatment step 
was missing, but the month and year were recorded, the day was defined as the 15th 
of the month and these cases were then used in analyses. First intervention was 
defined as earliest of either radiotherapy, chemotherapy, definitive surgery, or other 
surgical intervention such as abdominal paracentesis, gastric or oesophageal stent or 
jejeunostomy feeding tube insertion.  The SAS Univariate procedure was used to 
examine the distribution of data within all waiting time variables.  The procedure was 
also used to determine the 50% quantile (i.e. median time point), for the total cohort 
and for the Māori and non-Māori cohorts.  To test the significance of any differences 





Comparison of Cancer Survival 
Survival analyses were carried out using cancer specific survival methods.  Kaplan-
Meier survival curves were compared between Māori and non-Māori.  Cox 
proportional hazard modelling was carried out to calculate hazard ratios and assess 
the relative risk of dying after diagnosis for Māori compared with non-Māori 
(Kleinbaum and Klein, 2012; Robson and Purdie, 2007b).  All patients were followed-
up from date of diagnosis until death or December 31 2010, whichever came sooner; 
patients who were still alive at December 31, 2010 were censored at that date.  This 
resulted in a minimum follow-up time of two-years (and maximum of five-years) for 
each patient.  Person-years to end of follow-up were calculated for each patient in the 
study.  Kaplan-Meier survival curves were generated using the SAS Lifetest procedure, 
while Cox proportional hazard ratios and 95% confidence intervals used the SAS Phreg 
procedure.  Log-rank tests were used to compare the survival distributions of the 
Kaplan-Meier curves; 95% confidence intervals were determined to assess the 
precision of the hazard ratio result and the likely range of the estimate.   
Time to death for the Māori and non-Māori cohorts was assessed and compared using 
Kaplan-Meier survival curves, for both all-cause and stomach cancer specific survival.   
Stomach cancer specific modelling only was undertaken as few patients died of other 
causes and a primary aim of the study was to investigate how any differences in 
patient, disease, treatment and health care access factors impacted on survival from 
stomach cancer.   
Covariates used in Survival Modelling 
In order to explore key relationships between ethnicity and survival crude 
(unadjusted) Cox models were fitted, following which a series of potentially 
confounding covariates were introduced into the model in a sequential fashion to 




Figure 6: Direct acyclic graph for key relationships between ethnicity and survival  
 
Firstly the model was fitted using crude data; it was then adjusted sequentially for 
patient demographic and disease characteristics: age at diagnosis (continuous 
variable), gender, stage at diagnosis (categories: I, II, III, IV and unstaged) and tumour 
site (using imputed tumour site data, which included the collapsed tumour site 
variable).  The model was then adjusted for level of comorbidity, using a count of the 
twelve most common comorbid conditions in this study (continuous variable, 0-12).   
Finally the model was fitted with the variables used as proxy for markers of health 
care access, imputed deprivation (quintiles) and rurality (collapsed into three 
categories).   
Mortality hazard ratios (HR) and their 95% confidence intervals were compared for the 





Table 20: Variables used to calculate adjusted hazards ratios  
Variable Values Reference group 
Unadjusted Māori , non-Māori non-Māori 
Age Continuous Continuous 
Sex Male, Female Female 
Stage Stages I, II, III,IV, Unstaged Stage I 
Tumour site  Proximal, Distal Proximal 
Comorbidity – Top 12  Continuous Continuous 
NZDep Quintile 1, 2, 3, 4, 5 NZDep 1 
Rurality Urban, Independent Urban, Rural Urban 
Demographic Factors: Age and Sex 
Age and sex can be considered ‘pure’ confounders in the association between 
ethnicity and survival (Figure 6).  As previously outlined Māori compared to non-Māori 
populations have different age structures and sex distributions (Statistics New 
Zealand, 2007); both of these variables are known to impact on cancer survival.   
Chronological age is a predictor of survival in patients with stomach cancer with 
survival probability declining with increasing patient age at diagnosis (Saito et al., 
2006; Yang et al., 2011) in part due to differential treatment received by patients in 
older age groups (Saif et al., 2010).  Sex is also an important independent predictor of 
survival with women shown to have better survival likelihood (Yang et al., 2011).   
Thus these patient level factors were adjusted for first to ascertain how much of the 
survival differences were explained by these variables before adjusting for disease 
factors, patient comorbidity and health care access factors.    
Disease Factors: Stage and Tumour Site 
Stage and tumour site were both conceptualised as potential mediators between 
ethnicity and survival (Figure 6).   As outlined in the previous chapter, ethnicity can 
impact on stage at diagnosis through pathways such as differential access to primary 
health care or timely diagnostic investigation.  Ethnicity is also related to tumour site 
with Māori patients more likely to be diagnosed with distally located tumours.  Stage 




treatment and with a strong association to mortality (McLoughlin, 2004; Crew and 
Neugut, 2006; Abrams and Wang, 2010).  Likewise tumour site plays an important role 
in survival from stomach cancer impacting both on treatment options and prognosis 
(Mann and Thomas, 2001; Abrams and Wang, 2010).  These two variables were added 
next in order to ascertain if there were differences in survival once demographic and 
disease factors (or the factors not amenable to intervention in the secondary cancer 
care system) had been accounted for.  This then allowed the assessment how much of 
the remaining inequity was explained by patient comorbidity and factors related to 
access to health services.  
Patient Comorbidity 
Comorbidity was conceptualised as a potential mediator in the relationship between 
ethnicity and cancer survival (Figure 6).  It is well documented that Māori with cancer 
have higher levels of comorbidity than non-Māori (Hill et al., 2010a; Brewer et al., 
2011).  Comorbidity can impact on survival directly as well as indirectly through its 
negative impact on treatment receipt.   For example comorbidity is known to impact 
both on the quality of care received and on the likelihood of survival of patients from 
colorectal cancer (Hill et al., 2010a; Lemmens et al., 2005; Sarfati et al., 2009; Sarfati 
et al., 2014a).  It is also a mechanism through which inequitable survival outcomes can 
appear or widen once patients have been diagnosed with cancer.   Fitting comorbidity 
to the model subsequent to the factors that are not amenable to secondary sector 
intervention explores the effect that unequal comorbidity plays on Māori/non-Māori 
survival disparity once diagnosed with stomach cancer.   
Health Care Access Factors: Deprivation and Rurality 
Deprivation and health care utilisation are both independently related to survival in 
stomach cancer patients (Yim et al., 2012) thus small area deprivation (NZDep) and 
rurality were both considered potential mediators in this study (Figure 6).  As 
previously explained deprivation and rurality while conceptualised as markers of 
access to services are very crude measure of access and not a measure of health care 




deliberate attempt to explore the effect of health care access once key patient and 
disease factors have been accounted for or whether any residual survival disparity at 
this point is explained by differential access to, and through, services.  
Receipt of Treatment Factors and Stage Specific Survival 
Limited study numbers did not allow the meaningful assessment of patient survival for 
potentially curable stage I-III only.  However a model was constructed to explore the 
survival of the 172 patients with stage I – III disease.  This model replicates the step-
wise model described above for the total cohort, using the same variables in the same 
order   
Limited study numbers  also meant that variables pertaining directly to treatment such 
as, receipt of surgery, surgeon type or surgical facility type were not included in 
survival modelling.   
Other Possible Confounders or Mediators 
Factors such as smoking status or disease morphology may well impact on patient 
survival but were unable to be included in the model as data for these variables was 
not complete.  It is probable there were additional confounding factors that were not 
able to be adjusted for as data on these factors was not collected, or not complete.   
Summary of the Quantitative Phase  
The purpose of the quantitative phase of this study was to compare the presenting 
characteristics, treatment and management of Māori and non-Māori patients with 
stomach cancer and to examine the contribution of any differences to survival.  The 
target population was all Māori and non-Māori, aged 25 years and over and residing in 
the North Island of New Zealand with a first diagnosis of stomach cancer registered 
between 1 January 2006 and 31 December 2008.   
Once appropriate ethics approval was gained, individuals meeting the study criteria 




Registry records all Māori patients diagnosed during the study period and an equal-
sized random sample of all non-Māori patient were identified.  Study data were gained 
from national and cancer treatment centre databases while clinical data were 
primarily gained by a manual review of patient medical notes in individual hospitals 
attended by patients.  Patient medical notes, including pathology reports, were 
reviewed in detail and relevant information extracted onto a standardised 
questionnaire.  The study cohort was linked to the national mortality database to 
identify all deaths occurring to the end of 2010.  Deaths were classified into those 
attributed to stomach cancer and those due to other causes. 
All study data were entered and managed in a single electronic dataset and were 
analysed using SAS software.  Data were imputed for the key variables tumour site, 
deprivation and rurality.  Data were analysed in three parts.  Descriptive comparison 
of the presentation of the Māori and non-Māori cohorts was carried out; this included 
comparison of patient and disease factors and markers of health care access.  The 
management of the Māori and non-Māori cohorts including the receipt and timing of 
treatment were then compared.  In these two steps the variables were adjusted for 
pure confounders, age and sex, only.   Survival analyses were carried out last.  Cancer 
survival curves were compared for Māori and non-Māori cohorts and cancer specific 
hazard ratios were sequentially adjusted for age, sex, stage, tumour site, comorbidity, 






Background to the Qualitative Phase  
In order to build on the findings of phase one (the quantitative study) a qualitative 
phase was undertaken to investigate those points of the stomach cancer treatment 
pathway that the quantitative findings suggested were inequitable for Māori.   This 
was done through fifteen key informant (also referred to as participant) interviews 
intended to assess: 
a. What the sector sees as the issues impacting on equity for Māori within 
New Zealand’s stomach cancer treatment pathway. 
b. How the sector interprets the findings of the quantitative phase. 
c. The interventions the sector advises that could be implemented to 
improve the stomach cancer treatment pathway for New Zealanders 
with a focus on Māori.  
Phase Two Research Questions  
Two research questions guided the qualitative phase of this study, they are: 
1. What do key informants identify as issues for stomach cancer treatment in 
New Zealand, with a focus on Māori? 
2. Which interventions do key informants identify that may improve access to, 






The Study Population 
Participant Sampling 
Participants were selected for the interviews using purposive sampling.  Purposive 
sampling is commonly used in qualitative research to select information-rich 
participants who can generate insights and in-depth understanding of the questions 
under study (Patton, 2005; Padgett, 2011; Patton, 2014).  As this phase of the study 
was primarily interested in the response of people working in the health system to 
inequities within the stomach cancer treatment pathway the interview participants 
were all health care, or health policy, professionals.   
The eligibility criteria for participants were that they must have knowledge of the 
stomach cancer treatment pathway, be actively working within the health care system 
and have knowledge of the issues for Māori within cancer treatment services. 
The participants were purposefully drawn from: 
 Clinicians – Specialist and Generalist Surgeons, Medical Oncology 
 Māori Cancer Coordinators  
 Specialist Upper Gastrointestinal Nurses 
 Specialist Cancer Nurse Coordinators 
 Regional Cancer Networks – Managers and Equity Managers 
 District Health Board Planning and Funding 
 Ministry of Health Cancer Team. 
A maximum variation sampling approach was taken which involves purposefully 
selecting a range of participants in order to get variation on the factors of interest 
(Patton, 2005; Padgett, 2011; Patton, 2014).   In this case sampling aimed for a mix of 
Māori and non-Māori informants, clinician and policy professionals along with a mix of 
centre type in which the participants were employed (main centre and smaller 




of interest: indigeneity, health care professional role type and treatment centre type.  
This range of views then allowed for the identification of variations across these three 
factors as well as the identification of important common themes that cut across each 
of the three factors (Patton, 2005; Patton, 2014).  The final of these three factors was 
included, as differences in surgical management of patients were observed by 
treatment centre type in the quantitative phase of this study; this phase was, in part, 
undertaken to further investigate any points of the treatment pathway that the 
quantitative findings suggested were inequitable.  
Recruitment 
Recruitment of participants was undertaken using the snowball method which is 
useful to access specific populations.  Initial participants nominated other potential 
participants within their networks who met the eligibility criteria and could contribute 
specific knowledge to the study (Padgett, 2011; Liamputtong, 2012).    The interview 
schedule was discussed with one health care policy professional and trialled with one 
clinician whose advice was sought on others who met the sampling criteria and would 
be useful to interview.  Knowledge of my own and supervisors networks were also 
drawn on to establish an initial participant list.  All recommended participants were 
discussed with the study supervisors before recruitment.  At the completion of each 
interview each participant was asked to recommend future participants thus 
snowballing from the initial list.  As the number of interviews progressed participants 
were asked to recommend participants that would meet the maximum variation mix 
of participants.  Recruitment was discontinued once key names began to be repeated 
and no new names were suggested by participants. 
Once it was determined to include a potential participant an initial email was sent to 
them briefly discussing the study and requesting their involvement in a telephone 
interview.  If the potential participant agreed to an interview they were then emailed 
the study information sheet (see Appendix 3) and consent form (see Appendix 4).  In 




and digitally recorded at the beginning of the interview and an interview time 
arranged, for a time convenient to the participant.   
Data Collection  
The one-on-one key informant interview was chosen as the primary research tool for 
the qualitative phase of this study as key informant interviews are an effective way to 
gain in-depth insights into a topic of interest from well informed experts.  The key 
informant interview has been widely used in health care research over a number of 
decades, including research interested in the views of health care professionals and 
research interested in developing interventions within the cancer context 
internationally (Marshall, 1996; Boon et al., 2009; van der Weijden et al., 2013; 
Chubak et al., 2012; Hahn et al., 2013) and in New Zealand (Cormack et al., 2005; 
Cram, 2014b).  Additionally qualitative research can be useful to policymakers as it 
often describes the settings in which policies, or interventions, will be implemented 
(Anderson, 2010) 
The purpose of these interviews was to determine what key people working within 
services relevant to the New Zealand stomach cancer treatment pathway see as the 
issues impacting on equity for Māori within pathway, to present the findings of the 
quantitative phase and seek expert advice on them and to explore possible 
interventions to improve the pathway, with a focus on Māori. 
Development of the Interview Schedule 
The interview schedule was developed in three steps.  Firstly it was drafted using 
findings of the quantitative phase of this study and personal knowledge of the cancer 
sector.  This draft was reviewed by the supervisors of this study and revised to better 
reflect this study’s research questions.   Secondly in keeping with the advice by 
Padgett (Padgett, 2011) on conducting interviews, the draft interview schedule was 




interview schedule was again revised after this stage to better reflect current 
developments i.e. questions were specifically asked about the ‘Upper GI Service 
Delivery Standards’.  Thirdly the interview schedule was then trialled with a clinician 
working within the field of stomach cancer (and whose data was subsequently used in 
analysis as no issues were identified with the method or interview schedule).  Trialling 
interview questions on someone drawn from the population of interest is 
recommended to ensure the questions are not ambiguous and that they elicit the type 
of discussion needed (Padgett, 2011; Braun and Clarke, 2013).  This step also allowed 
assessment of the time needed for the interviews so future participants could be 
informed of the likely impact on their time.   
The interview schedule (see Appendix 5) was structured in the following order, with 
questions asked about: 
1. The participants’ role in relation to the stomach cancer treatment pathway. 
2. The stomach cancer treatment pathway: what is done well currently, what is 
not done well currently and whether there are particular issues for Māori or 
those with comorbidity. 
3. Treatment decision making: multidisciplinary meetings and whether anything 
significant had changed in the preceding five years to improve the treatment 
pathway. 
4. The National Upper GI Service Provision Standards: implementation of and 
their potential to impact on equity. 
5. At this stage the key findings of the quantitative phase of this study were 
discussed. 
6. Referral pathways into specialist care: both surgical and oncological. 
7. How to improve the pathway for all, but especially for Māori. 
8. What specific interventions would be useful and feasible in New Zealand. 
The semi-structured interview was chosen for this study as this type of interview 




interview as it progresses (Braun and Clarke, 2013; Padgett, 2011).  While the 
information being sought was complex, participants were purposefully sampled for 
their expertise in the area.  Interviewing these participants required a careful 
conversation and considered questioning to allow participants to discuss, at times 
sensitive, issues in depth.  The interview schedule was developed to reflect this semi-
structured nature.   The questions were open-ended allowing the participant to reveal 
issues of importance to them.  The questions developed sequentially around topics or 
categories of information and included prompts to allow further questioning in areas 
of interest so that participants could provide more detail where needed.  The semi-
structured interview schedule also allowed for questions to be skipped if they had 
been answered earlier in the interview (Padgett, 2011; Braun and Clarke, 2013). 
The order of questions is important in in-depth interviewing.  Starting with less 
sensitive ice-breaker questions is recommended (Padgett, 2011; Braun and Clarke, 
2013).  So while gaining knowledge about what the participants saw as issues within 
the stomach cancer treatment pathway was of primary interest, less challenging 
questions about the participants role in relation to stomach cancer and ‘what works 
well’ for patients in the pathway currently were asked first.  A question was also 
deliberately asked regarding whether there had been any improvements to the 
stomach cancer treatment pathway during the preceding five years before the 
findings of the quantitative phase were presented.  Five years was chosen as this was 
the length of time since the last date of diagnosis of patients in the quantitative phase 
of this study.  This question provided an opportunity for participants to discuss recent 
developments that might have impacted on the pathway in the timeframe subsequent 
to patients in the quantitative phase receiving their cancer care.  
Consent and Confidentiality 
Informed consent is described as “the provision of information to participants, about 
the purpose of the research, its procedures, risks, benefits and alternatives, so that 
the participant can make a voluntary decision whether to enrol and continue to 




form was emailed to potential participants.  Participants were asked to read the 
consent form carefully and consent was obtained verbally, and digitally recorded, at 
the start of the interview.  In the consent process participants were asked to agree to 
take part in the study and explicitly to the interview being recorded and were also 
asked to confirm that they knew they were free to withdraw from the study at any 
time during data collection without any disadvantage.     
Due to the relatively small sector from which participants were drawn (the New 
Zealand cancer sector) maintaining participant confidentiality was deemed important 
(Liamputtong, 2012).  A commitment was made to not identify participants personally 
in this thesis or any subsequent publications.  Participants were advised that their role 
and ethnicity would be recorded and used to describe the participants but that they 
would not be named and that every effort would be made to ensure that they were 
not identified in any reported data.   
As a number of the participants are in well-established roles and potentially 
recognisable within the cancer sector special care was taken to ensure that they 
would feel comfortable speaking freely and without discrimination now or in the 
future.  Padgett (Padgett, 2011) advises that consideration be given to limiting direct 
quotes from well-known ‘experts’ in order to maintain their confidentiality.  As a 
compromise participants were offered the ability to approve direct quotes.  Seven 
participants indicated that they wished at approve direct quotes taken from their 
interview.  Of these, direct quotes of four participants were used after approval was 
gained.  
Conducting the Interviews 
Generally interviewing by telephone is seen as an alternative measure if face-to-face 
interviewing is not possible (Padgett, 2011).  While some of the participants were 
available to be interviewed in person, in order to have a consistent method of data 
collection all participants were interviewed by telephone no matter where they were 




The interviews followed the previously prepared interview schedule and involved the 
following steps: 
1. Establishing rapport by explaining who I was, my professional background, how 
I became interested in the topic and thanking the participant for their time. 
2. Briefly outlining the study and its ‘fit’ into the wider C3 study if participants 
requested (in some cases participants thought they knew enough about the 
study from email contact and the information sheet).  
3. Obtaining consent verbally, reminding participants about their confidentiality 
and giving time for the participant to ask any questions or express concerns. 
4. Carrying out the interview guided by the interview schedule, starting with ice-
breaker questions and moving sequentially through the topic areas of interest. 
5. Ending the interview by asking if there was anything else the participant 
wished to discuss, asking for recommendations of further participants and 
collecting demographic data. 
All interviews were held at a time of the participants choosing and with the participant 
at a place of their choosing.  I conducted the interview in a private office using a 
speaker phone in order to record and take notes of the interview as it progressed.  
Each participant was formally interviewed once only.  
Recording and Transcription 
Capturing an accurate record of the interview is vital in qualitative research (Braun 
and Clarke, 2013) thus all interviews were recorded using a digital voice recorder 
(Olympus WS-1100).   Recording an interview allows the researcher to follow, and 
process, what the participant is saying instead of trying to take accurate and detailed 
notes.  Recording also allows for better interaction with the participant such as being 
able to probe when needed.  As well, transcripts of the interview in the participants 




As a back-up to the audio-recording, notes were taken as the participant spoke.  
Participants were informed at the start of the interview that some notes would be 
taken together with the audio-recording; importantly this was not intrusive as the 
participant could not see written notes being taken (Liamputtong, 2012).  These notes 
captured key points discussed and aligned to the interview schedule questions.  The 
information in these notes was synthesised and summarised throughout the 
interviewing stage of this study and discussed regularly with the study supervisors.  
Working in this way helped to clarify thinking about two key factors: the issues for 
Māori along the stomach cancer treatment pathway and possible ways of intervening 
to improve the quality of care.  In keeping with good interview practice as identified 
by Braun and Clarke (Braun and Clarke, 2013), field notes were taken after each 
interview.  These recorded perceptions of the interview and whether there were any 
important ideas or issues about the interview process to note.  
The interviews were all professionally transcribed.  Padgett (Padgett, 2011) advises 
that if using an ‘outside’ transcriber they be included as part of the research team 
wherever possible.  The transcriber employed for this study was concurrently working 
on transcribing data of the qualitative side of the overall C3 studies.  Thus the 
transcriber had some understanding of the context these interviews were held in and 
was familiar with the content.  The interviews were transcribed into a Word document 
with a mainly verbatim level of transcription which omitted verbal padding (e.g. ‘sort 
of thing’, ‘know what I mean) and hesitations (e.g. ‘er’, ‘um’).  The audio-recordings 
and transcripts were transferred to, and from, the transcriber through the University 
of Otago, Wellington secure drop-box in order to maintain confidentiality of the data.   
Using a professional transcriber meant that I missed what some say is a crucial step in 
beginning to understand and analyse the data (Padgett, 2011; Liamputtong, 2012).  
Transcribing your own audio-recordings allows one to get ‘up close and personal’ with 
the data, to remind oneself of the nuances and emotions of the participant response 
and to better understand your interviewing style and its impact on the data gathered.  
Transcription is described as “a form of data transformation that can either enrich or 




made when one does not transcribe their own data (Padgett, 2011).  As articulated 
above, the transcriber was a professional transcriber and familiar with the content 
area of these interviews.  We had email discussions about this study and why the 
participants were chosen.  We also negotiated the level of transcription required.  
When the first transcript was completed I listened to the entire interview while 
reading the transcript to ensure the transcriber had accurately captured the data.  
Through this process I was able to correct a key omission where ‘tumour stream’ was 
transcribed throughout as ‘chemistry’, otherwise the transcript was accurate. I proof-
read each transcript as it was delivered to me in order to become familiar with the 
data and throughout the data analysis phase I listened to each of the remaining 14 
interviews, checking them against the transcript and my field notes of the interview to 
assess whether any further important ideas or issues emerged. 
Six participants requested to approve their interview transcript and were sent a copy 
within a month of the transcript being typed.  Of these, four participants identified 
minor revisions only. These revisions were made before the transcripts were imported 
into NVivo for analysis. 
Data Analysis 
While data analysis is said to begin early in the process of data collection it is through 
immersion in the data or iterative processes of reading, re-reading, describing and 
interpreting that the researcher is able to make sense of what has been collected 
(Saldana, 2009; Liamputtong, 2012). 
A number of different types of data analysis are described as appropriate to 
qualitative research.  Content analysis looks to the data to count how many times a 
predetermined category occurs, in narrative analysis participants stories or ‘lived 
experiences’ are analysed and re-told and in discourse analysis the words and text 
themselves are analysed to determine the participant’s social reality (Liamputtong, 
2012). However thematic analysis was the most appropriate form of analysis to 




investigating people’s views and opinions (Joffe and Yardley, 2004) and because of its 
emphasis on identifying and interpreting emerging patterns within data (Liamputtong, 
2012; Padgett, 2011).  
NVivo 
Computer assisted qualitative data analysis software (NVivo 10) was used to manage 
and organise the qualitative data.   NVivo was used to easily allow data coding, 
retrieval and linking and to allow comparison of the data across the three key factors 
identified above: indigeneity, health care professional role type and centre size of 
employment.  Importantly, while computer assisted software can assist in data 
management; its use does not replace intellectual management of data.  Ultimately 
qualitative analysis needs human analytic reflection.  Analysis remains a process of 
interpretation, driven by what the researcher sees in the data, the opinions they form 
on what they see and how they make sense of those opinions (Liamputtong, 2012; 
Patton, 2014). 
The Word transcripts were imported into NVivo and attributes applied to each 
participant.  These attributes included gender, age group, ethnicity (Māori or non-
Māori), role in the health care system (policy or clinician, as well as a more detailed 
role title) and centre size of employment (small, main or national).  The data were 
then ready to begin coding and analysis. 
Coding 
Expressed simply coding is the process of naming or labelling units of data.  This 
labelling then is a method that enables the organisation or grouping of similarly coded 
data into categories which share a common characteristic.  In this way, patterns can 
be seen and themes begin to emerge (Braun and Clarke, 2013; Padgett, 2011).  





 Reading through the transcripts in NVivo and coding initially to the interview 
questions, including the question on relevant interventions. 
 Re-reading the transcripts and re-coding each interview question using a 
stomach cancer pathway framework.   
 Re-reading the transcripts and also re-coding each interview question 
according to emergent themes. 
 Simultaneously writing memos directly into NVivo which were attached to the 
participants data file in NVivo. 
As seen in the steps listed above the framework used to code evolved throughout the 
coding process.  Initially coding was undertaken using the interview schedule 
questions but this evolved into a coding framework that focussed on the stomach 
cancer pathway and emergent themes.  Coding is meant to be an on-going and cyclic 
process (Padgett, 2011; Liamputtong, 2012; Braun and Clarke, 2013).  As Saldana 
(Saldana, 2009) points out “rarely is the first cycle of coding data perfectly 
attempted”.  In fact the initial coding structure or framework may not be useful and 
often evolves as analysis progresses.  In some cases a modified or entirely different 
coding framework may be needed (Saldana, 2009). Each coding cycle in qualitative 
research allows the researcher to become more immersed in the data and further 
filters, highlights, and focuses the features of the data most relevant to the study.  
Through these cycles categories, themes, and concepts are generated and theories 
built (or in the case of this study, ideas of interventions generated) (Saldana, 2009). 
As the data analysis progressed NVivo was used to retrieve large amounts of coded 
data passages for comparison.  As any text passages can be coded with multiple 
keywords (or in multiple nodes) NVivo could be used to find where data were coded in 
multiple places, for example coded both as issues for Māori (which was an interview 
question) and specific points of the treatment pathway.  Specific queries were also run 
on key points of the treatment pathway that allowed the comparison of responses for 
the three key factors of interest.  For example a query was run to further investigate 
the differences and similarities in the responses of those working in smaller and larger 




happen to improve access to surgery.  These queries were printed out into hard-copy 
to allow easy reading and comparison. 
Ensuring Rigour 
Ensuring rigour in, and validity of, qualitative research has been subject to much 
debate (Padgett, 2011).  Quantitative research aims for validity, through adherence to 
rules and standards of a chosen methodology, and reliability, where findings are 
potentially reproducible by other researchers (Liamputtong, 2012).   This is not 
necessarily the case in qualitative research.  This phase of the current study was not 
intended to be reproducible nor generalisable to a wider set of people.  Rather it was 
conducted to give practical meaning and depth to the findings of the quantitative 
phase of this study, to stimulate the thinking of decision-makers within the health care 
system and ultimately to improve policy and practice, thus improving the quality of 
care given to people diagnosed with stomach cancer in New Zealand. 
Despite the debate around qualitative rigour there are certain processes that can be 
built into a qualitative study to help enhance the trustworthiness of its findings 
(Liamputtong, 2012; Padgett, 2011).  Commonly these processes are concerned with 
purposively selecting participants based on their unique knowledge, collecting 
appropriate and adequate data, in-depth documentation of both the research process 
and decisions made during the research process and gaining feedback on, or validation 
of, the findings.  In this study commitment was made to build in the following 
processes: 
 Carefully selecting a range of participants with in-depth and current knowledge 
of the stomach cancer treatment pathway and issues for Māori. 
 Triangulation of the data through holding key informant interviews and then 
building on the findings through discussion with C3 advisory groups and 
through presentation at Department of Public Health meetings and  meetings 
held specifically to feedback the findings of the C3 set of studies to interested 




 Building on the findings, especially the key themes and types of interventions 
put forward by participants, through discussion about emergent ideas with 
subsequent participants during the interview process, at the end of each 
subsequent interview. 
 Discussing findings with supervisors of this study, which also provided the 
opportunity to articulate internal thinking processes, clarify emergent ideas 
and to make new insights about the data. 
 Auditing or leaving a decision making trail as well as taking field notes of the 
interviews and notes on analysis within NVivo. 
 Taking a systematic approach to the collection and analysis of the data. 
Ethics 
Before data collection for this phase began ethical approval was gained.   As the 
interview participants were all health care or health policy professionals this study was 
considered ‘low-risk’ and thus this study was suitable for level B University of Otago 
departmental ethical approval.   
Summary of the Qualitative Phase 
A qualitative phase was undertaken to build on the findings of the quantitative phase 
of this study, to investigate those points of the stomach cancer treatment pathway 
that the quantitative findings suggested were inequitable for Māori and to assess 
possible interventions.    
Fifteen key informants were interviewed one-on-one.  Participants were purposively 
sampled; all were actively working within the health care system and had knowledge 
of the stomach cancer treatment pathway or of the issues for Māori within cancer 




interview schedule trialed with a clinician working within the field of stomach cancer.  
All interviews were digitally recorded and professionally transcribed.  
Data were managed and organised within computer assisted qualitative data analysis 
software (NVivo 10).  Data were coded and re-coded and number of times, they were 
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Chapter 6: Quantitative Results 
This chapter presents the results of quantitative data analysis.  It sets these results out 
in four sections: selection of study cohorts, comparison of study cohorts, comparison 
of patient management and treatment and comparison of patient survival.  
 The first section briefly outlines how the study cohort was derived from all 
patients diagnosed with stomach cancer and notified to the New Zealand 
Cancer Registry from 1 January 2006 to 31 December 2008. 
 The second section describes the final study cohort and compares the 
presenting characteristics of Māori and non-Māori patients, looking at patient 
level factors, disease level factors and markers of health care access. 
 The third section describes the management and treatment of the final cohort 
and compares the management and treatment of Māori and non-Māori 
patients. 
 The fourth section describes the cancer specific survival of the final cohort and 
compares the survival of Māori and non-Māori patients.  It then assesses the 
contribution of patient level factors, disease level factors and markers of 
health care access on survival for Māori and non-Māori patients. 
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Selection of Study Cohort 
This section describes the progression from the original cohort of patients identified 
from the New Zealand Cancer Registry (NZCR) though to the final study cohort.  It 
identifies which patients were included and excluded at each step in this process.  Of 
this final cohort, nine patients (4 Māori and 5 non-Māori) were diagnosed with a 
gastrointestinal stromal tumour; the remaining patients were diagnosed with 
adenocarcinoma.  
Table 21 shows the cohort numbers at each step of the study selection process.  The 
NZCR had a total of 1115 registrations for stomach cancer (ICD codes C16.0-16.6, 16.8, 
16.9) nationally during the study period, of which 210 were Māori and 893 non-Māori 
(Table 21: Step 1).  The study eligibility criteria were applied using the information 
available from NZCR records.  Patients with missing ethnicity data were included in the 
non-Māori cohort prior to random selection on the basis that their ethnicity was more 
likely to be non-Māori (Swan et al., 2006) and 278 patients (16 Māori and 262 non-
Māori) were excluded as they resided in the South Island of New Zealand (Table 21: 
Steps 2 - 7).  
After all study exclusion criteria were applied all eligible Māori (n=181) were included 
in the sample along with a randomly-selected equal number of eligible non-Māori 
patients (n=181).  This resulted in an initial total sample of 362 patients (Table 21: Step 
8).  Following a full clinical note review, 7.5% of the sampled study cohort (n=27) were 
observed to not meet the criteria of the study and were excluded at this stage.  This 
resulted in a final cohort of 335 patients (172 Māori and 163 non-Māori) (Table 21: 
Step 9).  Of this final cohort, nine patients (4 Māori and 5 non-Māori) were diagnosed 
with a gastrointestinal stromal tumour; the remaining patients were diagnosed with 
adenocarcinoma.  
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Table 21: Progression of exclusions: patient numbers at each step of the selection process 
  
Total Māori Non-Māori 
Missing 
Ethnicity 
1 Total Stomach Cancer Registrants  
1 Jan 2006 – 31 Dec 2008 
1115 210 893 12 
2 Excluding previous same cancer 
(2001-2005) 
1113 210 891 12 
3 Excluding Dx made > 90 days prior 
to NZCR Dx 
1106 208 886 12 
4 Excluding those aged under 25 
years at Dx 
1099 205 882 12 
5 Excluding non-NZ residents  1060 204 846 10 
6 Excluding Dx made on date of 
death or post-mortem 
1043 197 836 10 
7 Excluding South Island patients 765 181 584 0* 
8 Sample (+ Non-Māori group 
randomly selected) 
362 181 181 0* 
9 Excluding patients found ineligible 
after notes review 
335 172 163 0* 
Abbreviations: Dx = Diagnosis.  
* Patients with missing ethnicity data were merged with the non-Māori cohort prior to random 
selection of the control group. 
Table 22 gives a breakdown of those twenty seven cases (7.5% of sampled cohort) 
excluded after the clinical note review as they did not meet the criteria of the study.  
There were nine Māori and 21 non-Māori patients excluded during this stage.  
Common reasons for exclusion were patients with miscoded histological diagnosis, 
miscoded primary site (most commonly squamous cell cancer of the oesophagus) and 
being a non-resident of New Zealand or diagnosed out of this study’s registration date 
criteria.    All six patients with squamous cell carcinoma of the oesophagus were non-
Māori.  
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Table 22: Cases excluded (ineligible) after notes review (Step 9 of Table 21) 
 Total Māori non-Māori 
 n % of 
sampled 
(362) 
n % of 
sampled 
(181) 
n % of 
sampled 
(181) 
Total excluded as ineligible 27 7.5% 9 4.9% 21 11.6% 
Miscoded Primary site 8 2.2% 1 0.6% 7 3.8% 
Oesophageal 6 1.7% - - 6 3.3% 
Rectal 1 0.3% 1 0.6% - - 
Anal 1 0.3% - - 1 0.6% 
Not confirmed as adenocarcinoma 
or GIST 
13 3.6% 5 2.8% 8 4.4% 
Histology other than 
adenocarcinoma or GIST 
9 2.5% 5 2.8% 4 2.2% 
No histological diagnosis 4 1.1% 3 1.7% 1 0.6% 
Non-Resident of New Zealand 3 0.8% - - 3 1.7% 
Diagnosis outside of study date 2 0.6% 1 0.6% 1 0.6% 
Diagnosis made post-mortem 1 0.3% - - 1 0.6% 
Table 23 compares the final study cohort with cancer registrants who had a first time 
diagnosis of stomach cancer notified between January 2006 and December 2008 and 
who were not excluded in step 1 – 6 of this study’s exclusions.   The study cohort 
comprises 32% of all registrants during this period.  Patients in the final study cohort 
were more likely to be Māori which is in keeping with study design.  The final study 
cohort were also slightly younger at diagnosis and more likely to live in the most highly 
deprived quintile (9-10) and rurally most probably reflecting the higher proportion of 
Māori within the study cohort.  The NZCR extent of disease is also compared below 
with similar extent of disease seen between the study cohort and all stomach cancer 
registrants, although slightly less of the study cohort were unstaged (F). 
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Table 23: Comparison of study cohort with all stomach cancer registrants 2006 - 2008 
 Study cohort All registrants  
 n %  n %  P value 
Total 335  1043   
Māori 172 51% 197 19%  
Male 197 62% 668 64%  
Mean age  64.9 68.6  
Extent of Disease 
a)
       
B 43 13% 103 10%  
C 10 3% 38 4%  
D 65 19% 174 17%  
E 115 33% 333 32%  
F 102 32% 395 38% 0.23 
NZ Dep (Qunitile)      
1-2 25 9% 121 13%  
3-4 41 16% 149 16%  
5-6 52 18% 192 20%  
7-8 71 24% 243 25%  
9-10 134 33% 286 25% <0.001 
Rurality      
Urban 233 76% 732 75%  
Independent urban 47 13% 163 16%  
Rural 43 11% 96 9% <0.001 
a) Extent of disease (SEER summary system) is the staging system used by the NZCR  
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Comparison of Study Cohorts  
This section describes the Māori and non-Māori cohorts and compares their 
presenting characteristics looking at the patient and disease factors likely to impact on 
management, treatment and subsequent survival from stomach cancer.   
Patient Factors 
Age and Sex 
Table 24 shows the age and sex of the total cohort, and the Māori and non-Māori 
cohorts.  Figure 7 and Figure 8 show the age and sex proportions of the Māori and 
non-Māori cohorts.  
New Zealand’s Māori population has a younger age structure than does the non-Māori 
population (Statistics New Zealand, 2014; Robson and Harris, 2007a).  This is reflected 
in the study cohorts, with a younger age structure and younger average age at 
diagnosis in Māori compared with non-Māori.  The average age of Māori patients at 
diagnosis was 10 years younger than non-Māori (overall mean age at diagnosis: Māori 
60 years, non-Māori 70 years, p<0.01).  Within female patients, this ethnic difference 
was greater still (female mean age at diagnosis: Māori 57 years, non-Māori 70 years) 
(data not shown).   
While stomach cancer within in this study cohort was more common among males 
overall, a higher proportion of the Māori cohort were female (47% female) compared 
to the non-Māori cohort (35% female; p=0.11).  The higher proportion of women 
within the Māori cohort remained once the data were age standardised to account for 
the different age structures within the Māori and non-Māori cohorts.  
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Table 24: Total, Māori and non-Māori cohorts by age at diagnosis and sex 











 P value 
Age (years)          
25-49 64 16% 44 26% - 20 12% -  
50-64 87 22% 58 34% - 29 18% -  
65-74 91 28% 44 26% - 47 29% -  
>75 93 35% 26 15% - 67 41% -  
Total 335  172   163    
Mean age at diagnosis 64.9 60.0 70.0 < 0.01 
Sex          
Male 197 62% 91 53% 56% 106 65% 65%  
Female 138 38% 81 47% 44% 57 35% 35% 0.11 
Total 335  172   163    
Abbreviation: n, number 
a) Population estimates 
b) Crude  
c) Age standardised 
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Figure 8: Māori and non-Māori cohorts by sex 
 
Comorbidity 
Table 25 shows the prevalence of comorbidity within the total cohort and the Māori 
and non-Māori cohorts. Overall 70% of the total cohort (both Māori and non-Māori) 
had at least one chronic disease or other comorbid condition at the time of their 
stomach cancer diagnosis.  The proportion of Māori and non-Māori patients with no 
comorbidity at the time of diagnosis was similar; 30% of the Māori cohort had no 
comorbidity versus 34% of the non-Māori cohort (age- and sex-standardised; p =0.11).   
However it appears that compared with non-Māori, the Māori patients may have been 
more likely to present with multiple chronic diseases or other comorbid conditions 
alongside their stomach cancer.  The likelihood of three or more comorbidities was 
31% in Māori and 17% in non-Māori although the difference was not statistically 
significant (age- and sex-standardised; p =0.11). 
Of the 12 most common individual comorbid conditions noted in this study, 
hypertension was the most common overall, with age- and sex-standardised 
proportions of 43% in Māori and 39% in the non-Māori patients.  Māori were 
significantly more likely to have congestive heart failure (age- and sex-standardised 
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sex-standardised proportion: 11% in Māori vs 3% in non-Māori, p = <0.05).  Diabetes 
also appeared to be more common among Māori, but this was not statistically 
significant (age- and sex-standardised proportion: 26% in Māori vs 15% in non-Māori, 
p=0.09).  The age- and sex-standardised prevalence of myocardial infarction, mild and 
moderate/severe chronic pulmonary disease, cerebrovascular disease and other 
primary cancer were all similar between Māori and non-Māori patients.  
Table 25: Total, Māori and non-Māori cohorts by comorbidity 











 P value 
Comorbid conditions (count) 
d)
          
0    108 30% 64 37% 30% 44 27% 34%  
1    79 25% 37 22% 21% 42 26% 24%  
2    67 22% 27 16% 18% 40 25% 24%  
3    42 13% 21 12% 14% 21 13% 10%  
4+   39 11% 23 13% 17% 16 10% 7% 0.11 





         
Angina 52 16% 25 15% 18% 27 17% 12% 0.31 
Hypertension 133 41% 64 37% 43% 69 42% 39% 0.33 
Myocardial infarction 29 10% 12 7% 9% 17 10% 8% 0.97 
Arrhythmia 54 17% 25 15% 20% 29 18% 17% 0.76 
Mild CPD 22 7% 11 6% 8% 11 7% 7% 0.83 
Moderate/Severe CPD 27 9% 10 6% 7% 17 10% 8% 0.69 
Congestive heart failure 29 8% 18 10% 14% 11 7% 5% <0.05 
CVA 38 13% 13 8% 9% 25 15% 11% 0.49 
Obesity 21 5% 14 8% 8% 7 4% 4% 0.26 
Diabetes 70 19% 42 24% 26% 28 17% 15% 0.09 
Other primary cancer 29 9% 13 8% 9% 16 10% 9% 0.83 
Renal disease 22 5% 17 10% 11% 5 3% 3% <0.05 
Abbreviation: n, number; CPD, chronic pulmonary disease; CVA, cerebrovascular accident  
a) Population estimates 
b) Crude  
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c) Age and sex standardised  
d) 12 most common comorbid conditions in this study 
Smoking Status 
Smoking status was not well recorded within medical records and so these data had a 
large percentage either recorded as unknown or missing within the dataset.   Within 
the Māori cohort n=87 patients had smoking status data missing or recorded as 
unknown, while in  the non-Māori cohort n=102 patients had smoking status data 
missing or recorded as unknown.  The following represents crude data only.  
Of the 85 Māori who had data captured 49% (n=42) were recorded as current 
smokers, 32% (n=27) were ex-smokers and 19% (n=16) were non-smokers.  While of 
the 61 non-Māori who had data captured 21% (n=13) were recorded as current 
smokers, 38% (n=23) were ex-smokers and 41% (n=25) were non-smokers.   
Disease Factors 
Stage  
Nearly half (46%) of the total cohort were diagnosed at stage IV of disease (Table 26 
and Figure 9).  Table 26 and Figure 9 also show that there were no substantial 
differences in the overall distribution of tumour stage between Māori and non-Māori 
patients (p = 0.31). Fifteen percent of each of the Māori and non-Māori cohorts were 
diagnosed at stage I disease.  The proportion of patients diagnosed with stage IV 
disease was also very similar between ethnic groups; 47% of the Māori cohort and 
49% of the non-Māori cohort were diagnosed at stage IV (age- and sex-standardised).  
Five non-Māori remained unstaged after clinical note review, this compares with 109 
patients unstaged within the original New Zealand Cancer Registry data.  These five 
unstaged patients had an older age profile (age range from 85 years – 93 years) than 
that of the total cohort and had at least one comorbid condition (data not shown). 
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Table 26: Total, Māori and non-Māori cohorts by stage at diagnosis 











 P value 
Stage (TNM)          
Stage I 55 17% 25 15% 15% 30 18% 15%  
Stage II 58 16% 35 20% 23% 23 14% 14%  
Stage III 59 19% 27 16% 15% 32 20% 20%  
Stage IV 158 46% 85 49% 47% 73 45% 49%  
Unstaged 5 2% 0 0% 0% 5 3% 2% 0.31 
Total 335  172   163    
a) Population estimates 
b) Crude  
c) Age and sex standardised  





























Overall, 42% of the total cohort presented with a poorly differentiated grade of 
stomach cancer (i.e. a more aggressive cell type on histological examination). 
Table 27 shows that Māori appeared less likely to have a poorly differentiated cancer 
than non-Māori (age- and sex-standardised).  Māori also appeared more likely to have 
data missing from this variable, although when the missing grade data were removed, 
there was little difference between Māori and non-Māori in this measure (age- and 
sex-standardised proportion: 71% Māori poorly differentiated vs 72% non-Māori).   
Table 27: Total, Māori and non-Māori cohorts by grade of disease 











 P value 
Tumour grade          
Well differentiated 12 5% 3 2% 2% 9 6% 4%  
Moderately differentiated 43 13% 20 12% 14% 23 14% 11%  
Poorly differentiated 134 42% 64 37% 36% 70 43% 48%  
Missing 146 40% 85 49% 48% 61 37% 37% 0.14 
Total 335  172   163    
a) Population estimates 
b) Crude  
c) Age and sex standardised  
Tumour Site 
There were significant differences in the distribution of tumour site between Māori 
and non-Māori patients (Table 28). This difference remained when missing site data 
were removed (Figure 10).  Compared with non-Māori patients, Māori had a much 
higher proportion of distal stomach cancers and a lower proportion of proximal 
stomach cancers.  The age- and sex-standardised rates for distal tumour site were 43% 
in Māori vs 26% in non-Māori, p=0.004 (age- and sex-standardised proportion: 58% in 
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Māori vs 40% in non-Māori when the missing data were removed).  Conversely non-
Māori had a higher proportion of proximally located tumours. The age- and sex-
standardised rates for proximal tumour site were 25% in Māori and 34% in non-Māori, 
p = <0.05 (age- and sex-standardised proportion: 39% in Māori and 61% in non-Māori 
when the missing data were removed).   
Table 28: Total, Māori and non-Māori cohorts by tumour site 
a) Population estimates 
b) Crude  
c) Age and sex standardised   











     Proximal      Distal      Both Proximal
and Distal




























 P value 
Tumour site          
Proximal 107 35% 44 26% 25% 63 39% 34%  
Distal 103 26% 69 40% 43% 34 21% 26%  
Proximal and Distal 5 1% 3 2% 2% 2 1% 2%  
Other Description 11 2% 9 5% 5% 2 1% 1%  
Missing 109 35% 47 27% 26% 62 38% 36% <0.05 
Total 335  172   163    
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Stratifying the two main tumour sites (distal and proximal) by sex (Figure 11) shows 
that Māori women were the group least likely to present with a proximally located 
tumour while non-Māori men were the group most likely to present with a proximally 
located tumour (age- and sex-standardised proportion: 16% in Māori women vs 43% 
in non-Māori men).  On the converse Māori women were most likely to present with a 
distally located tumour (age- and sex-standardised proportion: 54% in Māori women 
vs 19% in non-Māori men).  Māori men were slightly more likely to present with a 
proximally located tumour than a distally located one (age- and sex-standardised 
proportion: 36% proximal vs 31% distal). Non-Māori women were equally as likely to 
present with either distally or proximally located tumours (29% for each, age- and sex-
standardised). 
Figure 11: Māori and non-Māori cohorts by sex and tumour site (proximal and distal only); age- and 
sex-standardised 
 
Health Care Access Factors 
Deprivation and Rurality 
As this study is primarily interested in patient management, treatment and survival 























Māori women Māori men non-Māori women non-Māori men
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deprivation (NZDep) and geographical location (rurality) were considered markers of 
access to cancer services.  Data on NZDep were missing for 12 patients, 7 Māori and 5 
non-Māori. 
There was a strong socioeconomic gradient for patients in this study; only a quarter of 
the total cohort resided in the least deprived quintiles (1-2), compared with 40% of 
the population by definition.  In contrast, over half of the total cohort resided in the 
most deprived quintiles (4-5) (Table 29).   Both Māori and non-Māori were more likely 
to live in areas of higher deprivation although this was more marked in the Māori 
patients, of whom 59% resided in the most deprived quintile (compared with 29% of 
non-Māori patients, age- and sex-standardised, p<0.01).   
The majority of patients lived in urban areas (Table 29).  Slightly less Māori (68%) than 
non-Māori (81%) lived in main or satellite urban areas, on the converse it appeared 
that more Māori lived in rural areas (age- and sex-standardised proportion: 16% Māori 
vs 7% non-Māori, p=0.02). 
Table 29: Total, Māori and non-Māori cohorts by NZDep and rurality 
a) Population estimates 
b) Crude  
c) Age and sex standardised    
  Total  Māori  Non-Māori    
  n % 
a)
















 1 25 9% 10 6% 7% 15 9% 7% 
 2 41 16% 10 6% 5% 31 20% 21% 
 3 52 18% 21 13% 11% 31 20% 15% 
 4 71 24% 30 18% 19% 41 26% 28% 








 Urban 233 76% 108 65% 68% 125 79% 81% 
 Independent Urban 47 13% 29 18% 16% 18 11% 12% 
 Rural 43 11% 28 17% 16% 15 9% 7% 0.02 
Total 323   165     158       
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Patient Treatment and Management  
This section describes the management and treatment of the total study cohort and 
compares the management and treatment received by Māori and non-Māori patients.  
When describing surgical and oncological treatment the results focus on those 
patients with potentially curable disease at diagnosis (i.e. those diagnosed with stage 
I-III disease).  Referral to palliative care services is shown for patients diagnosed with 
stage IV disease. 
Diagnosis and Staging Investigations 
Overall the majority of patients were diagnosed and staged by gastroscopy (n=319) 
and/or computerised tomography (CT) scan (n=300) while 81 patients also received a 
laparoscopy.  Only 14 patients received an MRI scan and four patients an endoscopic 
ultrasound as part of their staging process. 
There was little difference in the proportions of diagnostic and staging investigations 
received by Māori and non-Māori patients (Figure 12). 
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Figure 12: Māori and non-Māori cohorts by investigations; age- and sex-standardised 
 
Surgical Treatment 
Table 30 shows the characteristics of surgery for the total stage I-III cohort and the 
Māori and non-Māori stage I-III cohorts.  Of the 172 patients with stage I-III disease 
overall, two-thirds (66%) had definitive surgery including 4% of patients who received 
a laparotomy without resection or an ‘open and close’ procedure.  Māori and non-
Māori patients had similar rates of definitive surgery with age- and sex-standardised 
proportions of 71% for Māori and 68% for non-Māori (p = 0.79). Post-operative 
complications (within 30 days of definitive surgery) were also similar across the two 
groups (any post-operative complication at all, age- and sex-standardised proportion; 
Māori=59%, non-Māori=55%, p = 0.43). Only three patients died within 30 days post-
operatively. 
Differences in Surgical Management 
There were a number of key differences in the surgical management of the two groups 
































Although not statistically significant Māori appeared more likely to have a partial 
gastrectomy with age- and sex-standardised proportions of 59% for Māori and 49% for 
non-Māori (p=0.14).  On the converse non-Māori appeared more likely to have a total 
gastrectomy or Ivor-Lewis Oesophagectomy (both surgeries combined, age- and sex-
standardised proportion: 37% in Māori vs 48% in non-Māori, p=0.14).  This is 
consistent with the different tumour site distribution in the two groups. 
Surgical Facility Type and Surgeon Type  
There were statistically significant differences between Māori and non-Māori patients 
in two important areas; the type of facility where patients received their surgical 
treatment and the type of surgeon performing the surgery.  
Compared with non-Māori, Māori were less likely to receive their surgical treatment in 
a main centre (age- and sex-standardised proportion: 43% in Māori vs 83% in non-
Māori patients, p<0.01) and more likely to be treated in a smaller centre (age- and sex-
standardised proportion: 54% in Māori vs 12% in non-Māori patients, p<0.001).  
Overall, few patients received surgical treatment in a private facility (n=5).   
Māori were also less likely to have surgery performed by a specialist upper 
gastrointestinal surgeon (age- and sex-standardised proportion: 38% in Māori vs 79% 
in non-Māori patients, p<0.01), and more likely to have their surgery performed by a 
general surgeon (age- and sex-standardised proportion: 62% in Māori vs 21% in non-
Māori patients, p<0.01).  
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Table 30: Total, Māori and non-Māori cohorts (stage I - III) by characteristics of definitive surgery  











 P value 
Definitive surgery 119 66% 65 75% 71% 54 64% 68% 0.79 
Total 172  87   85    
Type of surgery 
d)
          
Local excision/EMR 2 2% 1 2% 1% 1 2% 1%  
Ivor-Lewis Oesophagectomy 9 11% 1 2% 3% 8 15% 12%  
Gastrojejunostomy 1 1% 0 0% 0% 1 2% 1%  
Partial Gastrectomy 56 43% 35 54% 59% 21 39% 49%  
Total Gastrectomy 46 39% 25 38% 34% 21 39% 36%  
Laparotomy without resection 5 4% 3 5% 3% 2 4% 2% 0.14 
Total 119  65   54    
Postoperative complications 
e)
          
Any Postoperative complication 70 62% 35 54% 59% 35 65% 55% 0.43 
Reoperation 
1)
 13 11% 7 11% 11% 6 11% 7% 0.78 
Organ failure 
2)
 13 12% 6 9% 9% 7 13% 8% 0.65 
Pneumonia 17 15% 8 12% 12% 9 17% 10% 0.97 
Sepsis 17 15% 9 14% 13% 8 15% 15% 0.93 
Death following surgery 3 3% 1 2% 1% 2 4% 2% 0.8 
Total 119  65   54    
Surgical facility type 
d)
          
Main centre 76 72% 33 51% 43% 43 80% 83% <0.01 
Smaller centre 38 23% 30 46% 54% 8 15% 12% <0.001 
Private 5 5% 2 3% 3% 3 6% 5% 0.54 
Total 119  65   54    
Type of surgeon 
d)
          
Specialist surgeon 69 66% 29 45% 38% 40 74% 79%  
General surgeon 50 34% 36 55% 62% 14 26% 21% <0.01 
Total 119  65   54    
Abbreviations: EMR, Endoscopic Mucosal Resection 
a)  Population estimates 
b)  Crude  
c)  Age and sex standardised 
d)  Limited to those who received definitive surgery   
e)  Limited to those who received definitive surgery  
1) Reasons for reoperation included anastomotic leakage, bleeding, infarcted bowel or 
stomach, division of adhesions and intra-abdominal abscess  
2) Includes cardiac, respiratory and renal failure  
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Assessment of Surgeon Type and Facility Type using Stratification 
As described in Chapter 5: Methods, to ascertain whether the differences observed 
above were related to the differences in surgery type received by Māori and non-
Māori the type of surgeon performing surgery and the type of facility where patients 
received their surgical treatment were further investigated through stratification by 
surgery type.  Surgery type was limited to the two main surgical procedures; partial 
and total gastrectomy.   As shown in Figure 13 regardless of whether a partial 
gastrectomy or a more complex total gastrectomy was performed, Māori appeared to 
be less likely than non-Māori to have their surgery performed by a specialist surgeon 
and more likely to have their surgery performed by a general surgeon (age- and sex-
standardised proportions).  
Figure 13: Māori and non-Māori cohorts (stage I –III) who had total or partial gastrectomy, by surgeon 
type; age- and sex-standardised 
 
Māori also appeared to remain less likely than non-Māori to be treated in a main 
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Figure 14: Māori and non-Māori cohorts (stage I –III) who had total or partial gastrectomy, by facility 
type; age- and sex-standardised 
 
The data were then reanalysed, to investigate the type of surgeon who performed 
surgery (any of the surgery types) within the centre types (main and smaller centres).   
Figure 15 shows that when age- and sex-standardised it appears that Māori remain 
less likely than non-Māori to have their surgery performed by a specialist upper 
gastrointestinal surgeon within either a main (p=0.12) or smaller centre (p=0.15), 
although the results do not reach statistical significance.  Conversely Māori are more 
likely to be treated by a general surgeon in both main (p=0.12) and smaller centres 
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Figure 15: Māori and non-Māori cohorts (stage I – III) who had surgery, by surgeon 




Assessment of Surgeon Type and Facility Type using Logistic Regression 
As all of the previous results indicated differential access to specialist surgical care for 
Māori, the surgeon and surgical facility type were further explored through logistic 
regression modelling.  Due to the small numbers of patients treated by specialist 
surgeons within smaller centres these results focus on patients who received their 
care within main (including private) centres only.  Thus the model investigated receipt 
of specialist surgical care within a main centre by ethnicity.   As described in Chapter 5: 
Methods, Māori/non-Māori hazard ratios were adjusted in a sequential manner using 
continuous or binary variables: age (continuous), stage (stage I and II versus stage III) 
and tumour site (proximal and distal only). 
After adjusting for age, Māori were half as likely to be treated by a specialist surgeon 
although the 95% confidence intervals are wide and include the null (HR 0.50; 95% CI, 
0.17 – 1.46) (Table 31).   Additional adjustment for stage produced little change to the 
hazard ratio (HR 0.54, 95% CI, 0.18 – 1.61).   However, following additional adjustment 
for tumour site the hazard ratio fell to 0.27, although the confidence intervals remain 
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In conclusion after adjusting for age, stage and tumour site, the differences observed 
between Māori and non-Māori remained, with Māori appearing 73% less likely than 
non-Māori to receive surgery by a specialist surgeon.    
Table 31: Hazard ratios for receipt of Specialist Surgeon for Māori and non-Māori cohorts (stage I – III) 
who received surgery within a main centre 
Adjusted for: HR (95% CI) 
Unadjusted  0.47 (0.17 - 1.28) 
Age 0.50 (0.17 – 1.46) 
Age and Stage 0.54 (0.18 – 1.61) 
Age, Stage & Tumour site  0.27 (0.07 – 1.04) 
Extent of Nodal Resection 
Of the n=119 stage I-III patients treated with definitive surgery, nodal resection would 
be expected in n=112 patients (removing EMR n=2 and laparotomy without resection 
n=5 from analysis).  However data were only found for n=96 of these patients (89% of 
eligible Māori had these data vs. 82% of non-Māori).  These data are discussed below. 
Table 32 shows that overall just over half (55%) of these patients had the 
recommended 15 or more nodes resected during surgery.  Similar proportions of 
Māori and non-Māori patients had 15 or more nodes resected (age- and sex-
standardised proportion: 61% of Māori vs 58% non-Māori, p<0.5). 
Table 32: Total, Māori and non-Māori cohorts (stage I – III) by number of nodes resected in patients 
who received surgery 











 P value 
Number of nodes resected 
d)
          
0-14 40 45% 20 37% 39% 20 48% 42%  
15+ 56 55% 34 63% 61% 22 52% 58% 0.5 
Total 96  54    42    
a)  Population estimates 
b)  Crude  
c)  Age and sex standardised 
d)  Limited to those with data and who received surgery, one of: Ivor-Lewis Oesophagectomy, 
Gastrojejunostomy, Partial Gastrectomy, Total Gastrectomy 
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Medical Oncology Treatment 
Of the patients in this study with stage I-III disease, 49% overall were referred to 
medical oncology.   Figure 16 shows that after adjusting for age, similar proportions of 
Māori and non-Māori patients were reviewed by medical oncology (Māori 46%, non-
Māori 53%, p=0.25), offered chemotherapy (Māori 28%, non-Māori 32%, p=0.48) and 
received chemotherapy (Māori 26%, non-Māori 30%, p=0.5).    
Figure 16: Māori and non-Māori cohorts (stage I - III) by receipt of medical oncology treatment; age- 
and sex-standardised 
 
Few patients received chemotherapy in conjunction with surgery (Table 33).  Overall 
15% of patients with stage I-III disease received pre-operative chemotherapy and 25% 
received post-operative chemotherapy.  There were differences in the proportions of 
Māori and non-Māori patients who received chemotherapy.  Although these were not 
statistically significant the results again suggest differential treatment (age- and sex-
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of non-Māori, p=0.99 and 22% of Māori received post-operative chemotherapy vs 34% 
of non-Māori, p=34). 
Table 33: Total, Māori and non-Māori cohorts (stage I - III) who received pre or post-operative 
chemotherapy 











 P value 
Chemotherapy 
d)
          
Pre-operative 20 15% 13 20% 13% 7 13% 20% 0.99 
Post-operative 31 25% 18 28% 22% 13 24% 34% 0.34 
Total 119  65   54    
a)  Population estimates  
b)  Crude  
c)  Age and sex standardised 
d)  Limited to those who received definitive surgery and curative chemotherapy 
Patient Management 
Timeliness to Cancer Treatment 
Table 34 shows the timeliness of care in the total stage I – III cohort and compares 
timeliness between Māori and non-Māori patients, based on median times between 
key steps in the treatment pathway.  Data were collected on initial patient referral 
into the system but these data were often missing and thus unreliable.   As outlined in 
Chapter 5: Methods, first intervention was defined as earliest of either radiotherapy, 
chemotherapy, definitive surgery, or other surgical intervention such as abdominal 
paracentesis, gastric or oesophageal stent or jejeunostomy feeding tube insertion.   
Overall, the median waiting time from first specialist appointment (FSA) until first 
intervention was 37 days, with Māori waiting on average 14 more days than non-
Māori for first intervention.  On average patients waited 31 days from date of 
diagnosis until first intervention and 35 days from diagnosis until definitive surgery 
was performed.   At each of these steps Māori patients appeared to experience 
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slightly longer delays through the treatment pathway than non-Māori.  Māori 
appeared to wait on average 13 days longer, once diagnosed, for definitive surgery 
although the differences were not statistically significant (median 47 days for Māori 
compared to 35 days for non-Māori patients, p=0.65).   
Māori patients also appeared to wait longer once diagnosed before referral to medical 
oncology (median 34 days for Māori compared to 25 days for non-Māori patients, 
p=0.31). However, once in the oncology treatment pathway, waiting times were very 
similar for Māori and non-Māori patients (median 70 days for Māori compared to 72 
days for non-Māori patients, p=0.33). 
In conclusion, Māori tended to wait longer for both first intervention and definitive 
surgery.   There was less difference between Māori and non-Māori within oncology 
services.  However differences were not statistically significant and these findings 
must be interpreted with caution.   
Table 34: Total, Māori and non-Māori cohorts (stage I – III) timeliness of care for patients with 
treatment dates available  







 P value  
Waiting time (days)     
Time FSA - First intervention
 c)
            (n=131) 37 49 35 0.03 
Time diagnosis - First intervention 
c)
     (n=139) 31 37 31 0.12 
Time diagnosis - Definitive surgery  (n=119) 35 48 35 0.65 
Chemotherapy 
f)
      
Diagnosis - Referred to Med Onc             (n=72)  25 34 25 0.31 
Referred Med Onc - Review by Med 
Onc  
(n=57)   15 14 15 
0.78 
Review Med Onc - Received chemo         (n=53)   24 21 26 0.58 
Diagnosis - Received chemo                     (n=56)   70 70 72 0.33 
Abbreviation: FSA, first specialist appointment; Med Onc, medical oncology 
a) Population estimates  
b) Crude  
c) First intervention is chemotherapy, definitive surgery or other intervention (i.e. stent, 
paracentesis,  jejeunostomy feeding tube)  
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Given the differences observed between Māori and non-Māori in the type of facility 
where patients received their surgical treatment these data were further investigated 
by stratifying waiting times by the two key surgical facility types: main and smaller 
centres.  Results are presented below in text. 
Median waiting times in a main centre from diagnosis until receipt of definite surgery 
for Māori were 56 days and non-Māori were 36 days (p=0.3) while for diagnosis until 
referral into medical oncology services for Māori were 43 days and non-Māori were 26 
days (p=0.2).   
In comparison in a smaller centre the median waiting times from diagnosis to receipt 
of definite surgery for Māori were 33 days and non-Māori were 46 days (p=0.8).  The 
median waiting times from diagnosis to referral into medical oncology services for 
Māori were 33 days while for non-Māori they were 42 days (p=0.4).   
Stage I – III Patients without Treatment 
There was a substantial group of patients with stage I-III disease who appeared to 
have no treatment at all (n=33 [19%] of stage I-III patients; n=14 Māori, n=19 non-
Māori).  This group were older (mean age 79 years) than the stage I-III patients that 
did have treatment (mean age 63 years) and were more likely to have comorbid 
conditions at diagnosis (mean comorbidity count of 3.1 versus a mean comorbidity 
count of 1.6 for those stage I-III patients that did have treatment).  Two-thirds of this 
group (n=22) were referred to a palliative service (data not shown). 
Palliative Care 
Referral into any palliative care service (palliative chemotherapy, palliative 
radiotherapy or other palliative care) was analysed for stage IV patients only.  
Radiotherapy was only given to a small number of patients in the palliative setting 
within this study (n=11).   
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While Māori patients are less likely to be referred to (or receive) chemotherapy it 
appears that they are more likely to be referred to (or receive) radiotherapy in the 
palliative setting than are non-Māori patients (Table 35 and Figure 17).  Note that the 
chemotherapy results are statistically significant however the radiotherapy results are 
based on very small numbers of patients and are not significant.   
It also appears that Māori are more likely to be referred to a hospice service than non-
Māori (age- and sex-standardised proportion: Māori 75% and non-Māori 59%, p=0.14).  
However, Māori (85%) and non-Māori (83%) patients were similarly likely to be 
referred to any palliative service when the data were age- and sex-standardised 
(p=0.85) (Table 35). 
Table 35:  Total, Māori and non-Māori cohorts (stage IV only) by palliative care  
 
Total           Māori Non-Māori 
   n % 
a)
















 Chemotherapy 60 40% 30 35% 28% 30 41% 44% 0.01 
Radiotherapy 16 8% 11 13% 16% 5 7% 7% 0.25 
Hospice 101 60% 60 71% 75% 41 56% 59% 0.14 








 Chemotherapy 44 29% 22 26% 20% 22 30% 34% 0.03 
Radiotherapy 11 6% 7 8% 12% 4 5% 5% 0.56 
Total 158   85 
 
  73 
 
  
 a)  Population estimates  
b)  Crude  
c)  Age and sex standardised 
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Figure 17: Māori and non-Māori cohorts (stage IV) by referral and receipt of palliative chemotherapy 

































This section describes the survival of the final cohort and compares the survival of 
Māori and non-Māori patients.  Crude survival, both all-cause and cancer specific, is 
illustrated by Kaplan-Meier plots of survival probability for the Māori and non-Māori 
cohorts.  The Māori/non-Māori hazard ratio of cancer-specific death is then examined 
and adjusted in a step-wise manner for various potentially confounding factors using 
multivariable Cox regression modelling. 
Overall Survival 
Overall, nearly eighty percent (78%) of the total cohort died during follow-up.  Time to 
death varied from to one day to 1822 days (4.9 years), depending on the patient’s 
date of diagnosis during the three-year study and date of death.   The majority of 
deaths were due to stomach cancer (n=244), with only 16 (4.8%) patients dying of 
other causes.  Seventy five patients remained alive at the end of follow-up.  There was 
little difference in the proportions of deaths between the Māori and non-Māori 
cohorts (Table 36).   
Table 36: Māori and non-Māori deaths due to stomach cancer and other causes 








Cohort 335  172  163  
Deaths 260 78% 133 77% 127 78% 
Stomach Cancer 244 73% 125 73% 119 73% 
Other 16 4.8% 8 4.7% 8 4.9% 
a)  Crude  
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Crude Māori/non-Māori Survival  
As stomach cancer has such a poor prognosis with few patients dying of other causes 
the Kaplan Meier curves for all-cause (Figure 18) and stomach cancer specific (Figure 
19) survival times were very similar.   Additionally, as demonstrated in Figure 18 and 
Figure 19 there was little difference between Māori and non-Māori patients in either 
crude all-cause (p=0.9) or stomach cancer specific survival (p=0.9).   This similar 
survival pattern was reflected in a crude Māori/non-Māori hazard ratio for stomach 
cancer specific mortality of 1.02 (95% CI 0.79 – 1.31) (Table 38).   
Median all-cause survival times were 269 days for Māori compared with 271 days for 
non-Māori, while median stomach cancer specific survival times were 294 days for 
Māori compared with 274 days for non-Māori.  














Days from Diagnosis 
Maori All Cause non-Maori All Cause
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Figure 19: Stomach Cancer Survival by ethnicity total cohort 
 
Adjusted Māori/non-Māori Survival  
This section outlines the covariates used in the modelling and discusses how they are 
associated with ethnicity (the exposure) using descriptive results from the current 
study and survival (the outcome) using the fully adjusted model (Table 37). 
The fully adjusted stomach cancer specific model shows the independent effect - as a 
predictor of stomach cancer survival - of each of the variables that were included in 
the sequentially adjusted multivariable Cox regression model (Table 38).  This table is 
presented using imputed tumour site, deprivation and rurality variables.   
Unfortunately study numbers were too limited to produce meaningful hazard ratio 
estimates stratified by stage (or for stage I-III patients), therefore hazard ratios are 
shown for the total cohort with adjustment for stage via Cox modelling. 
Patient Demographic Factors: Age and Sex  
Māori in this study were on average 10 years younger at diagnosis than non-Māori.  
The expectation of better survival in the Māori cohort due to their younger age 













Days from Diagnosis 
Maori non-Maori
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hazard ratio for age is 1.02.  As age is included as a continuous variable, this means 
that for each additional year of age of the patient there was a 2% greater likelihood of 
dying.   
A differential sex distribution was observed between Māori and non-Māori in this 
study, with proportionately more women within the Māori cohort than in the non-
Māori cohort.  As shown in Table 37 women are more likely to die with a hazard ratio 
of 0.79. 
Without adjustment for these variables (age and sex) the impact of them on survival 
estimates would be conflated, with Māori appearing to have better survival than they 
actually do. 
Disease Factors: Stage and Tumour Site 
In this study no substantial differences in stage between Māori and non-Māori were 
observed.  However Māori were more likely to have stage II disease and had less stage 
III and slightly less stage IV disease than non-Māori.  Additionally, no Māori patients 
remained unstaged in this study but 2% of non-Māori patients were unstaged.   Taken 
together this means that Māori actually have a slightly better stage profile than non-
Māori.  Unsurprisingly, stage is a strong independent predictor of survival within this 
study (as borne out in the fully adjusted model; Table 37).  Compared to patients with 
stage I disease the risk of mortality for patients with stage II disease was over twice as 
high and the risk of mortality for patients with stage III disease five times as high, 
while the mortality risk for stage IV patients was over 16 times that of stage I patients.  
The mortality risk for patients with unstaged cancer fell between that observed for 
stage III and stage IV patients.  
Tumour site is shown to be an important independent prognostic factor within this 
study, with patients diagnosed with proximal tumours having a better survival 
probability (Table 37).  Although with imputed site data the 95% confidence intervals 
are wide and imprecise (0.89 to 1.75), the best estimate is a 25% poorer survival for 
patients diagnosed with distal disease (Table 37).  Māori in this study were 
significantly more likely to be diagnosed with distally located tumours. 
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Without adjustment for these variables (stage and site) Māori would appear to have 
better survival than they actually do. 
Patient Comorbidity 
A high prevalence of comorbidity was observed in this study with 70% of the total 
cohort having at least one comorbid condition.  Māori patients in this study were 
more likely to have a number of comorbidities and/or present with multiple 
comorbidity; the likelihood of three or more comorbidities was 31% in Māori and 17% 
in non-Māori (age- and sex-standardised) albeit not statistically significant.  
Comorbidity was included in the model as a continuous variable (1 – 12).  As seen in 
Table 37 each additional comorbidity that a patient had increased the probability of 
mortality by 2%, although again the 95% confidence intervals are imprecise and 
include the null (0.92 to 1.13).   
Health Care Access Factors: Deprivation and Rurality 
There was a strong socioeconomic gradient for patients overall in this study but this 
was more pronounced for Māori with twice as many Māori patients than non-Māori 
living in the most deprived quintile.    In addition, over twice as many Māori patients 
compared with non-Māori lived rurally in areas far from New Zealand’s six main 
cancer centres.   Both deprivation and rurality appear to play some independent role 
in patient survival, although as seen in Table 37 it appears that the patients living in 
the most deprived quintiles or rurally have better survival than those living in less 
deprived quintiles and/or urban areas.  It must be noted that these variables are not a 
measure of health care quality as such, but are included as a crude measure of access 
to, and through, cancer services. 
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Table 37: Fully adjusted hazard ratios for stomach cancer specific mortality risk in the total cohort 
Adjusted for: HR 95% CI Reference Group 
Ethnicity 1.30 0.96 to 1.76 Non-Māori 
Age 1.02 1.00 to 1.03 Continuous 
Sex 0.79 0.60 to 1.05 Female 
Stage II 2.64 1.42 to 4.90 Stage I 
Stage III 5.05 2.75 to 9.28 Stage I 
Stage IV 16.37 9.25 to 28.28 Stage I 
Unstaged 6.68 2.09 to 21.24 Stage I 
Imputed Site 1.25 0.89 to 1.75 Proximal 
Comorbidity 
a)
 1.02 0.92 to 1.13 Continuous 
NZDep 3 - 4 1.05 0.58 to 1.91 NZDep 1 -2 
NZDep 5 - 6 1.14 0.65 to 1.98 NZDep 1 -2 
NZDep 7 - 8 0.54 0.32 to 0.93 NZDep 1 -2 
NZDep 9 - 10 0.84 0.50 to 1.40 NZDep 1 -2 
Independent Urban 0.94 0.65 to 1.36 Urban 
Rural 0.69 0.46 to 1.05 Urban 
a) 12 most common comorbid conditions in this study (as per Table 25) 
The Association between Ethnicity and Survival 
The similar survival pattern between Māori and non-Māori seen in the Kaplan Meier 
curves was reflected in the unadjusted hazard ratio for stomach cancer specific 
mortality of 1.02 (95% CI, 0.79 – 1.31) (Table 38). 
Adjusting for the pure confounders (demographic factors: age and sex) had some 
impact on the model estimates.  Although not a substantial or significant result, the 
hazard ratio rose to 1.08 (95% CI, 0.82 - 1.41).   
Adjusting for the disease factors (stage at diagnosis and tumour site) had the biggest 
impact on the model, with a rise in the hazard ratio to 1.28 (95% CI, 0.96 - 1.69).   In 
other words Māori appeared more likely to die than non-Māori after adjusting for age, 
sex, stage and tumour site, with an estimated 28% higher mortality; although 
confidence intervals around this estimate included the null. 
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Following additional adjustment for patient comorbidity the hazard ratio changed to 
1.25 (95% CI, 0.94 - 1.66) and so while the change in hazard ratio was not substantial 
and the confidence intervals continue to include the null and remain wide, it appears 
that comorbidity plays a small role in the survival disparity seen between Māori and 
non-Māori in this study. 
Additionally adjusting for differences in markers of health care access (deprivation and 
rurality) had a small impact on the hazard ratio but was not able to explain the excess 
mortality in Māori (HR 1.30; 95% CI, 0.96 – 1.76).  
After adjusting for patient demographics, disease factors, patient comorbidity and 
health care access factors (age, sex, stage, tumour site, comorbidity, deprivation and 
rurality) Māori patients had an estimated 30% higher mortality than non-Māori (HR 
1.30), with 95% confidence intervals showing a plausible range of 4% lower mortality 
to 76% higher mortality (Table 38).   So despite adjusting for a number of key factors 
including markers of access to cancer services, the apparent Māori/non-Māori survival 
disparity persisted, with the final best estimate being a 30% poorer survival for Māori 
compared with non-Māori.  
Table 38: Hazard ratios for stomach cancer specific mortality risk in Māori and non-Māori cohorts 
with sequential adjustment (using imputed variables: tumour site, NZDep and rurality) 
Adjusted for: HR 95% CI 
Unadjusted  1.02 0.79 to 1.31 
Demographic Factors   
Age and Sex 1.08 0.82 to 1.41 
Disease Factors   
Stage and Tumour site 1.28 0.96 to 1.69 
Comorbidity   
Patient Comorbidity 
(a
 1.25 0.94 to 1.66 
Health Care Access Factors   
NZDep and Rurality 1.30 0.96 to 1.76 
a) 12 most common comorbid conditions in this study (as per Table 25) 
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Very similar results were obtained using non-imputed tumour site data, with minimal 
difference between the two models (data not shown).    
Stage I – III Survival 
The results obtained when restricting the Māori/non-Māori HR estimates to stage I – 
III patients only followed a similar pattern to those of the total cohort (see Appendix 
6).  Because of the smaller numbers the HR were very imprecise with wide confidence 
intervals which included the null.  The final best estimate was a 21% poorer survival 
for Māori compared with non-Māori for those patients diagnosed with stage I – III 
disease.  
Summary of Quantitative Results 
This study found both similarities and differences in the presentation, management 
and survival of stomach cancer for Māori when compared with non-Māori patients.   
Presentation 
There were no significant differences in cancer grade or stage at diagnosis.  Māori 
were on average younger at diagnosis and were more likely to live in the most 
deprived quintiles and rurally. 
Māori had significantly higher prevalence of comorbid congestive heart failure and 
renal disease and appeared more likely to have multi-morbidity than did non-Māori.  
This was a highly comorbid cohort overall with 70% of both Māori and non-Māori 
having at least one chronic disease at the time of their stomach cancer diagnosis.    
 Māori also presented with a much higher proportion of distally located stomach 
cancers when compared with non-Māori patients and non-Māori with a higher 
proportion of proximally located tumours. 
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Treatment and Management 
Of those patients diagnosed with stage I–III disease, Māori were equally likely to 
receive definitive surgery as non-Māori.  Māori were more likely to undergo a partial 
gastrectomy while non-Māori were more likely to undergo the more complex total 
gastrectomy or Ivor-Lewis oesophagectomy. Māori were less likely to have surgery 
performed by a specialist upper gastrointestinal surgeon and less likely to be treated 
in a main centre.  Few patients overall received chemotherapy.  
On the whole timeliness through the treatment pathway was similar between the two 
groups although Māori patients did appear to wait on average 13 days longer between 
diagnosis and surgery than non-Māori.  
Nineteen percent of patients with stage I-III disease appeared to have no treatment at 
all.   This group was older and more likely to have comorbid conditions at diagnosis 
than the stage I-III patients that did have treatment.  Māori and non-Māori patients 
with stage IV disease were similarly likely to be referred to any palliative service when 
the data were age- and sex-standardised.  
Survival 
Māori in this cohort appeared less likely to survive once diagnosed with stomach 
cancer once patient and disease factors, comorbidity and health care access factors 
were adjusted for, although the study was underpowered to statistically confirm a 
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Chapter 7: Qualitative Results  
To build on the findings of the quantitative phase of this study a qualitative phase was 
undertaken to investigate those points of the stomach cancer treatment pathway that 
the quantitative findings suggested were inequitable for Māori.   One-on-one key 
informant interviews were used.  All informants were health care, or health policy, 
professionals recruited using the snowball method.  Fifteen informants were 
interviewed to assess what the sector sees as the issues impacting on equity for Māori 
within New Zealand’s stomach cancer treatment pathway, how they interpreted the 
findings of the quantitative phase of this study, and which interventions they believed 
would improve the stomach cancer treatment pathway.  
Two research questions guided the qualitative phase of this study; 
1. What do key informants identify as issues for stomach cancer treatment in 
New Zealand, with a focus on Māori? 
2. Which interventions do key informants identify that may improve access to, 
and quality of, stomach cancer treatment in New Zealand, with a focus on 
Māori? 
This chapter outlines the findings of the qualitative phase.  Firstly it identifies the final 
key informant sample and their attributes.  Secondly it highlights issues identified by 
key informants along the stomach cancer treatment pathway, including whether there 
are any particular issues for Māori or those patients with comorbid conditions.  Thirdly 
it highlights the issues key informants identified at specific points of the stomach 
cancer pathway.  Finally the interventions suggested by the key informants are 
identified at each point of the stomach cancer pathway and summarised according to 
Mandelblatt et al’s levels of barriers to access to cancer services (Mandelblatt et al., 
1999). 




QUALITATIVE RESULTS: HEALTH PROFESSIONALS’ PERSPECTIVES 
251 
 
Final Key Informant Sample 
Fifteen key informants (informants) were interviewed in the qualitative phase of this 
study.  All informants were actively working within the New Zealand health care 
system and were purposefully chosen as they had specific knowledge of the stomach 
cancer treatment pathway and/or of the issues for Māori within cancer treatment 
services.   This study used a snowball technique to identify potential informants with 
rich information.  Sampling was stopped once key names began to be repeated and no 
new names were suggested. The sampling goal of this study, which was to gain a 
range of perspectives, was met.   
Typically the interviews lasted at least 30 minutes although the length of time ranged 
from 25 minutes through to 110 minutes. Each of these two extreme times were from 
interviews with medical clinicians.  The interview of shortest duration was held while 
the clinician was on-duty whereas the interview of longest duration was held while the 
clinician was off-duty.  
Attributes of Key Informants 
Five informants self-identified as Māori and ten did not and thus were classed as non-
Māori.  One of the non-Māori informants held a role as an equity cancer nurse 
specialist which meant they held specific working knowledge of the issues for Māori 
within cancer treatment services.  
Six informants worked within a policy role; of these three identified as Māori.  Nine 
informants worked within a clinical role; of these two identified as Māori.    
Five informants held roles at a national or regional level, either within the Ministry of 
Health or one of New Zealand’s four Regional Cancer Networks.  Six held roles in a 
main centre (as defined in the quantitative phase of this study).  Of these six main 
centre informants five worked within clinical roles, including three specialist upper GI 
surgeons and two clinical nurse specialists who held either an equity or Māori 
QUALITATIVE RESULTS: HEALTH PROFESSIONALS’ PERSPECTIVES 
252 
 
focussed position.  The final four informants held roles in smaller centres, of these 
three were clinical nurse specialists (one with an upper GI cancer focus and one with a 
GI surgery focus) and one a general surgeon with an interest in Upper GI surgery.  
Below the informants are identified as either policy or clinical informants, and at times 
nursing or medical clinicians. 
What do Key Informants Identify as Issues? 
What is done well overall? 
When asked what the New Zealand health system does well for people with stomach 
cancer the majority of informants felt that overall the health-care system works well in 
New Zealand.   A number of informants talked about how at a national level there is a 
lot of work happening in cancer control.  Particularly highlighted were DHB targets for 
cancer treatment waiting times, the relatively new cancer nurse specialist roles, the 
recently developed Standards of Service Provision for Upper Gastrointestinal Cancer 
Patients (Service Provision Standards) (National HBP/Upper GI Tumour Standards 
Working Group, 2013) and improving collection and reporting of ethnicity data.  This 
last point led one policy-based informant to say "we are starting to see increasing 
transparency about the level and timeliness of care we are delivering and seeing how 
we can improve".   
At a regional level the ability to access more specialist services than is available in a 
particular DHB is seen as positive: "now we have this link to [X main centre DHB] it is 
much better".   There seemed to be the general view that, once diagnosed, most 
patients will proceed through the treatment pathway relatively quickly and be well 
linked with the appropriate clinical and support services. 
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What has improved in the preceding five years?  
The general consensus of key informants was that the stomach cancer treatment 
pathway had improved immensely between 2008, when the last patient in the 
quantitative phase of this study was diagnosed, and 2014 when these key informants 
were interviewed.  Only two informants, one policy and one clinical, were unable to 
identify any improvements with both citing that they had not been in the role long 
enough to comment.  In comparison one policy-based informant, at the end of the 
discussion about recent improvements, commented that “it's a hugely exciting time, 
actually.  There is a lot of work coming together”.  Along with the development of 
Regional Cancer Network's (RCN) in 2007 specific improvements mentioned included: 
 Cancer wait-time targets for radiotherapy from 2008, and chemotherapy from 
2012. 
 The Faster Cancer Treatment Programme from 2012, with monitoring for 
timeliness from the beginning of 2013.  
o The 57 cancer nurse specialists funded in 2012 with a focus on at-risk 
people or those with complex pathways, comorbidities or access issues. 
o The Service Provision Standards work carried out through 2012-13, 
including standards for upper GI cancers.   
 At the time of writing RCNs and DHBs were carrying out a 
process of quality improvement by reviewing their services 
against the standards, to assess current service delivery and 
identify gaps and overlaps.  
o Better functionality and coverage of Multi-Disciplinary Meetings 
(MDM).  
 The 2015 announcement of new funding for psychosocial care, with up to 20 
extra social workers and psychologists employed across New Zealand, to work 
with existing cancer support staff and as part of wider multidisciplinary cancer 
care teams. 
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Two policy informants specifically mentioned that the process of developing the 
Service Provision Standards in itself was beneficial; that having a broad range of 
clinical groups involved in conversations about standardisation of care and improving 
clinical practice has challenged their own practice: “so by default, they've actually 
moved practice forward, before standards were actually even put into place … I think it 
was the first time with cancer that we've really had the wider pathway, rather than 
just medical and radiation oncology".  
In terms of improvements specifically for Māori along the stomach cancer treatment 
pathway informants discussed initiatives such as Māori-specific cancer nurse 
specialists in some DHBs, the development of a national Māori cancer leadership 
group to provide a Māori voice at a policy level and that there is growing awareness by 
health professionals that certain groups in society have issues with health care access.  
This last point was coupled with a growing awareness that the health system has a 
responsibility to respond. 
What needs improving?  
Despite the comments above many informants believed there was still room for 
improvement.  Overall the main area of improvement, which was highlighted by over 
half the key informants, was that the delivery of cancer services is not consistent 
around the country.  Specific examples of inconsistency included that: 
 The 20 DHB's in New Zealand all deliver varying levels of cancer services. 
 DHBs and Regional Cancer Networks all prioritise different cancers. 
 The 57 new cancer nurse specialist roles work within one of four different 
models of care often with different spheres of practice. 
 Communication between, or within, DHBs can be people-dependent rather 
than a more formalised process-dependent practice. 
The need for improvement was exemplified by a clinical informant when they 
reflected that, 
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"Given the geography and resource in New Zealand, I think we do 
all right. But I think it is driven by people’s interest and passion. 
That if people really care about it and they make sure that a good 
service is provided, then its fine … but we can always improve". 
Are there any particular issues for Māori?  
When asked what New Zealand health services don't do well, particularly for Māori 
patients a policy informant replied with "we don't achieve the same outcomes, as to 
why we don't achieve the same outcomes I don't think there is one simple answer, I 
think it's probably multifactorial".  Another policy informant discussing the same 
question raised concerns: “I have a huge concern that from Vote Health 55 million 
dollars are going into cancer services in this last political period and we’re going to see 
outcomes that continue to privilege the privileged; I don't think we are going to see 
much of a gap-narrowing". 
All informants identified at least one specific issue particular to Māori within the 
stomach cancer treatment pathway.  A number of common issues were apparent; 
these included the mono-cultural focus of New Zealand's health care services, along 
with issues related to rurality and health literacy. 
In regards to the mono-cultural focus of New Zealand's health services; three Māori 
informants specifically mentioned this as being an issue for Māori.  This was raised in a 
broad way "so there are biases in the way we design, deliver and measure across 
health pathways".   As well a number of other informants, who were all in clinical 
positions, raised related points specifically to do with service delivery.  These points 
included the need for improved cultural friendliness and approachability of services, 
the need to make services patient focussed rather than provider focussed and that 
services need to accommodate a more holistic approach which encompasses whānau.  
While the medical clinicians were aware of these needs and took steps to meet these 
needs this was not always possible in the clinical environment.  As a specialist surgeon 
from a main centre stated:  
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"It certainly makes it easier if whānau are involved from the very 
first appointment.  So I think a more holistic, family-oriented 
meeting is important, but that requires more time at your clinic to 
discuss various treatment options. I do try to make a longer 
appointment if I can, or run the clinic late but that is not always 
possible." 
Issues to do with rurality and receiving care within smaller centres were raised in 
relation to Māori. The need for Māori to travel for multiple appointments with 
multiple providers and often within a DHB other than that in which they reside was 
seen as an issue by some, particularly when navigating these services is the 
responsibility of the patient: "at the moment I think a lot of health providers just go 
‘well we don't do that’, and it is left up to the patient, and that's the last thing people 
need." 
Health literacy was raised by both clinical and policy informants.   Each time it was 
raised however the informant spoke of the need for the health care system to support 
people to understand their stomach cancer journey rather than of the patient needing 
to understand the system.  There seemed to be willingness, and effort made, by 
clinicians to ensure that individual Māori and whānau were supported to see and 
understand their cancer journey.  Although some clinicians also expressed being 
unsure of how to best do this: "it's hard from my Pakeha point of view".  Some 
clinicians recognised that the needs of Māori were greater than non-Māori, as cancer 
needs for Māori were often exacerbated by issues to do with the underlying 
determinants of health and Māori were not always linked in with the support that 
would likely benefit them.    In comparison other clinicians believed that once 
diagnosed access for patients along the stomach cancer treatment pathway was the 
same irrespective of ethnicity. As highlighted by one clinical nursing informant: 
“I think from my perspective, some of the knowledge of health 
professionals about what ethnicity means ‘we treat everybody the 
same, we don't treat by ethnicity’ there's still not quite the depth 
of understanding about what health inequities are, in terms of it is 
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helping people meet a standard, to get to the same standard that 
others enjoy, as opposed to something extra, or privileged”. 
Policy-based informants all spoke of initiatives that are already happening to address 
equity for Māori.  For example all Regional Cancer Networks have equity manager 
positions, a commitment to employing Māori staff and regularly use established tools 
such as the HEAT tool2 to assess programmes and policy.  As another example, an 
informant in a DHB based policy position spoke of their hospitals use of ‘whānau ora’ 
assessments when discharging patients: “we say that Māori health does not stop at 
the door, so before a patient leaves … that their care continues, our hospital takes 
responsibility for ensuring that they are passed onto the most appropriate provider”.   
On a broader level, a number of policy informants specifically mentioned the Service 
Provision Standards and their ability to impact on equity for Māori in the future.  The 
general view seemed to be that the development, and more specifically the quality 
improvement review process, of the standards will help to identify gaps in the system 
and any differential treatment, providing transparency and impetus for change.    
Are there any particular issues for those with 
comorbidity?  
Each of the 15 informants provided an answer to this question, with the consensus 
view being that comorbidity is common among patients with stomach cancer and is an 
important issue, increasing complexity and impacting on both timeliness through the 
cancer pathway and clinical decision-making. 
Five clinical and three policy informants specifically reflected that the presence of 
comorbidity adds complexity to the patient journey.  This complexity was especially 
highlighted as the patient needing to see multiple services within multiple providers, 
which are often not well coordinated, impacting on the patient.  As stated by a nurse 
                                                          
2
 The Health Equity Assessment Tool (Equity Lens) for Tackling Inequalities in Health has a series of 12 questions to assist 
organisations to consider how particular inequalities in health have come about, and where the effective intervention points are 
to tackle them.  It is used by those working in the health and disability sector to apply a strong equity focus to their work Te 
Roopu Rangahau a Erü Pomare, Ministry of Health and Public Health Consultancy. (2003) A Health Equity Assessment Tool. In: 
Public Health Consultancy (ed). Wellington: Wellington School of Medicine and Health Sciences..   
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within a smaller centre: "it gets to be confusing for patients, when they’ve got so many 
people and so many appointments".   One nurse informant previously only had the 
ability to support patients with lower GI cancers (colorectal) within the description of 
her role.   This nurse advocated for the ability to also work with upper GI patients to 
be built in to the job’s role description as she saw that patients with upper GI cancers 
were not only more complex but also more likely to be treated outside of their DHB of 
domicile and thus “more vulnerable to getting lost in the system”. It was her belief 
that any DHB treating patients with upper GI cancers should ensure there are effective 
support and/or case coordination services wrapped around that patient and whānau. 
Four clinical and one policy informant also discussed this complexity as impacting on 
timeliness through the stomach cancer pathway, with all agreeing that comorbidity 
delays the patient journey.   The need to address comorbid medical issues before 
cancer treatment can begin appears to add significant time to the patient journey; this 
was especially highlighted by clinicians working within smaller DHBs with the need to 
refer patients to external providers outside of their DHB of domicile. 
Six clinicians also discussed the impact that comorbidity has on clinical decision-
making with most agreeing that comorbidity limits treatment options. Each of the 
medical clinicians spoke of holding in-depth conversations with patients about their 
comorbidity and treatment options, at times leaving the decision on whether to go 
ahead with treatment, or not, with the patient.   Treatment decision making in the 
presence of comorbidity was also talked about in a risk reduction manner, with the 
need to quantify and reduce the risk of complications to the patient as being key.  One 
clinician did stress that comorbidity actually means the patient will be discussed in 
more depth, with the MDM seen as playing a very important role in managing 
comorbidity and mitigating risk.  Another clinician stressed that while comorbidity 
increases operative risk to the patient it is up to the clinician to manage that risk on 
behalf of the patient: “it is my problem, not their problem”.  Yet another clinician 
highlighted that treatment options are still discussed, and commitment made to care 
for the patient, even when a patient’s level of comorbidity meant that active 
treatment was not possible: 
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“And as I'll say to the patients, ‘we'll care for you, but we may not 
be able to operate on you.  We may not be able to cure you, but 
we'll still care for you and look after you’. I guess it depends on 
what your treatment outcome is.  I'd like to think that benign 
neglect isn't part of the pathway".   
It seems that comorbidity is often thought of in clinical practice with one main centre 
DHB ensuring comorbidity is included in the cancer nurse specialist role descriptions 
and that IT systems enable not only effective referral pathways but also reporting by 
comorbidity: “it keeps track of the numbers of patients and tries to quantify the 
complexity of them … the idea for management that being able to quantify the work is 
as important as them providing good care”. In this case there is acknowledgement not 
only of the impact of comorbidity on the patient (providing good care) but also of the 
additional workload the presence of comorbidity places on staff and on services or 
health care resources more generally (quantifying the work involved in dealing with 
comorbid patients).  
Are There Issues Along the Stomach Cancer 
Pathway?  
Prevention and Screening 
While this thesis is focussed on the diagnosis treatment and survival of people with 
stomach cancer and no specific questions were asked about prevention or screening, 
some informants offered information relating to this.   
Four informants specifically mentioned prevention, three in policy roles and one 
cancer nurse specialist with a background in primary health care.  These informants all 
believe that a focus on stomach cancer prevention is vital to improving outcomes for 
Māori.  Two informants specifically highlighted the link between H. pylori and the 
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increased incidence of stomach cancer among Māori.  One nursing informant urged 
that “It’s some education in primary care about to think of these things, don't just treat 
the obvious”.  Another policy-based informant emphasised that all of the recently 
developed Standards of Service Provision have a section on prevention and screening 
in them as a mechanism for advancing this area.   
 “I think one of the ways forward across the cancer portfolio is 
really going to be about health education, health promotion, 
out in the community … people say that a third of cases are 
preventable, and another third should be able to be caught 
early.  That's one hell of a challenge to put out there.  But it 
actually means that we need to be focusing on that front end of 
the pathway”. 
However while there was some support for the prevention of stomach cancer this was 
not so for organised screening; even for people at high-risk of developing the disease.  
The two clinicians that raised the issue of screening for stomach cancer did so to warn 
that an organised screening programme would not be a viable option in New Zealand: 
“I don’t think that gastric cancer has a high enough incidence to be able to justify what 
is currently an overburdened system”.  Both clinicians specifically discussed this in the 
context of the Bowel Cancer Screening pilot currently running in Waitemata DHB, and 
emphasised that screening for bowel cancer should take precedence. 
Early Detection, Diagnosis and Staging 
Eleven informants, both policy and clinical, specifically discussed early detection, 
diagnosis and staging.  The general consensus was that while New Zealand has good 
services and a number of initiatives taking place to improve early detection and 
staging of stomach cancer that the delivery of services, or access to those services, is 
not consistent around the country or for certain groups in society.  As an upper GI 
surgeon in a main centre stated: 
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“I think it works very well with middle-class well-educated 
people, who sort of understand the system and are prepared to 
get back to their doctor. If you’re poorer and going to the family 
doctor is a big deal, then you’re actually a lot less likely to do 
that, and there’s a chance you can get lost”.    
Two current initiatives specifically mentioned were changes to Primary Health Care IT 
infrastructure to allow better streamlining and support of referral pathways and the 
National Endoscopy Quality Improvement Programme which is reviewing the quality 
and timeliness of endoscopy in New Zealand.  However, it was noted that the 
programme is currently focussed on colonoscopy in preparation for the rollout of the 
Bowel Cancer Screening pilot being conducted in Waitemata DHB, which once rolled 
out will potentially divert resource from already overburdened gastroscopy services. 
Despite these current initiatives all eleven informants that answered this question 
agreed that there is a need to improve the stage at diagnosis profile of patients with 
stomach cancer in New Zealand with three areas identified as possible areas of focus.   
Firstly, an organised and national approach to early detection (raised by five 
informants) which would include a three pronged approach of: targeted community 
awareness raising of signs and symptoms of stomach cancer, raising awareness within 
primary health care of signs and symptoms and referral pathways, and, streamlining of 
referral pathways.  Secondly, improving access to endoscopy services was specifically 
mentioned by six informants, with one clinician highlighting that "probably our biggest 
failing is access to early endoscopy … the reality is that the resource is just not there … 
but if you’re going to make a difference you've got to make it early" and another 
clinician, saying that "we have good endoscopy services around the country, but they 
can be quite difficult for patients to get them" and yet another nursing clinician 
lamenting the Monday to Friday functioning of New Zealand health services.   Each 
informant did however link this reduced access to available capacity, workforce and 
funding. 
"I think a huge barrier is still within the health profession, a lot 
of health professionals do not have the mind-set that we are a 
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24-hour, seven-day a week service.  Monday to Friday for the 
radiology department which is a huge component of diagnostics 
for the group that I work with ‘we can't fit them in, we can't fit 
them in’. Well let’s open seven days a week, and we'll fit them 
in alright". 
Thirdly standardising care nationally was seen as important.  Strengthening early 
detection within the current upper GI Service Provision Standards was discussed as an 
approach to achieving national consistency by three policy based informants.  
Improving access to diagnostic and staging investigations within smaller DHBs was 
highlighted by three clinical informants as they see variable access to specialist 
imaging around the country, despite being the standard of care for patients with 
stomach cancer.  Finally, demystifying the diagnostic and staging journey for all 
patients was seen as important by two informants. In this latter case, a cancer nurse 
within a smaller DHB had independently translated a larger DHBs pamphlet on PET 
scanning into lay terms and says considerable time is spent with patients discussing 
the need for the scan, why they must travel for the scan and possible outcomes as 
well as ensuring patients have travel and accommodation assistance.  
Surgical Management  
Different responses were observed between informants working in different 
treatment centre sizes when discussing the timeliness and accessibility of surgical 
oncology services.    
Cancer nurse specialists working within smaller centres all spoke about time delays in 
the treatment pathway, this was especially apparent when patients were being seen 
outside of their DHB of domicile, as was often needed.   At times patients need 
diagnostic and staging investigations in DHBs other than those in which they reside.  
More commonly, patients need treatment outside of their own DHB.  Nurses, who 
closely follow the patient and coordinate their care, spoke of frustration in accessing 
services in other DHBs: "once you have done that referral, you don't automatically get 
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in quickly ... you're then entering someone else's urgent waiting system".   Patients 
with acute problems are seen quickly and one nurse spoke of a patient who was seen 
within 24 hours in a large DHB once he began to bleed badly; the point made however 
was that he had been waiting over three weeks for an outpatient appointment within 
the larger DHB.   Nurses also spoke about the lack of capacity in their small DHBs to 
meet demand for urgent, or timely, investigations such as CT scans: "as soon as we 
find their tumours the person’s name is forwarded to [external DHB] two weekly MDM, 
but I’ve got to get the scans first and that takes on average 2 to 3 weeks, even when I 
go down there and beg, borrow and steal … they just don't have the capacity to get all 
these decent scans done".  All spoke of the need to access specialist surgical expertise 
and/or MDM advice often from other DHBs and the time delays in this process.  In one 
small DHB, specialist upper GI surgeons do hold monthly clinics (in the small DHB) to 
assess new patients or provide follow-up care, but often the wait times to access this 
clinic are too long, necessitating an appointment in the main DHB or a four to five-
hour car journey (one way) for the patient to be assessed by a specialist surgeon.   As 
summed up by one of the nurse informants from a smaller centre: "I keep saying - it's 
the inequity of a small DHB". 
In comparison the clinicians interviewed that worked in main centre DHBs highlighted 
a very different picture of the access patients appeared to have to the surgical 
treatment pathway in those DHBs.  For example, in one main centre DHB there are a 
number of specialist upper GI surgeons who are able to cover each other’s workload 
when needed and the same surgeon assesses and triages patient referrals providing 
consistent assessment and referral processes.  In the same main centre DHB there are 
gastroenterologists on staff performing most of the diagnostic endoscopies, who have 
weekly meetings with the surgical team and who in addition make e-referrals into 
surgical care immediately a tumour is confirmed, streamlining the referral process.  
One main centre surgeon spoke of patients being on two pathways simultaneously; 
awaiting assessment by a specialist surgeon while at the same time getting all staging 
investigations completed quickly: "they are going along a couple of pathways at the 
same time, which can save time".  The clinicians who worked within main centre DHBs 
also spoke of combining clinics, so that in the work up to surgery, patients see each 
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specialty needed in one day, greatly speeding up the time to surgery.  They also often 
have access to a cancer nurse specialist who specialises in GI or upper GI cancers 
providing a more targeted care coordination and support. 
In response to the findings of the quantitative phase that Māori were less likely to 
have a specialist upper GI surgeon perform their surgery a number of informants 
rationalised why this might be so, with geography often cited.  The general view was 
that Māori are more likely to live in rural and remote areas that are not serviced by a 
specialist surgical service and thus Māori would be less likely to receive specialist 
surgical care.  No informant was though able to articulate why Māori would be less 
likely to receive specialist surgical care within main centres, although one did state 
that this finding “smacks of racism”.  Two of the medical clinicians also raised that 
they see a different approach to treatment decision making between Māori and non-
Māori patients, with Māori going away and discussing treatment options with whānau 
before making a decision while non-Māori patients have said to have a more 
"individualistic approach".   This was offered as a reason for any possible longer 
timeframes in moving along the cancer treatment pathway for Māori compared to 
non-Māori.  
A number of other issues were raised more generally in response to the differences in 
surgical management observed between Māori and non-Māori in phase one of this 
study including centralisation of services, maintaining a current pathway of care and 
individual surgical expertise.  Centralisation of services (or concentrating services into 
fewer, larger, more specialised centres) was raised by both policy and clinical 
informants.  Pros and cons were often weighed up as the informant spoke, with the 
general consensus that debate on centralising services still needs to happen in New 
Zealand.  Increasing centralisation and specialisation could be useful in providing 
higher volumes of surgery and more specialised postsurgical care, although this would 
need to be balanced with the increased level of support that patients and whānau 
would need to access those services.  As well the needs of smaller DHB's, and 
clinicians working within these DHB’s, was highlighted as needing to be taken into 
consideration.  One informant, a general surgeon who works within a smaller DHB, 
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outlined giving patients the choice of where to have surgery within one of four 
options.  One, some patients are advised that they can be well managed within the 
smaller DHB.  Two, more complex patients are advised that they would be better 
managed within a main centre DHB.  Three, still other patients (albeit those with 
financial resource) are offered the choice to undertake surgical and medical oncology 
in Japan as in the surgeon’s opinion, Japan has the most current practice related to 
stomach cancer in the world.  Finally, for a final group of patients the decision is left 
with the patient whereby patients are advised that they have a choice of treatment 
centre, and thus surgeon.  The same surgeon cautioned, though, that the decision on 
surgical treatment centre is not solely about the surgeon and level of surgical 
expertise, but that other factors are important in the decision making process such as, 
the level of ICU care available, access to interventional radiology and support staff. 
Individual surgical expertise and surgical quality were raised, although only by the 
surgeons spoken to (both general and specialist).  In addition one policy informant 
highlighted the need for patients to be treated according to evidence-based and 
agreed protocols.  The clinicians also cited a lack of DHB or government mandated 
protocols in allowing different standards of clinical practice throughout the country, 
although they urged that any future development of such protocols be clinically led.  
Caution was expressed by two of the upper GI surgeons to not assume that an upper 
GI surgeon is ‘better’ than a general surgeon.  Rather the medical clinicians argued 
that clinical competence should be based on a number of factors such as level of 
training, level of experience, the level of surgical precision undertaken and 
engagement with peers and professional bodies: "a person who’s been through a two-
year fellowship program under the auspices of ANZGOSA, who are submitting their 
cases to the binational registry, who attend the meetings and interface with people 
who are talking about their approaches … who are participating, are highly likely to be 
doing better surgery".   When asked what else might need to change in the stomach 
cancer treatment pathway in the future one clinician spoke of "credentialing of 
surgeons for complex cancer surgery … a critical look at the regionalisation issue, 
where these cancers should be cared for … providing more upskilling opportunities for 
local surgeons through joining regional MDM and operating alongside a specialist 
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surgeon on more complex cases".  The general consensus observed was that the 
working model most likely to gain sector support was one of specialist surgical support 
of generalist surgical practice.  This model would enable the provision of surgical care 
wherever the patient and whānau were best suited to receive that care and help to 
ensure that all centres have a well-trained well-supported surgical workforce. 
Medical Oncology Treatment  
Eight clinicians and four policy informants specifically discussed medical oncology.  Of 
these, seven identified the MDM as the key referral mechanism for patients accessing 
medical oncology, with the view that the majority of patients with stomach cancer are 
discussed at an organised MDM and referrals set in place.  As with accessing surgical 
treatment, key informants highlighted that the access to medical oncology appears to 
work well for patients living close to main cancer centres but can be problematic for 
patients living within smaller DHB areas or rurally: “not all places have an easy 
relationship to facilitate those patients going for chemotherapy, bearing in mind that 
chemotherapy can be quite prolonged and often quite demanding”.  Clinicians in 
smaller centres spoke of delays between the MDM and receipt of medical oncology 
referral, slowing the journey for the patient: "it is a bit person dependent at the 
moment, but it shouldn't be.  It should be process dependent".  In contrast a main 
centre clinician spoke of a recent initiative whereby the MDM template, which is filled 
in electronically directly after the meeting, itself is sufficient for referral to medical 
oncology, speeding up the referral process. 
One clinician felt that increasing specialisation in the medical oncology workforce over 
the last decades has been beneficial, at least to the surgical workforce, with surgeons 
needing to ‘interface’ with fewer oncologists but ones with more specialist knowledge 
of upper GI cancers.   Each of the medical clinicians spoken with discussed the value of 
medical oncology within the overall treatment plan for stomach cancer, saying they 
prefer the patient to ‘at least’ discuss the options with a medical oncologist, although 
two clinicians did highlight that there is a need for clear clinical decision making 
criteria so that referral to medical oncology is consistent nation-wide. 




All 15 informants agreed that MDM meetings are an important part of the treatment 
pathway for people with a complex cancer such as stomach cancer.  Although, as 
pointed out by one policy informant, “MDMs are essentially a very cost-rich 
environment, with all of those heads around the table for that period of time”.  
Informants disclosed that there is currently extensive work nationally aimed at 
maximising the functionality of the MDM, such as moving current Ministry of Health 
MDM guidelines into more prescriptive standards.  There is also additional funding for 
DHBs to increase functioning of, and access to, the MDM which is being used to fund 
projects such as video conferencing and improved data collection.  Informants in this 
study thought that this level of activity was consistent with MDMs being a very 
important resource in the stomach cancer treatment pathway. 
Despite this extra funding, and its anticipated improvements in the future, currently 
MDM functioning and access varies around the country.  Again smaller DHBs are 
limited in their capacity to support MDMs within their own DHB, often needing to 
access MDMs from outside their region which can delay decision making and thus the 
patient’s journey.  As highlighted by a nurse clinician at a smaller DHB, “at the moment 
if you’re not physically at the meeting you don’t always find out straightaway, or as 
quickly as I’d like, the plan for the patient …  one day we were both away and we just 
didn’t find out for a week what had actually been discussed”.  It appeared that 
mechanisms for prompt feedback were lacking.  In comparison a medical clinician at a 
smaller DHB spoke of having an on-going collegial relationship with a specialist 
surgeon within a larger DHB who would “take patients forward” to the main centre 
upper GI MDM on his behalf and who would call soon after the MDM with the 
decisions, followed by the appropriate paperwork.  In this case decisions could be 
acted upon immediately by the smaller DHB.  It appears that communication into and 
out of MDM can be ‘relationship dependent’ rather than ‘process dependent’. 
Seven clinical informants stated that all patients with stomach cancer would be seen 
and discussed within an MDM, while four policy and two clinical informants stated 
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that some patients would not be discussed within an MDM.  The main reasons for not 
discussing patients were acute and/or advanced diagnosis, whereby a patient was 
placed directly on the palliative care pathway.  According to informants, comorbidity is 
generally considered within the MDM in the context of risk reduction; however 
ethnicity is not generally considered or discussed within the MDM setting.  There was 
though some agreement to actually consider ethnicity, if not directly within the MDM 
discussion, then in MDM monitoring and reporting by ethnicity.  Improved ethnicity 
reporting by MDM was seen as one method to improve equity.  As a policy-based 
informant stated “you know, the only way to address these problems is by getting 
transparency.  If you don't know the problem exists, you can't really address it”.   The 
fairly recent phenomenon of cancer nurse specialists attending MDMs was specifically 
mentioned by three medical clinicians within main centres as being a positive step 
towards better understanding the social context of patients. 
“I've actually found them good, because what we've missed at 
our MDMs is the where's the family at, where's the person at 
kind of information … it'd be nice if the GP could come along, 
but you see they can't.  And so those coordinators are now 
starting to tell us those things.  Like, ‘Well yeah, you wanted to 
see them this week, but they'd actually prefer to be seen next 
week, because then their husband will be back from Perth, 
where he's working in the mines.  So then he can come too’.  
Those sorts of really practical things”.   
Palliative Care 
Questions were not specifically asked about palliative care however two clinicians 
raised the importance of focusing on palliative care for a group of patients with a 
disease of poor prognosis such as stomach cancer:  
“And I think the other huge area that will make a massive 
difference is to do with our palliative care.  Because so many of 
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our patients ... are going to end up in a palliative situation,  if 
you want to make the biggest difference to the greatest number 
of patients and their quality of life … we have to focus on  them, 
almost a little more than the patients we can potentially cure”.   
Palliative care access was specifically mentioned by one clinician while discussing the 
pros and cons of centralisation of surgical care, with the argument being that palliative 
care (in all its forms: palliative radiotherapy, palliative chemotherapy, stents and 
hospice support) should be widely available and accessible “because 50% of your 
patients are never even going to see the shiny inside of a brand spanking new hospital 
built just to care for those patients, because they're never going to come to surgery”.   
How to Improve the Treatment Pathway, 
especially for Māori 
All informants provided answers on how the treatment pathway could be improved, 
especially for Māori.  Six key themes were identified and are discussed below.  These 
themes were standardisation of care, formalised relationships with shared care across 
DHBs, cancer workforce training and development, improving health literacy, accurate 
ethnicity data collection and reporting, and a stronger mandate around equity 
accountability and improving health outcomes for Māori.   
Standardisation of Care 
The general consensus was that standardisation of care across the country is 
important in improving outcomes for all patients, including Māori: “we’ve got to be 
very clear, and very robust, in what is the best clinical pathway for people, regardless 
of where they come from and what conditions they have ….  And everybody deserves 
the right to have those options open, clearly explained, and they have the right to 
choose”.   
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The newly developed upper GI Service Provision Standards are seen a key mechanism 
that will help to standardise the delivery of care for all patients with stomach cancer, 
and in the process will improve that care for Māori.  Informants were clear that these 
standards are aiming to establish the minimum level of infrastructure needed by DHBs 
to meet a minimum standard of care and to set the required outcomes of that care.  
They are not guidelines for care, clinical protocols nor the gold standard pathway for 
people with stomach cancer.  The development of the Service Provision Standards are 
however seen as an important first step in the standardisation of care, the second step 
being the review process currently being undertaken whereby cancer services within 
DHBs are being reviewed according to how they currently meet or don't meet those 
standards.  Standardisation is seen as important for equity for Māori: “but particularly 
with equity issues for Māori and particularly for stomach cancers ...  if we can improve 
the overall standards that will bring everyone up”.  In addition, the consistent use of 
established tools throughout the country was seen as important.  Currently 
informants believed that tools such as the HEAT tool, whānau ora assessments and 
the distress tool and problem checklist (which enables structured assessments at 
cancer diagnosis, cancer discharge and other key points of the patient journey) were 
being used by some centres but not others.  It was informants’ view that consistent 
use of these tools would help to standardise care across the country. 
Formalised Relationships with Shared Care 
It is also hoped that through the processes of developing and reviewing the Service 
Provision Standards more formalised relationships and shared care across DHBs will 
occur. This was both in the context of smaller DHBs being able to formally contract 
other larger DHBs to meet gaps in service delivery, for example PET scanning, and in 
the context of workforce training and development: "Particularly smaller hospitals, 
rural hospitals they [the Service Provision Standards] will encourage them and larger 
hospitals to form mutually beneficial relationships for their patients.  Not just smaller 
hospitals sending people off for surgery, but actually truly shared care".  Again this was 
seen as important for improving the standard care for all New Zealanders, but 
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especially for Māori as it was noted that Māori were more likely to be treated within a 
smaller hospital. 
Workforce Development 
Developing the cancer workforce’s knowledge of inequity and the underlying 
determinants of health was put forward as important by a number of informants.  As 
noted by a policy participant: “The other thing we are really interested in for a more 
long-term perspective is the workforce development, or the training, with our 
clinicians” and by a nurse clinical participant: “I think from my perspective improving 
the knowledge of health professionals about what ethnicity means”  Workforce 
development included developing clinical champions who could lead discussion and 
challenge clinician behaviour. 
Health Literacy 
Improvements to health literacy were also put forward as important by a number of 
informants.  Improved health literacy was always discussed as a health system issue, 
so that patients and whānau are better enabled to understand and participate in 
decision making throughout their cancer journey:  
… then once someone is in the system, the issues of health literacy, 
both from a personal perspective but also from the perspective of the 
health service and its provision to support people to understand their 
journey or appropriately make decisions that support that journey, is a 
concern to me.”    
Specific health literacy interventions discussed by participants included: 
 Use of the Ministry of Health’s newly developed organisational health literacy 
framework and guide (Ministry of Health, 2015c; Ministry of Health, 2015b). 
 Clinician training with increased understanding of their responsibility in 
effective communication with patients and whānau. 
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 The development of decision-making tools for patients and whānau.  
 Reviewing relevant resources from a health literacy viewpoint – e.g. Cancer 
Society resources. 
Ethnicity Data and Reporting 
Accurate data collection and reporting by ethnicity was also seen as important for 
Māori with a number of informants highlighting the importance of transparency of 
issues that can be seen with accurate data: "the big one is getting good data, so you 
can actually audit pathways … There’s so many different data sources that having 
good consistent data is a challenge, and is only then that we can actually look to see 
where the inequities are and start working through those".  In relation to this quote 
one informant suggested there was a need for a national-level ethnicity data role to 
lead the programme of work that would be needed in order to enable good 
monitoring for equity on all cancer related indicators. 
Accountability for Equity 
Finally a stronger mandate around equity accountability and improving health 
outcomes for Māori were seen as important by a number of informants:  "I want to 
see a stronger commitment from government through to DHB, and how they devolve 
funds to providers, written all through the pathway, and commitment to measuring, 
reporting and being accountable for improving equity".    
How to Improve Specific Points of the Treatment 
Pathway  
In addition to the interventions within the themes above a number of interventions at 
each step of the stomach cancer treatment pathway were put forward by informants.  
These interventions are briefly highlighted below.   
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Early Detection  
Early detection interventions were identified focussing on three areas: a national early 
detection programme, improved access to endoscopy and standardising care 
nationally.  
 A national early detection programme as is currently being developed for lung 
cancer in NZ comprised targeted community awareness raising of signs and 
symptoms, raising awareness within primary health care of signs and 
symptoms and referral pathways, and, streamlining of referral pathways into 
endoscopy services 
 Specific interventions to improve access to endoscopy services, included 
electronic referrals, an algorithm and checklist that prioritised Māori and 
assigning a red flag once a patient is prioritised 
 Standardising care nationally was seen as important through interventions 
such as: 
o Strengthening early detection within the current upper GI Service 
Provision Standards (i.e. Standards 1 – 4) during their upcoming review 
and rewrite process and passing any improvements through the upper 
GI tumour standards working group. 
o Improving access to diagnostic and staging investigations within smaller 
DHBs. 
o Demystifying the diagnostic and staging journey for all patients.   
Surgical Management  
Three interventions highlighted as important at this point of the treatment pathway 
were all focussed on patients living remotely or inter-DHB referrals.  The interventions 
were: 
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 Combining clinics so complex patients and those living remotely can be seen at 
one time or on one day and increased use of telehealth clinics to decrease 
travel for patients living remotely. 
 Undertaking a comparative review across two different DHBs (smaller and 
main centre) to investigate referral pathways, triage processes, patient flows, 
timeliness and care coordination to determine any differences between DHBs.  
 Requiring that all DHBs involved in the surgical resection of stomach cancer 
appoint a cancer nurse specialist to coordinate care within and across DHBs.   
Medical Oncology and Multi-Disciplinary Meetings  
Two key areas of improvement were put forward by informants to improve MDMs 
which informants believe to be the primary mechanism for referral to medical 
oncology. 
Again standardisation of MDM was seen as important to ensure equity of access for all 
patients.  Specifically informants suggested developing firm criteria on who is 
discussed at MDM, making consideration of ethnicity and comorbidity more explicit in 
MDM and the upskilling of MDM members in the impacts of ethnicity and comorbidity 
on cancer treatment and survival.  Informants also identified ethnicity data collection 
and monitoring of MDM as important.  As a minimum all MDM should record ethnicity 
of all patients discussed, they could also undertake a regular equity audit or review to 
investigate whether any differences in timelines and service access by ethnicity are 
present.  
Patients with Comorbidity 
The interventions put forward as important by informants to improve services for 
those with comorbidity were:  
 Developing the cancer workforce’s knowledge of comorbidity and its impacts 
on clinical decision making and outcomes. 
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 Ensuring that cancer nurse specialists have the ability to effectively work with 
comorbid patients by explicitly including comorbidity in contracts, job 
descriptions and reporting systems. 
 Extending, or developing new, cancer nurse specialist roles that include upper 
GI cancers was seen as important for a group of patients that are likely to be 
highly comorbid and thus experience a complex cancer journey. 
Mandelblatt: A Framework to Consider Interventions 
The interventions within the six themes particular to Māori, along with the key issues 
and interventions put forward by informants at each step of the stomach cancer 
treatment pathway, are now summarised according to Mandelblatt et al’s 
(Mandelblatt et al., 1999) levels of barriers to access to cancer services; health care 
system, health care process and patient levels.   The key findings are presented in 
Table 39. 
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Table 39: Interventions identified by key informants according to the framework of barriers to access; Mandelblatt et al 







Stronger mandate for equity accountability and improving health outcomes for Māori 
Develop a national-level ethnicity data role 
Develop clinical champions for equity 
Accurate data collection and reporting by ethnicity 
Accommodate a more holistic approach which encompasses whānau 
Improve the cultural friendliness and approachability of services 
Funding, Resourcing, 
Location and Inconsistent 
Delivery of Cancer Services  
Combine clinics and increase use of tele-clinics  
Formalise shared care across DHBs across the stomach cancer pathway, but especially focussed on surgical management 
All DHBs involved in surgical resection of stomach cancer have a cancer nurse specialist to coordinate care within and 
across DHBs 
Implementation and quality review processes of the upper GI service provision standards 
Standardise clinical pathways, develop evidence based protocols and clear clinical decision-making criteria 
Standardise early detection and diagnostic services nationally 






Patient navigation or care coordination for all patients with stomach cancer 
Include upper GI and comorbidity in cancer nurse specialist roles 
All DHBs involved in surgical resection of stomach cancer have a cancer nurse specialist to coordinate care within and 
across DHBs 
Undertake comparative clinical review or audit across different DHBs - Investigate referral pathways, triage processes, 
patient flows, timeliness and care coordination  
Consistent use of established tools, including discharge tools 
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Patient – Provider 
Communication 
Develop the cancer workforce’s knowledge and increase understanding of their responsibility in effective communication 
with patients and whānau 
Provider Bias Develop the cancer workforce’s knowledge of inequity and the underlying determinants of health 
Clear clinical criteria and consistent use of established tools 
Cancer Workforce Commitment to employing Māori within the cancer sector 
Health Literacy - the health 
care system supporting 
people to understand their 
stomach cancer journey 
Use MOH organisational health literacy framework and guide 
Review relevant resources from a health literacy viewpoint 
Develop decision-making tools for patients and whānau 
Patient- Level Patient Preference/ Choice Accommodate a more holistic approach which encompasses whānau 
Patient Comorbidity  Explicitly include comorbidity in cancer nurse specialist roles  
Include impacts of comorbidity in workforce development of the cancer sector 
Combine clinics, especially for complex patients, and increase use of telehealth clinics 




The complex and multilevel nature of access to, and through, cancer services are 
highlighted by these findings along with the subsequent need for a broad range of 
activities or interventions to improve that access.  Importantly key informants spoken 
to largely discussed structural issues and identified systems or process level solutions.  
They generally did not expect the people, Māori or their whānau, to change in order 
to get better quality care for stomach cancer.  Health literacy provides a good example 
of this, whereby this could have been framed as the need to improve the health 
literacy of people.  However whenever key informants discussed health literacy it was 
framed as a health system responsibility to enable patients and their whānau to better 
understand their journey with stomach cancer and be better equipped for effective 
decision-making along that journey.  The fact that most key informants recognised 
higher level structural reasons for, and solutions to, inequity is heartening.  
Summary of Qualitative Results 
Fifteen health professionals were interviewed in this study with the majority stating 
that overall the health-care system works well for people with stomach cancer in New 
Zealand.    
Informants agreed that the stomach cancer treatment pathway has improved 
immensely over the five years preceding the interviews, with a lot of activity noted 
nationally and regionally.  Still informants agreed that there was much more that 
could be done to improve the pathway and quality of care along that pathway.  The 
main issue, which was highlighted by over half of the key informants, was that the 
delivery of cancer services is not consistent around the country.  Patients within 
smaller DHBs appeared to be impacted to greater levels with lesser access to 
diagnostic and specialist services, lesser access to multi-disciplinary decision making 
through the MDM process and longer timeframes through the pathway.  Some 
informants also noted that this inconsistency impacted more on Māori, as Māori more 
often reside rurally and receive their care within smaller centres.   




Six key themes were identified to improve the pathway for all New Zealanders, but 
especially for Māori: standardisation of care, formalised relationships with shared care 
across DHBs, cancer workforce training and development, improving health literacy, 
accurate ethnicity data collection and reporting, and a stronger mandate around 
equity accountability and improving health outcomes for Māori.  It was also thought 
that the Upper GI Service Provision Standards would improve consistency of service 
delivery nationally and should impact on equity for Māori in the future.  As well a 
number of interventions were put forward by informants at each step of the stomach 
cancer treatment pathway.  These interventions align to Mandelblatt’s levels of 
barriers to access to cancer services with the majority of interventions put forward 









Chapter 8: Discussion  
This study found both similarities and differences in the presentation, treatment and 
management of Māori and non-Māori patients with stomach cancer.  There were no 
substantial differences in cancer stage, or grade, at diagnosis and no major differences 
in proportions of Māori and non-Māori patients who received curative treatments.  
However, Māori were less likely than non-Māori to have surgery performed by a 
specialist upper gastrointestinal surgeon or in a main centre.  A 30% excess mortality 
among Māori patients was unexplained by a number of factors, although the study 
was underpowered to confirm this. 
A qualitative phase based on interviews with health professionals, helped to make 
sense of, and largely supported, the quantitative results.  The main finding was that 
that the delivery of cancer services is not consistent around the country; this point 
was especially relevant for smaller, less well-resourced DHBs and impacted more on 
Māori patients and those with comorbidity.   The qualitative phase also helped to 
identify interventions that could improve access to, and quality of, stomach cancer 
services for all New Zealanders but especially for Māori. 
This chapter outlines the strengths and weakness of this study and discusses and 
interprets key findings in relation to existing knowledge on Māori/non-Māori inequity 
in cancer care.  It also makes suggestions and recommendations on interventions to 
address differential quality of cancer care for New Zealand Māori.  It acknowledges 
that achieving equitable care for Māori will require a variety of interventions along the 
stomach cancer pathway that combine health system level, health care process level 












Summary of the Study Results 
This study made some important observations. Key findings are highlighted below. 
Summary of Quantitative Study Results 
There were both similarities and differences in the presentation, treatment and 
survival of stomach cancer for Māori when compared with non-Māori patients in New 
Zealand.   
Presentation 
There were no significant differences between Māori and non-Māori in cancer grade 
or stage at diagnosis.  Māori presented with a higher proportion of distally located 
tumours (43% Māori vs 26% non-Māori, p = <0.05) and non-Māori with a higher 
proportion of proximally located tumours (25% Māori vs 34% non-Māori, p = <0.05).   
Overall 70% of patients had comorbidity, although Māori appeared more likely to have 
multi-morbidity than non-Māori.  A strong deprivation gradient was observed which 
was more pronounced for Māori (59% of Māori lived within the most deprived quintile 
vs 29% non-Māori, p=0.01).  More Māori than non-Māori lived rurally (16% Māori vs 
7% non-Māori, p=0.02).    
Treatment and Management 
Of stage I–III patients, the proportions of patients that received definitive surgery 
were similar.  Māori appeared more likely to undergo a partial gastrectomy (59% 
Māori vs 49% non-Māori, p=0.14).  Non-Māori appeared more likely to undergo total 





Notably, Māori were less likely to have their surgery performed in a main centre (43% 
Māori vs 83% non-Māori, p<0.01) or have surgery performed by a specialist upper 
gastrointestinal surgeon (38% Māori vs 79% non-Māori patients, p<0.01).  It appears 
that even when Māori had surgery within a main centre they were 73% less likely than 
non-Māori to have that surgery performed by a specialist surgeon once age, stage and 
tumour site were taken into account.  Post-operative complications and node harvest 
both appeared similar between the two groups. 
Timeliness through the treatment pathway was similar between the two groups 
although Māori patients appeared to wait on average 13 days longer between 
diagnosis and surgery than non-Māori (median 47 days Māori vs 35 days non-Māori, 
p=0.65).  Proportions of patients that received chemotherapy were similar. 
Survival 
Of the total cohort 78% died during follow-up with the majority of deaths due to 
stomach cancer.  Survival disparities between Māori and non-Māori were unexplained 
by patient, disease, comorbidity and health care access factors, although the study 
was underpowered to statistically confirm a 30% excess mortality among Māori (HR 
1.30; 95% CI, 0.96 – 1.76).  
Summary of Qualitative Study Results 
The qualitative phase helped to make practical sense of the quantitative findings, 
identified what health professionals saw as issues in the management of stomach 
cancer and considered how to intervene to improve access to, and quality of, stomach 
cancer treatment services. 
The Identification of Key Issues  
There was a general view from informants that, once diagnosed, most patients 





appropriate clinical and support services.  However through the interview process it 
became apparent that the delivery of cancer services was not consistent around the 
country.  This point was especially relevant for smaller and less well-resourced DHBs.   
All informants identified issues particular to Māori, these included the mono-cultural 
focus of New Zealand's health care services, along with issues related to rurality and 
health literacy.  Comorbidity was thought to further increase the complexity of 
stomach cancer care and impact both on timeliness through the treatment pathway 
and clinical decision-making.   
The Identification of Interventions 
A number of interventions were identified at health system, health care process and 
patient levels.  Of note, a number of informants specifically mentioned the ability of 
the Service Provision Standards to improve the stomach cancer treatment pathway for 
all New Zealanders as well as impact on equity for Māori in the future.  The standards 
and other specific interventions are discussed later in this chapter. 
Reflections on the Note Review Data Collection Process 
The use of a research diary allowed critical reflection on the note review process and 
data gathered, importantly, the diary was summarised before either the quantitative 
or qualitative findings were generated.  The complexity of some patient journeys was 
apparent, with multiple providers, delays across DHBs and different resources 
available to different DHBs impacting on the patient journey.  The opportunity for 
patients and whānau to ‘slip through the gaps’ was highlighted.   In addition, the 
impact of comorbidity on clinical decision making and patient pathways was evident.  
These issues seemed more prevalent among Māori or within DHBs with high Māori 
populations.  The impact of geographical isolation on health professionals, in terms of 






Strengths and Limitations of the Study 
The validity of any research depends on having the appropriate study design, 
implementation, and analysis in order to answer the research questions.  The research 
question type and thus study design, activities and analysis differ between 
quantitative and qualitative research, as do the likely strengths and limitations of each 
of these research approaches.  Thus this section discusses the strengths and 
limitations of the quantitative and qualitative phases of this study separately.  
However, three key strengths of the study overall are first identified and discussed, 
followed by the strengths and limitations of the quantitative phase and then the 
strengths and limitations of the qualitative phase. 
Strengths of the Study Overall 
There were three key strengths of this study overall.  Firstly this study used a 
sequential mixed method study design, a quantitative phase followed by a qualitative 
phase with each phase used to answer related but different research questions.  
Sequential methods are especially useful when the results from one method help to 
inform the other method (Creswell, 2003).  In the case of this study the quantitative 
phase was used to audit the stomach cancer pathway in New Zealand.  This included 
determining patient characteristics at presentation, along with treatment, 
management and survival and whether any of these differed between Māori and non-
Māori.  The qualitative phase then used data from key informant interviews with 
health professionals to explore their views on issues for Māori and possible 
interventions or solutions focussed on those points of the treatment pathway that the 
quantitative data suggested were inequitable.  Qualitative methods of inquiry are said 
to be especially relevant in health-related research as they can provide insight into 
health professionals’ perceptions and help to identify barriers to changing healthcare 
practice (Al-Busaidi, 2008).   Qualitative research is also said to be suitable for 





settings in which policies (or interventions) will be implemented (Anderson, 2010).  
Importantly the qualitative findings supported those of the quantitative phase, namely 
that the key informants on the whole believe that there are issues that are likely to 
impact more substantially on Māori with stomach cancer in New Zealand, with a key 
issue being geographical differences in the treatment and management of people with 
stomach cancer. 
Secondly the study used an analytic framework, that of Mandelblatt et al (Mandelblatt 
et al., 1999), which allowed the thesis and its recommendations to focus on structural 
barriers, those at the health system and health care process levels.  Just as behaviour 
that poses health risk can be seen as ‘the problem’ and thus changing one’s lifestyle is 
seen as ‘the solution’ to decrease disease risk or incidence,  so too solutions to 
improving health care access can be focussed on requiring an individual (or group of 
individuals) to change their behaviour in order to gain ‘better’ health care (Robson and 
Harris, 2007a).  All researchers should strive to minimise harm to those being 
researched.  This point is even more salient when non-indigenous researchers are 
studying issues concerning indigenous peoples.  Special care must be taken so that the 
research does not reinforce patterns of colonisation and power imbalances between 
the researcher and the researched.  (Smith, 1990; Smith, 1999) Thus this thesis 
explicitly chooses not to focus on ‘Māori’ as the problem but rather the health care 
system itself.  Institutionalised racism within the health system is seen as the 
predominant problem and thus the health system is looked at to provide the solution 
to equitable access to, and outcomes from, New Zealand’s stomach cancer treatment 
pathway.   Put simply, the explicit rejection of victim blaming ideology is a significant 
strength of this study.  
The third strength of this study overall is that in keeping with a principle of Māori 
centred research, the thesis moves beyond merely outlining a problem and looks for 
answers (Cram et al., 2003; Barnes, 2000; Smith, 1999).   The thesis sets out to create 
positive change which will improve the stomach cancer treatment pathway for all New 
Zealanders, but especially indigenous Māori – who currently experience a greatly 





Zealand.  This final strength is especially important as, while the study has been 
primarily undertaken by a Pakeha researcher, it involves Māori patients and data and 
it tackles an area of great importance to Māori, stomach cancer.  
Strengths of the Quantitative Phase of the Study 
The quantitative phase of this study had a number of important strengths. Its primary 
strength is that the study is based on rich clinical data collected through manual 
review of patient medical notes.  In addition, this study had a sample that was 
nationally representative of stomach cancer patients in New Zealand and had equal 
numbers of Māori and non-Māori giving the study equal explanatory power between 
the two ethnic groups.  Key strengths are further discussed below. 
Good Data Gained From a Manual Clinical Notes Review  
The primary strength of this study is that it is based on a full clinical notes review, 
which allowed for the collection of comprehensive presentation, treatment and 
management data on all eligible patients and to conduct a detailed comparison 
between Māori and non-Māori patients.   
The manual review of individual patient files was the most time intensive and costly 
part of this study however it added great value to the study.  The data gathered 
provided more detailed information than that routinely available from administrative 
databases.  In addition, in depth review of medical notes in a variety of hospitals 
allowed good understanding of the strengths and limitations of the data, facilitated 
the visualisation of the patient journey as a whole and provided insight into the 
context of the delivery of cancer care in the many different facilities of New Zealand. 
The most important variables able to be collected through the note review were 






The note review allowed accurate staging of patients diagnosed with stomach cancer 
in New Zealand within the study timeframes.  The New Zealand Cancer Registry 
(NZCR) uses pathology reporting as the primary source of extent of disease staging 
and so stomach cancer, which is often staged clinically, for example by CT Scan, only 
has around 60% complete extent of disease data on the NZCR (Gurney et al., 2013b).   
Importantly, while the NZCR reported 101 patients within this studies’ cohort as 
unstaged, we were able to determine stage at diagnosis for all but five patients and 
thus include this important treatment and prognostic factor in our analysis.   Only one 
previous study on stomach cancer in New Zealand has assessed clinical staging data 
through clinical notes review.  That study was a small study of patients at one health 
care facility (Biggar et al., 2011).  In comparison this study comprised a much larger 
and nationally representative sample.    
Review of medical notes also allowed a comprehensive assessment of patient factors, 
especially comorbid conditions present at time of diagnosis.  Many studies of cancer 
survival depend on national administrative data to identify comorbid conditions.  
National administrative data may provide incomplete data on comorbidity as these 
are derived from clinical coders review of patient discharge summaries or medical 
notes (Soo et al., 2014; Heng et al., 2011; Sarfati et al., 2010a).   Careful review of 
patient medical notes by a trained oncology nurse, as was carried out in this study, is 
likely to provide more detailed and accurate assessment of comorbidity relevant to 
the patients’ cancer diagnosis. 
The manual review of clinical notes provided the study with detailed data on the 
treatment and management of patients.  National administrative treatment data is 
shown to undercount receipt of surgery by 13-19% and receipt of chemo- or 
radiotherapy for cancer patients by 18% and 16% respectively (Gurney et al., 2013a).  
Collection of data through the clinical note review thus allowed an accurate 
comparison of the treatment and management of Māori and non-Māori patients 
throughout the entire treatment pathway. 
The manual and in-depth review of medical notes in a variety of hospitals in the North 





understanding of each patient’s journey as a whole and of the context of cancer care 
in New Zealand.  These benefits were strengthened by the use of a reflective diary 
which allowed for critical reflection on the note review process, the data gathered and 
the implications of the data. 
Nationally Representative Sample 
A second key strength of this study is that it comprises a sample that is nationally 
representative of all patients with stomach cancer in New Zealand.   As seen in 
Chapter 6: Quantitative Results, the final cohort of this study reflects the structure of 
all patients with stomach cancer in terms of a number of key variables: gender, age, 
extent of disease, deprivation and rurality.  This representativeness was achieved 
through the inclusion of all Māori patients diagnosed during the study period, except 
the 5% living with the South Island of New Zealand, along with a randomly selected 
equal sample of non-Māori patients. As a retrospective cohort study based on clinical 
note review and national administrative mortality data, once the final cohort was 
determined no patients were lost to follow up reducing the likelihood of selection 
bias. 
Equal Explanatory Power 
The inclusion of all Māori along with an equal randomly selected sample of non-Māori 
means this study has equal explanatory power for Māori and non-Māori (Te Röpü 
Rangahau Hauora a Eru Pomare, 2002).  Studies with equal explanatory power are 
able to produce results that have the same precision, or power, for Māori as for non-
Māori.  This is especially important in equity-based health research.  As Māori only 
comprise 15% of New Zealand’s population a random sample of all New Zealanders 
would not allow equal depth of information to be produced for both ethnic groups – 
instead the evidence would favour the numerically dominant.  If the research then 
informs policy or interventions, as is the intent of this study, the needs of non-Māori 





The Treaty of Waitangi provides a rights-based argument for undertaking research 
involving Māori that is of equal quality as that involving non-Māori; having adequate 
Māori sample size is then an essential requirement for reporting data in a way that 
recognises the rights and needs of Māori, rather than those needs being subsumed by 
those of the non-Māori New Zealand population (Te Röpü Rangahau Hauora a Eru 
Pomare, 2002).   As noted by Robson and Reid (Robson and Reid, 2001), “the full 
expression of tino rangatiratanga positions Māori statistical needs as being equally as 
valid as those of the total population and challenges the Crown to meet those needs 
as part of its Treaty obligations”.    
Limitations of the Quantitative Phase of the Study 
The quantitative phase of this study also had a number of limitations, the most 
important of which is its small sample size and thus limited power to determine some 
findings.   Despite the considerable resource used to undertake a manual review of 
patient medical notes, data remained missing from some key variables and these were 
either not used in analyses, were analysed with a missing category or were analysed 
using imputed data.  Another limitation was the potential for misclassification bias, of 
both the exposure (ethnicity) and outcome (survival or mortality).   
Small Sample Size and Limited Power  
With 335 patients within the final sample this study had limited power, meaning some 
of the findings were unable to be estimated with precision, small differences may 
have been difficult to detect with any certainty and it may have been difficult to 
identify if some differences actually exist. 
The small numbers in this study in part reflects New Zealand’s small population size 
including the size of the indigenous Māori population.   Stomach cancer, while more 





New Zealand each year, of whom around 60 are Māori (New Zealand Health 
Information Service, 2010; New Zealand Health Information Service, 2011). 
This current study is part of a larger study (C3 or Cancer, Care and Comorbidity).  A full 
clinical note review was undertaken concurrently for the three cancers within the C3 
study with poor staging data: primary liver, rectal and stomach cancers.  Initially this 
study was designed to collect data of people diagnosed over a two-year period.  In 
order to increase the sample and power of the study data of people diagnosed over a 
three year period were used.  Resource constraints meant the sample size could not 
be increased further. 
Firm conclusions were further limited as 46% of patients, i.e. those with stage IV 
disease at diagnosis, were excluded from some analyses, including the treatment 
analyses.  Limited power caused a lack of precision in effect measure estimates.  
However importantly while the findings are based on relatively small numbers they 
are consistent with other research showing disparities in care and outcomes for Māori 
with cancer.   
Missing Data 
Complete data for some key variables was unable to be collected.  Data on patient 
characteristics were complete except complete data on patient smoking status was 
unable to be obtained.  This variable was not included in analyses.  It is well evidenced 
that Māori have higher rates of smoking (The Quit Group and the Ministry of Health, 
2009; Ministry of Health, 2008) thus it is more likely that Māori patients within this 
study, compared to the non-Māori patients, were current or ex-smokers.   Patient 
smoking status largely impacts on prognosis indirectly through the impact of smoking 
on increased comorbidity.   It is possible that some of the probable excess morbidity 
seen within the Māori cohort is explained by higher rates of smoking; however 
comorbidity was adjusted for within survival analyses and so it is likely that any effect 





The disease characteristic variables, stage, grade and tumour site, all had missing data.  
Stage at diagnosis was the most critical variable to the study with data missing for five 
non-Māori patients (2%) once all data were collected.  This has already been discussed 
above.  However, complete data on the key tumour variables of grade (40% missing 
overall) and site (35% missing overall) were also unable to be obtained.  Māori were 
more likely to have missing grade data (48% Māori vs 37% non-Māori missing) and less 
likely to have missing site data (26% Māori vs 36% non-Māori missing).   These 
variables impact on patient prognosis directly though disease effects.  Both of these 
variables were analysed with a missing category.  Given the importance that tumour 
site plays in patient prognosis (McLoughlin, 2004; Abrams and Wang, 2010), it was 
decided to impute the missing data.  The imputation process has been explained in 
Chapter 5: Methods.  Imputed tumour site was then used within survival analyses and 
was shown to be an important independent prognostic factor within this study. 
Data on histological subtype, diffuse or intestinal, were not collected.  These data 
were not always available within the patient notes and currently the NZCR data on 
histological subtype includes a high percentage of missing or NOS (not otherwise 
specified) data preventing further investigation of these findings in a larger cohort of 
patients diagnosed with stomach cancer.  Māori have been shown to be more likely to 
present with diffuse stomach cancer which is thought to negatively impact on 
prognosis (Biggar et al., 2011; Blair et al., 2012).  It is possible that the poorer survival 
of Māori is partially accounted for by this; however the impact of not including this 
variable is difficult to ascertain.  
Health care access variables, deprivation and rurality, were missing data for 12 
patients or 4% of patients overall (n=7 Māori vs n=5 non-Māori missing).  These data 
were imputed, as explained in Chapter 5: Methods, and used within survival analyses. 
Misclassification Bias  
This study used national administrative databases to identify a number of key 





in either the exposure (ethnicity) or the outcome (survival).   Additionally it is possible 
that misclassification of clinical data gathered through medical note review could have 
occurred.   
Ethnicity for patients in this study was assigned on the basis of NZCR ethnicity data 
which uses an ‘ever-Māori’ approach.  In this approach patients are classified as being 
Māori if they have identified as Māori on any previous health record.   Māori ethnicity 
has historically been under-counted in health service databases (Robson et al., 2006; 
Robson et al., 2010; Robson and Purdie, 2007b; Swan et al., 2006), although there is 
some evidence that this is of smaller magnitude than it once was (Rumball-Smith and 
Sarfati, 2011).  Because of this it is possible that some Māori with stomach cancer 
were missed during the study selection process and that these patients differ from 
those that were included in some way (i.e. in patient, disease or health care access 
factors).    Patient ethnicity was checked during the manual review of patient medical 
notes with no misclassifications noted.  Additionally, assigning ethnicity using the 
‘ever-Māori’ approach helped to minimize the known under-count of Māori (Robson 
et al., 2006; Robson et al., 2010).   Furthermore, it has been shown empirically that 
using different methods of assigning ethnicity in a cohort study only results in a very 
slight variation in results (Simmonds, 2010) and this current study used the same 
method to assign ethnicity throughout.  So while it is possible that ethnicity 
misclassification bias exists in this study, if present it is likely to be of minimal 
importance to the results.  
This study used data from the National Mortality database to identify the outcome 
(survival) for patients in order to ascertain the relationship between ethnicity and 
survival.   Misclassification of mortality data could impact estimates of the strength of 
this relationship in two ways; firstly the fact of death itself, and secondly the cause of 
death. 
Misclassification of the fact of death is unlikely to be a major source of bias in this 
study.  Survival was determined by linking the study cohort to the national mortality 
database which captures all deaths occurring in New Zealand.  All study members who 





assumed to be alive at the end of follow-up.  It is highly unlikely that living people 
would be classified as having died and so misclassification of fact of death would only 
occur if the patient had died outside of New Zealand.  Each of the three patients who 
were excluded as being non-resident during the note review process (see Chapter 6: 
Quantitative Results), were in fact, diagnosed with stage IV disease and returned to 
their original country of residence.  Thus these patients were identified and excluded 
during the clinical note review. 
Misclassification of the cause of death can occur if stomach cancer deaths are 
classified as being due to other causes or if non-cancer deaths are classified as being 
due to stomach cancer.  These forms of misclassification would only alter the hazard 
ratio if misclassification was different for one group.  The three non-Māori study 
patients whose deaths were classified as malignant neoplasm of lower third of 
oesophagus (C155) on the National Mortality database but were assumed to have died 
of stomach cancer (and thus their death attributed to stomach cancer in this study) 
would have been unlikely to alter the hazard ratio significantly.    In this study there 
was little difference in the proportions of deaths (either stomach cancer or other 
causes) between the Māori and non-Māori cohorts.  It is unlikely that misclassification 
of cause of death was a major source of error in this study. 
There is also potential for misclassification of clinical data gathered through medical 
note review, including disease factors, patient comorbidity and data related to patient 
management or treatment.  Again these could be misclassified in two ways; firstly 
during the process of clinical assessment and the writing of medical notes, and 
secondly during the process of data extraction.   As discussed above the collection of 
clinical data though manual review of patient medical notes was a key strength of this 
study and provided more robust clinical data than that available within national 
administrative databases.  The potential for misclassification to occur during the 
second process, that of data extraction was ameliorated through the use of a 
standardised study proforma for the extraction of clinical data (See Appendix I: Study 





Confounding, Mediating and Adjustment 
Treatment, management and survival in Māori and non-Māori patients were adjusted 
for a range of covariates, some of which are pure confounders and others mediators in 
the relationship between ethnicity and the outcome. 
As discussed in Chapter 5: Methods, age and sex are considered ‘pure’ confounders in 
this study and all comparisons between the two ethnic groups were adjusted for these 
two confounders (including prevalence rates and hazard ratios).  All other covariates 
adjusted for in Cox proportional hazards modelling (disease factors: stage at diagnosis 
and tumour site, patient comorbidity and health care access factors: deprivation and 
rurality) were considered potential mediators in the relationship between ethnicity 
and survival (see Figure 6 Direct Acyclic Graph in Chapter 5).  In other words they are 
pathway factors in the causal chain between ethnicity and survival.  Sequential 
adjustment for these factors was undertaken to assess their contribution to any 
survival disparity between Māori and non-Māori.  Biased estimates of the contribution 
of these factors on survival may arise from misclassification (already discussed), from 
residual confounding or mediation or from the ordering of mediators in the sequential 
modelling.  
Residual confounding or mediation occurs when a confounder (or mediator) has not 
been adequately adjusted for in analysis, for example by using poorly measured 
proxies.   In this study age was fitted to the model as a continuous variable so it is 
unlikely that any residual confounding by age occurred, however residual confounding 
by comorbidity may have occurred.  While review of medical notes is likely to have 
provided more accurate assessment of comorbidity relevant to the patients’ cancer 
diagnosis than that able to be gained through administrative databases, it is possible 
that residual confounding occurred through the imperfect measurement of 
comorbidity within this study.   
The apparent contribution of the factors can also be changed by the ordering of 
mediators in the modelling.   However, in this study the mediators in the sequential 





pure confounders first, followed by the factors existing at the point of presentation 
before assessing the impact of factors that lie within the jurisdiction of the health care 
system.  
Chance 
Finally, as with all research it is not possible to rule out the possibility of chance 
findings.  As noted above, this study had limited power for some analyses causing lack 
of precision in some effect measure estimates.  Limited power also caused an inability 
to examine outcomes for subgroups.  As examples, the study was unable to determine 
if receipt of curative surgery, or the differences seen in surgical management of 
patients in this study, impacted on survival for those patients that were diagnosed 
with potentially curable disease (stage I - III) or to produce meaningful hazard ratio 
estimates stratified by stage.   
 It is also not possible to rule out the possibility of chance findings given the multiple 
numbers of comparisons.  However, as the key statistically significant findings (such as 
Māori having higher levels of comorbidity, more distal cancers and less access to 
specialised care) are those where we had a priori expectation of finding differences, it 
is unlikely that these are chance findings.   
Three further limitations of this study are 1) that 16 Māori diagnosed with stomach 
cancer and residing within the South island of New Zealand were not able to be 
included, although it is likely that the issues are similar to those highlighted in this 
thesis for Māori residing in the North Island of New Zealand  2) that the comparator 
groups are limited to Māori and non-Māori only; the inclusion of Pacific and Asian 
peoples, who also have high rates of stomach cancer, with the non-Māori group may 
have minimised the observed differences, and 2) that patients diagnosed with a 
gastrointestinal stromal tumour (GIST) are included within the study.  Patients with 
GIST may have a slightly different treatment pathway and different prognosis than 





total cohort (n=9) and were evenly spread between Māori (N=4) and non-Māori (n=5), 
thus their inclusion in the study is unlikely to have impacted on the results. 
Strengths of the Qualitative Phase of the Study 
The qualitative study had a number of strengths.  Processes were deliberately built 
into the qualitative phase of the study in order to enhance the trustworthiness of its 
findings.   Such processes are recommended by qualitative researchers (Liamputtong, 
2012; Padgett, 2011) and included: purposively selecting a range of informants based 
on their unique knowledge and taking a systematic, and well documented, approach 
to the collection and analysis of the data and decisions made during the research 
process.   Additionally feedback was gained on the findings in a number of ways.  
Firstly emergent ideas were discussed with subsequent informants during the 
interview process.  Secondly, discussions with supervisors with clarification of the 
findings happened regularly throughout the research process.  Thirdly the data and its 
interpretation were tested through discussion with the groups advising the 
overarching C3 study and through presentation at specific meetings.   Finally this 
phase of this study followed established research guidance, for example the interview 
schedule was developed collaboratively and trialled with potential informants before 
it was used in this study,  all key informant interviews were digitally recorded and 
transcribed as well as field notes taken and consent was gained for all informants.  
Another strength of the study was the diversity of the participant sample.   It was the 
intent of this phase of the study to gain a range of views across three key factors of 
interest: indigeneity, health care professional role type and treatment centre type, 
thus informants were purposefully selected according to these factors.  Using the 
snowball recruitment method worked well to gain a diversity of informants with in-
depth understanding of the stomach cancer treatment pathway and issues for Māori, 
as informants recommended future informants to meet the maximum variation mix of 
informants.  Importantly recruitment was discontinued once key names began to be 





Additionally, key informants offered rich data.  The interviews were based on a semi-
structured interview schedule with open-ended questions so that informants could 
share their thoughts and perspectives as fully as possible, and could raise the issues 
that mattered most to them.   As the informants were drawn from the relatively small 
New Zealand cancer sector, care was taken to ensure that they would feel 
comfortable speaking freely.  As examples a commitment was made to maintain 
confidentiality and informants were offered the ability to approve direct quotes.  
Building these processes into the study allowed the informants to discuss, at times 
sensitive and potentially challenging, issues in depth providing information-rich data 
to support the quantitative phase of this study. 
Limitations of the Qualitative Phase of the Study 
The qualitative phase also had three key limitations.  These relate to the size and 
diversity of the participant sample and possible biases introduced by the informants 
themselves or by myself as the researcher. 
While the participant sample was diverse it is possible that a larger and more diverse 
sample would have offered different ideas. However, those interviewed were among 
the leaders involved in the delivery of care to patients with stomach cancer, at both 
policy and clinical levels.  Thus the findings likely reflect the current situation of 
stomach cancer care delivery within New Zealand.  Also the purpose of these 
interviews was to determine what key people see as the issues impacting on Māori 
within the pathway, to present the findings of the quantitative phase and seek expert 
advice on them and to explore possible interventions to improve the pathway.  That 
the qualitative findings support the quantitative findings (as do my reflections on 
gathering the quantitative data) is reassuring 
It is possible that bias was introduced to the findings by the informants themselves.   
Purposefully selected key informants, while able to give information-rich data, may be 
more likely to express 'politically acceptable' views, or not criticise the system in which 





Alternatively purposefully selected key informants may have their own agenda which 
they wish to advance through participation in the study.  They are also likely to 
present their own account of how the system works which may, or may not, differ 
from how things actually are.  Nevertheless, the application of the key informant 
technique to this study is justified by the significant insight into the delivery of 
stomach cancer services and issues for Māori along with the generation of 
intervention ideas grounded in the reality of those working within the health system 
that were gained in a relatively short period of time. 
Finally it is unavoidable that my own personal biases had some impact in the 
qualitative phase of this study.  According to Choy (Choy, 2014: 102) “All researchers’ 
interpretations are limited.  As positioned subjects, personal experience and 
knowledge influence the observations and conclusions”.  As a public health 
professional committed to improving access to, and quality of, cancer services for 
Māori it is likely that the gathering, analysis and presentation of the data were 
undertaken and viewed through an equity lens.  However having an awareness of and 
paying attention to one’s potential biases is important in qualitative methodology; this 
thesis is explicit in its overarching intent to facilitate positive outcomes for Māori 
through a systems-based approach whereby solutions to the problem are focussed on 
changing systems rather than changing individuals or those who participate in the 
systems.  It is however also possible that personal bias I am unaware of may have 
influenced this study and its interpretations. 
External Validity of the of the Study Overall 
Whether the findings of this study are able to be applied to other populations depends 
on two key factors: the characteristics of the cancer patients and the context in which 
health care is delivered.  Both of these factors should be considered when generalising 
the findings of this study to cancer disparities in other cancers in New Zealand or  





The quantitative study population represented all New Zealanders diagnosed with 
stomach cancer between 2006 and 2008 and this study was intended to inform 
Māori/non-Māori differences in treatment and management of stomach cancer.  The 
study findings could be in part generalised to other cancers within New Zealand 
although attention would need to be paid to differences in the characteristics of the 
cancer and its recommended treatment. 
Although the findings of the qualitative phase are pertinent only to New Zealand as 
they focus on the context of the delivery of cancer services in New Zealand and could 
not be generalised internationally, they may be of interest to others involved in 
indigenous cancer research internationally.  These findings could well be transferable 
to other cancers in New Zealand.    
Overall the study findings may be relevant to cancer disparities in other indigenous 
populations; however attention should be paid to differences within the indigenous 
populations and the contexts in which they live and in which their health care is 
delivered.  Māori in New Zealand are a unique population with a unique history that 
differs in many respects from indigenous people within other countries - although 
there are likely to be some similarities, driven by common processes of colonisation, 
marginalisation and institutionalised racism.    Cancer care in New Zealand is delivered 
primarily within a publicly funded health care system that seeks to provide equal 
access to all patients based on need.   In addition, with New Zealand's small 
population size, services relevant to stomach cancer are low volume by nature.  As 
long as these factors are taken into consideration the findings of this study may well 
inform cancer disparities within other countries. 
In addition the study overall may contribute to an increased understanding, both 
nationally and internationally, of institutionalised racism, how it manifests in unequal 






Interpreting the Study Results 
The quantitative phase of this study found a number of key differences in the 
presentation, treatment and management of stomach cancer for Māori when 
compared with non-Māori patients in New Zealand.  Additionally, there was an 
apparent survival difference unexplained by a number of patient, disease and health 
care access factors.  There were also some surprising similarities between the two 
groups.  The quantitative findings fall into three main areas: 
Quantitative phase  
1. Māori and non-Māori patients with stomach cancer differ in terms of patient 
(age, sex, comorbidity), disease (tumour site only) and health care access 
(deprivation, rurality) characteristics but have similar disease (stage at 
diagnosis, grade) characteristics. 
2. There are differences in the treatment and management of Māori and non-
Māori patients with stomach cancer with Māori appearing to have lesser 
access to specialist surgical care, although some markers of surgical quality 
appear similar. 
3. These differences could contribute to an apparent 30% poorer survival from 
stomach cancer seen between Māori and non-Māori in New Zealand. 
The qualitative phase of this study helped to make practical sense of the quantitative 
findings.  It identified what key informants working within New Zealand’s health care 
system see as issues in the management of stomach cancer and considered how to 
intervene to improve access to, and quality of, stomach cancer treatment services.  






1. The issues identified along the stomach cancer treatment pathway in New 
Zealand support the findings of the quantitative phase of this study, as do my 
reflections on reading 335 patient notes. 
2. The delivery of cancer services is not consistent throughout New Zealand 
which especially impacts on smaller DHBs, Māori and patients with 
comorbidity. 
3. The recently released Upper GI Service Provision Standards have the potential 
to improve the system for all New Zealanders and impact on equity for Māori 
however a range of further interventions could be implemented. 
The following section explores these findings in more detail.  Study results, both 
quantitative and qualitative, are combined into one with the following interpretation 
and discussed in relation to existing knowledge of disparities in cancer care and 
survival among Māori and non-Māori.   
Differences in Presentation between Māori and non-
Māori with Stomach Cancer 
There were a number of key differences in the presenting characteristics of Māori and 
non-Māori New Zealanders with stomach cancer.  There were also some surprising 
similarities. 
Māori were found to have higher levels of comorbidity and evidence of poorer access 
to health care services.  These are two important findings.  Tumour site was markedly 
different between Māori and non-Māori patients while other tumour characteristics 






Age and Sex 
Māori patients were on average 10 years younger than the non-Māori patients, 
reflecting the younger age structure of Māori in New Zealand (Statistics New Zealand, 
2014; Robson and Harris, 2007a).   Within female patients this ethnic difference was 
even greater so that Māori women were on average 13 years younger than their non-
Māori counterparts. This differential average age at diagnosis may also be a true 
younger age at onset possibly due to a higher prevalence of known risk factors among 
Māori, such as H. pylori and smoking (The Quit Group and the Ministry of Health, 
2009; Fraser et al., 1996; Ministry of Health, 2008; Biggar et al., 2011).   It may also be 
due in part to the younger age at diagnosis seen in those with hereditary diffuse 
stomach cancer (mean age at diagnosis: 40 years) as there is a large Māori family in 
New Zealand who are known to carry the gene mutation for this form of stomach 
cancer (Blair et al., 2012).  However since the discovery of the gene mutation within 
this family in the 1980’s and subsequent genetic testing, screening and prophylactic 
gastrectomy it is unlikely that there was high enough incidence within this family to 
impact significantly on age at diagnosis at a population level.   
The primary care guideline (‘Suspected Cancer in Primary Care’) (New Zealand 
Guidelines Group, 2009) advises primary care practitioners to consider stomach 
cancer at a younger age, suggesting ten years earlier, when treating Māori patients 
compared to the general population.  This recommendation is supported by the 
findings of the current study.   
Overall the incidence of stomach cancer in this study was higher in males than females 
which is in keeping with international evidence (McLoughlin, 2004; World Health 
Organisation, 2008).  The magnitude of this difference internationally is in the ratio of 
1.5–2.5 for males to 1 for females (Crew and Neugut, 2006; Ferlay et al., 2010).  
However, within this study a higher proportion of the Māori cohort were female, with 
a nearly 1:1 ratio (47% female) compared to the non-Māori cohort who had a nearly 





remained once the data were age standardised to account for the different age 
structures within the Māori and non-Māori cohorts.  Dockerty also reported a high 
proportion of Māori women with stomach cancer (Dockerty et al., 1991) as did the 
New Zealand Cancer Registry between 2000 and 2009 (New Zealand Health 
Information Service, 2012).  Notably no other indigenous population in the world has 
such a high proportion of women compared to men as do New Zealand Māori.   All 
other indigenous populations have male age-standardised incidence rates (per 100 
000) two to three-fold that of their female counterparts (Arnold et al., 2014) 
Four key informants in the qualitative phase of this study offered unprompted 
information on the risk factors of stomach cancer, with each of them stressing that a 
focus on prevention is vital to improving outcomes of stomach cancer for Māori.   
Given the extremely high incidence of stomach cancer seen within Māori and the 
gender anomaly highlighted above further research into the risk factors of stomach 
cancer for Māori and the significant gender differences suggested by this study is 
warranted. 
All comparative analyses were adjusted for age and sex. 
Comorbidity 
This was a highly comorbid cohort, with 70% of both Māori and non-Māori having at 
least one comorbidity at the time of their stomach cancer diagnosis.  Māori had 
significantly higher prevalence of congestive heart failure and renal disease, non-
significantly higher prevalence of diabetes and appeared more likely to present with 
multi-morbidity (31% likelihood of three or more comorbidities compared to 17% 
likelihood in non-Māori).  All other comorbidities analysed were similar between 
Māori and non-Māori patients.    
Comorbidity among cancer patients is common with at least half of all New Zealand 
cancer patients having comorbid conditions (Sarfati et al., 2014a).  The observation 
that Māori were more likely to have comorbidities is consistent with previous studies 
which have found Māori patients to have higher rates of comorbidity than non-Māori 





Māori is also less likely to be well controlled than that among non-Māori due to the 
differential access to the underlying determinants of health and lesser access to 
primary health care, as discussed in Chapters 2 and 4.   
As Māori are more likely to be comorbid, comorbidity is of greater importance to 
Māori.   The impact of comorbidity on cancer outcomes could be reduced through 
measures to prevent disease and improve access to early intervention for all health 
conditions within the primary health setting for Māori.   
Disease Factors 
Stage  
Surprisingly, no substantial differences were found in stage at diagnosis between 
Māori and non-Māori patients.  In comparison previous studies that relied on national 
level data, rather than staging derived from clinical note review, have found that 
Māori are more likely to be diagnosed with localised disease than non-Māori (Robson 
et al., 2006) although the authors point out that stage was unknown for about a third 
of patients overall.  However a study at a single New Zealand facility that also utilised 
more accurate clinical note review data also found no apparent difference in stage at 
diagnosis between Māori and non-Māori patients (Biggar et al., 2011).   
Despite the lack of substantial stage difference between the two ethnic groups within 
this study, stage overall was poor with nearly half of the total cohort (46% or n= 158) 
diagnosed with metastatic stomach cancer.  During the process of gathering the data 
many examples were seen of complex and lengthy pathways, especially at the 
beginning of a patient’s cancer journey where early diagnosis matters to improved 
stage.  Key informants also raised the advanced stage of stomach cancer as an issue 
especially highlighting that access to early detection and staging services, is not 
consistent throughout New Zealand.    There are three points where improvements to 
stage could occur: within the public in general (or within specific subgroups), within 
the primary care sector or within secondary services once referred, although there is a 





of cancer (Richards, 2009).  Clearly though, there is a need to improve the stage profile 
of stomach cancer overall in New Zealand through systematic improvements to early 
detection and diagnosis of the disease. 
Grade 
Overall, 42% of the total cohort presented with a poorly differentiated grade of 
stomach cancer.  Although Māori were more likely to have data missing from this 
variable there was little difference between Māori and non-Māori patients in grade of 
disease at diagnosis.  Little difference between Māori and non-Māori remained when 
the missing grade data were removed.  This variable was not considered further. 
Tumour Site 
There were significant differences in the distribution of tumour site between Māori 
and non-Māori patients. Māori presented with a much higher proportion of distal 
stomach cancers, and a corresponding lower proportion of proximal stomach cancers, 
when compared with non-Māori patients.  Stratifying the two main tumour sites 
(distal and proximal) by sex showed that Māori women were most likely to present 
with a distally located tumour and least likely to present with a proximally located 
tumour while non-Māori men were the group most likely to present with a proximally 
located tumour and least likely to present with a distally located tumour.  This is in 
keep with international evidence that shows proximally located stomach cancers are 
more likely  in white males of more affluent societies (Kelley and Duggan, 2003).   
In comparison, high rates of distally located tumours have been reported for other 
indigenous people (Heise et al., 2009), especially American Indians and Alaskan 
Natives (Arnold et al., 2014; Wiggins et al., 2008)   although differentials by gender are 
not reported.  In the general population internationally non-cardia (distal) stomach 
cancer has a male-to-female ratio of approximately 2:1 whereas cancer located in the 
cardia of the stomach has a much higher male to female ratio (Crew and Neugut, 
2006; Kelley and Duggan, 2003).   In the USA the incidence of adenocarcinoma of the 





The observation of a higher proportion of distal cancer for Māori is also in keeping 
with previous New Zealand based studies (Biggar et al., 2011; Armstrong and Borman, 
1996).  This finding suggests that there may be differing aetiological factors driving the 
high incidence rates of stomach cancer observed for Māori.  Infection with H. pylori 
and smoking have both been shown to be more likely to lead to the development of 
distal stomach cancer over proximal (McLoughlin, 2004; Crew and Neugut, 2006; 
Biggar et al., 2011; Kamangar et al., 2006; Forman and Burley, 2006; Martin, 2002).  
The high proportion of distal stomach cancer among Māori women when compared 
with non-Māori men and women may be related to their higher rates of H. pylori 
(McDonald et al., 2015) in combination with a very high smoking prevalence and 
younger age at initiation (The Quit Group and the Ministry of Health, 2009; Ministry of 
Health, 2008; Fraser et al.; Biggar et al., 2011).  Māori women have one of the highest 
rates of smoking in the world, more than Māori men and over twice that of non-Māori 
women (The Quit Group and the Ministry of Health, 2009).  These two factors are 
thought to interact to increase the risk of distal stomach cancer more than would be 
expected given each risk factor alone (Forman and Burley, 2006; World Health 
Organisation, 2008).   
Again these findings reinforce the need for further research into the risk factors of 
stomach cancer for Māori.   These findings also add weight to a continued emphasis 
on reducing smoking as well as the development of interventions to prevent the 
transmission of, and to treat, H. pylori, particularly among Māori as discussed in 
Chapter 2: Background.    
In addition, the New Zealand Cancer Registry (NZCR) does not currently record the 
sub-site of stomach cancer preventing the verification of these findings to those of the 
NZCR or over time.  Improvements in the reporting of tumour sub-site to the NZCR 
would enable better monitoring of Māori/non-Māori differences and whether these 





Health Care Access Factors 
Māori had poorer access to health care services according to both of the factors that 
were considered markers of health care access within this study.    
Deprivation and Rurality 
There was a strong socioeconomic gradient for both Māori and non-Māori patients in 
this study.  Over half of the total cohort lived in the most deprived quintiles (7 -10) 
whereas only a quarter resided in the least deprived quintiles (1-4).   Previous New 
Zealand research has also shown evidence of a strong deprivation gradient for 
stomach cancer (Soeberg et al., 2012; Blakely et al., 2010), with incidence rates in New 
Zealand at least one-third higher among low income groups when compared to high 
income groups (Blakely et al., 2010).   Despite the strong deprivation gradient overall 
this association was more pronounced for Māori with 59% of Māori living within the 
most deprived quintiles compared with 29% of non-Māori patients.  The distribution 
of Māori by deprivation in this cohort is similar to that seen in the general Māori 
population, which is vastly overrepresented in highly deprived areas (Robson and 
Harris, 2007a).  
Māori with cancer are more likely to live in highly deprived areas (Hill et al., 2010a; 
Seneviratne et al., 2014c; Stevens et al., 2008b).  Previous New Zealand cancer survival 
studies show poorer cancer survival in patients living in areas of greater deprivation 
(Soeberg et al., 2012; Haynes et al., 2008; Jeffreys et al., 2009), primarily due to the 
effect of socioeconomic status on stage and receipt of cancer treatment (Haynes et 
al., 2008; Jeffreys et al., 2009). 
The majority of patients (78%) lived in urban areas.  Slightly fewer Māori (68%) than 
non-Māori (81%) lived in main or satellite urban areas, on the converse it appeared 
that more Māori lived in rural areas (16% Māori vs 7% non-Māori).   This is in 
accordance with previous reports showing that Māori are most likely to live in 
Auckland and other major cities (Statistics New Zealand, 2007) and more likely than 





Māori as shown in this study are more likely to live rurally, further from cancer 
services; thus differential geographical access especially impacts on Māori.  Place of 
residence is viewed as a marker of health care access.  Research shows that people 
living in rural areas experience far greater barriers in accessing health care, and cancer 
care (Moore et al., 2010; Diaz et al., 2015b; Seneviratne et al., 2014c).  The only New 
Zealand study that has looked at distance travelled and survival for stomach cancer 
concluded that the relationship between distance and survival was complex.  Poorer 
survival was found for all patients with stomach cancer, regardless of ethnicity, living 
51 – 100km from a cancer treatment centre while those living closest and furthest 
distances fared better, although the study did not assess distance to specialised 
surgical treatment services.  Given that surgery is the mainstay of curative treatment 
for stomach cancer this would have been a more interesting variable to assess (Gill 
and Martin, 2002).  
Notably only five patients within this current study had their stomach cancer resected 
in a private hospital (two Māori and three non-Māori) so it appears that little care was 
delivered within the private sector.  It is possible though that some patients received 
private specialist assessment and diagnostic investigation and then went on to have 
surgery within the public sector, thus enabling a quicker diagnostic pathway.  
Although this is speculation, as these data were incomplete and unable to be 
analysed, it is likely that more non-Māori than Māori would have benefited from an 
expedited ‘private’ pathway.  Non-Māori New Zealanders are more likely than Māori 
to have private medical insurance (Cumming et al., 2014).  Recent research into 
pathways of care for breast cancer shows more non-Māori women receive their care 
within the private sector (Seneviratne et al., 2014c). 
The findings of the qualitative phase of this study supported those of the quantitative 
phase; namely that key informants raised issues to do with rurality and receiving care 
within smaller centres as an issue and one that especially impacts on Māori.  The need 
for patients to travel for multiple appointments with multiple providers and often 
within a DHB other than that in which they reside was seen as an issue by key 





for the quantitative phase of this study.  This was viewed as particularly problematic 
by key informants when the responsibility of navigating these services was left to the 
patient rather than to the health system supporting the patient and whānau cancer 
journey or working to improve the navigability of their services.    
These findings raise some important questions about the accessibility of cancer 
services in New Zealand and how to ensure that Māori receive the same access as 
non-Māori patients. 
Differences in Patient Management and Treatment 
between Māori and non-Māori with Stomach Cancer 
Comparative management and treatment-based analyses were undertaken on those 
patients amenable to curative treatment (those diagnosed at stage I-III of disease) 
only.  All were adjusted for age and sex. 
Diagnosis and Staging Investigations 
There was little difference in the proportions of diagnostic and staging investigations 
received by Māori and non-Māori patients.  The majority of patients were diagnosed 
and staged by gastroscopy and/or computerised tomography (CT) scan while 81 
patients also received a laparoscopy.   Overall the numbers of patients receiving these 
diagnostic and staging investigations were similar to those seen in the note review 
study by Biggar et al (Biggar et al., 2011).  Correspondingly, similar proportions of 
Māori and non-Māori patients received diagnostic investigations in studies on lung 
cancer (Stevens et al., 2008b) and colon cancer management (Hill et al., 2010b) 
A New Zealand study published in 2002 highlighted the need for better staging and 
treatment planning offered by endoscopic ultrasonography in conjunction with CT 
scanning (Martin, 2002).  This study, using data collected between 1995–1997, found 
that 10% of patients receiving an operation for a gastro-oesphageal tumour had an 





surgical planning information gained by endoscopic ultrasonography prior to surgery.  
Despite these recommendations, and the fact that endoscopic ultrasonography is 
considered one of the most valuable tools in the staging of stomach cancer (Dicken et 
al., 2005) this study’s findings indicate that clinical practice has remained unchanged a 
decade later, with only four patients receiving an endoscopic ultrasound.  Of note, five 
stage I – III patients (3% Māori vs 2% non-Māori) underwent a potentially avoidable 
‘open and close’ surgical procedure. 
Surgical Treatment and Management 
There were a number of similarities in the surgical management of patients in this 
study. Of the 172 patients with stage I-III disease overall, two-thirds (66%) had 
definitive surgery with similar rates of surgery observed between Māori and non-
Māori.  Surgery was observed to be the primary treatment modality over our study 
period, which is consistent with international guidelines in use at the time (Allum et 
al., 2002; National Health Service Scotland, 2006; Nakajima, 2002).  Just over half 
(55%) of all stage I-III patients had the recommended 15 or more nodes resected 
during surgery with similar proportions observed between Māori and non-Māori 
patients, although more non-Māori had missing data for this variable (11% missing 
Māori vs. 18% missing non-Māori).  Overall this is a good finding in international terms 
but is less than that observed in the United Kingdom where around 76% of patients 
having curative gastrectomy had 15 or more nodes resected (National Clinical Audit 
and Patient Outcomes Programme, 2013) or that seen in a single Australian facility 
where 83% of stage I – III patents had 15 or more nodes resected (Chen et al., 2014).  
It is though more than the rates of 18% reported in the United States (Dicken et al., 
2005).   Post-operative complications (within 30 days of definitive surgery) were 
similar across the two groups and few patients died post-operatively (n=3), another 
good result in the international context.   
There were however a number of key differences in the surgical management of the 
two groups, namely surgery type, surgical facility type and surgeon type.  Māori in this 





complex partial gastrectomy.  However, our findings suggest that the international 
guideline recommendations of the time were not being met, particularly for Māori 
patients.  International guidelines, published in 2002 and 2006, recommended that all 
patients should have treatment planned within the multi-disciplinary context, and that 
at all stages of disease surgery should be undertaken by experienced surgeons in high-
volume specialised units (National Health Service Scotland, 2006; Allum et al., 2002) 
with appropriate post-operative care available (Allum et al., 2002).    While we were 
unable to accurately measure multi-disciplinary treatment planning, Māori were less 
likely than non-Māori to have a specialist upper gastrointestinal surgeon perform their 
surgery (38% Māori vs 79% non-Māori) or to have surgery performed in a main centre 
(43% Māori vs 83% non-Māori) with specialist post-operative support 
These findings were further explored through stratification.  It appears that Māori 
remained less likely than non-Māori to have their surgery performed by a specialist 
upper gastrointestinal surgeon whether their surgery was performed within a main or 
smaller centre or whether a partial gastrectomy or a more complex total gastrectomy 
was performed.  While the results were not conclusive it does appear that even when 
Māori have their surgery within a main centre they are 73% (95% CI, 0.07 – 1.04) less 
likely than non-Māori to have that surgery performed by a specialist surgeon once 
age, stage of disease and tumour site are taken into account. A specialist surgeon is 
highly likely to be experienced in all potential presentations and problems related to 
complex upper GI surgery and importantly they are likely to be surrounded by a team 
of other specialists in upper GI surgery (such as radiologists, anaesthetists, intensivists, 
dietitians).  Specialist surgeons are also likely to audit and publish their results and 
interact with their peers in a robust and meaningful way, which was highlighted within 
the qualitative findings as being important to sound clinical practice. 
These differences raise serious questions about Māori access to specialist surgical 
stomach cancer services.  This location and resourcing of cancer services may be a 
factor with more Māori living in minor urban and rural areas (Robson et al., 2010) and 
so they are more likely to access care from smaller public facilities; indeed this was 





differences in specialist surgical care between the ethnic groups.  However the 
quantitative findings indicate there is differential access to specialised surgical care for 
Māori no matter which surgical facility type treatment occurs in.   Other studies have 
shown that Māori receive poorer quality care within New Zealand’s public hospitals 
than non-Māori (Davis et al., 2006; Grey et al., 2014; Wang et al., 2013; Ellis et al., 
2010).  Poorer quality care for Māori has also been shown to impact on subsequent 
cancer survival (Hill et al., 2010a; Seneviratne et al., 2015a; Seneviratne et al., 2014a).   
This current study was not able to assess either variation in individual surgeon practice 
or variation between facilities; it is likely variation within and across different surgical 
facilities exists.  Nor was this study able to assess whether the observed differences in 
surgical management impacted on treatment outcomes or patient survival.  The need 
for further research in this area is highlighted, especially focussed on the impact of 
hospital type and surgeon type on patient outcomes in New Zealand.  These findings 
also underscore the need to consider more than absolute intervention rates when 
monitoring treatment disparity. 
Medical Oncology Treatment 
Of the 172 patients in this study with stage I-III disease, 49% were referred to medical 
oncology; however few patients received chemotherapy with similar proportions 
observed between Māori (26%) and non-Māori (30%).  Additionally, few patients 
overall received chemotherapy in conjunction with surgery despite international 
guidelines of the time recommending both pre and post-operative chemotherapy in 
patients with curative intent (Allum et al., 2011).  Overall 15% of patients with stage I-
III disease received pre-operative chemotherapy and 25% received post-operative 
chemotherapy.   The New Zealand study published in 2002 and based on 1995 – 1997 
data discussed previously in relation to endoscopic ultrasonography (Martin, 2002) 
also found that few patients with stomach cancer received multi-modality therapy 
despite evidence at the time increasingly supporting such treatment.  As with 
endoscopic ultrasonography it appears that clinical practice has remained unchanged 





Other studies have found evidence of treatment differences between Māori and non-
Māori patients, with Māori less likely to receive potentially curative medical oncology 
treatment (Seneviratne et al., 2014a; Hill et al., 2010b; Stevens et al., 2008b).   
Furthermore these disparities were not explained by differences in tumour 
characteristics, patient comorbidity, deprivation (Seneviratne et al., 2014a; Hill et al., 
2010b; Stevens et al., 2008b) or, in the case of lung cancer patients, refusal of 
treatment (Stevens et al., 2008b).  
Informants in the qualitative phase of this study identified the Multi-Disciplinary 
Meeting (MDM) as the key referral mechanism into medical oncology.  However it 
appears that MDM pathways also differ throughout New Zealand and are especially 
problematic for patients living within smaller DHB areas or rurally.  Again Māori are 
more likely to be disadvantaged as they are more likely to reside rurally.  This warrants 
further investigation. 
Patient Management 
Waiting times through the treatment pathway were similar for Māori and non-Māori.   
Māori appeared to wait on average 13 days longer, once diagnosed, for both 
definitive surgery (median 47 days for Māori compared to 35 days for non-Māori, 
p=0.65) and before referral to medical oncology (median 34 days for Māori compared 
to 25 days for non-Māori patients, p=0.31).  However, once in the oncology treatment 
pathway, waiting times were similar for Māori and non-Māori patients. 
The following findings were not statistically significant and must be interpreted with 
caution.  However, stratifying waiting times by the two key surgical facility types (main 
and smaller centres) suggested that Māori who receive their surgery in a main centre 
have longer delays from diagnosis until both definitive surgical treatment and referral 
into medical oncology services than either non-Māori treated in main centres or Māori 
treated within smaller centres.  This may be because Māori are more likely to have 
comorbidity than non-Māori slowing their journey within a main centre.  Māori may 
also be more likely to have their cancer diagnosed within a smaller facility and then be 





resources available to smaller centres to adequately care for more complex patients.  
Certainly my reflections on gathering the data by clinical note review support this 
hypothesis.  Informants in the qualitative phase of this study also spoke of delays in 
patients’ journeys, especially when dealing with multiple providers across multiple 
DHBs.  In addition, several clinicians highlighted the fact that Māori often wish to 
discuss treatment options with whānau before finalising their treatment plan.  While 
these clinicians were aware of and tried to accommodate a whānau-based approach 
to decision making this was not always possible within a busy clinical environment and 
at times this inability to accommodate a whānau approach slowed the patient 
journey.  
These findings compare with other evidence of disparity in timeliness to cancer 
treatment.  Differences have been shown between Māori and non-Māori New 
Zealanders across a number of cancers; namely colon (Hill et al., 2010b), lung (Stevens 
et al., 2008b), breast (Seneviratne et al., 2014a; Seneviratne et al., 2014c) and rectal 
(Swart et al., 2013) cancers.  In the case of breast cancer a high proportion of women 
did not receive surgical treatment within the Ministry of Health 31 day guideline, 
especially those women treated within the public sector (in which Māori feature more 
highly) (Seneviratne et al., 2014c).  Public sector treatment was also associated with 
delays in women receiving adjuvant chemotherapy and radiotherapy, with higher 
proportions of Māori compared to New Zealand European women, and women 
residing rurally compared with urban residency, experiencing delays to treatment.   
Furthermore there is some evidence these delays may be contributing towards the 
higher breast cancer mortality seen in Māori women (Seneviratne et al., 2014a). 
As surgery is the primary curative treatment for stomach cancer, timely access to 
surgical services is important and potential survival gains could be made for Māori 
through ensuring timely access to surgery no matter where that surgery is performed. 
Palliative Care 
Referral into a palliative care service (palliative chemotherapy, palliative radiotherapy 





disease only.  While similar proportions of Māori and non-Māori were referred to any 
palliative care service (85% vs 83%) Māori patients are less likely to be referred to (and 
receive) chemotherapy than are non-Māori patients (28% vs 44%, referred for 
chemotherapy).  On the converse, it does appear that Māori patients are more likely 
to be referred to (and receive) radiotherapy in the palliative setting (16% vs 7%, 
referred for radiotherapy) however these latter results are based on very small 
numbers of patients and are not statistically significant.   
Palliative care is a critical part of the treatment pathway for a cohort of patients that 
are highly likely to be diagnosed with stage IV disease.   Indeed a specialist surgeon 
within the qualitative phase of this study stressed that the health system must 
maintain focus on palliative patients, and on ensuring that they have the best possible 
quality of life, in order to make the most difference to the greatest number of people 
with stomach cancer. 
There is evidence of under-treatment with chemotherapy for patients with higher 
levels of comorbidity (Sarfati et al., 2009; Sogaard et al., 2013).  Thus the lower 
likelihood of being referred or receiving chemotherapy among Māori patients may be 
due to the higher levels of comorbidity among Māori.  Given the evidence for 
improved quality of life and up to 10 month median survival benefit of palliative 
chemotherapy over supportive care alone (Dicken et al., 2005; Allum et al., 2011; 
Okines et al., 2010) whether (and why) there are ethnic differences as suggested by 
this study’s findings warrants further investigation.   
Differences in Patient Survival between Māori and non-
Māori with Stomach Cancer 
That nearly 80% of the total cohort overall died during follow-up reflects the poor 
prognosis of stomach cancer.  This is an unsurprising finding with most countries 
reporting five-year survival rates between 10% and 30% (Mercer and Robinson, 2008; 
Crew and Neugut, 2006; Dicken et al., 2005; Forman and Burley, 2006).   Overall there 





specific, between the Māori and non-Māori cohorts.  Nor was any difference observed 
in either median all-cause or cancer specific survival times. 
However Māori patients appeared to have poorer survival compared with non-Māori, 
with a probable 30% higher risk of cancer-specific death in Māori although the study 
was underpowered to statistically confirm this.   This does support the finding of 25% 
excess mortality in Māori with stomach cancer, over that of non-Māori, reported in a 
large cancer survival trend study that investigated survival from 1991 to 2004 
(Soeberg et al., 2012).  In this current study the estimated 30% higher mortality in 
Māori patients was not explained by a number of key factors: patient demographics, 
disease factors, patient comorbidity, or markers of health care access.   
The unadjusted hazard ratio for stomach cancer specific mortality of 1.02 (95% CI 0.79 
– 1.31) reflects the similar proportions of deaths overall between Māori and non-
Māori in this study.  Adjustment for patient demographic factors: age and sex had 
little impact on the Māori/non-Māori hazard ratio. 
Adjustment for disease factors (stage at diagnosis and tumour site), had the biggest 
impact on the model.  Stage alone made the biggest difference to the model with a 
change in the hazard ratio from 1.08 to 1.21 (95% CI 0.92 – 1.58).  Stage in particular is 
an important mediator between ethnicity and survival among cancer patients; it is a 
crucial individual measure influencing patient survival and is the most important 
predictor of stomach cancer survival with a strong association to mortality 
(McLoughlin, 2004; Crew and Neugut, 2006; Abrams and Wang, 2010).  Unsurprisingly 
stage was a strong independent predictor of survival within this study; with a 13-fold 
risk of dying observed in stage IV compared with stage I patients.   At a population 
level, stage at diagnosis can indicate levels of access to primary health care and/or 
cancer screening, along with access to prompt referral and timely diagnostic 
investigation; differences in stage by ethnicity can reflect differential access to these 
services.   Indigenous Australians (Moore et al., 2014a; Condon et al., 2006; Valery et 
al., 2006; Chong and Roder, 2010) and Americans  (Young et al., 1984; Gilliland et al., 
1998; Samet et al., 1987; Jemal et al., 2004) were more likely to be diagnosed with a 





the poorer survival outcomes seen within them when compared to their non-
Indigenous counterparts.  
In comparison to other indigenous people, in this study there were no substantial 
differences in stage between Māori and non-Māori.  In fact Māori actually had a 
slightly better stage profile than non-Māori, with more stage II and less stage III 
disease, although differences within these stage groups were not determined.   Given 
their slightly better stage profile it could be expected that Māori would be more likely 
to survive their cancer however we see after adjustment for stage the survival 
disparity remains.    
Patient comorbidity only explained a small amount of the survival disparity seen 
between Māori and non-Māori in this study. There was a very small, and non-
significant change in the hazard ratio from 1.28 to 1.25 (95% CI 0.94 - 1.66) following 
adjustment for this factor.   This is because this was a highly comorbid cohort overall 
with only small differences in prevalence of comorbidity between the Māori and non-
Māori cohorts. 
Comorbidity has been shown to mediate ethnic disparities in survival in other cancer 
survival research (Valery et al., 2006; Hill et al., 2010a; Moore et al., 2014a).  Most of 
the effect of comorbidity seems to be mediated through ethnic differences in receipt 
of treatment (Hill et al., 2010a).  However Moore and colleagues (Moore et al., 2014a) 
found that Indigenous Australians without comorbidity remained less likely to receive 
cancer treatment (including surgical treatment) than their non-Indigenous 
counterparts suggesting factors other than comorbidity play a role in cancer 
treatment. 
While it does not appear that comorbidity plays a large role in the survival disparity 
seen between Māori and non-Māori in this study, and it is most probably an important 
driver of survival overall, probably mediated through its effects on treatment 
decisions.  The fact that the group of stage I-III patients in this study who did not 
receive any treatment had higher levels of comorbidity than those who did receive 





effect of comorbidity on stomach cancer treatment and survival deserves further 
investigation.    
Additionally adjusting for differences in markers of health care access (deprivation and 
rurality) was not able to explain the excess mortality in Māori with the final best 
estimate being a 30% poorer survival for Māori compared with non-Māori (HR 1.30; 
95% CI, 0.96 – 1.76).  These variables were included as a crude measure of access to, 
and through, cancer services.  There are likely to be other measures of health care 
access and quality that were unable to be measured within this study.  It is important 
to note that it is possible for a health care system to deliver poorer quality care to one 
ethnic group even if individuals or individual facilities within that system deliver 
quality care.   
It is likely that treatment type, quality or other non-treatment factors unable to be 
collected (or analysed) within this study play a role in the observed Māori/non-Māori 
survival disparity. Further research is needed to better understand the impact of 
health service access and delivery factors on ethnic disparities in cancer care and 






Why might there be ethnic disparities in access to New 
Zealand’s health system and what can be done about it? 
Results from this study align with other research which together provides compelling 
evidence that Māori are less likely than non-Māori to receive quality, and timely, care 
for a number of cancers.    Importantly these differences in care have been evidenced 
to contribute to the poorer survival profile of Māori with colon (Sarfati et al., 2009; Hill 
et al., 2010a) and breast cancers (Seneviratne et al., 2014a; Seneviratne et al., 2015).   
This current study supports the Māori/non-Māori stomach cancer survival differences 
seen in previous research, finding a probable 30% poorer survival in Māori than non-
Māori patients.  While this apparent survival difference was unexplained by a number 
of key factors, it is concerning.   
The findings of the qualitative phase of this study largely confirmed the quantitative 
findings.  Differential access to stomach cancer treatment services by centre type was 
apparent as well as specific issues for Māori within the cancer care pathway 
highlighted.  For a number of cancers, including stomach cancer, there may be 
institutional factors within the health system that privilege non-Māori and 
discriminate against Māori.   Furthermore this privileging of non-Māori over Māori 
contravenes the Treaty of Waitangi.   The Treaty places a responsibility on the New 
Zealand government to ensure health services are accessible to, and address the 
health needs of, Māori.  The Treaty also requires equity in health outcomes for Māori 
and non-Māori New Zealanders.  Quite clearly Māori with stomach cancer do not have 
the same access to care as do non-Māori and there appear to be disparate Māori/non-
Māori stomach cancer survival outcomes. 
New Zealand is however not an isolated case.  International evidence suggests that 
other developed nations have health care systems that do not provide equitable 
cancer care for their indigenous people (Moore et al., 2014a; Condon et al., 2014; 
McCramb et al., 2012; Samet et al., 1987; Gilliland et al., 1998).   Nor do they seem to 
provide equitable stomach cancer care for their indigenous people (Morrell et al., 





Samet et al., 1987; Jemal et al., 2004; Heise et al., 2009).  Questions about access to, 
and the quality of, care provided to Māori when compared to non-Māori patients with 
stomach cancer have been raised by this study.   The remainder of this chapter 
considers explanations for this and offer answers to what can be done to provide 
more equitable care for Māori.   
Mandelblatt et al’s framework of barriers to accessing cancer services (Mandelblatt et 
al., 1999) provided guidance to this study, its design and analysis.  The framework is 
now used below to structure discussion.   In keeping with the intent of this thesis to 
not require that Māori change their behaviour in order to receive better quality care 
the most emphasis is placed on discussing health system and health care process 
levels. 
Importantly, there has been considerable work to improve cancer services across New 
Zealand in the decade preceding this thesis.  This work has grown in impetus since 
2007 and the advent of Regional Cancer Networks to work towards more equitable 
access to cancer services across District Health Boards.  Still there is much to be done 
to improve stomach cancer services in New Zealand.  As highlighted by one key 
informant in the qualitative phase of this study ‘... if people really care about it and 
they make sure a good service is provided, then it’s fine … but we can always improve”.  
The section below outlines some ways in which those improvements can occur to help 
ensure New Zealand’s health care system provides equitable care to all New 
Zealanders regardless of their ethnicity, socioeconomic status or place of residence.    
Health System Factors 
Health system-level factors include the focus, funding and location of cancer services 
which in turn affect the accessibility of services according to socioeconomic status, 
geographical location and, as discussed below, by ethnicity.   This study raises 
important questions about the accessibility of specialist stomach cancer services and 





The section below considers key health system level factors in relation to these 
questions. 
In this study we used two variables in quantitative data analyses as proxies for health 
care access at the health system level - deprivation and rurality.  I argue that patient 
comorbidity should also be considered at the health system level of Mandelblatt et 
al’s framework as this current study and the work of others clearly shows that level of 
comorbidity impacts both on treatment and survival from cancer.  Yet receipt of 
curative treatment, even in those patients with higher levels of comorbidity, can 
improve survival (Sarfati et al., 2009).  With this in mind the onus must be on the 
health care system to better meet the needs of patients with cancer and concomitant 
comorbid conditions.  Thus comorbidity is considered a health system level factor and 
discussed in the section following. 
Cancer Service Focus on Total Population 
New Zealand’s institutions, including the health care system, were modelled on those 
of the British (French et al., 2001), these institutions tend to mainstream Pākehā and 
require non-Pākehā to adapt to their language, culture and protocols.  Until recent 
decades there has been almost no Māori involvement in decision making within the 
health sector, although recent changes have seen increased Māori representation in 
health service policy, governance and organisation.  Recent decades have also seen 
the development of Māori health providers although these Māori-led health services 
are largely confined to services within the primary care sector and represent a small 
proportion of all health care provided in New Zealand. 
In New Zealand cancer treatment services are delivered primarily through the publicly-
funded health system (Cormack et al., 2005).  Thus most Māori cancer patients receive 
their care for stomach cancer from a provider that mainstreams Pākehā and requires 
non-Pākehā to adapt to it, rather than the other way around.  So despite New 
Zealand’s health care system being one of universal access its inherently mono-
cultural approach means there are marked differences in access according to 





health services as an issue for Māori.   This was raised in a broad way in terms of how 
New Zealand’s health care system is designed and organised and how health care 
services and health outcomes are measured.  The mono-cultural focus was also raised 
more specifically to do with service delivery.  Medical clinicians were generally aware 
of the negative impact of the mono-cultural focus of the health care system on Māori 
and attempted to mitigate this through measures such as speaking basic te reo (Māori 
language) or allowing for longer clinic appointment times when seeing Māori patients.  
However incorporating a more holistic and whānau focussed approach was discussed 
as not always being possible in the busy clinical environment and so it appears that 
this is an area in which clinical and cultural needs may conflict.  Finding ways to 
accommodate whānau and whānau-based decision-making while still maintaining 
timely access through the treatment pathway is important but may be difficult. 
Strategies were suggested in the literature to develop a less mono-culturally focussed 
health care system, one that is more responsive to Māori need.  These strategies 
ranged from developing supportive policy to supporting a focus on Māori in clinical 
practice, including providing opportunities for whānau participation in patient support 
and decision-making (Walker et al., 2008; Cormack et al., 2005; Cram, 2014a; Cram, 
2014b).    
Interventions to develop a less mono-culturally focussed system identified within the 
literature and those identified by key informants in the qualitative phase of this study 
are summarised in Table 40 at the end of this section.  Synergies between the two are 
noted within four key areas: Strengthening policy and accountability for equity, 
leadership, accurate data and monitoring, and accommodating Māori approaches to 
care.  
Funding, Resourcing and Location of Cancer Services 
The funding, resourcing and location of cancer services influence accessibility, with 
particular problems noted in New Zealand.  New Zealand has a relatively small 
population with communities spread widely across a diverse geography and despite 





reality access to health care varies according to a patient's socioeconomic status and 
place of residence.   Currently 20 regional DHBs are responsible for the bulk of 
primary, secondary and tertiary care within their geographical boundaries (Ministry of 
Health, 2013d), but not all DHBs (nor all hospitals) have the same resource available 
nor can they offer the same level of services (McLeod et al., 2004).    Historically in 
New Zealand, areas with larger non-Māori populations have tended to be advantaged 
in terms of health system resourcing relative to population size (Gauld, 2001).   
In particular, the geographical location of health care services impacts on access to, 
and through, specialist care.  Treatment disparity within specialist cardiac care is 
shown to be, in part, related to access to and type of treatment facility (Ellis et al., 
2013; Ellis et al., 2010; Ellis et al., 2004).   Likewise the geographical location of cancer 
services also impacts on access to, and through, cancer care.   Specialist surgical and 
cancer services tend to be concentrated in major metropolitan areas and so issues 
such as travel times or transport reduce the accessibility of services for those living 
further away from providers (Cormack et al., 2005).  Distance travelled for treatment 
plays a role in differential treatment for women with breast cancer (Seneviratne et al., 
2014a) and impacts on cancer mortality and survival for a number of cancers (Haynes 
et al., 2008; Brewer et al., 2012a; Brewer et al., 2012b)  including upper GI cancers 
(Gill and Martin, 2002). 
The geographical location of cancer services has the potential to impact more 
markedly on Māori who in New Zealand are more likely to live in areas further from 
health care facilities, as shown in this current study and previously (Hill et al., 2010a; 
Seneviratne et al., 2014c; Robson et al., 2010).  In addition, funding and resource 
structures especially impact on people of lower socio-economic status (in which Māori 
predominate) who have fewer economic resources and are less able to overcome 
financial barriers to care.    Māori with cancer are more likely to live in highly deprived 
areas (Hill et al., 2010a; Seneviratne et al., 2014c; Stevens et al., 2008b) while poorer 
cancer survival is noted in patients living in areas of greater deprivation (Haynes et al., 
2008; Jeffreys et al., 2009; Soeberg et al., 2012).  Cancer treatment in New Zealand is 





and accommodation expenses, on a patient and their whānau (Cormack et al., 2005).    
These costs are likely a greater barrier for Māori than for non-Māori with stomach 
cancer.   Importantly though, while the patterning of socio-economic status of Māori 
compared to non-Māori plays an important role in explaining ethnic disparities in 
cancer, socio-economic position alone cannot explain the inequities observed.   This is 
evidenced by the fact that within social strata, Māori/non-Māori inequities remain 
(Sporle et al., 2002), as they do after adjusting for socio-economic position (Blakely et 
al., 2007). 
The findings of the qualitative phase of this study support those of the quantitative 
phase.  The main issue highlighted by over half the informants in the qualitative phase 
of this study was that of geographical inconsistency in the delivery of cancer services, 
with the greatest negative impact appearing to be within smaller (less well-resourced) 
DHBs.  One of the nurse informants from a smaller centre summed up her interview 
by emphasising what she described as the inequity of a small DHB.  Examples of 
inconsistency between different sized DHBs were given by informants at most points 
of the treatment pathway.   In addition, key informants specifically raised issues to do 
with rurality and receiving care within smaller centres in relation to Māori.  The need 
for Māori to travel for multiple appointments with multiple providers and often within 
a DHB other than that in which they reside was seen as an issue by key informants.  
This was seen as particularly problematic when navigating these services was the 
responsibility of the patient rather than the health system supporting the patient and 
whānau cancer journey or working to improve the navigability of their services. 
Centralising surgical services into fewer, larger, more specialised centres was raised by 
both policy and clinical informants of this study, although informants did not commit 
to a preference.  Rather consensus was that the debate on centralising stomach 
cancer services (or upper GI cancers in combination) needs to happen in New Zealand.    
Reorganisation of services to a more specialist and centralised model has been carried 
out within the United Kingdom (Palser et al., 2009) and a number of European 





patients dependent on the hospital-type of their presentation (Monkhouse et al., 
2013; National Clinical Audit and Patient Outcomes Programme, 2013).   
While a link has been demonstrated between surgical volume, of both the individual 
surgeon and the facility, with improved surgical outcomes and patient survival 
observed when stomach cancer surgeries are performed by surgeons with higher 
volumes in fully supported institutions (Thrumurthy et al., 2013; Dikken et al., 2013a; 
Coupland et al., 2013; Mahar et al., 2012; Markar et al., 2012), the context of cancer 
care is very different in New Zealand to that internationally.  With its small population, 
New Zealand would need to centralise services to a small number of facilities to 
perform the volumes of surgery needed to attain international-level high volume 
status (Beenen et al., 2013) often considered to be a minimum of 20 resections 
annually per facility (Dikken et al., 2013a; Allum et al., 2011; Coupland et al., 2013; 
Okines et al., 2010; Dikken et al., 2013b).  Furthermore, despite having low surgical 
volumes by international standards, outcomes for upper GI patients comparable to 
those of tertiary hospitals published internationally have been documented in two 
non-tertiary New Zealand hospitals (Al-Herz et al., 2012; Beenen et al., 2013).  
Centralisation could also exacerbate existing inequities in access to care and so would 
need to be carefully managed with additional support provided.  In the meantime 
equity of access to specialist stomach cancer services could be improved through 
increased support for regional services and concomitant additional support provided 
to patients and whānau to access specialist services. 
Some informants discussed the future role of the Service Provision Standards in not 
only assessing but also requiring the level of services necessary within each DHB, with 
a view that more formalised relationships and shared care across DHBs will occur in 
the future.  This was both in the context of service delivery but also in workforce 
training, support and development.   In terms of surgical services a model of care that 
enables the provision of care in a facility closer to the patient and whānau’s place of 
residence, one of specialist support of generalist surgical practice was put forward as 
the model most likely to gain sector support.   Informants also believed that the Upper 





process whereby DHBs are assessing their level of service provision alongside the 
minimum recommended in the Standards, will help to identify gaps in the system and 
any differential treatment, providing transparency and impetus for change.   The 
general view seemed to be that this process will help to standardise care throughout 
New Zealand which has the potential to positively impact on equity for Māori in the 
future.  Certainly there is evidence to show that standardisation of care, though New 
Zealand’s national breast cancer screening programme, impacts positively on receipt 
and timeliness of treatment and breast cancer survival in New Zealand (Seneviratne et 
al., 2015a; Seneviratne et al., 2014c).  Thus women diagnosed through the programme 
are privileged by the programmes quality standards and associated auditing and 
monitoring processes.  That the screening programme is less accessible for Māori 
women means that fewer Māori receive the advantage that the quality standards and 
auditing of the programme confer on those diagnosed in this way.   
The interventions regarding funding, resourcing and location of cancer services 
identified within the literature and by key informants of this study are summarised at 
the end of this section Table 40.  Synergies are seen within two key areas: better 
addressing regional care and use of guidelines and standardised clinical pathways.    
In addition, the literature reviewed for this study calls for better resourcing of Māori 
health providers to deal with cancer.  Māori providers were strongly praised by 
participants of qualitative studies reviewed previously (Slater et al., 2013; Walker et 
al., 2008).  Māori providers provided practical assistance, such as transport to 
appointments or helping to understand health literature; they also provided 
emotional and spiritual support to patients and their whānau through working in a 
‘whānau ora’ model of care (Slater et al., 2013; Walker et al., 2008).  As concluded by 
Slater et al (Slater et al., 2013: 313) “Māori health providers are already providing 
informal cancer navigation.   This begs the question of whether they are recognised 
and resourced appropriately to do this important work”.  The Ministry of Health has 
previously funded three 3-year (2008 – 2010) community based pilots for cancer 
navigation and support in two urban areas with high Māori populations, and in a rural 





pilots were successful in improving patient and whānau quality of life and in reducing 
DNAs (Do Not Attends) (Health Outcomes International, 2011).  Perhaps now is the 
time to answer the call to look outside of DHB services and systematically and 
adequately resource Māori-led cancer support and navigation services in New 
Zealand. 
The literature reviewed for this study also asks the health system to: strengthen 
networks with other organisations that have commitment to improving Māori access 
to health care, engage with Māori leaders and communities, locate services in Māori 
settings where appropriate and, enable partnerships to include culturally competent 
expertise in teams.  While these measures were not specified by key informants of this 
study they have merit, are recommended and should be investigated. 
Comorbidity 
Comorbidity is known to impact on the quality of care received by patients.  Comorbid 
patients are less likely to receive curative treatment for their cancer than those 
without comorbidity (Stevens et al., 2008b; Hill et al., 2010a; Sarfati et al., 2009).  
When comorbidity is discussed within the multidisciplinary meeting setting, the key 
mechanism for cancer treatment planning, there is evidence a more conservative 
treatment pathway is taken (Stairmand et al., 2015).  Comorbidity also impacts on the 
likelihood of survival from cancer (Hill et al., 2010a; Sarfati et al., 2009; Lee et al., 
2011; Sogaard et al., 2013) and has been shown to be responsible for a third of the 
colon cancer survival disparity between Māori and non-Māori (Hill et al., 2010a).  
However evidence also suggests that patients with comorbidity may well benefit from 
treatment if given (Hill et al., 2010a; Sarfati et al., 2009; Sogaard et al., 2013; Lee et al., 
2011).    
Comorbidity is also common, especially in the context of stomach cancer.  The risk 
factors for stomach cancer include poverty, tobacco use, heavy alcohol consumption, 
obesity, infection with H pylori and chronic gastritis (Layke and Lopez, 2004; NHS 
Executive, 2001; Allum et al., 2011; Blakely et al., 2010) therefore many patients have 





in this study with 70% of both Māori and non-Māori having at least one comorbidity at 
the time of their stomach cancer diagnosis.   Although Māori had significantly higher 
prevalence of two key comorbid conditions and appeared more likely to have multi-
morbidity.     
My reflections on the note review process and the views of the key informants both 
support the need to focus on comorbidity when dealing with patients with stomach 
cancer.   Through the clinical note review the impact of comorbidity on the treatment 
pathway was visible.  It was apparent from reading patient notes in their entirety that 
comorbidity impacted on clinical decision-making, changed or delayed patient 
pathways and necessitated care in DHBs away from patients DHB of domicile.    Key 
informants also saw comorbidity as an issue for patients with stomach cancer in New 
Zealand and emphasied that its presence increases the complexity of an already 
complex pathway.   The impact comorbidity has on both timeliness through the cancer 
pathway and clinical decision-making were raised.   There was also acknowledgement 
of the impact of comorbidity, not only on the patient, but also of the additional 
workload the presence of comorbidity places on staff, on services and on health care 
resources more generally.   
Key informants put forward a number of interventions to improve services for those 
with comorbidity.  Interventions such as developing the cancer workforce’s knowledge 
of comorbidity and its impacts on clinical decision making and outcomes, ensuring 
that cancer nurse specialists have the ability to effectively work with comorbid 
patients by explicitly including comorbidity in contracts, job descriptions and reporting 
systems and extending, or developing new, cancer nurse specialist roles to include 
upper GI cancers are important for a group of patients that are likely to be highly 
comorbid and thus experience a complex cancer journey.  Interestingly the three key 
reports on improving access to cancer services for Māori reviewed for this thesis do 
not focus on comorbidity.  Comorbidity is absent within the work of Cormack et al 
(Cormack et al., 2005) and while comorbidity is considered within the work of Cram 
(Cram, 2014a; Cram, 2014b) it appears to be considered only as three major diseases 





comorbidity on Māori accessing health care was not emphasied.  It is a limitation of 
these pieces of work. 
The effect of comorbidity on the treatment of stomach cancer and subsequent 
survival requires further investigation.   Attention to the optimal management of 
comorbidity once diagnosed, either through primary health care or as an organised 
part of cancer management within secondary services, could improve cancer 
outcomes in all patients with stomach cancer, but especially in Māori patients.  The 
interventions regarding comorbidity identified by key informants in the qualitative 





Table 40: Health System-Level Interventions identified in the literature and by key informants 
Framework Level Issue identified Literature Interventions  Key Informant Interventions  





Develop cancer control policy for Māori and/or 
strengthen inequities focus in existing policy 
Stronger mandate for equity accountability and 
improving health outcomes for Māori 
Have commitment to, and leadership in, improving 
equity 
Develop a national-level ethnicity data role 
Develop clinical champions for equity 
Use local and/or relevant data to plan and monitor 
services  
Accurate data collection and reporting by ethnicity 
Incorporate Māori healing interventions and a 
whānau-based approach to care 
Accommodate a more holistic approach which 
encompasses whānau 
Improved cultural friendliness and approachability of 
services 
Funding Resourcing,  
Location and inconsistent 
of Services 
 
Address differential access to services and 
entitlements by region and provide community based 
or outreach services 
Combine clinics and increase use of tele-clinics 
Formalised and shared care across DHBs 
All DHBs involved in surgical resection of SC have a 
cancer nurse specialist to coordinate care within and 
across DHBs 
Ensure any guidelines are implemented and 
monitored 
Implementation and quality review of upper GI service 
provision standards 
Standardising clinical pathways/evidence based 
protocols/clear clinical decision-making criteria 
Standardising early detection and diagnostic services 
nationally 
Standardising MDM including process-dependent 





 Patient Comorbidity   Explicitly include comorbidity in cancer nurse specialist 
roles 
Extend -or develop new- cancer nurse specialist roles 
to include upper GI cancers 
Include the impacts of comorbidity in cancer sector 
workforce development 





Health Care Process Factors 
Health care process-level factors include communication between services and 
between services or providers of care and patients and their whānau; these in turn 
may impact on the pathways of care experienced by patients.  In this study surgical 
and medical oncology intervention rates and waiting times are all conceptualised as 
health care process-level factors as are surgical facility and surgeon type.   
While similar rates of both surgical and medical oncology interventions were observed 
between Māori and non-Māori patients in the quantitative analyses, the differential 
surgical management of patients and the slightly longer waiting times for Māori point 
to health care processes that better meets the needs of non-Māori patients. 
Health literacy was not measured within the quantitative phase of this study, however 
it was a theme within the intervention literature and frequently raised by informants 
of the qualitative phase.  As the onus should be on the health system and its services 
to ensure that patients and whānau understand their cancer journey and are 
empowered to make informed decisions health literacy is considered as a health care 
process factor and discussed in the following section. 
Communication between Services 
Cancer is a complex disease; a number of factors make the management of stomach 
cancer particularly complex.  There have been considerable changes in both the 
epidemiology and treatment of stomach cancer internationally in the decades 
preceding this study (Palser et al., 2009; Martin, 2002; Okines et al., 2010; Nakajima, 
2002; Allum et al., 2002; Allum et al., 2011; NHS Executive, 2001) thus the 
management of stomach cancer has been open to variability according to hospital or 
clinician decision (Nakajima, 2002).  Its primary treatment modality, surgery, is major, 
is demanding on the patient, technically complex for the clinician and places 





Allum et al., 2002; Martin, 2002; NHS Executive, 2001).  As a result of these factors, 
and their high levels of comorbidity, patients diagnosed with stomach cancer have 
diverse and complex clinical needs necessitating care from many different professional 
groups (Palser et al., 2009; NHS Executive, 2001).    
The complexity of the journey for someone with stomach cancer was apparent while 
gathering the quantitative data by clinical note review and was confirmed qualitatively 
by key informants.  Complexity is thought to contribute to Māori/non-Māori inequities 
in cancer treatment and outcomes overall (Cormack et al., 2005).   Effective and timely 
communication between, and within, services is vital; this includes ensuring cancer 
services are easy to navigate.   A number of ways to help mitigate the effects of 
complex patient journeys are discussed below.  They are: navigation, the use of clinical 
guidelines and clinical decision making in the context of MDM. 
Navigation 
Better coordination of care, especially when it necessitates care from services that 
cross DHB boundaries, may help to improve equity of access through stomach cancer 
services for different population groups.  The 57 new Cancer Nurse Coordinator roles 
that have been implemented within DHBs across New Zealand since 2012 will 
undoubtedly help in supporting patients to navigate cancer services.  These roles are 
however operationalised differently in each DHB and few focus on upper GI cancers or 
explicitly on equity.  
There is no consensus definition of patient navigation (Dohan and Schrag, 2005: 1126; 
Wells et al., 2008) and little literature on navigation specific to indigenous people 
(Whop et al., 2012).  Professional or lay, secondary or primary care based, navigator 
role type and having an indigenous background or not are all debated (Gilbert et al., 
2011; Dohan and Schrag, 2005: 1126; Whop et al., 2012).  Despite this debate patient 
navigation approaches are shown to improve diagnostic attendance and timeliness 
(Cram, 2014a; Nash et al., 2006; Wells et al., 2008; Gilbert et al., 2011; Gabram et al., 
2008; Whop et al., 2012), to improve the patient experience (Nash et al., 2006; Gilbert 





treatment for indigenous peoples (Wells et al., 2008) and enhance the diagnostic 
process from the clinician viewpoint (Gilbert et al., 2011).  There is also evidence that 
a model which combines hospital and community-based navigators working together 
improves access to cancer care, and completion of cancer treatment, in indigenous 
people (Domingo et al., 2011).  This adds weight to the point made in the preceding 
section on better resourcing Māori health providers to attend to cancer. 
A number of this study’s key informants discussed navigation as a necessary part of 
the patient pathway for a complex cancer such as stomach cancer.  One had even 
advocated having their job description changed to accommodate working with upper 
GI patients alongside lower GI patients, due to perceived patient complexity.   Again 
this is especially relevant to Māori where issues to do with rurality and receiving care 
within smaller centres are more prevalent.  Requiring that all DHBs involved in the 
surgical resection of stomach cancer appoint a cancer nurse specialist to coordinate 
care within, and across, DHBs may help to 1) facilitate communication between 
services and providers, 2) ensure cancer care for all patients meets current clinical 
guidelines and 3) ensure patients and their whānau do not become lost in the system.   
The intervention literature and qualitative key informants were however also clear 
that the health care system should not rely upon patient navigation alone, rather the 
system must also work to ensure that their services are easy to navigate.  One step 
towards achieving this put forward by key informants was to audit referral pathways, 
timeliness and care coordination across different DHBs to investigate any disparity.  
There is precedent internationally for this approach in a study that found significant 
differences in the journeys experiences between patients with stomach cancer 
presenting at two different hospital-types: a local district general hospital and a 
centralised tertiary hospital (Monkhouse et al., 2013).   
Clinical Guidelines 
Standardisation of care for all patients with stomach cancer was viewed by informants 
in the qualitative phase as being vital to improving equity.  As mentioned in the 





Provision Standards (National HBP/Upper GI Tumour Standards Working Group, 2013) 
has the potential to standardise care throughout New Zealand and positively impact 
on equity for Māori in the future.  However while they give guidance on the minimum 
level of service needed by providers wishing to provide care to patients with stomach 
cancer in New Zealand, they do not provide clinical treatment protocols.  As outlined 
in Chapter 2: Background a number of countries internationally have developed 
clinical guidelines specifically aimed at standardising treatment.  Although these 
international guidelines do not always reach consensus, there is enough commonality 
within them to provide some direction on the clinical management of patients in the 
New Zealand context.    It is though imperative that the Service Provision Standards 
are implemented and monitored with an equity focus that prioritises the needs of 
Māori. 
Clinical Decision Making 
The MDM is increasing recognised as a key decision-making mechanism for people 
with cancer, especially a complex cancer such as stomach cancer (Blazeby et al., 2006).  
Since 2002 international guidelines have recommended that treatment decisions for 
all patients with upper GI cancer should be made in the MDM context (Allum et al., 
2002; Allum et al., 2011).  While access to MDMs was not able to be quantified and 
compared between Māori and non-Māori patients within this study, key informants 
within the qualitative phase all agreed that the MDM is an important part of the care 
pathway for patients with stomach cancer.   It was apparent through discussions with 
key informants that access to, and processes of, MDM are inconsistent around the 
country.  Again smaller DHBs appear to be adversely impacted, with their smaller size 
meaning MDM expertise for their patients is accessed outside of the DHB region, 
often slowing the patient journey.  In addition a recent New Zealand study showed an 
apparent disadvantage if patients had not been physically seen by one of the MDM 
team members (Dew et al., 2014).  This meant that clinical decisions were made at a 
distance with difficulties in determining which patient issues were most important and 
what the MDM recommendations should be.   As Māori are more likely to live rurally 





Māori, are impacted through this mechanism.  Key informants also indicated that 
ethnicity is not often considered within the MDM setting, supporting the research of 
Dew et al (Dew et al., 2014).   Given the inequities in cancer treatment and outcome 
between ethnic groups in New Zealand, perhaps the impacts of ethnicity should be 
considered in the future.  The ongoing work led by the Ministry of Health aimed at 
increasing the functionality of MDM is important, including supporting remote video-
conferencing within MDMs.  Attention to consistent referral criteria and process into, 
and communication from, MDMs across the country is needed.  In addition, it may be 
useful to audit MDM practice in the future and compare access, decision-making and 
decision-making coherence by ethnicity.   These measures combined could impact on 
equity for Māori.  
Interventions to address the complexity of, and communication between, cancer 
services identified within the literature and by key informants in the qualitative phase 
of this study are summarised in Table 41 at the end of this section.    
Communication between Provider and Patient  
Effective communication between health care professionals and patients is also 
important.  At the clinical level the interaction between the health care provider and 
the patient or whānau is of importance.  Betancourt et al (Betancourt et al., 2003: 
297) argue that “extensive research shows that patient-provider communication is 
directly linked to patient satisfaction, adherence to treatment plans and subsequently 
to health outcomes”.   Yet there is evidence that this is of lesser quality for Māori 
patients than it is for non-Māori patients (Crengle et al., 2005; Jansen et al., 2008) with 
many Māori reporting poor rapport with health care professionals (Slater et al., 2013; 
McCreanor and Naim, 2002), including those within the cancer sector (Walker et al., 
2008).  However the ethnicity of the health care professional is not always important 
rather the qualities demonstrated are; qualities such as competence, warmth, 
honesty, respect, a caring attitude and a willingness to engage with and understand 





Māori may also be disadvantaged by individual clinician bias, albeit most likely 
unconscious bias (Hill et al., 2013; McCreanor and Naim, 2002).   When health care 
professionals do not take social and cultural factors into account they can resort to 
stereotyping which leads to biased clinical decision making.  This bias can then in turn 
lead to inequitable health outcomes (Betancourt et al., 2003).   The quantitative phase 
of this study did not examine the clinician-patient relationship or clinician decision 
making and so cannot provide any direct evidence of any differences by ethnicity.  
However the variation in surgeon-type and surgical treatment type observed between 
Māori and non-Māori patients in this study possibly provides indirect evidence and 
suggests different referral patterns for different ethnic groups.  Internationally there is 
evidence of variation in referral patterns to surgical treatment centre type by ethnicity 
(Chang et al., 2009; Al-Refaie et al., 2012).  Further work is needed to better 
understand whether clinician bias exists and the impact of the health care 
professional/patient encounter within the context of stomach cancer service delivery 
in New Zealand.  Audit of clinical practice could be valuable in this regard. 
Clinical Audit 
It may be useful for clinicians to audit their own practice against clinical guidelines to 
see if all patients are receiving the best-practice treatment available.  Interestingly 
surgical expertise was only raised by the surgeons within the qualitative phase of this 
study, although policy participants did speak of the need for evidence-based and 
agreed protocols.   The Australian and New Zealand Gastric and Oesophageal Surgical 
Association (ANZGOSA) surgical audit provides an appropriate opportunity for New 
Zealand surgeons operating on oesophago-gastric cancer or gastrointestinal stromal 
tumours (Australian and New Zealand Gastric and Oesophageal Surgical Association, 
2006).  The ANZGOSA audit is a quality improvement tool whereby clinical practice 
and outcomes are assessed and compared to standards and/or that of peers. 
Participating in peer-reviewed surgical audit is mandated as part of an upper GI 
Surgical Fellow's professional development recertification but is currently not 





practice could be evaluated and assessed by ethnicity in the context of the MDM 
meeting.   
Workforce 
The ethnic composition of the cancer workforce along with the cultural competence 
or safety of those working within the health sector can also impact on the pathways of 
care experienced by patients.  
Māori are significantly underrepresented in all parts of the health workforce (Durie, 
1998; Ministry of Health, 2007) thus most health care encounters take place between 
Māori patients and non-Māori health care professionals.  This underrepresentation 
can exacerbate health inequity (Boulton et al., 2004) as the more a health worker is 
able to appreciate the cultural needs of clients the greater the opportunity is for 
effective health care (Boulton et al., 2004; Durie, 1998).   Greater recruitment and 
retention of Māori within the cancer workforce will likely help to grow a workforce 
that is responsive to the needs of Māori (Walker et al., 2008; Slater et al., 2013).  
Likewise improving the cultural competence or safety of those already working within 
the cancer sector will help to grow a workforce that is responsive to the needs of 
Māori.  Provider education on cross-cultural issues is identified as one strategy to 
address inequities in health and health care (Betancourt et al., 2003) and was 
identified as important both within the intervention literature and by this study’s 
qualitative key informants.  The interventions identified within the intervention 
literature and by key informants in the qualitative phase of this study are summarised 
in Table 41 at the end of this section.   
Health Literacy 
Health literacy is defined “as the ability to obtain, process, and understand basic 
health information and services in order to make informed and appropriate health 
decisions” (Ministry of Health, 2010c: iii).  There is growing awareness that low health 





impacts on health status (Ministry of Health, 2010c; Kickbusch et al., 2005; Agency for 
Healthcare Research and Quality, 2014; National Network of Libraries of Medicine, 
2014).   While on average, New Zealanders have poor health literacy skills Māori have 
worse health literacy than non-Māori across all indicators measured (Ministry of 
Health, 2010c).  Other indigenous people and minority groups are also likely to have 
lower levels of health literacy than majority populations (Jiwa et al., 2013; Agency for 
Healthcare Research and Quality, 2014; National Network of Libraries of Medicine, 
2014).   
Importantly to this thesis, disparities in health literacy are shown to be an important 
factor contributing to cancer disparities with minority group patients more likely to be 
diagnosed with later stage disease and less likely to understand treatment options and 
thus make suboptimal treatment decisions, all due to ineffective information and 
communication (Merriman et al., 2002). 
Health literacy is not viewed as a knowledge deficit in an individual patient rather it is 
seen as a systems issue, whereby the onus is on health systems, health care providers 
and practitioners to support patients to access care, navigate services and manage 
their own health and wellbeing (Kickbusch, 2001; Kickbusch et al., 2005; Agency for 
Healthcare Research and Quality, 2014; National Network of Libraries of Medicine, 
2014; Ministry of Health, 2015b).  According to the Ministry of Health (Ministry of 
Health, 2015c: 2) “a health-literate organisation makes health literacy part of all 
aspects of its service planning, design, delivery and performance evaluation to reduce 
the health literacy demands on consumers”. 
Health literacy was not able to be measured quantitatively within this study; still a 
number of key informants raised health literacy as an issue, especially for Māori 
patients.  Hearteningly key informants’ views on health literacy seemed to be 
congruent with the systemic-type definitions above.   There seemed to be willingness, 
and effort made, by clinicians to ensure that individual Māori and whānau were 
supported to see and understand their cancer journey, although some also expressed 
being unsure of how to best do this.  Health literacy was also widely raised in the key 





providers’ ability to provide culturally responsive information and services to Māori 
patients and their whānau” again in keeping with a systems-type approach.  Two 
interventions noted in Cram’s literature review focussed on improving health 
professional ability to communicate effectively with minority group populations.  Both 
improved the health care provider’s self-rated efficacy in working with minority 
groups (Cram, 2014a).  Attention to the health literacy framework (Ministry of Health, 
2015b) and organisational health literacy review guide (Ministry of Health, 2015c) 





Table 41: Health Care Process-Level Interventions identified in the literature and by key informants 
Framework Level Issue identified Literature Interventions  Key Informant Interventions 
Health Care Process Communication between 
services 
Patient navigation or care coordination Patient navigation or care coordination for all patients 
with stomach cancer 
Change health workforce roles and funding formulas 
to support an increased nursing workforce 
Include upper GI and comorbidity in cancer nurse 
specialist roles  
All DHBs involved in surgical resection of stomach 
cancer have a cancer nurse specialist to coordinate 
care within and across DHBs 
Make services easier to navigate alongside the use of 
patient navigators or nursing care coordinators 
Undertake comparative clinical review or audit across 
DHBs - Investigate referral pathways, triage processes, 
patient flows, timeliness and care coordination across 
different DHBs 
Care plans and comprehensive discharge planning Consistent use of established tools, including discharge 
tools 
Patient – provider 
communication and 
provider bias 
Build a culturally competent and health literate 
workforce i.e. through training of health practitioners  
Develop the cancer workforce’s knowledge and 
increase understanding of their responsibility in 
effective communication with patients and whānau 
Develop clear decision-making tools and guidelines Use clear clinical criteria with consistent use of 
established tools 
Cancer workforce  Debunk health practitioner stereotypes of Māori Develop the cancer workforce’s knowledge of inequity 
and determinants of health  
Employ more Māori within cancer care including in 
governance roles 






Health literacy - the health 
system and services 
supports people to 
understand their stomach 
cancer journey 
Provide culturally tailored and responsive information 
and services 
Use MOH organisational health literacy framework and 
guide 
Review relevant resources from a health literacy 
viewpoint 






Patient-level factors are factors existing at presentation to secondary services and so 
lie outside of the dominion of the secondary and tertiary cancer care system.   In this 
study patient (age, sex and comorbidity) and disease factors (grade and site) are 
conceptualised as patient-level factors.  These factors have been discussed at the 
patient level in descriptive analyses and have already been attended to earlier in this 
discussion.  As argued earlier in this discussion patient comorbidity could also be 
thought of as a health system factor whereby the onus on the health system to better 
manage comorbidity in patients both at the primary and secondary or tertiary levels of 
care.  Patient choice alone is discussed below in relation to the Mandelblatt et al 
framework. 
Patient Choice 
This study was unable to measure patient treatment choice.  Previous studies that 
have investigated cancer treatment decline have reported both higher rates (Stevens 
et al., 2008b) and no difference (Hill et al., 2010b) in declining treatment in Māori 
compared with non-Māori patients.  Research by Mandelblatt and colleagues 
described a fatalistic view of, and fears and misconceptions about, cancer within 
minority groups (Mandelblatt et al., 1999).  Although recent New Zealand research 
with Māori cancer patients refutes these views.   Māori are concerned about their 
health and they do not want to be unwell (Dew et al., 2015; Walker et al., 2008; Slater 
et al., 2013; Cram et al., 2003).  To the contrary Māori want to receive good health 
care that is mindful of their needs as Māori.  These needs include whānau involvement 
in the cancer journey and taking a holistic approach to health which includes 
emotional and spiritual support from within Māori culture (Dew et al., 2015; Walker et 
al., 2008; Slater et al., 2013).   A longstanding relationship with a primary care 
provider, either a Māori health provider (Slater et al., 2013; Walker et al., 2008) or 




journey.   Māori health providers in particular help to provide both practical assistance 
and emotional and spiritual support alongside that provided by whānau members 
(Slater et al., 2013; Walker et al., 2008). 
As seen in Table 42 below, the intervention literature and key informants of this study 
both identified whānau and holistic health views as important patient level factors.  
However while the clinicians spoken to in this study were aware of the needs of Māori 
patients and took steps to meet these needs this was not always possible in the busy 
clinical environment.   Investigating ways to better accommodate the needs of Māori 
and to incorporate Māori ways of attending to their health within cancer service 
delivery is important.    
Table 42: Patient-Level Interventions identified in the literature and by key informants 




Support whānau-based and 
holistic self management 
Accommodate a more holistic 
approach which encompasses 
whānau 
Summary and Key Messages 
The section above on why the health system might deliver less quality care to Māori 
and what can be done to change it has provided detailed discussion and raised a large 
number of possible interventions.  However as previously highlighted In order to 
optimise the responsiveness of cancer services and effectively address equity multiple 
issues must be addressed and multi-faceted interventions implements.  The key take-
home messages with respect to what needs to change within New Zealand’s health 
care system are provided below.   
 Strengthen policy, leadership, monitoring and accountability for equity.  
 Standardise and address regional variations in cancer care. 
 Improve services for those with comorbidity, either through primary health 




 Ensure cancer services are easy to navigate through the investigation of 
current patient flows across DHBs and the use of enhanced patient navigation 
approaches, consistently applied clinical guidelines and effective clinical 
decision making in the context of MDM. 
 Consistently use clinical audit tools such as the ANZGOSA surgical audit. 
 Implement the health literacy tools recently released by the Ministry of Health 
and upskill the cancer workforce. 
 Better accommodate Māori approaches to care.    
 Finally, partner with and better resource Māori health providers to attend to 
the needs of their clients, and whānau, with cancer. 
Conclusion 
The findings of this study add to the literature on Māori/non-Māori inequities in 
cancer treatment and survival in New Zealand.  They also add to the literature on the 
role of the health system in contributing to those inequities and how the health 
system can intervene to improve access to, and quality of, cancer care for all New 
Zealanders, but especially for Māori.  
The specific objectives of this study were to investigate: 
Quantitative phase  
1. Patient (age, sex, comorbidity), disease (stage at diagnosis, tumour site, grade), 
treatment (receipt and timing of surgery, chemo and radiotherapy), health 
care access (deprivation, rurality) and outcome (survival) characteristics of a 
cohort of patients with stomach cancer in New Zealand. 
2. Whether there were Māori/non-Māori differences in treatment timeliness, 




3. If differences exist, how these differences contribute to Māori/non-Māori 
stomach cancer survival. 
Qualitative phase 
4. What key informants identify as issues for stomach cancer treatment in New 
Zealand, with a focus on Māori. 
5. The interventions key informants identify that may improve access to, and 
quality of, stomach cancer treatment in New Zealand, with a focus on Māori. 
Despite the fact that New Zealand’s indigenous Māori are much more likely to be 
diagnosed with stomach cancer than non-Māori, have worse mortality and poorer 
survival once diagnosed, no previous studies have examined Māori/non-Māori 
differences in treatment and management of stomach cancer and whether this 
impacts on survival for Māori.   This study’s key strengths are that it is based on rich 
clinical data gathered by manual clinical note review and that it included a qualitative 
phase that in effect validated the quantitative findings and allowed the thesis to move 
beyond merely describing the problem and into investigating how and where to 
intervene to improve access to, and the quality of, stomach cancer services.   Its main 
limitation was its small sample size (n= 335) which meant it had limited power to 
detect some associations or differences. 
Specifically what this study’s findings add to the literature are, that it; 
 Confirms the differential tumour site between Māori and non-Māori, most 
probably related to higher rates of infection by H. pylori in Māori.  
 Shows that there are no difference in stage at diagnosis, treatment 
intervention rates and some markers of surgical quality between Māori and 
non-Māori. 
 Shows differential access to specialist surgical care for Māori and non-Māori, 
both by centre type and surgeon type. 
 Supports the differential survival for Māori, which remains unexplained by a 




 Supports the proposal that in order to optimise cancer services responsiveness 
to priority groups and effectively address equity the health system must 
address multiple issues and implement multi-faceted interventions.  
 In addition, key informants confirmed the differential access to stomach cancer 
treatment services by centre type and that there are specific issues for Māori 
along the cancer care pathway. 
Importantly this study helps to give transparency to the issue of institutionalised 
racism within New Zealand’s health care system.  As a policy-based participant of 
this study stated “You know, the only way to address these problems is by getting 
transparency.  If you don't know the problem exists, you can't really address it”.   
Addressing the disparities highlighted within this study will take effort.  Access to, 
and through, cancer services is complex; especially when you are dealing with a 
particularly complex cancer like stomach cancer.    Achieving equitable care and 
outcomes for Māori will require a variety of interventions along the stomach 
cancer pathway that combine health system, health care process and patient-level 
factors.  It will also require commitment, leadership, and engagement with Māori 
at all levels of the health care system.  
It must be noted that even a well-designed, fully functioning and equitable health 
system is only intervening at the level of health services.  The broader underlying 
determinants of health also need to be addressed.  This is particularly salient for a 
cancer with incidence rates that are driven by underlying poverty and differential 
access to the resources of society.   Addressing stomach cancer inequity will 
require a broad approach to health that extends beyond the health sector. 
Over recent years substantial work has been carried out in New Zealand to 
improve the access to, and the quality of, cancer services generally.  This work 
should continue, however it is imperative that emphasis continues on ensuring 
there are improvements to Māori health and reducing inequities for Māori.   
Māori with stomach cancer deserve excellence in cancer care, including equitable 
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Appendix 1: Quantitative Proforma 
3  1st presentation to health 
system 
4  Referral for specialist review 5   First seen by  specialist  
Date ………………….. Date ………………….. Date ………………….. 
O Date unknown O Date unknown O Date unknown 
Seen by (type i.e. GP) Referred from Seen by (type i.e. GI) 
Data source Data source Data source 
O 1. GP letter O 1. GP letter O 1. GP letter 
O 2. Specialist letter O 2. Specialist letter O 2. Specialist letter 
O 3. Medical notes O 3. Medical notes O 3. Medical notes 
O 4. Other………….. O 4. Other…………… O 4. Other…………… 
      
Signs & symptoms noted at presentation 
6 Any signs & symptoms noted? 
O 1. Yes O 2. No O 3. Unknown  2. No O 3. Unknown 
 If yes, for how long? 
O   O 1. < 1 month O 2.  1-3 months 
O   O 3. 3 – 6 months O 4. > 6 months 
O On surveillance   
    
7 If signs & symptoms noted, which? 
O   O 1. Abdominal Pain O 2. Anorexia 
O   O 3. Nausea O 4. Dysphagia 
O   O 5. Fatigue O 6. Unintentional weight loss 
O 7. Bloating O 8. Changes on bowel habits 




O 11. Anaemia   
O   O 12. Other (specify): ................................................................................................................................. 
Comorbidities recorded up to and including date at diagnosis 
8 Any comorbidities documented?  
  O O 1. Yes             O 2. No 
9 CVS  
(1=history noted but not currently active; 2=currently on medication, controlled; 3=currently 
active/on medication and not well controlled) 
O 1. Angina   
1 O 2 O 3 O 
O 2. Hypertension  
1 O 2 O 3 O 
O 3. Myocardial infarction  
1 O 2 O 3 O 
O 3. Arrhythmia  
1 O 2 O 3 O 
O 5. Valvular disease  
1 O 2 O 3 O 
O 6. Congestive heart failure  
1 O 2 O 3 O 
O 7. PVD  
1 O 2 O 3 O 
O 8. Previous PE (anticoagulated)  
O 9. Other CVS ................................................................................................................................. 
10 Resp 
O 1. Mild chronic pulm disease O 2. Moderate/severe CPD 
O 3. Other resp ................................................................................................................................. 
11 Haematological 
O 1. Blood loss anaemia O 2. Deficiency anaemia 
O 3. Other haem .............................................................................................................. 
12 GI 
O 1. Ulcer disease O 2. GI bleeding 
O 3. Inflammatory bowel disease O 4. Mild liver disease 
O 5. Mod/severe liver disease O 6. Other GI ............................................... 
13 Neuro 
O 1. Cerebrovascular disease O 2. Hemiplegia or paraplegia 
O 3. Dementia O 4. Multiple sclerosis 





(1=history noted but not currently active; 2=currently on medication, controlled; 3=currently 
active and not well controlled) 
O 1. Diabetes (uncomplicated)  
1 O 2 O 3 O 
O 2. Diabetes (end organ damage) 
O O 3. Hypothyroidism O 4. Other endo ........................................... 
15 Malig 
O   O 1. Leukaemia O 2. Lymphoma 
O   O 3. Tumour O 4. Metastatic tumour 
 Define (if available: 
..................................................................... 
 Define (if available: 
.................................................................. 
16 Other mental health disorder (see also Psychoses below) 
   O   O 1. Substance dependence/abuse O 2. Alcohol dependence/abuse 
O   O 3. Other ................................................................................................................................. 
17 Psychoses 
(1= history noted, 2= on medication, 3= under care of secondary or tertiary mental health 
services (+/- meds) 
O 1. Major depression  
1 O 2 O 3 O 
O 2. Anxiety disorders  
1 O 2 O 3 O 
O 3. Bipolar disorder  
1 O 2 O 3 O  
O 4. Schizophrenia and other psychoses 
1 O 2 O 3 O 
O   5. Other ................................................................................................................................. 
18 Other 
O 1. Connective tissue disease O 2. Mild renal disease 
O 3. Moderate/severe renal disease O 4. AIDS 
O   O 5. Coagulopathy O 6. Weight loss 
O 7. Obesity   
O   O 8. Other ................................................................................................................................. 
Other behaviours/comorbidity recorded up to and including date at diagnosis 
19 Smoking 
O   O 1. Current smoker?  
Amount? ………… Years smoked?  ........... 
O 2. Ex-smoker. Years smoked? ............ 





20 Refused all treatment? 21 Refused some treatment? 
O 1. Yes     O 2. No     O 1. Yes     O 2. No     
Reason noted? 
22 Reviewed at MDM? 
O   O 1. Yes  2     No O 3.    Unknown 
MDM type    O GI      O CRC      O Oncology     O Other MDM date ……………………… 
23  MDM Decisions noted  . 
O   O 1. Referred Surgery O 2  Referred Oncology 
O 3. Referred Palliative O 4. Other  ………………………………………. 
24   Reviewed at more than one MDM  . O 1. Yes O 2     No 
 MDM dates ………………………    …………………………………..   ……………………………… 
Investigations and Diagnosis 
25   Diagnostic and staging investigations:     
1. Gastroscopy (all) O Date  ……………… 4. Laparoscopy 
(some, new pathway) 
O Date …………… 
2. 2. CT scan (all) O Date ……………… 5. Biopsy O Date …………… 
3. Endo ultrasound 
(some, new pathway) 
O Date ……………… 6. MRI O Date ……………. 
26 Alcohol use O 1. Yes O 2. No O 3.Unknown Amount …………………….. 
27 Cirrhosis? O 1. Yes O 2. No O 3.Unknown Date diagnosed …………………….. 




Surgery?    Date of initial surgery  Nature of surgery: 
O 1. Yes 
  
O 1. Elective 
O 2. No  Hospital where surgery 
undertaken 
O 2. Acute 








If no surgery -> reason: 
 
 Obstruction at surgery? 
O 1. Not offered 
 
Type of operation: O 1. Yes 
O 2. Declined O 1. EMR O 2. No 
O 3. Other ……….……….. O 2. Partial gastrectomy O 3. Unknown 
 ………………………….. O 3. Total gastrectomy Perforation at surgery? 
 
………………………….. O 4. Other………………… O 1. Yes 
O 4. Unknown 
 
……………………………. O 2. No 
 
If  not offered -> reason: O 5. Unknown O 3. Unknown 
O 1. Patient too sick/ 
comorbidities 
34 Surgery delayed?  Surgeon type: 
O 2. Died before surgery O 1. Patient too sick O 1. Specialist/ Upper GI 
O 3. Other ……….……….. O 2. Patient DNA O 2. General 
 
…………………………... O 3. Other ……….……….. O 3. Unknown 
O 4. Unknown O 4. Unknown 
 
 





O Curative O Palliative O Unknown 
 
   Resection of liver metastases? O 1. Yes   Date: ………………….. O 2. No O 3. Unknown 
   Other treatment for liver mets? O 1. Yes   Specify: …………………………….. Date: ………………….. 
Postoperative complications (within 30 days post-op) 

















 Nature of complications: 
 
Other complications: 
O Reoperation for: O  1. Bleeding Date: …………... O 6. Pneumonia 
  
O  2. Other……………… Date: …………... O 7. Sepsis 
O Organ failure: O  3. Cardiac   O 8. MI 
  
O   4. Respiratory O 9. Stroke 
  
O 5. Renal O 10. DVT/PE 
O 11. Other………………… 
Other treatment 
 Other treatment noted O 1. Yes   O 2. No O 3. Unknown 
O 1. ……………………. Date: …………... O 3. ………………… Date: ……….. 
  
O 2. ……………………… Date: …………... 
Definitive Staging (at time of definitive diagnosis) OR to probable staging 
 Tumour site: Tumour at resection margins? 48   Lympho/Vascular invasion? 
O 1. Proximal O 1. Yes/+ve O 1. Yes 
O 2. Distal O 2. No/-ve/clear O 2. No 
O 3. Unknown O 3. Unknown O 3. Unknown 
O 4. Other description         Tumour grade?        Number of nodes resected? 
 Tumour size …………mm O 1. Well-differentiated O < 15 
O Tumour size unknown O 2. Moderately differentiated O > 15 
 
Tumour depth   ………mm O 3. Poorly differentiated O unknown 
O Tumour depth unknown O 4. Unknown Total number resected ……. ….  
Total number involved …………. 
 










 Tumour O T1 Tumour invades submucosa 
 O T2 Tumour invades muscularis propria 
 O T3 Tumour is growing into the subserosa layer 
 O T4 Tumour has grown through the stomach wall and into the serosa and may 
be growing into a nearby organ or other structures/major blood vessels 
52   Nodes O N0  Nodes not involved 
 O N1 1-2  regional lymph nodes involved  
 O N2 3 - 6 regional lymph nodes 
 O N3  7+ regional lymph nodes 
 Metastases O M0 No distant metastases 
 O M1 Distant metastases 






O     Stage 0   Tis, N0, M0 
O     Stage 1a  T1, N0, M0 
O   Stage 1b  Any of the following - T1, N1, M0 or T2, N0, M0 
O    Stage 2a   Any of the following - T1, N2, M0 or T2, N1, M0 or T3, N0, M0 
O    Stage 2b   Any of - T1, N3, M0 or T2, N2, M0 or T3, N1, M0 or T4a, N0, M0 
 
 
O    Stage 3a   Any of the following - T2, N3, M0 or T3, N2, M0 or T4a, N1, M0 
 O    Stage 3b  Any of -  T3, N3, M0 or T4a, N2, M0 or T4b, N0 or N1, M0 
 O    Stage 3c   Any of the following - T4a, N3, M0 or T4b, N2 or N3, M0 
 O    Stage 4 Any T, any N, M1 
Probable Staging a (if definitive diagnosis not available) OR 
 TNM staging possible? O 1.No TNM reviewed (notes): From: 
 
Date: 
Tumour T ……..     N ……..    M ………. (if known) 
 O Stage 1  









 O Stage 3  
 O Stage 4  
Probable Staging b (at time of probable diagnosis) 
 TNM staging possible? O 1.No TNM reviewed (notes): From: 
 
Date: 
Tumour  T ……..     N ……..    M ………. (if known) 
  O Stage 1  
 O Stage 2  
 O Stage 3  
 O Stage 4  
Oncology  
Referred to Medical  Onc ?   Offered chemo?      Offered chemo? 
O 1. Yes Date ……………….. O 1. Yes O 1. Yes 
O 2. No O 2. No O 2. No 
O 3. Unknown O 3. Unknown O 3. Unknown 
 If YES -> oncology 
review? 
 If YES -> received chemo?  If YES -> received chemo? 
i. O 
1. Yes Date ……………….. O 1. Yes 
start 




O 2. No O 2. No O 2. No 
O 3. Unknown O 3. Unknown O 3. Unknown 
 If not reviewed -> 
reason: 
    If not received -> reason:  If not received -> reason: 
O 1. Died before appointment O 1. Died before appointment O 1. Died before appointment 
O 2. Declined O 2. Declined O 2. Declined 
O 3 DNA O 3 DNA O 3 DNA 










O 4. Other ………………… O 4. Other ………………… O 4. Other ………………… 
O 5. Unknown O 5. Unknown O 5. Unknown 
 Treatment Intent O 1 Curative O 2 Palliative O 3 Unknown 
  
68 Completed Pre op Chemotherapy? 
O   O 1. Yes  Date …………… O 2. No     O  3. Unknown     
If No, Reason noted? O 1. Died before completion 
O 2. Declined O 3. Patient DNA 
O 4. Other ………………… O 5. Reason unknown 
69 Completed Post op Chemotherapy? 
O   O 1. Yes  Date …………… O 2. No     O  3. Unknown     
If No, Reason noted? O 1. Died before completion 
O 2. Declined O 3. Patient DNA 
O 4. Other ………………… O 5. Reason unknown 
Referred to Palliative Care 











Appendix 2: Reflections on the Data Collection Process 
Manual review of individual patient files added immense value to the study.  Not only 
did it provide more detailed information than that routinely available from 
administrative databases, it allowed a good understanding of the strengths and 
limitations of the data gathered.  It also allowed the visualization of the patient 
journey as a whole, better engagement with the health system and those who work 
within it and provided insight into the context of the delivery of cancer care in the 
many different facilities of New Zealand.  A reflective diary was kept daily during the 
data collection process.  Of note, the diary was written and summarised before the 
quantitative findings were generated or the key informants interviewed to gather 
their views on the stomach cancer treatment pathway, yet it appears to support the 
findings of this study.   Key reflections from that diary are presented below. 
In-Depth Understanding of the Data 
The process of reviewing individual patient medical notes allowed for an awareness of 
the data and its limitations.  Firstly, the medical notes had an incomplete perspective.  
They were written from a clinician perspective with no real patient voice within them; 
patients were often labelled: feisty, lovely, large whānau, non-compliant or DNA (did 
not attend).  Yet these labels were given without explanation or context and 
information on patient ‘non-compliance’, refusal of treatment or wish to involve 
whānau in decision making was confined to what was documented by the clinician in 
the medical notes.  Secondly, an appreciation was gained of why some variables had 
incomplete data.  At times medical notes can be sketchy or contradictory, with, for 
example, different medical disciplines writing different dates for key events.  The most 
comprehensive information was written within the oncology new patient histories 
(both medical and radiation oncology).  If patients were seen within oncology these 
histories provided a good overall review of the patient’s journey, otherwise gathering 
data on all variables within each patient’s individual proforma required patience, time 




The manual review of medical notes also allowed an in-depth understanding of the 
the data implications that might not have otherwise been possible.  The presence of 
comorbid conditions and their impact on treatment is exampled below.   
 There appeared to be few patients in the study that did not have any comorbid 
condition and multi-morbidity was common.  Even multiple cancer diagnoses were not 
uncommon.   I was astounded by the level of morbidity that many people have, with 
multiple medical and often severe chronic conditions.  It seemed to me that the 
presence of multi-morbidity was more prevalent within District Health Boards (DHB) 
with high Māori populations.  The impact of comorbidity, or multi-morbidity, on the 
treatment pathway was also evident.  Patients were often not referred, referred but 
treatment not offered, referred but a lesser or different treatment offered or sent to a 
larger hospital for treatment.  As highlighted in one patient’s notes “our ICU would not 
cope with them post-surgery”.   Delays in treatment were inevitable and evident. 
The Patient Journey 
The manual review of patient medical notes also allowed the visualisation of each 
patient’s cancer journey as a complete journey, certainly a more complete journey 
than that previously seen as a nurse providing episodic care during patient visits to 
hospital based cancer treatment.  I was struck by the pathways some patients take 
through the system; seeing multiple health practitioners, in multiple facilities, in 
multiple towns and in some cases multiple DHBs.   I also realised that cancer is a 
complex issue and medicine not an exact science.  Biopsies miss tumours, often 
multiple times.  At times variables were difficult to determine, for example to which 
specialist people first presented, the date of diagnosis (in the case of multiple 
gastroscopy for example) or the date the patient first saw a specialist relevant to the 
cancer diagnosis.  These examples are all at the beginning of the pathway, where early 
diagnosis matters.  I reflected that if I - a trained oncology nurse - found reading 
patient medical notes complex, and often confusing, then how do the patient and 




Engagement with the Health System  
Engagement with the health system in a way not previously possible in my capacity as 
an oncology nurse was also possible.  I gained better appreciation for all who work 
within it.  The staff within medical records departments in particular left a lasting 
impression.  They appeared to be an undervalued workforce doing a highly efficient, 
highly organised and physically demanding role which the health system arguably 
would not be able to operate without.   The physical environment of the medical 
record department in itself was often challenging.  Many patient notes were stored in 
underground, musty, cluttered and quite frankly scary dungeons, yet staff were able 
to maintain order and be quickly responsive to the needs of the facility in which they 
work. 
The Context of Cancer Care in Aotearoa/New Zealand 
Undertaking a clinical note review was also a journey I experienced, both physically 
and reflectively.  Of note, it allowed insight into the context in which cancer care is 
delivered in New Zealand.  This is important to understanding the implications of this 
study.   
The different resources available to various DHBs were evident.  This was apparent 
not only in the resource allocated to housing and maintaining clinical records but was 
evident when reading about the patients within these records.  For example Auckland 
hospital, a facility within a large and relatively well-resourced DHB, has converted all 
clinical records into electronic form with all information: clinic letters, medical and 
nursing notes and referral letters, scanned into individual electronic records.  
Pathology and investigation results were linked to each patient and available 
electronically.  Auckland hospital had a purpose built medical records department 
with dedicated space for research purposes.  As well, they had a staff member 
specifically allocated to assisting researchers and auditors.  On the converse smaller 
facilities, such as Gisborne or Thames hospitals, still operated a paper-based system 




for a researcher to operate within.  Instead staff chose to seat me in professional 
offices.   
Geography also appeared to make a difference to the services available with access to 
specialist services differing by DHB.  Auckland hospital provides many specialised 
cancer services, such as New Zealand’s only dedicated Hepatobiliary/Upper GI Cancer 
Unit, a Familial Gastrointestinal Cancer Service and has specialist Upper GI surgeons.  
For Auckland based patients these services are reasonably accessible.  As an example 
of this accessibility Auckland based people with suspected stomach cancer were at 
times referred directly from primary care to a specialist upper GI surgeon, potentially 
shortening the waiting time until diagnosis.  On the converse there were many 
instances in smaller facilities, in which Māori patients seemed to predominate, where 
opinions on patients were sought from outside the DHB and/or patients were sent to 
another DHB.  This was apparent in particular for treatment where the DHB either did 
not have the specialist service available or the patient had comorbidities that 
necessitated specialised intensive care post-operatively.   
New Zealand has six regional cancer treatment centres servicing the entire country 
and one specialist upper GI cancer unit based in Auckland.  The distance covered by 
regional cancer treatment centres, for example holding regular clinics in peripheral 
centres, appears a large amount of work.  However my observation is that it seems to 
work well.  Doctors based regionally know when peripheral clinics are being held and 
communication seems collegial and fairly prompt between the doctors within 
different DHBs.  Relationships between the Auckland Upper GI Unit and the rest of the 
North Island also seem to work well, with prompt communication and a regular 
Auckland MDM which regional doctors are aware of and use to obtain specialist 
opinions on their patients. Despite these reflections the impacts of geographical 
isolation and fewer resources within smaller DHBs were evident for the health 
professional and for the patient and whānau.  In the latter case this often translates 
into longer journeys through the cancer treatment pathway and the necessity of care 





Appendix 3:  Qualitative Information Sheet 
 
Inequities and Interventions: The Case of Stomach Cancer in Aotearoa/New Zealand 
PARTICIPANT INFORMATION SHEET   
Thank you for showing an interest in this project.  Please read this information sheet carefully 
before deciding whether or not to participate.  If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request.   
Who is doing this study? 
This study is being led by researchers at the University of Otago, Victoria University and 
Waitemata DHB.  It is being undertaken as part of a PhD by Virginia Signal.  It is part of a larger 
group of studies, called the C3: Cancer, Comorbidity and Care studies, which are investigating 
the effects of ethnicity and comorbidity on cancer survival at a population level and are 
funded by the Health Research Council. 
What is the aim of the study? 
In Phase One of this study, we have investigated stomach cancer presentation, treatment and 
survival in New Zealand using data from a clinical note review of 335 newly diagnosed 
patients.  In Phase Two of the study, we aim to use these findings to identify, investigate and 
recommend interventions that will help to improve the stomach cancer pathway in New 
Zealand.  
Who are we looking for? 
This study is interested in the health systems response to improving the stomach cancer 
pathway so we are seeking the opinion of health care professionals and policy makers in 
Phase Two of this study.  We aim to conduct up to 20 key informant interviews, and would like 
to draw participants from the wider community of Clinicians, Specialist GI Nurses, Upper GI 
Cancer Coordinators, Regional Cancer Networks, District Health Board Planning and Funding, 
Ministry of Health Cancer Team, Māori Cancer Coordinators and the C3 Māori/Community 




What does your participation in the study involve? 
If you decide to take part you will be asked to participate in a 30 minute telephone interview 
which will be recorded.   The interview will be held with the PhD candidate (Virginia Signal) 
and arranged at a time which suits you.  Your verbal consent will be gained at the beginning of 
the telephone interview.  Following the interview, some email contact may be necessary to 
follow up and clarify points of discussion.  You will be given the opportunity to review the 
transcript of the interview once it has been typed and to approve any quotes used in the 
thesis or resulting publications (if you choose to do so). 
Participation in this study is voluntary.  You may withdraw from this study at any time during 
the period of data collection.  If you withdraw the information from the interview you 
participated in will not be used in the research.  If you do participate the data gained will be 
used in a PhD thesis, there may also be resulting publications.  Every effort will be made to 
ensure that you are not identified in any reported data or publications.  You will not be named 
but information about your role and ethnicity will be used to describe the people who 
participated in the research.  Transcripts and audio recordings will be kept on password 
protected computers and in locked filing cabinets for five years, at which time they will be 
destroyed. You can to request a copy of the results of the research should you wish.   
Ethics approval 
This study has received Otago University Level B ethical approval from the Department of 
Public Health, Wellington. 
If you have any concerns about the ethical conduct of the research you may contact the 
University of Otago Human Ethics Committee through the Human Ethics Committee 
Administrator (ph 03 479-8256). Any issues you raise will be treated in confidence and 
investigated and you will be informed of the outcome. 
If you have any questions about the study please contact:  
Virginia Signal PhD Candidate, Ph (06) 918-6188 Department of Public Health, University of 
Otago, Wellington, email virginia.signal@otago.ac.nz  
or Associate Professor Diana Sarfati Ph (04) 918-6042, Department of Public Health, University 





Appendix 4: Qualitative Consent Form 
 
Inequities and Interventions: The Case of Stomach Cancer in Aotearoa/New Zealand 
PARTICIPANT CONSENT FORM  
 I have read and understood the Information Sheet about this study.   
 I have had the opportunity to discuss this study and all my questions have 
been answered to my satisfaction.   
I understand that:- 
1. I will be asked to take part in a 30 minute telephone interview; 
2. My consent to participate in this study will be verbally obtained at the 
beginning of the telephone interview; 
3. The telephone interview will be recorded; 
4. My participation in the study is entirely voluntary; 
5. I am free to withdraw from the study at any time without any disadvantage;  
6. I am free to request further information at any stage; 
7. I have the opportunity to review the transcript of my interview and any direct 
quotes used; 
8. I will not be named and that every effort will be made to ensure that I am not 
identified in any reported data; 
9. Personal identifying information [audio-tapes] will be destroyed at the 
conclusion of the study but any raw data on which the results of the project 
depend will be retained in secure storage for at least five years; 
10. The results of the study may be published and will be available in the 
University of Otago Library (Wellington, New Zealand) but every attempt will 
be made to preserve my anonymity.   
I will be asked at the beginning of the telephone interview whether I: 
 agree to take part in this research 
 wish to review the transcript of my interview 










Appendix 5: Qualitative Interview Schedule 
Inequities and Interventions: The Case of Stomach Cancer in Aotearoa/New Zealand 
INTERVIEW QUESTIONS 
1. RESEARCH QUESTIONS FOR PHASE TWO 
Which interventions will facilitate changes in health care process and systems factors and 
will help to ensure equal access to, and quality of, stomach cancer treatment for Māori?  
Which interventions will be the most feasible in New Zealand and should be 
recommended to reduce stomach cancer inequalities?  
2. INTERVIEWER INTRODUCTIONS 
Mihimihi as appropriate to the participant 
Reconfirm the amount of time the participant has available for the interview 
Check that they are happy to be recorded and remind that they can request a copy of the 
transcript 
3. INTERVIEWER TO REVISE THE STUDY WITH PARTICIPANTS  
Ask if the participant had time to read the Information sheet and consent form previously 
sent to them – any questions? 
Explain that I am about to turn on the tape recorder and that I will need to record names, 
date & time and gain verbal consent first 
Ask and revise the study if needed 
This study is by researchers at the Wellington campus of the University of Otago, Victoria 
University and Waitemata DHB. 
This is phase two of a two phase study.  The study has already investigated the stomach 
cancer treatment pathway for 335 patients diagnosed between 2006 and 2008.  It has 
used data from a clinical note review and compared patient factors, treatment factors 
and survival between Māori and non-Māori.  
We are now interested in the health systems response to the inequities we have seen 
and so we are seeking the opinion of health care professionals and policy makers for this 
phase of the study. 
4. INTERVIEWER TO RECORD (turn on recorder & check numbers moving) 
Date and time, Name of researcher, Name of Participant, Participants organisation. 
Obtain Consent for Interview:  Participant agrees to take part in this study, agrees to the 
interview being recorded, knows they are free to withdraw from the study at any time 
without any disadvantage.  
Remind: Participant that their confidentiality will be maintained – they will not be 
identified personally but their role and ethnicity will be recorded 
Check whether: Participant wants to review the transcript of the interview, or approve any 




5. PARTICIPANT QUESTIONS 
A. Opening 
 Can you briefly tell me about your role in relation to the stomach 
cancer treatment pathway? 
B. Stomach Cancer Treatment Pathway for Māori 
 Thinking about the pathway of care for patients with stomach cancer, 
what do you think NZ health services do really well?  
 What do you think NZ health services do not do really well? Prompts 
below: 
 Health System level - funding policies, resources, service 
organisation and configuration, physical accessibility of services, 
waiting times, cost and the cultural appropriateness of services.  
 Health Care Process level - the way in which services and 
providers operate and how they work together and 
communicate with each other, the characteristics of physicians 
or providers themselves, such as age, gender, training and 
competence, communication skills, values, attitudes and biases 
and clinician/patient communication 
 Patient level – socioeconomic position, transportation, 
knowledge, attitudes and beliefs and patient decision-
making/preferences 
 Are these issues the same for Māori patients? (if not covered above) 
 Are these issues the same for complex patients? Comorbid/multi-
morbid? (if not covered above) 
C. Treatment decision making 
 How often are treatment decisions made in the context of an MDM? 
Prompts below: 
 Are all stomach cancer patients discussed at MDM? 
 Are MDM operating and functioning well, if not how could they 
improve?   
 Is ethnicity considered when discussing patients? 
 Is comorbidity considered when discussing patients? 
  Has anything changed in the last five years that has improved the SC 
treatment pathway for all NZers?   
 Has anything changed in the last five years that has improved the SC 
treatment pathway for Māori? 




 As you may be aware the Ministry of Health (and a working group) has 
recently developed national upper GI tumour standards intended to 
ensure best-practice management of patients with stomach cancer 
(and a range of other cancers).   How do you think these standards will 
impact on the SC treatment pathway? 
 What is needed to ensure that these are implemented? Facilitators and 
barriers? 
 Do you think the standards will impact on equity?  What is needed to 
ensure that they do? 
E. VS to revise key findings of the quantitative data. Prompts below: 
 Started with equal numbers of Māori and non-Māori, final cohort 335, 
high numbers of Māori women, roughly half overall stage 4 at 
diagnosis. 
 No differences in: stage at diagnosis, diagnostic investigations, 
timeliness through the pathway, numbers who had curative surgery 
 Statistically significant differences in: age at diagnosis by 10 years, level 
of comorbidity, tumour site, surgery type, access to specialist surgical 
care, access to major treatment centres – some differences in nodal 
harvest but not significant 
 Few patients overall referred to or received chemotherapy – 15% pre-
op, 25% post-op.  Some differences between Māori and non-Māori but 
not statistically significant 
 Probable differences in: survival by 27%, adjusted for age, stage, 
tumour site, comorbidity 
F. Referral pathways into specialist care 
 Can you tell me about the mechanisms of access to specialised surgical 
services? The referral process, who refers and how? Who makes the 
decisions about patient flows between DHBs? 
 How could the surgical referral process improve? 
 Can you tell me about mechanisms of access and referral to medical 
oncology? 
 How could the oncology referral process improve? 
G. How to improve the Treatment Pathway for all, but especially for Māori 
 Do you have any other thoughts on what needs to change in the SC 
Treatment pathway in the future? In relation to Māori?  In relation to 
complex patients? Prompts below: 
 Look for health system and process levels answers 




I. Anything else? 
 Can you think of anything else relevant that we have not discussed 
 Is there anybody else you think I should speak with? Why is it important 
I speak with them? 
 What is the best way to contact you if there are any follow up questions 
or points of clarification afterwards? 
J. Collect Demographics 
 Finally, I just need to ask a few quick demographic questions 
o Gender 
o Ethnicity – which ethnicity do you identify as?  
o Age bracket –  up to 25, 25 - 49, 50 – 64, 64 plus 






Appendix 6: Survival Analyses for Stage I – III Patients 
Table 43: Hazard ratios for stomach cancer specific mortality risk in Māori and non-Māori cohorts 
with sequential adjustment (using imputed variables: tumour site, NZDep and rurality) - Stage I - III 
Adjusted for: HR 95% CI 
Unadjusted  0.87 0.56 to 1.32 
Demographic Factors   
Age and Sex 1.10 0.71 to 1.71 
Disease Factors   
Stage and Tumour site 1.26 0.79 to 2.00 
Comorbidity   
Patient Comorbidity 
(a
 1.26 0.79 to 2.02 
Health Care Access Factors   
NZDep and Rurality 1.21 0.71 to 2.05 
 
 
 
 
